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Abstract
The steroid hormone progesterone is essential for the maintenance of pregnancy
in mammalian species, but its role at term and during labour is not fully under-
stood. While the effects of progesterone be either genomic or non-genomic, this
thesis focuses on the genomic effects of progesterone, and its withdrawal, on rat
uterine tissues. Using laser Capture Microdissection, homogeneous cell populations
from the the outer myometrium, inner myometrium, and decidua basalis were iso-
lated from uterine horns obtained from timed-pregnant Sprague Dawley rats that
were randomised to receive either progesterone, mifepristone, or vehicle treatment.
These rats had a 22-day gestational period, with natural systemic withdrawal of
progesterone occurring on the 19th day of gestation (GD19). RNA sequencing
was employed in the examination of the transcriptomes of the uterine layers, as
well as gene expression profiling between GD19 and term. Analysis of the spa-
tial expression of mRNA and proteins in the uterine tissues revealed localisation of
thyrotropin-releasing hormone mRNA, as well as the Trh protein, to the decidua
in late pregnancy. In addition, tenascin-n mRNA and proteins localised to the in-
ner myometrium but not the outer myometrium during late pregnancy. Analysis of
the temporal expression of mRNA transcripts showed distinct patterns of expres-
sion within each of the analysed tissues. Following the withdrawal of progesterone
on GD19, changes first occur in the outer myometrium, followed by the inner my-
ometrium, then the decidua where mRNA expression increases between GD22 before
labour and GD22 during labour. In conclusion, this thesis presents a novel approach
in which rat uterine tissues were studied separately. Potential tissue-specific markers
for the decidua and the inner myometrium in late pregnancy were identified. The
increase in gene expression prior to labour in the decidua would suggest a signal
for the onset of labour. Furthermore, changes in the myometrial tissues suggest the
presence of an in-built mechanism through which the myometrium knows when to
prepare for labour.
Part I
Introduction
xl
Chapter 1
Motivation
The incidence of preterm birth, defined as birth before the completion of 37 weeks
of gestation (Goldenberg et al., 2008), is high in developed countries. Of the
726,572 children who were born in England and Wales in 2012, 7.3% were born
preterm (Office for National Statistics, 2014). Most infant deaths are attributed
to preterm birth and over 50% of neonatal illnesses are a result of being born too
early (Goldenberg et al., 2008). While many of the babies that are born preterm
survive, they have increased risk of impeded growth, disability, impaired neurological
development, and respiratory complications (Goldenberg et al., 2008). Several
risk factors are associated with preterm labour, for instance, women aged 35 and
above (Astolfi & Zonta, 1999) and women younger than 18 years of age (Fraser
et al., 1995) are at higher risk of delivering their babies preterm compared to
other age groups. History of preterm delivery or spontaneous abortion and the
weight of the mother have also been shown to increase the risk of preterm delivery
(Goldenberg et al., 2008). Although there is high correlation between some risk
factors and the incidence of preterm labour, the underlying molecular processes
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leading to preterm labour, and labour at term, are poorly understood (Zakar &
Hertelendy, 2007).
Prior to the onset of labour, the uterus is in a state of quiescence which is influenced
by progesterone, a steroid hormone that is widely accepted as an essential component
in the maintenance of pregnancy in mammals (Blanks & Brosens, 2012). Proges-
terone is essential for the maintenance of pregnancy and is used in the prevention
of preterm labour in single-fetus pregnancies (Garfield et al., 2012). The onset of
labour involves the transformation of the uterus into a stimulus-responsive organ,
which contracts, resulting in the expulsion of the fetus(es) through a softened and
dilating cervix (Smith, 2007). These uterine contractions are controlled mainly by
the electrical activity of the myometrium (Laforet et al., 2011), whereby the move-
ment of ions into and out of myometrial cells generates bursts of action potentials
that have been shown to direct contractility of the uterus during labour by stimulat-
ing Ca2+ entry (Young, 2007; Lammers et al., 2008). Labour in some mammalian
species, e.g., in rabbits, rats, and mice, is preceded by a significant drop in the levels
of circulating progesterone (Hoffman et al., 2009; Vodstrcil et al., 2010). However,
labour at term in humans occurs in the presence of high and sometimes increas-
ing levels of progesterone (Snegovskikh et al., 2006), meaning that humans do not
depend on the systemic withdrawal of progesterone for them to go into labour. In-
terestingly, the withdrawal of progesterone at any stage in human pregnancy, e.g.,
by the administration of the partial progesterone receptor antagonist mifepristone
results in the onset of labour (Smith et al., 2007), suggesting that progesterone
withdrawal may have a role in the onset of parturition in humans.
While the mechanisms involved in contractility and the role of progesterone during
pregnancy have been established, the molecular mechanisms by which the uterus is
activated remain poorly understood. Gaining knowledge of these mechanisms will
2
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help in understanding the timing of birth and, more importantly, the mechanisms
involved in preterm birth. This thesis, therefore, analyses the effects of proges-
terone on the transcriptome of the uterus during pregnancy and at term in the rat
model.
1.1 Thesis Overview
This thesis consists of four parts, the first of which contains the introductory chapter
which provides the motivation of the thesis and an overview of the structure of the
thesis. The ensuing chapters in the first part of the thesis give a background into
progesterone, its effects, and the mechanisms by which it acts, and a brief overview of
the processes that are involved in the parturition process. In addition, comparisons
are made between the human and rat reproductive systems. The first part of the
thesis concludes by detailing the aims and objectives of the thesis.
Part II of this thesis is made up of three chapters, the first of which lists all the
materials and equipment used in the study on which this thesis is based. The sec-
ond chapter details the experimental protocols that were used in the study, while
the third chapter provides details on the data analysis protocols that were em-
ployed.
The results of the study are presented and discussed in the third part of this thesis.
In the first chapter of Part III, the transcriptomes of rat uterine tissues obtained from
animals treated with sesame seed oil (the control group) are profiled. Transcripts
that are expressed predominantly in the decidua, as well as those that are expressed
in the myometrial tissues are identified in this chapter. As well as the identification
of transcripts whose expression changes with the progression of pregnancy, between
3
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day 19+6hrs of gestation and day 22 during labour, transcriptional differences be-
tween uterine tissues are analysed. The second chapter looks at uterine smooth
muscle activation by calcium (Ca2+) and the expression patterns of genes involved
in uterine smooth muscle contraction in the control animal group. In the third chap-
ter, transcriptomic profiling of rat uterine tissues from mifepristone-treated animals
(accelerated progesterone withdrawal group), is conducted. Here the differential ex-
pression of transcripts with the progression of gestation and between uterine tissues
is assessed. In the fourth chapter, transcripts that are differentially expressed in
response to treatment with progesterone are identified. Transcripts that respond
to progesterone treatment as well as those that change in response to progesterone
withdrawal are analysed for the presence of common regulatory factors. The results
part of the thesis concludes with a summary and discussion of the main findings, as
well as suggestions for future work.
The fourth part of the thesis contains a list of references, and the thesis concludes
with appendices .
4
Chapter 2
Progesterone
Deriving its name from the phrase “progestational steroidal ketone”, progesterone
(P4) was first discovered in mammals in 1930 (Allen, 1930, 1970). As its name
suggests, P4 is a steroid hormone that is involved in the maintenance of pregnancy,
as well as the preparation of uterine tissues for pregnancy, and has ketone func-
tional groups (Dewick, 2001). More details on steroid hormones are provided in
Section 2.1, while the biological actions of P4 will be discussed in Section 2.4 and
Section 2.5. In addition, the chemical structure of the P4 molecule is described in
Section 2.2.
2.1 Steroid Hormones
Steroid hormones are synthesised from cholesterol and have a four-ring nuclear struc-
ture consisting of 17 carbon atoms, as well as side chains that determine their speci-
ficity (Nussey & Whitehead, 2002; Rehfeld & Bundgaard, 2010). Steroid carbon
atoms and rings are numbered and named following the International Union of Pure
5
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1	  
2	  
3	   4	  
28	   29	  
5	  
6	  
7	  
8	  
9	  
10	  
19	  
30	  
11	  
12	  
13	  
18	  
14	  
15	  
16	  
17	  
20	  
21	   22	  
23	  
24	  
241	  
242	  
25	  
26	  
27	  
A	   B	  
C	   D	  
Figure 2.1: Steroid naming convention. The carbon atoms are numbered 1–30 and the rings
are lettered A–D. Superscripted numbers, e.g., 241 and 242, indicate the numbering convention that
is adopted for the shorter of 2 side chains that are attached to the same carbon atom. Adapted
from IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) (1989).
and Applied Chemistry (IUPAC) recommendations (IUPAC-IUB Joint Commission
on Biochemical Nomenclature (JCBN), 1989) shown in Figure 2.1.
2.1.1 Steroid Hormone Synthesis
Steroid hormones are classified into five groups; androgens, estrogens, glucocor-
ticoids, mineralocorticoids, and progestogens (Zhang et al., 2004). The synthe-
sis of steroid hormones from cholesterol relies upon the action of specific enzymes
such as the cholesterol side chain cleavage enzyme (P450scc), and 17α-hydroxylase
(P450c17) (Hall, 1985; Miller et al., 2007). Cholesterol is converted to the pro-
gestogen pregnenolone through the shortening of the cholesterol side chain, a process
that is catalysed by the P450scc enzyme. Two other progestogens, P4 and 17α-
hydroxypregnenolone, are synthesised from pregnenolone by 3β-hydroxysteroid de-
hydrogenase (3β-HSD) and P450c17, respectively. P4 is a precursor in the synthesis
of the corticosteroids and mineralocorticoids through the action of 21α-hydroxylase
(P450c21), 11β-hydroxylase (P450c11), and aldosterone synthase enzymes. Syn-
thesis of both P4 and 17α-hydroxypregnenolone precedes the synthesis of the glu-
6
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cocorticoids, androgens, and estrogens, processes that are made possible by the
P450c17, 17β-hydroxysteroid dehydrogenase (17β-HSD), and aromatase enzymes
(Miller et al., 2007). The synthesis of the five groups of steroid hormones from
cholesterol is illustrated in Figure 2.2.
The enzyme that enables the conversion of P4 and 17α-hydroxypregnenolone to the
appropriate precursors for the synthesis of androgens, estrogens, and glucocorti-
coids is the P450c17 enzyme, the absence of which hinders the progression of the
steroid biosynthesis pathway (Hall, 1985; Miller et al., 2007). As such, during
pregnancy in humans and higher primates, the synthesis of steroids from cholesterol
stops with the formation of P4 because the placenta does not have the P450c17
enzyme required to convert pregnenolone to 17α-hydroxypregnenolone and P4 to
17α-hydroxyprogesterone (Mesiano, 2009). Instead, the placenta utilises the pre-
cursors dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEA-S) from both
the fetal and maternal circulations in the synthesis of androgens and estrogens as
illustrated in Figure 2.3. The fetal hypothalamus releases corticotropin-releasing
hormone (CRH), which is transported to the fetal anterior pituitary where it stimu-
lates the release of adrenocorticotropic hormone (ACTH). ACTH stimulates the
synthesis of DHEA-S by the fetal adrenal cortex, which is used in the synthe-
sis of estrone (E1) and estradiol (E2). In the fetal liver, DHEA-S is converted
to 15-hydroxy-dehydroepiandrosterone sulfate (15-OH-DHEA-S) and 16-hydroxy-
dehydroepiandrosterone sulfate (16-OH-DHEA-S), which are subsequently converted
by the placenta to estetrol (E4) and estriol (E3), respectively. Maternal DHEA-S and
DHEA are converted to androstenedione and testosterone, which are also converted
into E1 and E2 by the placenta. The reliance of the placenta on precursors from the
fetus and the mother in the synthesis of androgens and estrogens is the foundation of
the feto-placental-maternal unit (Cunningham et al., 2005; Mesiano, 2009).
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2.1. Steroid Hormones
2.1.2 Rapid Effects of Steroid Hormones
Steroid hormone effects are mediated by specific receptors in target tissues (Wendler
et al., 2010), which include steroid cell surface receptors that mediate the rapid
effects of steroid hormones. Rapid effects of steroid hormones were first observed in
the 1940s (Selye, 1942), and numerous studies have since identified rapid steroid
hormone effects in various tissues. Examples of the rapid effects of the five steroid
groups are summarised in Table 2.1.
Table 2.1: Rapid actions of steroid hormones. Examples of rapid physiological effects of
steroid hormones. Not all of these effects are mediated by cell surface receptors. In the case of
rapid progestogen effects, the mechanism of action is unknown. Abbreviations: ERK: extracellular
signal-regulated kinase; ATPase: adenosine triphosphatase. Adapted from Wendler et al. (2010).
Steroid type Effect Reference(s)
Androgens
Anti-proliferative effects on androgen-sensitive Hatzoglou et al. (2005)
human prostate adenocarcinoma cells
Proliferative effects on human breast cancer cells Lin et al. (2009b)
Estrogens
Activation of extracellular signal-regulated kinase Chen et al. (2004)
(ERK) in sheep uterine endothelial cells
ERK activation & Increase in insulin synthesis Alonso-Magdalena et al. (2008)
Glucocorticoids
Increase in ATPase activity in Sunny & Oommen (2001)
Oreochromis mossambicus
Inhibition of smooth muscle contraction in Sun et al. (2006)
guinea pig trachea
Mineralocorticoids
Increase of intracellular pH in human arteries Alzamora et al. (2000)
Increase in phosphorylation of myosin light chain Gros et al. (2007)
clonal vascular smooth muscle cells
Progestogens
Oocyte maturation in Xenopus Ferrell (1999)
Acrosome reaction in human sperm Luconi et al. (2004)
2.1.3 Genomic Effects of Steroid Hormones
In addition to cell surface receptors, steroid hormone effects are mediated by intra-
cellular transcription factors known as nuclear steroid receptors (Bain et al., 2007).
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Nuclear steroid receptors, including the androgen receptor (AR), estrogen recep-
tor (ER), glucocorticoid receptor (GR), mineralocorticoid receptor (MR), and P4
receptor (PR), are ligand-dependent members of the superfamily of nuclear recep-
tors whose members are classified according to the homology of their sequences as
summarised in Supplementary Table A.1 (Nuclear Receptors Nomenclature Com-
mittee, 1999; Germain et al., 2006). The general structure of nuclear receptors
can be subdivided into the six domains that are shown in Figure 2.4 (Beato, 1989).
Domains A and B are located in the amino acid (N-) terminal region of nuclear
receptors, which contains a transactivation function, TAF-1. Domain C, the DNA-
binding domain (DBD), is a conserved domain among nuclear receptors which en-
ables binding of receptors to specific DNA sequences in the promoter regions of
target genes (response elements). A hinge section, domain D, separates the DBD
from the ligand-binding domain (LBD), domain E, located in the carboxyl (C-)
terminal region of the nuclear receptor protein. The LBD is a conserved domain
which contains a transactivation function (TAF-2) to which other regulatory pro-
teins known as coactivators bind (Kumar & Thompson, 1999; Bain et al., 2007;
Pardee et al., 2011). Coactivators enhance transcription by aiding the remodelling
of chromatin and the binding of other proteins (Tetel, 2009). The LBD also func-
tions as the region where receptor dimerisation occurs (Kumar & Thompson, 1999;
Bain et al., 2007; Pardee et al., 2011). A domain in the C-terminal region of
nuclear receptor proteins, domain F, is present in some nuclear receptors (Pardee
et al., 2011; Burris et al., 2013).
In the classic genomic mechanism of steroid nuclear receptor action, the nuclear
receptor is bound to chaperone proteins in the absence of the ligand. Since steroids
are small hydrophobic molecules, they can pass through the cell membrane into the
cytoplasm to bind nuclear steroid receptors. Once the nuclear receptor is bound to
11
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Figure 2.4: Organisation of the nuclear receptor domains. Shown are: A/B: domains A
and B; C: domain C; D: domain D; E: domain E; F: domain F; N–: amino acid terminus; –C:
carboxyl terminus; DBD: DNA-binding domain; LBD: ligand-binding domain; and hinge section.
Adapted from Pardee et al. (2011).
a ligand, the chaperone proteins dissociate and the receptor-ligand complex translo-
cates into the nucleus where it forms a dimer with a similar complex. The dimerised
receptor-ligand complex binds to a response element in the promoter region of a
target gene and recruits coregulators which enable the regulation of transcription
(Beato, 1989; Chen et al., 2006).
Steroid receptor coregulators can enhance transcription (coactivators) or inhibit
transcription (corepressors) (McKenna et al., 1999). Some coactivators, such as the
p160 steroid receptor coactivator (SRC) family of coactivators, provide a connection
between ligand-bound receptors and the basal transcriptional machinery, which is
composed of general transcription factors that interact with RNA polymerase II
(Carlberg & Molna´r, 2014), while other coactivators, such as the cAMP response
element binding protein (CREB)-binding protein (CBP) and p300 factors, contain
the enzyme histone acetyltransferase, which catalyses the acetylation of the lysine
residues of histones, leading to changes in chromatin structure that enable ligand-
bound receptors to interact with the response elements of target genes. On the other
hand, corepressors such as the nuclear receptor corepressors (NCoRs), interact with
proteins that contain the enzyme histone deacetylase, which catalyses the deacety-
lation of the lysine residues of histones, which makes the chromatin of target genes
compact and their response elements difficult to reach. NCoRs interact with NRs
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that are either bound to antagonists, or unbound (McKenna et al., 1999; Leonhardt
et al., 2003; Condon et al., 2003; McEwan, 2009).
Steroid hormones play an important role in regulating physiological functions, in-
cluding female reproductive functions (Couse et al., 2006). This thesis focuses
on the effects exerted by the steroid hormone P4 on uterine tissues, the synthe-
sis, mechanisms of action, and biological effects of which are described in the next
section.
2.2 Progesterone Structure and Synthesis
The 21-carbon steroid hormone P4 is synthesised from cholesterol in the ovaries, pla-
centa, adrenal glands, and the central nervous system (Rone et al., 2009). Natural
synthesis of P4 is achieved through the conversion of cholesterol into pregnenolone
and subsequent oxidation of pregnenolone. P4 is also a precursor in the synthesis of
mineralocorticoids, glucocorticoids, androgens, and estrogens as shown in Figure 2.2.
In addition to the four steroid rings described in Section 2.1, the P4 molecule has
methyl (CH3) groups attached to the carbon atom at position number 10 (C10) and
at C13, and ketone functional [RC(= O)R
′] groups at C3 and at C20 (Figure 2.5). A
ketone functional group contains a double bond between carbon and oxygen atoms,
the former of which is attached to two carbon containing groups as illustrated in
the insert in Figure 2.5.
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Figure 2.5: Chemical structure of progesterone and ketone functional group. Proges-
terone has the 4 rings typical of steroid hormones as well as methyl groups at C10 and C13, and
functional ketone groups at C3 and C20. Insert: Structure of a ketone functional group.
2.3 Mechanisms of Action
Like other steroid hormones, the biological effects of P4 can be transcription-dependent
(genomic effects) or independent of transcription (Tan et al., 2012). Non-genomic
effects of P4 tend to be rapid, and can thus be observed within a few seconds or
minutes of treatment with P4. Rapid P4 effects were first described by Selye (1942)
in a study that assessed the pharmacological actions of the steroids. Subsequent
studies have identified rapid effects of P4 in a host of physiological processes, for
example, activation of the release of enzymes from the head of human sperm, known
as acrosome reaction (Luconi et al., 2004), and the promotion of Xenopus oocyte
maturation (Ferrell, 1999). This thesis focuses on the transcription-dependent ef-
fects of P4. The rapid non-genomic effects of P4 are not discussed further in this
thesis, but can be found in various reviews such as the review conducted by Gellersen
et al. (2009).
Unlike the non-genomic effects of P4, genomic effects regulate gene expression, and
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are typically slow, taking several hours to be observed (Steinman & Trainor, 2010).
The genomic effects of P4 are mediated by the nuclear P4 receptor (PR), a ligand-
activated transcription factor which is a member of the nuclear receptor super family
(Wetendorf & DeMayo, 2012).
2.3.1 Nuclear Progesterone Receptor
Most of the genomic effects of P4 are mediated by two PR isoforms, P4 receptor
A (PRA) and P4 receptor B (PRB), that are encoded by the same gene using two
distinct transcription start sites and translated from alternating start codons (Con-
neely et al., 2001; Wetendorf & DeMayo, 2012). PRA and PRB have structures
that are common to the members of the NR superfamily of transcription factors
(Section 2.1.3). The PRA and PRB proteins are similar except for an additional
sequence of 164 amino acids present in the N-terminus of the PRB protein, which
contains a third transactivation function (TAF-3) as shown in Figure 2.6. PR con-
sists of an N-terminal regulatory domain, DBD, a hinge section, a C-terminal LBD,
as well as TAFs (Lydon et al., 2000; Leonhardt et al., 2003; Wetendorf & De-
Mayo, 2012).
The role of PR was established through gene mutation studies; Lydon et al. (1995)
generated a PR knock-out (PRKO-/-), which appeared physically normal but did
not ovulate. Despite having mature follicles within their ovaries, PRKO-/- mice
still failed to ovulate when stimulated artificially. In addition to having an anovu-
latory phenotype, PRKO-/- mice had defective implantation. Additionally, Lydon
et al. (1995) observed that the development of the ducts in the mammary glands of
PRKO-/- mice was reduced, while the lobular-alveolar structures that are essential
for lactation were absent. Lydon et al. (1995) showed that that PR-mediated effects
15
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Figure 2.6: Progesterone receptor isoform domain structure. Structure of progesterone
receptor isoforms showing the N-terminal domain, DNA binding domain (DBD), ligand binding
domain (LBD), and transactivation functions (TAF-1, TAF-2 and TAF-3).
of P4 are essential for ovulation, successful implantation, and the development of
mammary gland ducts as well as lobular-alveolar structures.
The roles of the two main PR isoforms, PRA and PRB, have also been estab-
lished through gene mutation studies. In mice where PRA was selectively ablated,
(PRAKO-/-), reduced numbers of oocytes were produced in comparison to wild-type
mice, despite having a large number of mature follicles within their ovaries (Mulac-
Jericevic, 2000). Like in PRKO-/- mice, PRAKO-/- mice did not fall pregnant on
mating with wild-type bucks. However, the effects of P4 in the mammary glands and
thymus of PRAKO mice were not impeded, suggesting that PRB mediates P4 effects
in the mammary glands (Conneely et al., 2001; Tan et al., 2012). In another mouse
study, where PRB was selectively ablated, Mulac-Jericevic et al. (2003) demon-
strated that ovulation was not affected in (PRBKO-/-). In addition, PRBKO-/-
mice exhibited normal mammary gland development similar to that of wild-type
mice, confirming that PRB mediates P4 effects in the mammary glands.
Although PRA and PRB tend to be coexpressed in target tissues, Richer & Manning
(2002) observed that PRA and PRB uniquely regulated subsets of P4-responsive
genes, while nearly 25% of the P4-responsive genes studied were regulated by both
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Figure 2.7: Genomic actions of progesterone. P4 diffuses into the nucleus where it binds
to PR, the PR-P4 complex dimerizes and approaches the chromatin, binds to PREs on target
genes, and recruits co-regulators. The co-regulators interact with general transcription factors
(basal transcriptional machinery) which, in turn interact with RNA polymerase II and initiate
transcription. Abbreviations: P4: progesterone; PR: progesterone receptor; PRE: progesterone
response element;
PR isoforms in human breast cancer cells. PRB has also been shown to bind co-
activators that are different from those that bind PRA, and the two isoforms respond
uniquely to modulators such as the PR partial antagonist mifepristone, which in-
hibits the action of PRA while it acts as a weak agonist for PRB (Meyer et al., 1990;
Hovland, 1998; Giangrande et al., 2000; Leo & Lin, 2008; Tung et al., 2006).
2.3.2 Genomic Mechanism of Action
While possessing distinct functions, PRA and PRB both act through the classic
mechanism of nuclear receptor action which is illustrated in Figure 2.7. In the
classic or genomic mechanism of P4 action, the inactive receptor is normally bound
to a chaperone protein in the cytoplasm which is cleaved off following the binding of
P4 to PR in the nucleus. The P4-PR complex dimerises and recruits co-regulators
17
2.3. Mechanisms of Action
that mediate changes in the chromatin structure at promoters, thereby allowing or
inhibiting the PR-P4 dimer to bind to P4 response elements (PREs) in the promoter
regions of target genes. Co-regulators interact with other protein complexes as well
as the basal transcriptional machinery initiating the transcription of the genes as
described in Section 2.1.3 (Leonhardt et al., 2003; McEwan, 2009; Wetendorf &
DeMayo, 2012). Coregulators are essential for normal PR-mediated transcription
as evidenced by the reduced growth and development of various tissues including
the uterus and mammary glands, and resistance to progesterone in mice lacking
the coactivator SRC-1. While, mice lacking the coactivator SRC-2 had delayed
onset of puberty, and produced less oocytes than their wild-type counterparts (Xu
et al., 1998; Tetel, 2009). In addition, (Condon et al., 2003) observed that
the levels of the coregulators CPB and SRC were reduced in samples of labouring
human and mouse myometrium, suggesting that the reduction in the number of PR
coactivators available for recruitment may reduce PR-mediated quiescent effects of
P4 at term. Nuclear receptor interacting protein 1 (NRIP1), also known as RIP140,
is also a PR coregulator that affects PR action through its interaction with agonist-
bound ER-α and TAF-2 on PR (Caballero et al., 2005; Nautiyal et al., 2013).
While NRIP1 knock-out (RIPKO-/-) mice exhibit an anovulatory phenotype similar
to that observed in PRKO-/-, the endocrine function of the ovaries in RIPKO-/-
mice is normal as opposed to that of PRKO-/- mice (Robker et al., 2000; White
et al., 2000; Leonardsson et al., 2002). Although NRIP1 is expressed in numerous
reproductive tissues, Leonardsson et al. (2002) observed that the effects of NRIP1
on fertility were confined to the ovaries. In addition to its effect on ovulation,
Leonardsson et al. (2002) suggested that NRIP1 may play a role in the maintenance
of pregnancy as RIPKO-/- mice exhibited prolonged pregnancies when compared to
wild-type mice.
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2.3.3 Progesterone Receptor Antagonists
As well as coregulators and agonists, PR interacts with ligands, known as antago-
nists, that inhibit or diminish the effect of P4. While antagonists are structurally
similar to P4, they tend to bind to PR with higher affinity as compared to P4. There
are three main types of PR antagonists defined by their effects once bound to the
receptor; Type I, Type II, and Type III (Afhu¨ppe et al., 2010). Type I antagonists
bind to the receptor and induce changes in the structure of the receptor-antagonist
complex, which prevent the complex from binding to response elements on target
genes. ZK-98299 (Onapristone) is an example of a Type I P4 receptor antagonist,
which was developed by Schering AG (Neef et al., 1984). Onapristone is a pure
PR antagonist that has been shown to possess anti-tumour characteristics. (Jonat
et al., 2013; Kougioumtzi et al., 2014). Type II antagonists also induce conforma-
tional changes to the receptor-antagonist complex, but do not prevent the receptor-
antagonist complex from binding to response elements on target genes. However,
the receptor-antagonist complex formed with a Type II antagonist cannot initiate
transcription, because its structure does not allow TAF-2 to interact with coregula-
tors (Cadepond et al., 1997; Cabeza et al., 2015). RU486 (Mifepristone) is a Type
II antagonist, which was first synthesised in 1981. Mifepristone binds to both PR
and GR with high affinity (Philibert et al., 1985). Like Type II antagonists, Type
III antagonists allow the receptor-antagonist complex to bind to response elements
on target genes. However in contrast to Type II antagonists, the Type III receptor-
antagonist complex is able to recruit and interact with corepressors, thus directly
inhibiting transcription of target genes (Afhu¨ppe et al., 2010). ZK-230211 (Lon-
aprisan) is a Type III antagonist that exhibits anti-proliferative characteristics and
has been shown to increase the recruitment of nuclear receptor corepressor (NCoR)
when bound to PR (Afhu¨ppe et al., 2010; Jonat et al., 2013).
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Figure 2.8: Chemical structure of mifepristone.
Mifepristone
The chemical structure of mifepristone is similar to that of progesterone as it con-
tains four carbon rings, which allows the antagonist to bind to PR (Figure 2.8)
Mifepristone has a range of clinical applications including, the prevention of preg-
nancy in the form of the morning-after pill and the induction of labour following
intrauterine fetal death (Amer-Alshiek et al., 2015; Carp, 2015). Mifepristone
cannot induce abortion during the second trimester in humans, however, treatment
with mifepristone prior to the administration prostaglandins reduces the time taken
for the fetus to be aborted (Thong & Baird, 1992).
Mifepristone has been used in the study of PR activation (Leonhardt et al., 2003).
It has also been shown that mifepristone increases the expression gap junction pro-
teins, which are usually suppressed by P4 (Gibb et al., 2006). Mifepristone has
been shown to act as a PRB agonist in the presence of cyclic guanosine monophos-
phate (cGMP) and cyclic adenosine monophosphate (cAMP) (Sartorius et al., 1993;
Edwards et al., 1993). In addition, Han et al. (2007) observed that mifepristone
enhanced PR activity in the uterus and the mammary gland following a 3-day treat-
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ment regimen with mifepristone.
In rats, mifepristone can induce abortion and preterm labour (Chwalisz, 1994). As
such, mifepristone was used to induce pre-term labour in the present study.
2.4 Non-Uterine Functions of Progesterone
2.4.1 Neurological Effects
Progesterone has numerous neurological effects as it affects the neurotransmitters
noradrenaline and histamine in rats (Chaudhuri et al., 1992). The neuroprotective
effects of progesterone have been observed in animals with traumatic brain injury
(TBI), neonatal hypoxic-ischemic encephalopathy, ischemic stroke, spinal cord in-
jury, and multiple sclerosis (Lopez-Rodriguez et al., 2015; Peterson et al., 2015;
Yousuf et al., 2014; De Nicola et al., 2013). The clinical benefits of progesterone in
the treatment of TBI could, however, not be determined as the encouraging results
of Phase II clinical trials could not be replicated in the Phase III trials (Lopez-
Rodriguez et al., 2015). In one Phase III trial, the proportion of patients who
showed signs of improvement following treatment with progesterone was similar to
that of patients treated with the placebo. In addition, the proportion of patients
who died while under treatment with progesterone was similar to that of patients
taking the placebo (Skolnick et al., 2014).
2.4.2 Breast
Progesterone is involved in mammary gland and lobular development in the breast,
where its nuclear receptors PRA and PRB are both expressed (Obr & Edwards, 2012).
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While both PRA and PRB are coexpressed in normal breast tissues, their expression
was seen to vary considerably in breast cancer, suggesting a role for progesterone in
the development of breast cancer (Conneely et al., 2008; Mote et al., 2008). The ab-
sence of regulation of PR-mediated P4 signalling is associated with the development
of cancer, not only in breast tissue, but in all tissues in which the steroid hormone
P4 exerts its effects (Kougioumtzi et al., 2014). Breast cancer cells that express PR
are termed PR-positive (PR+) and have been the subject of studies involving Type I
and Type II PR antagonists (Robertson et al., 1999). A Phase II randomised study
was conducted in 2013 to determine whether the Type III PR antagonist Lonaprisan
would be effective as a second-line therapy for PR+ breast cancer. While Lonaprisan
had not been previously associated with liver toxicity as had been observed with
Onapristone, a Type I PR antagonist, patients in the study developed adverse side
effects and Lonaprisan was deemed unsuitable for the treatment of breast cancer
(Jonat et al., 2013). Wargon et al. (2015) postulated that the responsiveness of
PR+ breast cancer to treatment with PR antagonists is dependent upon the ratio
of the PR isoforms PRA and PRB, further suggesting that tumours with a high
PRA/PRB ratio could benefit from combined treatment with PR antagonists and
the standard endocrine treatment with tamoxifen or progestogens.
2.4.3 Bones
The elevation of bone mass and an increase in the rate of bone formation in mice
lacking the progesterone receptor as well as in wild-type mice that had been treated
with mifipristone in comparison to their untreated counterparts, indicated the in-
volvement of progesterone in bone development (Yao et al., 2010; Imai et al., 2013).
Progesterone’s role in bone development was further substantiated by the reduction
of bone mineral density due to the use of oral contraceptives that contained proges-
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terone (Yao et al., 2010).
2.5 Reproductive Functions of Progesterone
In concert with other hormones, P4 is vital to female reproductive processes, such
as ovulation and the maintenance of the endometrium during pregnancy. (Conneely
et al., 2003; Smith et al., 2007). In order to fully appreciate the reproductive roles
of P4, the female reproductive system (Figure 2.9a) is described below.
2.5.1 Female Reproductive System
The female reproductive system consists of a set of organs that work in concert to
fulfil the reproductive role of the female adult. The ovaries are the source of female
gametes, all of which are produced prior to birth. As such, females are born with
a finite number of immature gametes (oocytes) that mature into ova during their
reproductive years (Cunningham et al., 2005). When the ovum, is released by the
ovary, it is swept into the uterine tube by the fimbriae. Once in the uterine tube,
the transportation of the ovum towards the uterus is facilitated by the cilia of the
cells that line the wall of the uterine tube (Strauss & Lessey, 2009). It is in the
uterine tube where the ovum may fuse with a sperm, the male gamete that would
have travelled through the vagina, and continues the journey towards the uterine
cavity where it later implants and develops into a fetus. In the absence of sperm,
the ovum still travels to the uterine cavity but instead of implanting it is passed out
of the body through the vagina along with the lining of the uterus as menstrual flow,
a process which occurs periodically (Jabbour et al., 2006). The following sections
describe the structure of the human uterus in detail, as well as the hormonal control
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of the cyclical release of ova and shedding of the uterine lining.
The Human Uterus
The human uterus is a hollow muscular organ whose main body (uterine cavity)
is surrounded by a wall that consists of three layers; an inner mucous layer called
the endometrium, a layer of smooth muscle called the myometrium, and a thin
outer layer called the serosa (Aguilar & Mitchell, 2010). The dome-shaped top
of the uterus (fundus) sits above the points to which the two uterine tubes are
connected, while the cylindrical-shaped bottom (cervix) is connected to the vagina
(Figure 2.9a).
In the non-pregnant uterus, the endometrium consists of a functional layer and a
basal layer (Figure 2.9b), the former of which contains a compact layer and a spongy
layer that are both built-up and shed periodically. Unlike the functional layer, the
basal layer of the endometrium does not thicken and is shed periodically (Jabbour
et al., 2006; Strauss & Lessey, 2009). The changes in the endometrial layers of
the uterus that are governed by P4 and other hormones, form part of the human
menstrual cycle which is described in Section 2.5.2.
2.5.2 The Menstrual Cycle
During female reproductive years in humans, the uterus periodically prepares for
pregnancy, a process which involves the thickening of the functional layer of the
endometrium. In the absence of a fertilised ovum, implantation does not occur
and the uterine lining is shed. The periodic thickening and shedding of the uterine
lining and the associated ovarian changes are known as the menstrual cycle. As
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Figure 2.9: The female reproductive system. (a) Illustration of the frontal section of the
female reproductive organs showing the ovaries, uterine tubes, uterus, and vagina. (b) Schematic
of the uterine wall showing the layers of the endometrium as well as the myometrium.
2.5. Reproductive Functions of Progesterone
such, the menstrual cycle consists of the ovarian cycle and the uterine cycle, both of
which are under hormonal control. The main hormones involved in the regulation of
the menstrual cycle are gonadotropin releasing hormone (GnRH) which is secreted
by the hypothalamus, follicle stimulating hormone (FSH) and luteinizing hormone
(LH), which are secreted by the pituitary gland, as well as E2, inhibin, and P4,
which are produced in the ovaries (Messinis, 2006; Hall, 2009).
The Ovarian Cycle
The ovarian cycle consists of two phases, one characterised by the growth and mat-
uration of follicles (follicular phase) and another characterised by the development
and degeneration of the ruptured follicle (luteal phase), that are separated by fol-
licular rupture and release of an ovum as illustrated in Figure 2.10.
The oocytes with which females are born, are contained within follicles that are
also immature. During the follicular phase of the ovarian cycle, an increase in
the pulsatile secretion of GnRH stimulates the secretion of FSH, which stimulates
the growth and development of the E2-releasing immature follicles (Pansky, 1982;
Marshall et al., 1993). While one of the stimulated follicles grows at a faster rate
than the others and matures, E2 stimulates the release of LH which results in a
surge of LH that precipitates ovulation, the rupture of a mature follicle and release
of the ovum contained therein.
In the luteal phase, the ruptured follicle is transformed into the corpus luteum which
produces copious amounts of P4, as well as moderate quantities of E2 and inhibin.
Together, these hormones prevent the production and release of FSH and LH thus
enabling P4 to maintain the functional layer of the endometrium in preparation
for implantation. If, however, the released ovum does not fuse with a sperm cell,
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Figure 2.10: Illustration of the 28-day menstrual cycle. (a) Regulation of gonadotropins
by ovarian hormones. Prior to ovulation, E2 exerts both inhibitory and stimulatory effects on the
synthesis of gonadotropins. During the post-ovulatory phase of the menstrual cycle, the ovarian
hormones inhibit the synthesis of gonadotropins. (b) Changes in the concentration of gonadotropins
in the blood during the menstrual cycle. The surge in LH levels, occurring after the spike in E2 levels,
precipitates ovulation. FSH levels are at their peak during ovulation. (c) The ovarian cycle has two
phases, follicular and luteal, that are separated by ovulation. The follicular phase is characterised
by follicle development while the luteal phase is characterised by the formation and degeneration
of the corpus luteum. (d) Changes in the ovarian hormones E2, P4, and inhibin that are associated
with the menstrual cycle. A spike in E2 levels precedes ovulation, while P4 and inhibin levels reach
their peak in the middle of the luteal phase of the ovarian cycle. (e) Phases of the uterine cycle.
Abbreviations: E2: estradiol; FSH: follicle stimulating hormone; GnRH: gonadotropin releasing
hormone; LH: luteinizing hormone; P4: progesterone.
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implantation will not take place, and the corpus luteum degenerates as a result
(Strauss & Williams, 2009).
Uterine Cycle
The uterine cycle consists of three phases as illustrated in Figure 2.10. The first
is the menstrual phase, which is characterised by the break-down of the functional
layer of the endometrium and its elimination from the body through the vagina. This
phase lasts between 3–6 days and occurs approximately every 28 days (Hall, 2009).
The second is the proliferative phase, in which the functional endometrial tissue
regenerates under the influence of the E2 secreted by the growing follicles. Both the
menstrual and the proliferative phases of the uterine cycle occur prior to ovulation.
The third phase of the uterine cycle, known as the secretory phase occurs after ovu-
lation. This phase involves the growth of the spiral arteries and the uterine glands
under the influence of the P4 secreted by the corpus luteum. Glandular secretions
that are favourable for implantation are also produced during this phase (Gellersen
et al., 2007). If fertilisation does not occur, implantation will not take place. As
a result, the corpus luteum degenerates resulting in the decrease of P4 levels and
the break-down of the functional endometrial layer (Strauss & Williams, 2009;
Hall, 2009).
If fertilisation occurs, the fertilised ovum goes through phases of development and
change for approximately 7 days, resulting in the formation of a blastocyst. A
blastocyst consists of an inner cell mass which later develops into the embryo, a
cavity, and an outer layer composed of trophoblast cells. Implantation of the blas-
tocyst occurs on the 8th or 9th day following fertilisation, when the conditions in
the uterus are favourable for implantation. As soon as implantation occurs, the
28
2.5. Reproductive Functions of Progesterone
Decidua	  vera	  
Decidua	  capsularis	  
Decidua	  basalis	  
Uterine	  cavity	  
Myometrium	  
Embryo	  
.	  
Figure 2.11: The decidua. Illustration of the location of the three decidual zones.
trophoblast cells secrete the human chorionic gonadotropin (hCG) hormone which
maintains the corpus luteum. The corpus luteum, therefore, does not degenerate
and continues to secrete E2, inhibin, and P4 until about the 7th week of pregnancy
when the placenta takes over the production of these hormones (Jaffe et al., 1969;
Mesiano, 2009).
Under the influence of P4, the endometrial stromal cells go through morphological
and functional changes known as decidualisation, a process which can occur in the
absence of implantation. The process of decidualisation involves the enlargement of
endometrial stromal cells, accumulation of lipids and glycogen, and transformation
of the stromal cells to a secretory phenotype. While P4 is involved in the decidu-
alisation process, endometrial stromal cells require priming by cAMP prior to P4
action (Gellersen et al., 2007). Mulac-Jericevic (2004) demonstrated that decid-
ualisation is blocked, even when stimulated artificially, in PRAKO mice unlike in
PRBKO mice, suggesting that P4 effects in the decidualisation process are mediated
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by PRA. In addition, Large & DeMayo (2012) observed that during decidualisation,
the expression of PRB was reduced while that of PRA was maintained in epithelial
stromal cells.
During pregnancy, the decidualised endometrium, known as the decidua, has three
different zones that are identified in relation to their location; the basal decidua,
known as decidua basalis, is the site of implantation and is adjacent to the my-
ometrium; decidua capsularis, the decidual layer that encloses the fetal membranes;
and decidua vera, the decidua that is located on the opposite side of the uterus
with respect to the implantation site (Cunningham et al., 2005), as illustrated in
Figure 2.11. The decidua can be considered to be an endocrine organ as it produces
prostaglandins, relaxin, and prolactin which have been implicated in the onset of
parturition, and in addition it enables the exchange of nutrition, waste and other
substances between fetal and maternal tissues (Riddick & Kusmik, 1977; Riddick
et al., 1978; Golander et al., 1978; Bigazzi et al., 1979; Bryant-Greenwood, 1982;
Kredentser et al., 1995; Hirst et al., 1998).
Once pregnancy is established, the uterus remains in a state of relevant quiescence
until term, when the fetus is expelled. The next section outlines the current knowl-
edge relating to the processes leading up to the expulsion of the fetus from the
uterus.
2.6 Parturition
The uterus is quiescent prior to the onset of labour, and is transformed into a
stimulus-responsive organ, which contracts, once stimulated, resulting in the expul-
sion of the fetus through a softening and dilating cervix, at term. The physiological
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process by which the fetus is expelled from the uterus is called parturition. In many
mammals, e.g., rabbits (Hoffman et al., 2009), rats, and mice, parturition is pre-
ceded by a significant reduction in the levels of P4 in the maternal system (Vodstrcil
et al., 2010). In rats, a drop in the levels of circulating P4 coincides with a change
in electrical activity of the uterus (de Paiva & Csapo, 1973; Garfield, 2008), sug-
gesting an important role for P4 during labour. In humans, however, the P4 levels
do not decrease at term or during labour, but the withdrawal of P4 at any stage in
human pregnancy, e.g., by administering the P4 antagonist mifepristone, can initiate
parturition (Chwalisz, 1994; Zakar & Hertelendy, 2007).
2.6.1 Phases of Parturition
There are four phases of parturition (Figure 2.12): Phase 0, is the prelude to parturi-
tion that is characterised by uterine quiescence; Phase 1, involves preparation of the
uterus for labour by activation of the uterus from the quiescent state to a contractile
state; Phase 2, which involves the softening and dilation of the cervix to allow the
fetus, placenta and membranes through the birth canal; and Phase 3, which involves
the restoration of the uterus to the non-pregnant state (Gibb et al., 2006).
Phase 0: Quiescence
For most of pregnancy, the uterus is relaxed and non-responsive to stimulants such
as oxytocin (OT) and prostaglandins (PGs). Uterine quiescence is maintained by
pro-gestational agents such as CRH, P4, prostacyclin (PGI2), relaxin, nitric oxide
(NO), and parathyroid hormone-related peptide (PTHrP).
P4 suppresses the expression of the mRNA encoding the gap junction protein
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Figure 2.12: Phases of parturition. A summary of the hormones involved in uterine quiescence,
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connexin-43, which can be increased by the PR antagonist mifepristone (Petrocelli
& Lye, 1993). In addition, (Garfield et al., 2012) showed that P4 dampens the
electrical activity of the myometrium. PGI2 is synthesised from membrane phos-
pholipids through the action of PLA2, COX enzymes, peroxidase activity, and PGI
synthase (Michal & Schomburg, 2012, p. 310). PGI2 is known to elevate cAMP
through PGI2 receptors (IPs) thus aiding in the relaxation of the uterus (Gibb
et al., 2006). Wikland et al. (1983) observed that PGI2 induced the relaxation of
human myometrium in-vitro, following an initial activation. Fetalvero et al. (2008),
however, showed that the activation of IP lead to an increase in the expression of
CAPs in-vitro, suggesting a dual role for PGI2 in the uterus. Relaxin, which is
structurally similar to insulin, is expressed in the decidua and the placenta (Gibb
et al., 2006). Relaxin stimulates the production of cAMP in the myometrium,
thus suppressing uterine contractility, while regulating cervical ripening (Challis
et al., 2000; Gibb et al., 2006). Endogenous NO is synthesised in the myometrium
as well as in fetal membranes, and has been shown to relax smooth muscle (Gibb
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et al., 2006). PTHrP, whose synthesis in the myometrium is upregulated by P4,
inhibits the increase in the expression of connexin-43 at term (Gibb et al., 2006)
During pregnancy, CRH stimulates the production of DHEA-S by the fetal and ma-
ternal adrenal glands, as well as the production of DHEA by the maternal adrenal
glands. Both DHEA and DHEA-S are precursors in the synthesis of androgens and
estrogens (Cunningham et al., 2005).
Phase 1: Activation
During this phase, the myometrium and the cervix are modified in preparation for
the expulsion of the fetus from the uterus. The softening, thinning, and dilation of
the cervix, collectively known as cervical ripening, is also influenced by the degrada-
tion of collagen fibres by metalloproteases, which lead to changes in the structure of
the cervix. In addition, the actions of prostaglandins, i.e., prostaglandin E2 (PGE2)
and prostaglandin F2 (PGF2), also influence cervical ripening (Osman et al., 2003).
While the cervix is ripening, the uterus is transformed from a non-responsive organ
to a contracting and powerful organ. An increase in the expression of CAPs such
as gap junction proteins, ion channels, uterotonin receptors such as OT receptors
(OTRs) and PG receptors (PGRs), and enzymes, is associated with the initiation
of labor (Fuchs et al., 1984).
Phase 2: Labour
Labour is characterised by regular uterine contractions, cervical ripening, and cer-
vical dilatation. Labour has three stages, the first of which is characterised by
rhythmic contractions, uterine transformation, and cervical changes. During the
second stage of labour, there are changes in the pelvic floor. In addition, the fetus
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begins to descend. The third stage of labour is the one in which the fetal membranes
and placenta are delivered (Gibb et al., 2006).
Phase 3: Involution
The last phase of parturition commences after the delivery of the placenta and fetal
membranes. During this phase, myometrial contractions are maintained under the
influence of OT facilitating the recovery and restoration of the uterus to its former
state. The cervix also reverts to the closed and static state (Gibb et al., 2006).
While there are numerous changes that occur in the cervix in preparation for and
during parturition, the following sections focus on myometrial changes that occur
in Phases 1 and 2 of parturition. Cervical changes occurring at term, and pre-term,
are detailed in the review conducted by Mahendroo (2012).
2.6.2 Activation of the Myometrium
The myometrium is mostly muscular and is composed of spindle-shaped cells that
are tapered at both ends, known as smooth muscle cells (SMCs), as illustrated in
Figure 2.13a. SMCs contain a single cylindrical nucleus which is located in the
centre of the cell. The SMC cytoplasm contains an abundance of mitochondria as
well as well as the sarcoplasmic reticulum, the latter of which store calcium ions
(Ca2+) (Jain et al., 2000). In addition, there are numerous thick, intermediate,
and thin filaments that are connected to α-actin dense bodies across the cytoplasm.
Thick filaments are composed of the protein myosin, while intermediate filaments
are made from intermediate filament proteins such as vimentin (Tang, 2008), and
the proteins actin, tropomyosin and caldesmon are the main constituents of thin
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filaments in SMCs (Marston & Smith, 1985). These filaments form a “criss-cross”
pattern in the cytoplasm as shown in Figure 2.13a, and are the basis of the smooth
muscle contractile machinery (Smith, 2007). When contracting, the myosin fila-
ments slide over the thin filaments causing the SMCs to become short and wide.
The nucleus of the contracted SMC becomes spiral-shaped as shown in Figure 2.13b
(Thiriet, 2013).
Gap Junctions
During pregnancy, adjacent SMCs are joined by small channels, as well as connective
tissue, forming sheets or bundles of muscle that contract in unison. The small
channels, which are formed when two connexons (Figure 2.14), each composed of six
gap junction proteins (connexin proteins), are joined allowing the flow of ions, small
molecules, and electrical signals between neighbouring cells (Hille, 2001; Alberts
et al., 2002). There are approximately 20 different types of connexin proteins
deriving their names from their molecular weights, e.g., connexin-26 (Cx-26) is a
26-kDa polypeptide, while connexin-45 (Cx-45) is a 45-kDa polypeptide (Alberts
et al., 2002).
The role of gap junctions in parturition was first documented by Garfield et al.
(1978), and since then, the connexin proteins Cx-26, connexin-40 (Cx-40), Cx-43,
and connexin-45 (Cx-45) have been identified in the myometrium (Ou et al., 1997;
Kidder & Winterhager, 2009; Sheldon et al., 2014). Cx-26 expression levels de-
cline sharply at term prior to the onset of labour, while expression of Cx-43 in the
myometrium is inhibited by P4 and upregulated by E2 expression (Ou et al., 1997;
Kidder & Winterhager, 2009; Terzidou, 2007). The importance of Cx-43 pro-
teins in the electrical coupling of SMCs during labour was demonstrated by Do¨ring
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Figure 2.13: Smooth muscle cells. (a)Relaxed and (b) contracted smooth muscle cells. The
contracted smooth muscle cells are thicker and shorter than relaxed smooth muscle cells. Key: →←
direction of movement of thick filaments.
et al. (2006), whereby mutant mice generated through the specific deletion of the
Cx-43 gene coding region in SMCs exhibited prolonged labour. Cx-43 proteins are
upregulated at term and during labour, thus increasing the connectivity between
SMCs, and promoting synchronised contractions (Garfield et al., 1978; Garfield &
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Figure 2.14: Coupling of adjacent smooth muscle cells through connexons. Each cell
contributes a connexon to form a channel through which ions and small molecules are flow. Abbre-
viations: SMC A: smooth muscle cell A; SMC B: smooth muscle cell B.
Maner, 2007). Cx-45 proteins are expressed in both pregnant and non-pregnant my-
ometrium, but are down-regulated prior to term (Albrecht et al., 1996). Albrecht
et al. (1996) hypothesised that the expression patterns of Cx-43 and Cx-45 were
important in the electrical coupling of SMCs during labour. Using a mathematical
model, Sheldon et al. (2014) showed that the down-regulation of Cx-45 allows for
SMC-coupling which is favourable for synchronised myometrium contractions. The
role of Cx-40 during parturition is not defined, but Cx-40 proteins are expressed in
the myometrium at term (Kidder & Winterhager, 2009).
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2.6.3 Uterine Contractions
The protein calmodulin binds Ca2+ in the cytosol and induces conformational
changes that enable the Ca2+-calmodulin complex to activate myosin light-chain ki-
nase enzymes. The myosin light-chain kinase enzymes phosphorylate myosin, thus
activating myosin and enabling its interaction with actin, which results in SMC
contractions (Vrachnis et al., 2011; Blackburn, 2014).
There are various pathways through which the entry of Ca2+ ions into the cytoplasm
is mediated; one such pathway is through OT signalling (Michal & Schomburg, 2012,
p. 292). The effects of OT are mediated by the OTR, a seven-transmembrane
receptor. Like other seven-transmembrane receptors, OTR is located in the plasma
membrane with both intra- and extracellular regions. The extracellular region of
OTR contains the OT-binding site while its intracellular region is bound to a G-
protein, which is composed of three subunits when inactive; Gαq/11, Gβ, and Gγ
(Gimpl & Fahrenholz, 2001).
When OT binds OTR, it induces conformational changes in the receptor that re-
sult in the activation of the receptor. Once the receptor is activated, the G-protein
separates into its constituent subunits. The Gαq/11 subunit binds to the enzyme
phospholipase-C (PLC), activating the enzyme which goes on to hydrolyse a com-
ponent of the cell membrane called phosphatidylinositol 4,5-bisphosphate (PIP2).
The hydrolysis of PIP2 results in the formation of inositol 1,4,5-trisphosphate (IP3)
and diacyl-glycerol (DAG), the latter of which aids in the activation of protein ki-
nase C (PKC) and the mitogen-activated protein kinases (MAPK) cascade leading
to the synthesis of prostaglandins. IP3, on the other hand, binds to the IP3 re-
ceptors located on the sarcoplasmic reticulum, opening Ca2+ channels thus releas-
ing Ca2+ ions from intracellular calcium stores. Intracellular Ca2+ binds calmod-
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ulin resulting in smooth muscle contractions as illustrated in Figure 2.15 (Vrachnis
et al., 2011).
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While OT induces the release of Ca2+ from intracellular stores, it also activates
plasma membrane voltage-gated calcium channels, through which most of the Ca2+
involved in smooth muscle contraction enters the cytoplasm. The extracellular Ca2+
binds to calmodulin, resulting in the activation of myosin and smooth muscle con-
tractions (Garfield & Maner, 2007). Another mechanism by which Ca2+ can enter
the cytoplasm of SMCs is through channels that are sensitive to changes in the
electrical properties of the SMCs. The depolarisation and repolarisation of the
membrane through the movement of ions into and out of SMCs, generates bursts of
action potentials that have been shown to influence the contractility of the uterus
during labour (Laforet et al., 2011; Young, 2007; Lammers et al., 2008).
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The effects of P4, and P4 withdrawal, on the mRNA transcripts encoding the pro-
teins involved in the activation and contraction of SMCs will be analysed in Chap-
ter 8. The next chapter in this part of the thesis gives an overview of the rat model
whose study is documented in this thesis.
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Chapter 3
The Female Rat
The laboratory rat (Rattus norvegicus) has been used in experimental studies since
the early 1900s (Sengupta, 2013). A lot of knowledge has since been gained through
the use of rats as model animals (Hedrich, 2000). The work presented in thesis was
conducted on tissues obtained from pregnant Spague-Dawley rats. As such, in this
chapter, the anatomy and characteristics of the female rat reproductive system are
described, as well as compared and contrasted with the human female reproductive
system. In addition, the rat uterine and ovarian cycles are also compared with those
of humans. The process of parturition in the rat is subsequently described, and the
chapter concludes by summarising the aims of this thesis.
3.1 The Female Rat Reproductive System
The rat reproductive system contains all the constituent organs as those of the
human reproductive system, i.e., the ovary, uterine tube, uterus, cervix, and vagina.
The anatomy of the female reproductive system in the rat, however, differs from
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the human reproductive system in that the rat uterus is duplex, i.e., it is composed
of two separate horns (Figure 3.1a). Each uterine horn is connected to an ovary,
via a uterine tube, and has its own cervix. The uterine horns are joined at the
vagina, forming a “Y-shape” (Koma´rek et al., 2000). Similar to human uterine
walls, the walls of rat uterine horns consist of endometrial and serosal layers that
sandwich the uterine muscle, but unlike human myometrium, the rat myometrial
layer is composed of two distinct layers that are separated by a vascular layer as
illustrated in Figure 3.1b. The inner layer of the myometrium, i.e., the one adjacent
to the endometrium, is composed of SMC fibers that envelope the uterine horn in a
circular fashion. The outer layer of the myometrium, which is sandwiched between
the vascular layer and the serosa, contains SMC fibers that are arranged in “parallel”
with the uterine horn (Jain et al., 2000). The inner layer is also called the circular
myometrium, while the outer layer is called the longitudinal myometrium.
Unlike humans who menstruate, the uterine lining of the rat uterus is not shed
and passed out of the body. Instead, the endometrial layer of the rat uterus is
periodically transformed. The periodic changes in the endometrium, as well as
changes that occur in the ovaries and vagina, are part of the rat estrus cycle (West-
wood, 2008).
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Figure 3.1: The female reproductive system in rats. (a) Illustration of the duplex uterus of
the rat showing each horn with its respective ovary, uterine tube, and cervix, as well as the vagina.
(b) Schematic of the walls of the uterine horns showing the distinct layers of the myometrium that
are separated by a vascular layer, and sandwiched between the endometrium and serosa.
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Premature oocytes in female rats, as in humans, periodically develop and grow until
ovulation after which they are transformed into corpora lutea. Puberty in the female
rat is marked by the opening of the vagina 7 weeks after birth, and the ensuing regu-
lar estrus cycles (Ojeda & Skinner, 2006; Sengupta, 2013). The estrus cycle in rats,
which is non-seasonal, lasts between four to five days, and can be divided into four
stages; proestrus, estrus, metestrus, and diestrus (Mandl, 1951; Freeman, 2006).
The main hormones that regulate the rat estrus cycle are: GnRH, which is secreted
by the hypothalamus and stimulates the release of gonadotropins by the pituitary
gland; the gonadotropins LH and FSH secreted by the pituitary gland; the ovarian
hormones E2, P4 and inhibin, which are synthesised in the ovaries; and prolactin,
which is secreted by the pituitary gland following mating (Freeman, 2006).
3.2.1 Ovarian Cycle
During proestrus, E2-secreting follicles grow under the influence of FSH, increasing
the secretion of E2 (Fortune, 1994; Maeda et al., 2000). The resulting surge in
E2 stimulates the release of LH by the pituitary gland, which in turn stimulates
ovulation during the estrus stage of the cycle. When in estrus, rats are sexually
receptive and mating can occur. Within 24-48 hours of the LH surge, ovulation
occurs and the follicles are transformed into corpora lutea. The corpora lutea grow
during metestrus and reach a maximum size two to four hours post-ovulation, while
secreting both P4 and its analog 20α-hydroxyprogesterone, which is a non-active
form of P4, as well as inhibin. In diestrus, the corpora lutea continue to secrete
high quantities of P4. It is during this stage of the estrus cycle that FSH levels
begin to increase in the absence of pregnancy, and stimulate the growth of a new
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set of follicles, which will occur in the proestrus stage of the ensuing cycle (Free-
man, 2006; Westwood, 2008). It is worth noting that while corpora lutea reduce
in size in subsequent stages of the estrus cycle and become “non-functional”, their
functionality can be rescued in pseudopregnancy and in pregnancy (Freeman, 2006).
Pseudopregnancy and pregnancy will be described in Section 3.3.1.
While there are similarities in the growth and maturation of follicles prior to ovu-
lation between humans and rats, the number of ova that are released at ovulation,
as well as the functionality of the corpora lutea differ (see Section 2.5.2). Humans
normally release one ovum in each menstrual cycle, while rats, being a polytocous
species, release several ova in each estrus cycle. Another difference between the
ovarian cycles of these species is the method by which the released ova travel to
the uterine cavity. Ova in humans are released from the ovaries and swept into
the uterine tubes by the fimbriae of the uterine tubes (Section 2.5.2), while rat ova
are released directly into the uterine tubes that are connected to the ovaries. Once
in the tubes, the ova are directed towards the uterine horns, suspended in uterine
fluid, by uterine contractions, which create waves in the fluid that move towards the
uterine horns (Freeman, 2006).
3.2.2 Changes in the Uterus and Vagina
In proestrus, the surge in E2 levels precipitates the proliferation of vaginal epithelial
cells which appear rounded and nucleated in vaginal smears. At the same time,
the endometrium and the uterine glands begin to grow, also under the influence
of E2 (Maeda et al., 2000; Westwood, 2008). During estrus, vaginal epithelial
cells are transformed from cuboidal to stratified squamous cells without nuclei, and
the uterine horns are filled with fluid, movement of which is generated by uterine
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contractions and aids in the transportation of sperm and ova into the uterine horns.
Meanwhile, the endometrial lining begins to degenerate and the glands begin to
reduce in size. In metestrus, the lining of the endometrium continues to degenerate,
while the amount of fluid in the uterine horns and the uterine contractions decrease.
During this stage of the estrus cycle, vaginal smears have leukocytes as well as
nucleated and non-nucleated cells. In diestrus, the endometrial layer is reduced in
size, and the uterine contractions cease (Koma´rek et al., 2000; Freeman, 2006;
Westwood, 2008).
3.3 Pregnancy and Parturition
The reproductive differences between rats and humans are not limited to the struc-
ture of their reproductive organs and cycles (see Section 3.1 and Section 3.2), but
also extend to pregnancy and parturition. Rats carry multiple offspring and have
short gestations of ∼ 22 days, while humans usually have singleton pregnancies of
∼ 39–40 weeks (Sengupta, 2013; Mesiano, 2009). Apart from the number of off-
spring, pregnancy in these two species is maintained by different endocrine organs.
Pregnancy in humans is maintained by P4 synthesised in the corpus luteum during
the first seven weeks of pregnancy, a role which is taken over by the placenta from
week 12 to term (Mesiano, 2009). While in the rat, despite the development of
several P4-secreting placentae, pregnancy is maintained by the corpora lutea, such
that the removal of the ovaries results in labour and delivery of the pups (Maeda
et al., 2000).
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3.3.1 Pregnancy
If mating occurs at estrus, the cervix is stimulated and it signals for the release of
prolactin by the pituitary gland. The secretion of prolactin inhibits the conversion of
P4 to 20α-hydroxyprogesterone, thus maintaining the lining of the uterus through
the secretion of high levels of P4 by the corpora lutea (Freeman, 2006). The
rescuing and maintenance of luteal function in the absence of pregnancy is called
pseudopregnancy, a state that usually persists for ∼ 11 days, before luteolysis occurs
(Maeda et al., 2000; Stouffer, 2006).
If, however, the mating at estrus is fertile, fertilisation occurs and blastocysts im-
plant ∼ 5 days after mating. Decidualisation in the rat is confined to the site of
implantation, unlike in humans where the whole endometrium is decidualised, sug-
gesting that the implanting embryos are involved in triggering the decidual reaction
in rats (Maeda et al., 2000). While the placentae in rats secrete P4, the major
source of the P4 that maintains pregnancy in rats is synthesised by the corpora
lutea, which are sustained during the first half of gestation by prolactin and by
placental lactogens during the latter half of gestation. In addition, E2 is also in-
volved in maintaining the synthesis of steroid hormones by the corpora lutea (Maeda
et al., 2000).
3.3.2 Parturition
Parturition in the rat, and mouse, is preceded by a sharp decline in the levels of
circulating P4, a phenomenon that is not observed in human parturition. In fact,
labour in humans occurs in the presence of high, and sometimes increasing, levels
of P4 (Zakar & Hertelendy, 2007). The systemic withdrawal of P4 that precedes
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Figure 3.2: Synthesis of PGF2α. PLA2 converts membrane phospholipids to arachidonic acid,
which is in turn converted to PGG2 by COX enzymes. Peroxide activity results in the formation of
PGH2, an unstable PG that is immediately converted to PGF2α by PGF synthase. Abbreviations:
PLA2: phospholipase A2; COX: cyclooxygenase; PGH2: prostaglandin H2; PGF: prostaglandin F;
PGF2α: prostaglandin F2α.
labour in rats, and mice, is brought about by the luteolytic effects of prostaglandin
(PG) F2α (PGF2α). PGF2α is synthesised from arachidonic acid, which is derived
from membrane phospholipids, through the action of phospholipase A2 (PLA2),
cyclooxygenase (COX) enzymes, peroxidase, and prostaglandin F synthase as illus-
trated in Figure 3.2 (Michal & Schomburg, 2012, p. 310). There are two types
of COX enzymes: one which is normally expressed in various tissues of the body,
COX-1; and another COX-2 whose expression can be induced (Vane et al., 1998).
The effects of PGF2α are mediated by the PGF2α receptor (FP), a G-protein cou-
pled receptor. Through FPs on corpora lutea, PGF2α induces luteolysis resulting in
the systemic withdrawal of P4 and the onset of labour (Ratajczak & Muglia, 2008;
Sugimoto et al., 2015). PGF2α − FP signalling has also been shown to stimulate
contractility through the increase of intracellular Ca2+ (Funk et al., 2009).
The role of PGF2α in the initiation of labour in mice was confirmed in studies of
genetically altered mice; Sugimoto et al. (1997) demonstrated that labour could not
be initiated in FP knock-out mice, FP-/-, as luteolysis and P4 withdrawal did not
occur. In addition to the maintenance of high circulating levels of P4 in FP-/- mice,
OTR expression was not upregulated in uterine tissues as is consistent with the onset
of labour. In mice lacking PLA2, and mice lacking the constitutive COX-1 enzyme,
P4 levels remained elevated and labour was delayed, suggesting that PLA2, COX-1,
PGF2α, and FP are required for luteolysis and the systemic withdrawal of P4 in mice
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at term (Ratajczak & Muglia, 2008; Funk et al., 2009; Sugimoto et al., 2015).
Condon et al. (2004) proposed that the signal for the initiation of parturition at term
in mice originates from the fetus through the augmented production of surfactant
protein A (SP-A) from maturing pup lungs. SP-A is a component of pulmonary
surfactant, which is necessary for breathing following birth as it reduces surface
tension at the interface between air and water in lung alveoli (Khubchandani &
Snyder, 2001). SP-A interacts with amniotic fluid macrophage Toll-like receptors
culminating in their activation and migration into the uterus, thus increasing the
production of interleukin-1β (IL-1β), as well as activating a nuclear factor (NF)-
κB. The increase in IL-1β production and activation of NF-κB upregulates the
expression of PLA2, and induces the expression of the COX-2 enzyme leading to the
increased production of PGF2α, luteolysis, and the withdrawal of progesterone. In
a subsequent study, Montalbano et al. (2013) showed that SP-A-deficient, SP-A-/-,
mice delivered at term during their first pregnancies. In subsequent pregnancies,
however, the onset of labour was delayed and was accompanied by a decrease in
the expression of IL-1β as well as other pro-inflammatory markers, suggesting that
initiation of the parturition cascade by fetal SP-A may not occur in first pregnancies,
but in subsequent ones. Recently, using genetically altered mice, Gao et al. (2015)
showed that mice lacking both SRC-1 and SRC-2, coactivators involved in regulating
the transcription of the gene that encodes SP-A, had delayed parturition as a result
of the inability of the pups to produce SP-A. Gao et al. (2015) further demonstrated
that wild-type female mice that were mated with SRC-1/SRC-2-deficient males had
delayed luteolysis and elevated levels of circulating P4 at term, suggesting that
fetal signals to initiate parturition require mature lungs that can produce adequate
amounts of surfactant lipoproteins such as SP-A.
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3.4 Aims
The main aim of the present thesis is to identify and analyse the effects of proges-
terone and progesterone withdrawal on the transcriptome of the rat uterus. The
work presented in this thesis follows on from the work conducted by Garfield et al.
(2012) who carried out myometrial activity studies in which recordings of the electri-
cal activity of the myometrium were made using electromyography (EMG), following
treatment with P4. A catheter was implanted surgically into the myometrium of a
pregnant rat, together with fine-wire electrodes that enabled the recording of sin-
gle muscle activity with little cross-talk from other muscles within the body. The
catheter was used to deliver P4 and carrier oils directly onto the myometrial tis-
sue. Following treatment with P4, the electrical activity of the myometrium was
dampened in comparison to vehicle-treated myometrium. The effects of P4 on the
electrical properties of the uterus were observed 24 to 48 hours after administration
of the hormone, a time-lag which is consistent with genomic signalling. The delay
in response to treatment with P4 indicated that the effects of the hormone on the
rat uterus were too slow to be non-genomic.
Laser Capture Microdissection (LCM) a technique that enables the isolation of
single cells or homogeneous tissue from samples of heterogeneous tissue (Simone
et al., 1998), as well as RNA Sequencing (RNAseq) will be employed in this thesis.
LCM will, for the first time, enable the distinct determination of the spatio-temporal
expression of genes within uterine tissues, hence the identification of tissue-specific
transcriptomic changes that occur during the transition of the uterus from a quies-
cence to a contractile state.
Given the responsiveness of the decidua to steroid hormones, there is reason to
believe that the switch may be occurring in the basal decidua. Analysis of the tran-
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scriptome of the decidua may help to corroborate or disprove this hypothesis. The
identification of differences in response to P4 withdrawal at the early time-point be-
tween Mifepristone-treated animals and control animals will provide information on
the molecular changes that occur in pre-term labour. While comparison of natural
labour and mifepristone-induced labour may provide insights into underlying differ-
ences between pre-term and term labour. In addition, the analysis of the changes in
the expression of mRNA transcripts will allow a comparison of these data to data
obtained from similar studies in humans.
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Chapter 4
Materials
This chapter details the materials that were used in the study.
4.1 Animals
Sprague-Dawley rats (Charles-River Laboratories, Wilmington, MA)
4.2 Chemicals and Reagents
Ethanol (Fisher Scientific, Loughborough, UK )
Xylene (Fisher Scientific, Loughborough, UK )
Haematoxylin (VWR International, Lutterworth, UK )
O.C.T. Compound (Fisher Scientific, Loughborough, UK )
Rapid Coolant (Leica Biosystems, Milton Keynes, UK )
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4.3. Anaesthetic
BLOXALLTM Blocking Solution (Vector Laboratories, Peterborough, UK )
Haematoxylin (Vector Laboratories, Peterborough, UK )
10% Neutral Buffered Formalin (Genta Medical, York, UK )
TaqMan® Gene Expression Master Mix (Fisher Scientific, Loughborough,
UK )
4.3 Anaesthetic
Xylazine (Burns Veterinary Supply Inc, Rockville Centre, NY )
Ketamine Hydrochlochride (Fort Dodge Laboratories Inc, Fort Dodge, IA)
4.4 PR Antagonists and Agonists
Crystalline Progesterone (Sigma Chemical Company, St. Louis, MO)
Mifepristone (RU486) (Sigma Chemical Company, St. Louis, MO)
Sesame Seed Carrier Oil (Sigma Chemical Company, St. Louis, MO)
4.5 Kits
4.5.1 LCM Staining Kit (Fisher Scientific, Loughborough, UK )
Acridine Orange Stain
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4.5. Kits
Cresyl Violet Stain
Slide Chambers
Dehydration Beads
RNaseZap® Solution
Bottles
Barrier Pen
Nuclease-free Water
4.5.2 RNAqueous®-Micro Kit (Fisher Scientific, Loughborough,
UK )
Micro Filter Cartridge Assembly
Micro Elution Tubes
Wash Solution 1 Concentrate
Wash Solution 2/3 Concentrate
Lysis Solution
LCM Additive
DNase (2 U/µl)
10× DNase I Buffer
DNase Inactivation Reagent
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4.5. Kits
Elution Solution
4.5.3 RNase-Free DNase I Set (Omega Bio-Tek)
OBI DNase I Digestion Buffer
RNase-free DNase I
4.5.4 Agilent RNA 6000 Pico Kit (Agilent Technologies, Stockport,
UK )
RNA 6000 Pico Chips
Electrode Cleaners
RNA 6000 Pico Dye Concentrate
RNA 6000 Pico Marker
RNA 6000 Pico Conditioning Solution
RNA 6000 Pico Gel Matrix
RNA 6000 Pico Ladder
Spin Filters
Safe-Lock Eppendorf Tubes PCR clean (DNase/RNase free) for gel-dye mix
Syringe
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4.5. Kits
4.5.5 Ovation® RNA-Seq System V2 (NuGEN Technologies, Leek,
The Netherlands)
First Strand cDNA Reagents
First Strand Primer Mix
First Strand Buffer Mix
First Strand Enzyme Mix
Second Strand cDNA Reagents
Second Strand Buffer Mix
Second Strand Enzyme Mix
SPIA® Amplification Reagents
SPIA Primer Mix
SPIA Buffer Mix
SPIA Enzyme Mix
Nuclease-free Water
Agencourt RNAClean XP Beads
4.5.6 Ovation® Ultralow DR Multiplex Systems 1–8 (NuGEN Tech-
nologies, The Netherlands, The Netherlands)
End Repair Buffer Mix
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4.5. Kits
End Repair Enzyme Mix
End Repair Enhancer
Ligation Buffer Mix
Ligation Adaptor Mix (×8 different sequences)
Ligation Enzyme Mix
Amplification Buffer Mix
Amplification Primer Mix
Amplification Enzyme Mix
DMSO
Nuclease-free Water
Agencourt RNAClean XP Beads
4.5.7 DAB Substrate Kit for Peroxidase (Vector Laboratories, Pe-
terborough, UK )
Buffer Stock Solution
DAB Stock Solution
Hydrogen Peroxide Stock Solution
Nickel Solution
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4.6. Primary Antibodies
4.5.8 ImmPRESS® Reagent Kit (Vector Laboratories, Peterbor-
ough, UK )
ImmPRESS® Anti-Rabbit Ig Reagent
Normal Horse Serum
4.5.9 High-Capacity cDNA Reverse Transcription Kit (Fisher Sci-
entific, Loughborough, UK )
10× RT Buffer
10× RT Random Buffers
25× dNTP Mix
MultiScribeTM Reverse Transcriptase
4.6 Primary Antibodies
Polyclonal Antibody to Thyrotropin-releasing Hormone (Acris Antibodies, Her-
ford, Germany)
Polyclonal Antibody to Tenascin N (Sigma Life Science, Dorset, UK )
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4.7. TaqMan® Gene Expression Assays (Fisher Scientific, Loughborough, UK)
4.7 TaqMan® Gene Expression Assays (Fisher Scien-
tific, Loughborough, UK)
Gene Symbol (Assay ID) with FAM Reporter and MGB-NFQ Quencher
Actb (Rn00667869 m1 )
Gja1 (Rn01433957 m1 )
Gja7 (Rn01750705 m1 )
Oxt (Rn00564446 g1 )
Oxtr (Rn00563503 m1 )
Ptgs1 (Rn00566881 m1 )
Ptgs2 (Rn01483828 m1 )
4.8 Equipment and Accessories
Microscope Slides (VWR International, Lutterworth, UK )
Cryomolds (VWR International, Lutterworth, UK )
Dessicator (VWR International, Lutterworth, UK )
Desiccant (VWR International, Lutterworth, UK )
Disposable Microtome Blades (Feather Safety Razor Co. Ltd)
Membrane Slides (Molecular Machines and Industries, Eching, Germany)
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4.8. Equipment and Accessories
Isolation Caps with Diffuser (Molecular Machines and Industries, Eching, Ger-
many)
BioAnalyzer (Agilent Technologies, Stockport, UK )
LCM Workstation (Molecular Machines and Industries, Eching, Germany)
7500 Fast Real-Time PCR System (Fisher Scientific, Loughborough, UK )
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Chapter 5
Experimental Methods
5.1 Animals
Twenty timed-pregnant Sprague-Dawley rats (Supplementary Table B.1), with day
1 of pregnancy being the point in time at which a sperm plug was observed, were
transferred to the animal care facilities on gestational day (GD) 17, where they
were housed separately under constant 12-hour light-dark cycles, with free access to
food and water. The rats were treated, by subcutaneous injection, with either 4 mg
progesterone (P4), 3 mg mifepristone (RU486), or the vehicle (sesame seed oil), on
GD19. Control pregnant rats delivered spontaneously on GD22. The animals were
allocated at random to the treatment groups as follows:
1. Three vehicle-treated (control) rats, from which tissues were collected 6 hrs
post treatment, i.e., on GD19+6hrs;
2. Three mifepristone-treated rats whose tissues were harvested on GD19+6hrs;
3. Three control rats whose tissues were collected on GD20;
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4. Three mifepristone-treated rats whose tissues were harvested on GD20;
5. Three control rats that had tissues collected on GD22, before going into labour;
6. Two control rats that had tissues collected on GD22, during labour, i.e, after
the delivery of one pup;
7. Three rats that were treated daily with P4 from GD19 to GD22, and samples
harvested on GD22. Animals in this group will not deliver even if they are
left to get to the 25th day of gestation.
The animals were anaesthetised by an intra-peritoneal injection consisting of a com-
bination of Xylazine and Ketamine hydrochloride, then whole uterine horns with the
fetuses intact were flash-frozen in liquid nitrogen and then stored at −80◦C until
they were shipped to the UK on dry ice. On arrival in the UK, the samples were
checked visually to make sure that they were still frozen and then stored at −80◦C,
as shown in Supplementary Figure B.1. Following visual assessment, the uterine
horns were catalogued and weighed (Supplementary Table B.2).
5.2 RNA Isolation From 5 g Tissue Sections
Pieces of tissue approximately 5 g in weight were cut from each of the uterine samples
using a blade that had been cleaned with 100% ethanol and RNaseZap®. The 5 g
pieces of tissue were wrapped in RNaseZap®-treated foil paper and smashed with
a mallet while on the bench. The pieces of foil paper were placed in liquid nitrogen
to keep the tissue frozen. The smashed pieces of tissue were placed in 50 ml Falcon
tubes. An aliquot of 1 ml RNA-Stat60 was added to each tube and the tubes were
placed on dry ice. The samples were thawed and homogenised using a LabGen® 7
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Series Homogeniser, then transferred to 1.5 ml Eppendorf tubes and placed on dry
ice.
After thawing, 200 µl of chloroform was added to each of the homogenates and
vortexed for 30 s. The mixtures were placed on dry ice for 20 min then thawed
and centrifuged for 30 min, separating the mixtures into layers. The upper aqueous
layers were transferred into clean tubes to which 200 µl of isopropanol was added.
The tubes were left at room temperature (∼ 20◦C) for 10 min, then centrifuged
for 15 min. The supernatants were removed from the tubes using a pipette. The
RNA pellets were washed in 1 ml of 75% ethanol and centrifuged for 15 min. The
supernatants were removed and the pellets were air dried under the flow hood for
15 min. The pellets were each dissolved in 85 µl of nuclease-free water and placed
on dry ice.
DNA digestion was performed by adding 10 µl of RDD Buffer and 5 µl of DNase I,
from the Qiagen® RNase-Free DNase Set, to each of the RNA samples. The
Qiagen® RNeasy® Mini-Kit was used to cleanup the RNA. All centrifugation steps
were performed at 4◦C at 13,000 g.
RNA was eluted in nuclease-free water and RNA quantitation and quality checks
were performed using the Thermo Scientific NanoDrop® 1000 Spectrophotometer
and the Agilent® RNA 6000 Nano chip on The Agilent® 2100 Bioanalyzer, respec-
tively. The quantitation and quality check results are summarised in Supplementary
Table B.3 and Supplementary Figure B.2, respectively. RNA was then stored at
−80◦C.
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5.3 Tissue Preparation for Sectioning
The uterine horns were removed from storage (−80◦C) and placed on dry ice. Metal
specimen stages were placed on dry ice to cool. Once cooled, Thermo Scientific®
Shandon® Cryomatrix OCT embedding compound was applied to the metal spec-
imen stages and allowed to cool but not freeze. Sections of the uterine horns con-
taining a single pup were broken off from the main tissue samples and pressed
onto individual metal specimen stages. OCT was applied onto the samples until
each sample was completely covered in OCT. The samples were sprayed with Leica
Microsystems® Frostbite® to freeze the OCT quickly and were stored on dry ice
ready for sectioning.
5.3.1 Tissue Sectioning
The cryostat was cooled to −30◦C. The microtome blade holder and anti-roll glass
were cleaned with 100% ethanol each time a new sample was sectioned. The brushes
for use during sectioning were washed in 100% ethanol followed by RNaseZap®.
OCT-embedded samples were then individually removed from the dry ice and placed
in the cryostat and allowed to equilibrate to the temperature of the cryostat for
10 min. A new blade was put on the microtome before sectioning each sample.
Sections of 8 µm in thickness were cut and each section was adhered to a membrane
slide (Molecular Machines & Industries). Staining was performed immediately after
adhesion of tissue sections onto slides.
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5.3.2 Staining
Staining was performed using a 7:3 ratio mix of ethanolic solutions of Cresyl Violet
(CV) nuclear stain and Eosin Yellow (EY) cytoplasmic stain. The staining solutions
were mixed just prior to staining as described by Cle´ment-Ziza et al. (2008). The
membrane slides with adhered tissue were placed in 95% ethanol for 30 s to fix
the tissue onto the slides. Excess ethanol was drained off by tapping the slides
on absorbent paper. The Ambion® Barrier® Pen was used to mark the areas
around the tissue sections so as to keep the dye on the tissue. 100 µl of 7:3 CV-EY
stain solution were placed on each of the tissue sections and allowed to stain for
1 min in the flow hood. Excess stain was tapped off the slides and the slides were
placed in a fresh solution of 95% ethanol for 10 s to destain the tissue. The slides
were transferred to another 95% ethanol solution for a further 10 s. The slides were
transferred into 100% ethanol to dehydrate for 10 s. The slides were then transferred
into a chamber containing xylene and were dehydrated for a further 5 min. The slides
were desiccated for 5 min under vacuum. New wash and dehydration solutions were
used for each sample to ensure that slides of sections from the same sample were
washed and dehydrated in the same solutions. Following desiccation, laser capture
microdissection (LCM) was performed immediately.
5.4 Laser Capture Microdissection
LCM was developed by the National Institutes of Health to aid the isolation and
analysis of homogeneous cells from heterogeneous tumours (Simone et al., 1998).
LCM involves the use of an infrared laser beam to isolate cells of interest from homo-
geneous tissue samples that are adhered to membrane slides. The cells that are cut
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Figure 5.1: Laser-capture microdissection (LCM). Cutting: The collection tube is lowered
and the surface of the adhesive cap connects with the membrane. A laser beam is used to cut the
tissue of interest (shown by the red dotted lines). Capturing: After cutting, the collection tube is
lifted together with the cut homogeneous tissue. The cap may be closed and the captured tissue
can be used for analysis.
out by the laser beam are then ‘captured’ by the adhesive lid of a specially designed
collection tube as illustrated in Figure 5.1 (Murray, 2008). The LCM components
of the work presented in this thesis were performed using the mmiCellCut® laser
microdissection system as described below.
A glass slide cleaned with RNaseZap® was placed on the flat side of each membrane
slide sandwiching the tissue sections. Decidual and myometrial cells were obtained
separately, while avoiding blood vessels, glands, and other tissue. Microdissected
tissue sections were collected using the 500 µl mmi-Isolation® tubes with adhesive
lid and diffuser. Collected tissue sections were immersed in a lysis solution and
stored at −80◦C before RNA isolation. Acquisition time was kept below 30 min so
as to minimise the degradation of the RNA within the tissue.
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5.5 RNA Isolation from LCM Tissue Sections
After LCM, 50 µl of extraction buffer were pipetted into the mmi-Isolation® tubes.
The tubes were then inverted to ensure that the LCM tissues were completely cov-
ered by the extraction buffer. The tubes were vortexed briefly to dislodge the LCM
tissues from the cap and then stored at −80◦C. The lysates were thawed at room
temperature, then incubated for 30 min at 42◦C, followed by centrifugation at 800×g
for 2 min. A 50 µl aliquot of 70% ethanol was added to each of the tubes and mixed
by pipetting. Prior to transferring the ethanol-lysate mixtures onto RNA purifica-
tion columns, the columns were incubated for 5 min in 250 µL of conditioning buffer
and centrifuged at 16,000×g for 1 min. Once the ethanol-lysate mixtures were trans-
ferred onto the columns, the columns were centrifuged for 2 min at 100×g, to allow
the RNA to bind to the column, followed immediately by centrifugation at 16,000×g
for half a minute.
5.5.1 DNase Treatment
Genomic DNA was removed by pipetting a 40 µL solution, composed of 5 µL of the
Qiagen DNase I stock solution and 35 µL of Buffer RDD, directly onto the membrane
of each purification column. The columns were incubated at room temperature for
15 min before 40 µL of wash solution 1 (see Section 4.5) were added to each of the
columns. The columns were then centrifuged at 8,000×g for 15 s.
Subsequent washes were carried out following the recommendations in the RNAqueous®-
Micro Kit, and the RNA was eluted in 11 µl of elution buffer. Each RNA sample
was allocated to two aliquots, one for sequencing (5 µL), and the other for quality
control and validation (6 µL).
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5.5.2 RNA Quantity and Quality Check
The RNA in the samples was quantitated using the Thermo Scientific NanoDrop®
1000 Spectrophotometer. To ascertain the quality of the RNA, the Agilent® RNA
6000 Pico Kit and Agilent® 2100 Bioanalyzer were used. An aliquot of 550 µl of
RNA 6000 Pico gel matrix was pipetted onto a spin filter and centrifuged at 1500 g
for 10 min at room temperature. The filtered gel was stored as 65 µl aliquots at
−80◦C. The RNA 6000 Pico dye was allowed to equilibrate to room temperature
for 30 min, then vortexed and spun down. An aliquot of 1 µl of the dye was added
to a thawed aliquot of filtered gel. The gel-dye mix was vortexed thoroughly and
centrifuged at 13000 g for 10 min at room temperature. A new RNA 6000 Pico chip
was put on the chip priming station for each batch of 11 samples. The chips were
prepared and run on the Bioanalyzer following the manufacturer’s recommenda-
tions. The Bioanalyzer generated a virtual gel, an electropherogram detailing visual
assessment of the quality of the RNA, and an RNA integrity number (RIN) indi-
cating the level of RNA degradation; a RIN score of 1 indicates the most degraded
and a score of 10 is indicative of the most intact RNA (Mueller et al., 2004). Work
previously conducted in the laboratory by Chan et al. (2014), determined that RNA
samples with RIN ≥ 6 were of acceptable quality. As such, the RNA samples used
in the present study had RIN scores of 6 or greater.
5.6 Library Preparation and Sequencing
RNA of acceptable quality was amplified using the Nugen Ovation RNA-Seq Sys-
tem V2. Amplification was initiated at the 3′ end as well as at random throughout
the whole transcriptome in the sample. The Nugen Ovation Ultralow DR Multi-
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plex System (1–8) kit was used for library preparation. Double-stranded cDNA
was fragmented, followed by end repair. Adapters were ligated to the cDNA frag-
ments, and the final libraries were produced after amplification of the fragments
using PCR. Libraries were validated using a DNA 1000 chip on an Agilent 2100
Bioanalyzer (Agilent Technologies, Stockport, UK) according to the manufacturer’s
instructions.
Libraries were sequenced on the Illumina HiSeq 2500 platform (Illumina, San Diego,
CA, USA) using a 51bp paired-end indexed run. Each of the sequenced bases was
assigned a Phred quality score (Ewing & Green, 1998), which expresses the proba-
bility of incorrectly identifying a nucleotide. The Phred score of a given nucleotide,
Q, is defined as
Q = −10 log10 P ; (5.1)
where P is the estimated probability of the base call being incorrect, which may be
calculated from the Phred score as follows:
P = 10
−Q/10. (5.2)
A higher Phred score is to be preferred as this is indicative of a lower error proba-
bility.
5.7 Spatial Expression of Proteins
Immunohistochemistry was performed on formalin-fixed paraffin-embedded tissues
that were cut into 5 µm sections and incubated at 65◦C on positively charged slides.
Tissue sections were deparaffinised by washing three times Xylene for 5 min and
hydrated in series-graded alcohol, then washed twice for 5 min in distilled water.
70
5.7. Spatial Expression of Proteins
To break the protein cross-links formed by formalin fixation, slides were brought
to a boil in 10 mM sodium citrate buffer (pH 6.0), and maintained at sub-boiling
temperature for 2 h. Tissue slides were allowed to cool at room temperature for
30 min and then washed in distilled water before staining commenced.
To neutralise endogenous peroxidase, tissue sections were incubated in BLOXALLTM
for 10 min at room temperature. The sections were then washed twice for 5 min
each time in Phosphate Buffered Saline (PBS) with Tween®20 (PBS-T). A litre of
PBS-T was prepared by adding 100 ml of PBS and 500 µl of Tween®20 to 900 ml
of MilliQ water. To block unspecific binding sites, tissues were incubated in horse
serum blocking solution for 20 min, followed by two washes in PBS-T. The slides
were then placed in a humidified chamber where 100 µl of primary antibody diluted
in PBS-T (1:200 dilution) was added to the tissue sections, while only PBS-T was
placed on control tissue sections instead of the diluted antibody. The humidified
chamber was incubated at 4◦C overnight.
Following overnight incubation at 4◦C, the sections were washed twice in PBS-T
and incubated for 30 min in ImmPRESS® anti-rabbit reagent, then washed again in
PBS-T for 5 min. While the sections were in the wash solution, a working solution of
Diaminobenzidine (DAB) was prepared by adding 2 drops of buffer stock solution,
4 drops of DAB stock, and 2 drops of the hydrogen peroxide solution to 5 ml of
distilled water. To detect the antibody, the tissue sections were incubated in the
DAB working solution until desired staining intensity was achieved. The slides
were then rinsed under a distilled water tap for 5 min, and counterstained with
haematoxylin for 1 min. The counterstained slides were rinsed under a distilled
water tap for 10 minutes, dehydrated, cleared, and mounted. The stained slides
were then scanned using MIRAX SCAN (Carl Zeiss), and the resulting images were
processed using Pannoramic Viewer software (3D Histech).
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5.8 Validation of Gene Expression
Quantitative real-time PCR (qPCR) experiments were conducted to validate the
gene expression patterns observed from RNAseq data.
5.8.1 Synthesis of cDNA
Reverse transcription of total RNA from LCM tissues was performed by adding 2 µl
10× RT buffer, 0.8 µl 25× dNTP mix, 2 µl 10× RT primers, 1 µl Multiscribe reverse
transcriptase, and 4.2 µl of nuclease-free water to each RNA sample. The solution
was incubated at 25◦C for 10 min, followed by a 120 min incubation at 37◦C. The
reverse transcriptase was inactivated by incubating the solution at 85◦C for 5 min.
The cDNA was then stored at −20◦C until required.
5.8.2 RT-qPCR Experimental Setup and Data Analysis
Inventoried Taqman® gene expression assays were purchased from Applied Biosys-
tems (see Section 4.7 for full list of probes used). Each PCR reaction was made
up of 100 ng of cDNA in 20 µl reaction volume containing 1 µl 20× Taqman®
gene expression assay, 10 µl 2× Taqman® gene expression master mix, and 8 µl of
RNAse-free water. At least 2 biological replicates per gestational time point and
3 technical replicates per biological replicate were run on the Applied Biosystems
Fast 96-well platform. The RT-qPCR program was run for 10 minutes at 95◦C ,
followed by 40 cycles of 95◦C for 15 s and 60◦C for 1 min.
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5.8.3 Analysis of RT-qPCR Data
The threshold cycle number (Ct) for each replicate was determined by setting a
horizontal threshold, unique to each gene, which cut across the exponential phase
of each amplification plot. First, the mean Ct value among the technical replicates
of each sample was calculated for a single gene as follows:
Ctrep−mean =
n∑
i=1
Cttech−rep(i)
n
, (5.3)
where i = {1, · · · , n} represents the number of technical replicates. This was fol-
lowed by the subtraction of the lowest Ctrep−mean value (Ctmean−min) from all other
Ctrep−mean values for that particular gene, i.e.,
∆Ctj = Ctrep−mean(j) − Ctmean−min, (5.4)
where j = {1, · · · ,m} represents the number of samples. The efficiency of all the
probes was guaranteed by the manufacturer. Accordingly, the transcript abundance
was calculated as 2−∆Ctj for each sample. The abundance relative to the reference
(housekeeping) gene β-Actin (Actb), was calculated through dividing the transcript
abundance in a sample of the gene of interest (goi) by the transcript abundance in
the same sample of Actb, thus relative abundance is
2−∆∆Ct, (5.5)
where ∆∆Ct = ∆Ctgoi − ∆CtActb. Relative transcript abundances were plotted
using GraphPad Prism® and significant differences in transcript abundance between
gestational time-points were tested using Kruskal-Wallis test coupled with Dunn’s
multiple testing correction approach with a 5% significance level.
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Data Quality Assessment and
Analysis
The 51bp paired-end sequencing reads were presented in FASTQ format, which
stores biological sequences and their corresponding Phred quality scores. The FASTQ
files were inspected for low quality scores, adapter sequence contamination, and
other overrepresented sequences, using FastQC (Andrews, 2012).
TopHat2 (Kim et al., 2013), a fast-splice junction mapper that aligns RNA-Seq
reads to genomes, was used to align the reads against the UCSC Rattus norvegicus
(rn5) reference transcriptome (Rat Genome Sequencing Project Consortium, 2004),
obtained from the Illumina iGenomes resource. TopHat2 employs Bowtie (Langmead
& Salzberg, 2012), a short read aligner, to re-align poorly mapped or previously
unmapped reads. For each pair of FASTQ files, Tophat2 produced a BAM (binary
alignment map) file with the reads that are aligned to the genome (accepted hits.bam),
a BAM file containing the reads that failed to align to the genome or transcriptome
(unmapped.bam), a UCSC BED track of junctions (junctions.bed), and UCSC BED
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tracks of insertions (insertions.bed) and deletions (deletions.bed) as output.
The accepted hits.bam files were sorted and indexed using SAMtools (Li et al., 2009),
to enable viewing of the sequences on the Integrative Genomics Viewer (IGV) (Robin-
son et al., 2011; Thorvaldsdo´ttir et al., 2012). SAMtools was also used to sort the
accepted hits.bam files by name and convert them into SAM (sequence alignment
map) format, which is an uncompressed text version of the BAM format. SAM files
were used as input for HTSeq (Anders et al., 2015), a piece of feature-counting
software that was used to estimate transcript and gene counts.
6.1 Principal Component Analysis
Principal Component Analysis (PCA) is a technique in which variables are trans-
formed into a set of uncorrelated variables called principal components ( PCs), that
are linear combinations of the original data. PCA is used to obtain insight into
patterns or trends within data sets, and to identify the sources of variation within
the data, which may not be discernible (Johnson & Wichern, 2002).
6.1.1 The Model
Let n be the number of gene transcripts, and p be the number of samples. Then
the matrix of gene transcript expression levels can be denoted by an n × p data
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matrix
X =

x11 x12 · · · x1p
x21 x22 · · · x2p
...
...
. . .
...
xn1 xn2 · · · xnp

(6.1)
with mean vector x¯ = (x¯1, x¯2, . . . , x¯p) where
x¯j =
1
n
n∑
i=1
xij (6.2)
with j = 1, . . . , p, and p× p covariance matrix S, which is symmetric, i.e., S> = S,
as well as correlation matrix R, which is also symmetric.
Suppose S = BΛB> is the spectral decomposition of S, then B is an orthogonal
matrix of the eigenvectors (βj) of S, and Λ is the diagonal matrix of the correspond-
ing eigenvalues (λj) where j = 1, . . . , p and λ1 ≤ λ2 ≤ · · · ≤ λp. The eigenvectors
determine the p PCs, with (p ≤ n− 1). The data, X, may be transformed into PCs,
Y, as follows:
Y = B>(X− x¯), (6.3)
where Y has mean 0 and variance Λ (Ha¨rdle & Hla´vka, 2015).
The correlation matrix R may also be used to compute PCs; Timm (2002a) discusses
the use of the correlation matrix in detail. The elements of the PCs represent the
coefficients of the variables, sometimes referred to as the PC loadings, which provide
a summary of the influence of the original variables on the principal components.
A coefficient of large magnitude corresponds to a high loading, while a coefficient
near zero has a low loading. A plot of the loadings gives a visual impression of the
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patterns within the data (Timm, 2002a).
6.1.2 Selection of Principal Components
Let r be the number of principal components to be retained for analysis, which can be
determined by considering the variance within the original data that is accounted
for by each of the PCs; the kth PC, yk, is the direction in which the data have
variance λk. Thus the proportion of the total variance within the original data that
is captured by yk, vk, is calculated as
vk =
λk
p∑
j=1
λj
. (6.4)
The PCs whose cumulative variance is equal to or surpasses a predetermined thresh-
old are retained for further analysis. Ewens & Grant (2001a) suggested a threshold
of 90%, while Timm (2002a) suggested a proportion between 70% – 80%, and Jolliffe
(2002a) suggested a proportion between 80% – 90%. Evidently, there is no specific
threshold at which PCs are retained. As such, the individual performing the analysis
may use their discretion.
Another method by which r may be determined is by plotting of the eigenvalues, λj ,
against j as illustrated in Figure 6.1. This plot, called a scree plot, is used to visually
determine r by selecting the PCs whose eigenvalues are located above the point at
which the variance accounted for represents a flat line (Ha¨rdle & Hla´vka, 2015).
The work presented in this thesis employed a minimum threshold of 85% for the
cumulative variance captured by the PCs, as well as scree plots, to determine the
number of PCs to retain for analysis. Jolliffe (2002b) discusses other methods that
may be employed in determining r.
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Figure 6.1: Illustration of a scree plot. The eigenvalues are plotted in descending order. The
scree plot shown here indicates that the slope flattens at i = 3. In this case, therefore, r = 2.
Adapted from Timm (2002a).
6.2 Differential Expression and Statistical Analysis
As there is no general agreement as to which differential gene expression method is
the best, several comparisons have been conducted to identify the “best” method
(Robles et al., 2012; Wesolowski et al., 2013; Soneson & Delorenzi, 2013). However,
the methods that are currently available have differing strengths and weaknesses,
which makes it difficult to select a single method.
Wesolowski et al. (2013), for example, compared the true positive rates of Cuffdiff
(Trapnell et al., 2012), DESeq (Anders & Huber, 2010), baySeq (Hardcastle &
Kelly, 2010), as well as an hierarchical empirical Bayes method (R-EBSeq), and
noted that while DESeq identified the first half of a list of known differentially ex-
pressed transcripts from a synthetic data set, Cuffdiff and R-EBSeq were better at
identifying differentially expressed transcripts. Soneson & Delorenzi (2013) com-
pared eleven differential expression approaches, including DESeq and edgeR (Robin-
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son et al., 2010), and noted that both DESeq and edgeR were the best performing
methods for small sample sizes (n = 2), and that with an increase in sample size
from 2 to 3, the false positive rate of DESeq decreased noticeably. However, Sone-
son & Delorenzi (2013) also observed that DESeq was more conservative than other
RNA-seq differential expression analysis tools, an observation that was also made
by Robles et al. (2012). Another differential expression analysis method, DESeq2
(Love et al., 2014), was described as having better specificity compared to that
of Cuffdiff and its predecessor DESeq, but had poorer specificity in comparison to
edgeR. Love et al. (2014) also noted that the “old DESeq” and Cuffdiff were “overly”
conservative in the control of false positive results.
In order to have a balance of parametric and non-parametric approaches, strictness,
sensitivity and accuracy, differential expression analysis in this thesis was performed
using the following three methods:
1. Cuffdiff, a non-parametric method which is part of the Cuﬄinks package (Trap-
nell et al., 2012), based on a measurement of the distance between the relative
abundance of transcripts in two different experimental conditions;
2. DESeq2, a parametric method, which models read counts as following the
negative binomial distribution and utilises the Wald test (Love et al., 2014);
and
3. edgeR, a parametric method, which also models read counts as negative bi-
nomial distributed, that utilises the exact test for pairwise comparisons, and
the generalised linear model (GLM) likelihood ratio test for more complex
comparisons (Robinson et al., 2010).
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6.2.1 Data Normalisation
Transcript abundance estimates that are calculated from RNAseq data are sus-
ceptible to bias associated with the length of gene transcripts and the preferential
alignment of reads to the reference transcriptome (Roberts et al., 2011). In addi-
tion, bias may arise due to an imbalance in the nucleotide content of the sequenced
fragments (Risso et al., 2011). Normalisation minimises the influence of sequenc-
ing depth on the data, as high sequencing depths result in high numbers of reads.
It also minimises the dependence on gene transcript length, which arises due to
gene counts being proportional to transcript length and the mRNA expression lev-
els (Zheng et al., 2011). By minimising bias, normalisation enables the analysis of
the underlying biological variations within the data.
Cuﬄinks
Cuﬄinks uses the reads per Kilobase per million mapped reads (RPKM) normalisa-
tion method, calculated as
RPKM =
109 × C
N× L , (6.5)
where C is the number of reads mapping to a particular feature, N is the total
number of mappable reads in the experiment, and L is the feature length (Mor-
tazavi et al., 2008). RPKM reflects the concentration of a transcript in a sample
by normalising for transcript length and the total number of reads. While the
RPKM normalization gives an unbiased measure of feature expression, accounting
for transcript length introduces a length bias (Oshlack & Wakefield, 2009).
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Transcripts per Million
In light of the length bias associated with RPKM normalisation, Wagner et al. (2012)
proposed an alternative normalisation approach: transcripts per million (TPM). The
TPM value for a transcript represents the proportion of the transcriptome that is
occupied by that transcript, while the TPM value for a gene is a sum of all the
TPMs of that gene’s isoforms. It is calculated as
TPM =
rg × rl× 106
flg × T , (6.6)
where rg represents the number of reads mapping to transcript g, rl represents
the mean read length, flg is the length of transcript g, and T represents the total
number of mappable reads. While TPM and RPKM are proportional within a
sample, the scaling factors of the two methods are different between samples (Wagner
et al., 2012). Sailfish (Patro et al., 2014), an alignment-free algorithm, was used to
estimate the TPM values presented in this thesis. Since Sailfish does not align reads
to a reference transcriptome, it is faster than other abundance estimation methods.
Instead, Sailfish uses counts of k-mers, sequences of length k, that are found in reads
to estimate transcript abundance (Patro et al., 2014).
DESeq2
For each gene i in sample j in DESeq2, it is considered that read counts (Xij)
follow the negative binomial (NB) distribution with mean µij and dispersion αi.
The mean is considered to be a product of a quantity qij that is proportional to
the concentration of cDNA fragments in sample j, and a normalization factor which
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accounts for differences between sample sequencing depths, sij , such that
µij = sijqij ; (6.7)
and
Xij ∼ NB(sijqij , αi). (6.8)
The median-of-ratios method described by Anders & Huber (2010) is then used in
the estimation of the normalization factors (Love et al., 2014).
EdgeR
Similar to DESeq2, for each gene i in sample j, read counts Xij are modelled as NB
random variables with mean µij and dispersion αi in edgeR. With the treatment
group k to which sample j belongs, the mean is considered to be a product of the
relative abundance of gene i in the treatment group k, pik, and the total number of
reads in sample j, Mj , such that
µij = Mjpik; (6.9)
and
Xij ∼ NB(Mjpik, αi). (6.10)
Unlike in DESeq2 where the median-of-ratios method is employed, the total number
of reads is used as a normalisation factor in edgeR (Robinson et al., 2010).
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6.2.2 Testing for Significant Differential Expression
Under the null hypothesis (H0) that a gene was not differentially expressed between
two conditions, a test for differential expression was considered significant if the
estimated probability of rejecting H0 given that H0 was true (p-value) was less than
0.05 using all the differential expression analysis methods.
Correcting for Multiple Testing
When there are many independent null hypotheses being tested, it is likely that some
of these null hypotheses may be rejected by chance even though they are true. In
such cases, multiple testing correction (MTC) methods are employed with the aim
of reducing the chance rejection of true hypotheses (Ewens & Grant, 2001b). There
are two main approaches for controlling false statistically significant results; the
control of the family-wise error rate (FWER), and the control of the false discovery
rate (FDR). The FWER is defined as the probability of the presence of at least one
false significant result, whereas the FDR is a representation of the number of false
significant results expressed as a proportion of all the significant results (Gyorffy
et al., 2005).
There are two main types of FWER correction; single-step methods in which all
p-values are adjusted by the same factor, and sequential methods in which adaptive
adjustments are made to each p-value. An example of a single step method is the
Bonferroni method, which rejects an hypothesis whose estimated p-value < α/m,
where α is the predefined probability of rejecting H0 when H0 is true, and m is
the number of hypotheses being tested. Sequential or multi-step methods, on the
other hand, do not adjust all p-values with the same factor. Instead, unadjusted
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p-values are ordered such that p1 ≤ p2 ≤ . . . ≤ pm. Each estimated p-value is
then adjusted sequentially, by different factors, and only those tests whose adjusted
p-value < FWER are considered statistically significant. While methods that correct
for the FWER reduce the chances of incorrectly rejecting a true H0, they also reduce
the chances of correctly rejecting a false H0 (Ewens & Grant, 2001b).
When the presence of a “known negligible” proportion of false statistically significant
results is acceptable, as opposed to limiting any false significant results in the case
of FWER correction, FDR correction methods are employed (Rice et al., 2008).
The Benjamini & Hochberg (1995) FDR , a MTC method that controls the number
of false significant results, was employed in the reduction of the chance rejection of
true hypotheses in this thesis. The Benjamini-Hochberg correction determines FDR-
adjusted p-values known as q-values, adjusted p-values, and FDR in Cuffdiff, DESeq
and edgeR, respectively. An FDR-adjusted p-value less than 0.05 was required for a
gene transcript to be considered significantly differentially expressed in this thesis.
Controlling for the FDR has the advantage of increasing the probability of correctly
rejecting a false H0, but also increases the chances of incorrectly rejecting a true H0
(Mayer & Glasbey, 2005; Rice et al., 2008). In addition to employing the FDR
in this thesis, therefore, gene transcripts were only considered to be significantly
differentially expressed if they were identified by at least two of the differential
expression methods used.
6.3 Hierarchical Clustering
An agglomerative hierarchical clustering (Timm, 2002b) method was employed to
provide insights into the relationships among differentially expressed genes, tissue
types, and treatments. Before clustering was performed on differentially expressed
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genes, z-scores of the gene expression values (TPMs) were calculated. The z-score
of the expression value of a gene at a time point or within a treatment group i,
TPMi, was calculated as follows:
z =
TPMi − µTPM
σTPM
(6.11)
where µTPM represents the mean of the TPM values of a gene across all time points
or treatments and σTPM represents the standard deviation of the set of expression
values.
The Algorithm
The steps by which hierarchical clustering was performed are listed below.
1. Each object of interest, be it a gene, a sample, or a treatment, is defined as a
group and a matrix of distances between each of the objects, D is computed;
2. The smallest non-zero element of the matrix D is then identified, and the
corresponding groups combined;
3. A new matrix D* which is composed of distances between the new group and
the remaining groups is computed; then
4. Steps 2 and 3 are repeated until there is only group left.
The heatmap.2 function in R was used to conduct PCA as well as to produced
heat maps with dendrograms that illustrated the grouping of genes, samples, or
treatments.
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6.4 Functional Enrichment Analysis
The analysis of Gene Ontology (GO) term enrichment is used in the annotation of
the molecular function of genes, as well as the biological processes in which the genes
are involved, and the location of gene products within the cell (Huntley et al., 2015).
Using the entire genome of the rat as a reference gene set containing N genes, n
of which have the GO term of interest, and N − n of the genes do not contain the
GO term. A set of m genes that are coexpressed contains both genes with the GO
term and those without. The probability that the number of genes within the set
of coexpressed genes that have the GO term is k can be expressed in terms of a
random variable X that follows the hypergeometric probability, as follows:
P (X = k) =
(
n
k
)(
N−n
m−k
)(
N
m
) . (6.12)
BiNGO (Maere et al., 2005) was used to test for GO term enrichment using the whole
rat genome as the reference set. Overrepresentation of GO terms was established
through the calculation of the number of times a GO term occurred within a set of
co-expressed genes, followed by the hypergeometric test coupled with the Benjamini
& Hochberg (1995) FDR correction, with a 5% level of significance.
6.5 Predicted Progesterone Response Elements
The human consensus sequence for the progesterone response element (hPRE),
GNACANNNTGTNC, was identified using chromatin immunoprecipitation (ChIP)
experiments on breast cancer and uterine leiomyoma cell lines by Yin et al. (2012). In
order to identify the positions and base sequences for the hPRE sequence in the Rat-
tus norvegicus rn5 genome, the R package called seqinR (Charif & Lobry, 2007) was
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used. In addition, the positions of the complementary sequence of the hPRE, CNT-
GTNNNACANG, were also identified in the Rattus norvegicus rn5 genome.
Using CruzDB (Pedersen et al., 2013) the hPRE positions were submitted to the
UCSC database to detect the first downstream and upstream genes on the same
strand as the hPRE in the rn5 genome positive and negative strand, respectively.
These genes were subsequently compared to lists of differentially expressed genes
identified in this thesis to determine if the hPRE-associated genes in the rat were
differentially expressed in rat uterine tissues during late pregnancy and parturi-
tion.
6.6 Predicted Progesterone Receptor Binding Sites
In a mouse study by Rubel et al. (2012), ChIP experiments were conducted to
identify progesterone receptor (PR) binding sites in ovariectomised mice. The ex-
periments were conducted using uterine samples from mice treated with oil (vehicle),
P4, a sample where no ChIP antibody was used, and a final sample of uterus ep-
ithelium that was P4-treated.
All sample coordinates in the supplementary material (Rubel et al., 2012) were cor-
rected for background using the ChIP background site coordinates. The background-
corrected data were compared to the vehicle PR site coordinates. Each comparison
step involved looking for overlaps in the coordinate sets using the mergeBed function
from BedTools (Quinlan & Hall, 2010). Putative rat uterine PR-binding sites within
P4-responsive genes were obtained by taking into consideration the background-
corrected and vehicle-corrected P4 treated uterine PR site coordinates.
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6.6.1 Genes with a PR-bound Upstream Region that Overlaps with
Predicted PRE Site
To assess the uterine PR-binding sites that are associated with the PRE, the putative
rat PR-binding sites were compared to predicted hPRE sites in the mouse genome.
The site coordinates were merged using mergeBed, creating a list of uterine P4-
responsive PR-binding sites, each associated with a varying number of predicted
mouse hPREs sites. The first downstream genes on the same strand as the mouse
hPREs were identified in the mm9 genome using the methods outlined in Section
6.5. This led to a unique list of mouse genes, which were associated with the uterine
P4-responsive PR-binding sites. These data were subsequently compared to lists
of P4-responsive genes identified in this thesis, to determine whether the hPRE-
associated genes in the rat were PR-bound and differentially expressed in response
to P4 treatment, and withdrawal, within uterine tissues.
6.7 Motif Analysis
A motif is a small sequence of nucleotides that may have biological function, e.g.,
a transcription factor binding site in the promoter region of a gene. There are two
types of computational methods that are used in the analysis of motifs: algorithms
that search for patterns that occur in multiple sequences within a set; and the
assessment of statistical over-representation of known motifs within sequences.
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6.7.1 Motif Search
To determine whether groups of differentially expressed genes were associated with
the binding of common regulatory factors, regions upstream of the transcriptional
start sites of genes, promoter regions, were analysed to identify common motifs.
Promoter sequences with a maximum length of 500, 1000, and 2000 nucleotides,
allowing for truncation if the neighbouring gene was within 2kb, were downloaded
from BioMart (Kasprzyk, 2011) using the Rattus norvegicus (Rnor 5.0) dataset from
the Ensembl Genes 75 database (Flicek et al., 2013), together with the rat genome
database (RGD) gene symbols (Laulederkind et al., 2013). Repeat masking, a pro-
cess by which sequences of repeated bases are hidden by replacing the repeats with
Ns, was performed on the promoter sequences using RepeatMasker (Smit et al., 2010)
so as to remove sequence similarities that were not representative of binding motifs.
The repeat-masked sequences were used as input in MEME-LaB (Brown et al., 2013)
to identify motifs that were enriched within the promoters of differentially expressed
gene sets.
6.7.2 Motif Enrichment in Random Sets of Genes
To ensure that enriched motifs were unique to the treatments subjected to the
uterine tissues, motif enrichment analysis was carried out on sets of genes that were
selected at random from the expressed transcriptome.
Genes were selected at random, using the Uniform Distribution in R, from the
expressed rat uterus transcriptome. Regions that are upstream of the selected genes
were analysed for motif enrichment as described in Section 6.7.1.
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6.7.3 Statistical Significance of Motif Enrichment
Using the whole rat genome as the reference set of genes, some of which contain
a particular transcription factor (TF) motif within their promoter regions, the hy-
pergeometric test was used to determine whether the overlap between the set of
genes containing a motif in their promoters and another set of co-expressed genes
was significantly large. Significance of TF motifs was established by employing the
following steps:
1. The promoter regions of all the genes within the rat genome were inspected for
the presence of all motifs. Here, three promoter lengths were considered; 500
bp, 1000 bp, and 2000 bp. Taking into account the number of times a motif
was identified within the promoter as well as the number of motifs identified,
a p-value was calculated for each promoter.
2. Given the p-values, a motif was considered present within the promoter regions
if its p-value was below a set threshold of 0.0001
3. Hypergeometric p-values were subsequently computed for the motifs that were
considered present, and a motif was considered significant if its p-value was
less than 0.01.
4. JASPAR (http://jaspar.genereg.net) was used to lookup significant motifs.
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Chapter 7
Transcriptomic Profiling of Rat
Uterine Tissues
In this chapter, the transcriptional changes that occur in rat uterine tissues following
the systemic withdrawal of progesterone on the 19th day of gestation are studied,
in order to: document the full complement of RNA in rat uterine tissues, namely;
the basal decidua, the inner circular myometrium and the outer myometrium in
late pregnancy and at term; as well as to determine the patterns of gene transcript
expression associated with each tissue at 4 gestational time points; GD19+6hrs,
GD20, GD22(NL) and GD22(L).
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7.1 Transcriptomic Landscape of the Rat Uterus in Late
Pregnancy and at Term
A total of 11 Sprague-Dawley rats were injected with sesame seed oil as described in
Section 5.1, and whole uterine horns were obtained at 4 time points: on GD19+6hrs;
GD20; GD22(NL); and GD22(L) as illustrated in Figure 7.1. This preparation of
the animal tissue was conducted by Professor Robert Garfield (St. Joseph’s Hospital
and Medical Center – Phoenix, USA). The uterine horns were then flash-frozen in
liquid nitrogen and shipped to the UK. On arrival, the samples were checked visually
to make sure that they were still frozen and then stored at −80◦C (Supplementary
Figure B.1).
Laser-capture microdissection (LCM) was performed in order to separate the basal
decidua, the inner circular myometrial layer, and the outer longitudinal myometrial
layer from uterine samples following the procedure described in Section 5.4. Total
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Figure 7.1: Protocol for the collection of uterine samples. The black arrows indicate the
days on which animals were killed, and the numbers on top of the black arrows indicate the sample
sizes. At term labouring (lab) and not-in-labour (nil) samples were collected.
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Figure 7.2: Number of reads in the sequencing files. The average number of reads generated
from decidua, inner myometrium and outer myometrium samples obtained on GD19+6hrs, GD20,
GD22(NL), and GD22(L). The error bars indicate the standard deviation of the number of reads
within a group of biological replicates.
RNA was isolated from LCM tissues and checked for integrity using the Agilent 2100
Bioanalyzer as described in Section 5.5.2, and RNA of acceptable quality was used
to prepare libraries that were sequenced on the Illumina HiSeq 2500 platform.
The transcript expression data presented here were created as described in Section
5.6. In total, 974.63 million paired-end reads, each 51 nucleotides in length, were
generated across all libraries as illustrated in Figure 7.2. A full list of the number of
reads per sample is provided in Table 7.1. On average, 14.77 million paired-end reads
were sequenced per sample. The files with the sequencing data, in FASTQ format,
for samples obtained GD19+6hrs contained between 18,172,495 and 47,412,999 reads
each. Reads for GD20 samples were between 14,984,755 and 42,069,289, while those
for GD22(NL) samples were between 17,906,163 and 59,347,487. Samples collected
on GD22(L) had between 20,405,112 and 22,841,338 reads.
Prior to the alignment of reads to the rat transcriptome, the quality of the reads
within the FastQ files was assessed using FastQC. Each quality check could return
any of three results; pass, warn, or fail. Files that failed three or more of the
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quality checks were discarded. Reads obtained from one GD20 decidua sample, and
one GD19+6hrs decidua sample, failed several of the tests including: sequence GC
content; sequence duplication; overrepresented sequences; and k-mer content. The
reads generated from these samples were not trimmed at this stage. Instead new
LCM tissues were isolated from the corresponding samples, from which RNA was
extracted and sent for library preparation and sequencing as described in Sections
5.4–5.6. The data files were subsequently inspected using FastQC. The results of the
FastQC tests conducted on sequencing data files are shown in Supplementary Table
C.1.
To verify that reads were aligned correctly, sorted BAM files were loaded onto the
IGV Browser to enable visual assessment of the alignments. Representative exam-
ples of alignment to the progesterone receptor gene (Pgr) of reads obtained from
GD19+6hrs, GD20, GD22(NL), and GD22(L), are shown in Figures 7.3, 7.4, 7.5,
and 7.6, respectively. Of the sequenced reads, 79.87% were aligned to the reference
transcriptome using Tophat2, and 70.59% of the aligned reads were determined to
be expressed across all gestational time points and tissues. The expressed transcrip-
tome was covered 12.67×, 13.41×, 17.25×, and 11.88× on average in the samples
obtained on GD19+6hrs, GD20, GD22(NL), and GD22(L), respectively (details in
Table 7.1).
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Table 7.1: Alignment of sequenced reads to the Rattus norvegicus transcriptome and
coverage statistics of sequences. Gestation - The day during pregnancy on which the uterine
sample was collected. Tissue - The layer of the uterus that was separated from the other tissues
using laser-capture microdissection. The number illustrates the replicate number. % Aligned
- The proportion of the sequenced reads that were aligned successfully to the Rattus norvegicus
transcriptome using Tophat2. % Expressed features - The proportion of genes to which counts
were assigned by HTSeq. Expressed transcriptome (× covered) - The number of times the
expressed transcriptome was covered by the sequenced reads.
Sample Expressed
% Expressed transcriptome
Gestation Tissue Total reads % Aligned features (× covered)
GD19+6hrs Decidua 1 47,412,999 84.90 74.96 21.1
GD19+6hrs Decidua 2 22,970,447 84.60 84.65 6.94
GD19+6hrs Decidua 3 31,654,340 81.50 72.39 14.06
GD19+6hrs Inner Myo 1 21,711,951 80.90 66.37 6.67
GD19+6hrs Inner Myo 2 31,035,607 83.20 71.41 11.83
GD19+6hrs Inner Myo 3 31,434,913 73.60 74.13 9.05
GD19+6hrs Outer Myo 1 39,135,788 84.00 66.24 30.61
GD19+6hrs Outer Myo 2 16,941,814 76.90 69.56 5.23
GD19+6hrs Outer Myo 3 18,172,495 76.50 74.49 8.53
GD20 Decidua 1 30,757,580 77.70 73.98 7.89
GD20 Decidua 2 35,081,695 56.20 44.02 0.86
GD20 Decidua 3 29,305,075 79.00 61.41 19.45
GD20 Inner Myo 1 20,758,801 76.20 57.73 15.11
GD20 Inner Myo 2 33,340,488 83.30 76.76 9.69
GD20 Inner Myo 3 14,984,755 71.40 61.48 7.38
GD20 Outer Myo 1 40,458,136 79.30 74.86 23.42
GD20 Outer Myo 2 22,414,900 80.20 73.93 13.32
GD20 Outer Myo 3 42,069,289 86.90 75.87 23.53
GD22(NL) Decidua 1 17,906,163 79.10 84.03 3.62
GD22(NL) Decidua 2 29,604,137 83.90 72.27 18.46
GD22(NL) Decidua 3 41,196,358 84.40 68.90 26.42
GD22(NL) Inner Myo 1 38,897,796 87.00 73.05 28.99
GD22(NL) Inner Myo 2 21,843,013 72.00 57.51 5.9
GD22(NL) Inner Myo 3 59,347,484 84.50 71.95 31.51
GD22(NL) Outer Myo 1 46,366,358 84.20 71.31 22.64
GD22(NL) Outer Myo 2 24,476,132 79.10 80.33 4.84
GD22(NL) Outer Myo 3 35,100,798 85.80 76.31 12.9
GD22(L) Decidua 1 21,339,531 79.70 64.48 11.71
GD22(L) Decidua 2 21,789,441 82.60 66.33 11.17
GD22(L) Inner Myo 1 22,465,983 80.00 73.05 4.29
GD22(L) Inner Myo 2 20,405,112 84.20 70.94 10.56
GD22(L) Outer Myo 1 22,841,338 82.10 72.87 15.76
GD22(L) Outer Myo 1 21,409,111 70.70 71.88 17.79
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7.2. Analysis of the Expression of Tissue-Specific Gene Transcripts
7.2 Analysis of the Expression of Tissue-Specific Gene
Transcripts
The expression levels of gene transcripts within samples were estimated using three
approaches, the first of which employed Sailfish to estimate transcripts per million
(TPM) values, the second used Cuﬄinks to estimate reads per kilobase per million
(RPKM), and the third used HTSeq to estimate raw gene transcript counts. To
determine whether LCM had been successfully employed in the collection of pure
decidual and myometrial tissues, the mean TPM expression values in the decidua
were divided by the mean TPM values in the myometrium for each gestational time
point. A higher ratio indicated that a gene transcript was expressed more in the
decidua than in myometrial tissues.
Transcripts encoding thyrotropin releasing hormone (Trh) were, on average (mean±
SD), highly expressed in the decidua in comparison to the inner and outer layers
of the myometrium (Table 7.2). Trh mRNA expression was highest in the decidua
on GD19+6hrs (553.73 ± 372.47 TPM) and lowest at term (89.26 ± 89.80 TPM).
On GD20 and during labour, Trh mRNA expression were 364.66±583.45 TPM and
188.66±66.99 TPM, respectively. In the myometrial layers, the highest expression of
Trh mRNA transcripts was observed on GD19+6hrs in the outer layer (37.31±63.06
TPM). Immunohistochemical (IHC) staining for Trh was conducted on samples from
all time-points to confirm the mRNA expression data. IHC studies showed that Trh
was mainly localised to the decidua on GD19+6hrs (Figure 7.7). On GD20, all
three layers showed Trh presence, but with the strongest staining intensity in the
decidua (Figure 7.7). Staining for Trh on GD22(NL) was distinct in the decidua as
well as the inner layer of the myometrium, with slightly stronger staining for Trh
in the decidua (Figure 7.8). While Trh staining is present in all three uterine layers
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Table 7.2: Expression of tenascin n (Tnn) and thyrotropin releasing hormone (Trh)
mRNA in uterine tissues. Transcript expression values are shown in transcript per million
values (mean±SD).
Tnn Trh
Mean ±SD Mean ±SD
D
ec
id
u
a
GD19+6hrs 5.55 4.77 553.73 372.47
GD20 20.17 24.33 364.66 583.45
GD22(NL) 38.22 39.91 89.26 89.80
GD22(L) 12.82 18.06 188.66 66.99
Overall 19.77 25.43 309.11 366.29
In
n
er
M
y
o
GD19+6hrs 86.47 39.28 1.55 2.06
GD20 48.53 41.35 0.53 0.14
GD22(NL) 61.51 30.36 0.17 0.27
GD22(L) 9.89 13.41 0.92 0.23
Overall 55.39 39.78 0.78 1.09
O
u
te
r
M
y
o
GD19+6hrs 0.41 0.33 37.31 63.06
GD20 5.53 3.96 0.45 0.29
GD22(NL) 5.69 4.16 0.13 0.13
GD22(L) 10.11 11.31 26.63 36.85
Overall 5.01 5.58 15.18 35.18
on GD22(L), the intensity of staining is strongest in the decidua (Figure 7.8). The
intensity of immunohistochemical staining in the decidua at each time-point would
suggest that Trh may be used to identify the basal decidua in late pregnancy.
Tenascin-n (Tnn) mRNA expression was high the inner myometrium compared to
that in the decidua, as well as in comparison to the outer layer of the myometrium
(Table 7.2). Average Tnn expression across the four gestational time points was
19.77 ± 25.43 TPM in the decidua, 55.39 ± 39.78 TPM in the inner myometrium,
and 5.01 ± 5.58 TPM in the outer myometrium. Immunohistochemical staining
showed that Tnn was distinctly present in the decidua and the inner myometrium,
but less so in the outer myometrium on GD19+6hrs and GD20 (Figure 7.9), as well
as on GD22(L) (Figure 7.10). On GD22(NL), the intensity of staining for Tnn in
the decidua was low, however, there was strong staining in the inner myometrium
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and no staining for Tnn in the outer myometrium. Evidence suggests that Tnn
expression at both the mRNA and protein level may be used to distinguish the
inner layer of the myometrium from the outer layer of the myometrium.
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Figure 7.7: Thyrotropin-releasing hormone (Trh) is mainly localised to the decidua.
Top: Expression of Trh in uterine tissues on GD19+6hrs. Negative control: tissues without
staining. Trh: tissues stained for Trh. Trh (20x): zoomed in image of tissues stained for Trh with
20x magnification. Bottom: Trh protein expression in the rat uterus on GD20. Negative control:
tissues without staining. Trh: tissues stained for Trh. Trh (20x): zoomed in image of tissues
stained for Trh with 20x magnification. p: placenta; d: decidua; and m: myometrium. Scale bars
= 500 µm [Negative control and Trh] and 100 µm [Trh (20x)].
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Figure 7.8: Immunohistochemical (IHC) staining for Trh in uterine tissues. Top: IHC
staining for Trh in the uterus on GD22(NL). Negative control: tissues without staining. Trh:
tissues stained for Trh. Trh (40x): zoomed in image of tissues stained for Trh with 40x magnifica-
tion. Scale bars = 200 µm [Negative control and Trh] and 50 µm [Trh (40x)]. Bottom: IHC staining
for Trh on GD22(L). Trh: tissues stained for Trh. Trh (20x): zoomed in image of tissues stained
for Trh with 20x magnification. Scale bars = 500 µm [Negative control and Trh] and 100 µm [Trh
(20x)]. p: placenta; d: decidua; and m: myometrium.
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Figure 7.9: Immunohistochemical (IHC) staining for Tnn in uterine tissues. Top:
Negative control: tissues without staining. Tnn: tissues stained for Tnn. Tnn (40x): zoomed
in image of tissues stained for Tnn with 40x magnification. Scale bars = 500 µm [Negative control
and Tnn] and 50 µm [Tnn (40x)]. Bottom: IHC staining for Tnn on GD20. Tnn: tissues stained
for Tnn. Tnn (40x): zoomed in image of tissues stained for Tnn with 40x magnification. Scale
bars = 200 µm [Tnn] and 50 µm [Tnn (40x)]. p: placenta; d: decidua; and m: myometrium.
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Figure 7.10: Immunohistochemical (IHC) staining for Tnn in uterine tissues. Top:
Negative control: tissues without staining. Tnn: tissues stained for Tnn. Tnn (40x): zoomed in
image of tissues stained for Tnn with 40x magnification. Scale bars = 500 µm [Negative control and
Tnn] and 50 µm [Tnn (40x)]. Bottom: Negative control: tissues without staining. Tnn: tissues
stained for Tnn. Tnn (40x): zoomed in image of tissues stained for Tnn with 40x magnification.
Scale bars = 500 µm [Negative control and Tnn] and 100 µm [Tnn (40x)]. p: placenta; d: decidua;
and m: myometrium.
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7.3 Principal Component Analysis
Principal component analysis (PCA) of the TPM values was employed to further
assess the patterns of expression of gene transcripts within the uterine tissues. To
perform PCA as described in Section 6.1, the princomp function in R was used as
follows:
myPCA = princomp(∼.,data = myData, na.action = na.exclude, cor = FALSE),
where ∼. indicates that all the variables (tissue samples) in the data matrix myData were
used in the estimation of principal components (PCs), while na.action = na.include indicates
that any gene transcripts whose expression values were denoted by NA were excluded, and
cor = FALSE indicates that the covariance matrix was used in the estimation of PCs instead
of the correlation matrix. The number of PCs used to assess the relationship among the
data were selected using two methods; the cumulative variance captured by the PCs of 85%,
and plots of the eigenvalues as described in Section 6.1.2.
7.3.1 GD19+6hrs
Following the estimation of the PCs of the mRNA transcripts expressed on GD19+6hrs
in uterine tissues, both the cumulative variance captured by the PCs (Table 7.3) and a
plot of the eigenvalues were used to determine the number of PCs to retain for analysis.
The first PC (PC1) accounted for 66.3% of the variance in the data, while the second PC
(PC2) accounted for 17.6%. Together, PC1 and PC2 accounted for 83.9% of the variance
in the data. To reach the set threshold of 85% of the variance accounted for by the PCs,
the third PC (PC3), which accounted for 11.4% was also retained. The plot of eigenvalues
in Figure 7.11 showed that PC1 accounted for the majority of the variance, however, the
next two PCs, PC2 and PC3, also accounted for a sizeable proportion of the variance.
Hence three PCs were retained for analysis in this section. A three-dimensional plot of the
retained PCs shows that the inner myometrium samples grouped together (Figure 7.12),
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Table 7.3: Variance accounted for by principal components. Shown are the proportions of
variance accounted for by principal components, as well as the cumulative proportion of variance,
on GD19+6hrs, GD20, GD22(NL), and GD22(L). PV (%): proportion of variance explained,
expressed as a percentage; CP (%): cumulative variance explained, expressed as a percentage; and
Comp.: principal component.
GD19+6hrs GD20 GD22(NL) GD22(L)
PV (%) CP (%) PV (%) CP (%) PV (%) CP (%) PV (%) CP (%)
Comp.1 66.3% 66.3% 59.2% 59.2% 79.1% 79.1% 70.1% 70.1%
Comp.2 17.6% 83.9% 36.9% 96.1% 19.0% 98.1% 27.8% 97.9%
Comp.3 11.4% 95.3% 2.4% 98.5% 0.9% 99.0% 1.4% 99.3%
Comp.4 2.3% 97.5% 0.5% 99.0% 0.4% 99.4% 0.4% 99.7%
Comp.5 1.3% 98.8% 0.5% 99.5% 0.3% 99.7% 0.2% 99.9%
Comp.6 0.7% 99.5% 0.4% 99.8% 0.2% 99.9% 0.1% 100.0%
Comp.7 0.3% 99.8% 0.1% 99.9% 0.1% 99.9%
Comp.8 0.2% 99.9% 0.0% 100.0% 0.0% 100.0%
Comp.9 0.1% 100.0% 0.0% 100.0% 0.0% 100.0%
while two of the outer myometrium samples, as well as two of the decidua samples, were
separated from the other uterine samples. One outer myometrium sample and one decidua
sample were not separated from the inner myometrium samples. Given that the inner
myometrium is sandwiched between the decidua and the outer myometrium, it may be
that some inner myometrium cells were present in the two samples that were not grouped
with their respective replicates. In addition, there was clear variability among the outer
myometrium samples, which may also be a result of contamination with cells from other
tissues. Apart from contamination with cells from other tissues, the relationships among the
mRNA expression levels in different tissues may not be linear. Thus other methods which
do not consider the linear relationship between variables may need be employed.
7.3.2 GD20
Since the scree plot and cumulative variance methods used in Section 7.3.1 suggested the
same number of PCs for analysis, this section as well as subsequent sections employed the
cumulative variance approach to determine the number of PCs to retain for analysis. Cu-
mulatively, PC1 and PC2 accounted for 96.1% of the variance within the mRNA expression
data for GD20 samples (Table 7.3). As such, a plot of these two PCs was used to assess the
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Figure 7.11: Plot of the eigenvalues of the covariance matrix of GD19+6hrs data. The
low variance accounted for by principal component (Comp.) numbers 4–9 suggested that the first
three PCs should be retained for analysis.
relationships among the GD20 mRNA expression data (Figure 7.13). PCA did not separate
the tissues distinctly at this time-point.
7.3.3 GD22(NL) and GD22(L)
On GD22(NL) and GD22(L), 98.1% and 97.9% of the total variance was accounted for by
the first two PCs, respectively. The plots of the PCs are shown in Figure 7.14. While PCA
did not separate the mRNA expression levels in the uterine tissues distinctly on GD22(NL),
there was distinct separation of tissues on GD22(L). However, the two inner myometrium
exhibited a high degree of variability between them.
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Figure 7.13: Principal component analysis (PCA) of mRNA expression on GD20.
Transcripts per million (TPM) abundances were used for PCA. The variance within the data which
is accounted for by each of the principal components is displayed next to the corresponding principal
component. PC1: the first principal component; and PC2: the second principal component;
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Figure 7.14: Principal component analysis (PCA) of term-pregnant rat uterine tissues.
Transcripts per million (TPM) abundances were used for PCA of samples that were collected on
(Top) GD22(NL) and (Bottom) GD22(L). The variance within the data which is accounted for
by each of the first three principal components is displayed next to the corresponding principal
component. PC1: the first principal component; PC2: the second principal component;
7.4. Differential Expression Analyses
7.4 Differential Expression Analyses
To asses the patterns of gene transcript expression within the uterine samples, estimated
abundances were subjected to differential expression analysis using three methods: Cuffdiff;
edgeR; and DESeq2. Cuffdiff takes RPKM values estimated by Cuﬄinks as input, while edgeR
and DESeq2 take raw gene transcript counts estimated by HTSeq as input. In each method,
a gene transcript was considered differentially expressed if the associated p-value was less
than a threshold of 5%. Multiple testing correction was employed in all methods and a
threshold of 5% applied to the q-value in Cuffdiff, false discovery rate (FDR) in edgeR, and the
adjusted p-value in DESeq2. For each pair of comparisons, a list of gene transcripts that had
been identified by at least two of the three differential expression methods as differentially
expressed was used for further analysis. To identify those gene transcripts whose expression
patterns differed between uterine tissues, differential gene transcript expression analyses
were conducted between uterine tissues at each gestational time point.
7.4.1 GD19+6hrs
A total of 361 gene transcripts were identified by Cuffdiff, 674 by edgeR, and 661 by DESeq2
as differentially expressed between the decidua and the inner myometrium, of which 480
gene transcripts were identified by at least 2 of the methods (Figure 7.15a). Of the 480
gene transcripts that were significantly differentially expressed between the decidua and the
inner myometrium, 64% were upregulated in the inner layer of the myometrium (Table D.1).
Between the decidua and the outer myometrium, 154 differentially expressed gene transcripts
were found by Cuffdiff, 124 by edgeR and 60 by DESeq2. Sixty-nine gene transcripts were
identified by at least two methods (Figure 7.15c), 74% of which were upregulated in the outer
myometrium (Table D.2). The comparison between the myometrial layers yielded a set of 22
gene transcripts that were found by at least two methods from sets of 215, 30, and 15 gene
transcripts that were identified as differentially expressed by Cuffdiff, edgeR and DESeq2,
respectively (Figure 7.15e). Approximately 45% of the gene transcripts were upregulated
in the outer myometrium (Table D.3). To further analyse the relationships among the
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uterine tissues, z-scores of the TPM values were calculated and used in clustering analysis.
Heat maps of the relationships shown in Figure 7.15, indicate the differences in expression
patterns of gene transcripts between the tissues, particularly between the inner and outer
myometrial layers.
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Figure 7.15: Comparisons of differentially expressed gene transcripts on GD19+6hrs. Gene
transcripts were identified as differentially expressed by Cuffdiff (Cuff), edgeR, and DESeq2 between
the (a – b) decidua and the inner myometrium, (c – d) decidua and the outer myometrium, and (e –
f) between the inner and outer myometrial layers. Agglomerative hierarchical clustering was used to
identify the relationships among the decidua (dec), inner (inn) circular myometrium (myo), and outer
longitudinal myometrium (out). The tissues and gene transcripts were represented by the columns and
rows, respectively.
7.4. Differential Expression Analyses
7.4.2 GD20
On GD20, differential expression analysis using three methods identified varying numbers
of gene transcripts. As regards the decidua in comparison to the inner myometrium, Cuffdiff
identified 600 differentially expressed gene transcripts while edgeR and DESeq2 identified
32 and 48 differentially expressed (DE) gene transcripts, respectively. While there were no
significantly DE gene transcripts in common between edgeR and DESeq2, 22 gene transcripts
were found in both the Cuffdiff and DESeq2 sets of DE gene transcripts, and 12 in the Cuffdiff
as well as the edgeR set of differentially expressed gene transcripts (Figure 7.16a).
Of the 34 common DE gene transcripts, approximately 68% were upregulated in the inner
myometrium (Table D.4). Comparison between the decidua and the outer myometrium
yielded 443 (Cuffdiff), 882 (edgeR), and 213 (DESeq2) DE gene transcripts (Figure 7.16c).
A set of 232 DE gene transcripts was identified by at least two of the three methods, and
68% of them were upregulated in the outer myometrium (Table D.5). The myometrial
layers had 154, 41 and 98 differentially expressed gene transcripts between them identified
by Cuffdiff, edgeR and DESeq2, respectively (Figure 7.16e). Thirty-eight DE gene transcripts
were identified by at least two methods, with 66% of them being upregulated in the outer
myometrium as shown in Table 7.4.
Table 7.4: Genes that were differentially expressed in the outer myometrium compared
to the inner myometrium on GD20. Transcript expression levels are shown in transcripts per
million values (mean±SD).
Inner Outer
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in outer myometrium
Krt17 keratin 17 0.01 0.01 31.54 29.38
LOC304131 similar to C21ORF7 0.03 0.05 3.90 2.70
Cldn15 claudin 15 0.00 0.00 2.39 1.15
Mal mal, T-cell differentiation protein 0.06 0.05 4.86 3.76
Spc25 SPC25, NDC80 kinetochore complex component 0.01 0.02 3.67 1.85
Clec1b C-type lectin domain family 1, member B 0.41 0.72 9.81 4.12
Tbx20 T-box 20 0.01 0.01 2.76 2.15
Continued on next page
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Table 7.4 – continued from previous page
Inner Outer
Gene symbol Gene name TPM ±SD TPM ±SD
Nrgn neurogranin 3.56 2.74 17.36 10.33
Troap trophinin associated protein 0.00 0.00 5.95 0.96
Msln mesothelin 0.11 0.20 85.93 46.24
Pkhd1l1 polycystic kidney and hepatic disease 1-like 1 0.06 0.05 7.73 5.84
Clic3 chloride intracellular channel 3 0.06 0.10 36.05 28.16
Alox15 arachidonate 15-lipoxygenase 0.36 0.33 14.83 8.44
Gpr39 G protein-coupled receptor 39 0.28 0.26 9.37 10.06
F2rl2 coagulation factor II (thrombin) receptor-like 2 0.27 0.17 6.30 3.45
Sgcd sarcoglycan, delta 0.32 0.46 16.96 10.50
(dystrophin-associated glycoprotein)
Stmn4 stathmin-like 4 0.07 0.07 9.56 4.83
Bnc1 basonuclin 1 0.40 0.27 2.53 1.05
Kcng1 potassium voltage-gated channel, subfamily G, 0.02 0.03 4.39 1.66
member 1
Fgf18 fibroblast growth factor 18 0.00 0.00 6.27 7.39
Krt13 keratin 13 0.00 0.00 15.56 12.22
Slc51a solute carrier family 51, alpha subunit 0.01 0.02 5.79 3.84
G0s2 G0/G1switch 2 1.41 2.38 13.00 2.59
Vegfc vascular endothelial growth factor C 0.00 0.01 5.24 2.71
Col14a1 collagen, type XIV, alpha 1 0.51 0.09 36.36 29.16
Down-regulated in outer myometrium
Prl7a4 prolactin family 7, subfamily a, member 4 615.67 1059.81 0.00 0.00
Prl8a2 prolactin family 8, subfamily a, member 2 1143.72 1959.30 3.19 2.34
Prl3a1 Prolactin family 3, subfamily a, member 1 47.32 77.57 0.00 0.00
Htr1d 5-hydroxytryptamine (serotonin) receptor 1D, 19.98 33.10 0.00 0.00
G protein-coupled
LOC171573 spleen protein 1 precursor 420.99 704.37 4.43 4.96
Dmrtc1c DMRT-like family C1c 24.73 42.72 0.00 0.00
Kit v-kit Hardy-Zuckerman 4 feline sarcoma 22.02 17.80 2.72 1.07
viral oncogene homolog
Fhod1 formin homology 2 domain containing 1 47.92 38.98 10.60 5.52
Mthfd2 methylenetetrahydrofolate dehydrogenase 40.92 35.76 7.10 0.63
(NADP+ dependent) 2, methenyltetrahydrofolate
cyclohydrolase
Grhl2 grainyhead-like 2 (Drosophila) 19.06 14.90 2.15 1.90
Slc11a2 solute carrier family 11, member 2 58.61 48.83 11.87 3.80
Fbxl12 F-box and leucine-rich repeat protein 12 34.71 25.31 6.65 0.69
Esrrg estrogen-related receptor gamma 17.58 16.18 0.62 0.21
Clustering analysis of the gene transcripts that were differentially expressed between the
decidua and the inner myometrium (Figure 7.16b), however, did not group all the tissue
replicates together. As with the case in which the decidua was compared to the inner
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myometrium, clustering analysis of the gene transcripts that were differentially expressed
between the decidua and the outer myometrium (Figure 7.16d) did not separate the tissues
into distinct groups either. In addition, clustering analysis of the DE gene transcripts
between the myometrial layers did not group the tissues appropriately (Figure 7.16f).
7.4.3 GD22(NL)
At term, gene transcripts that were differentially expressed between uterine tissues were
identified using three methods as listed in Table 7.5.
Table 7.5: Genes that were differentially expressed in non-labouring samples at term.
Differentially expressed genes between decidua, inner myometrium and outer myometrium were
identified using Cuffdiff, edgeR and DESeq2. A significance level of 5% as well as a multiple testing
correction threshold of 5% was applied in all cases.
Differential Analysis Method Identified by at
Comparison between: Cuffdiff DESeq2 edgeR least 2 methods
decidua & inner myometrium 195 51 307 136
decidua & outer myometrium 443 213 882 434
inner myometrium & outer myometrium 301 117 393 187
When compared to the decidua, 195 (Cuffdiff), 307 (edgeR), and 51 (DESeq2) gene tran-
scripts were differentially expressed in the inner myometrium at term in non-labouring,
GD22(NL), samples. A set of 136 gene transcripts, that were identified by at least two
methods, was considered to be the final set of DE gene transcripts between the decidua and
the inner myometrium. Of the 136 DE gene transcripts, 53% were upregulated in the inner
myometrium (Table D.6). In the outer myometrium, 434 gene transcripts were differentially
expressed compared to the decidua, and of these gene transcripts 77% were upregulated
(Table D.7), while 187 gene transcripts were differentially expressed compared to the inner
myometrium, 93% of which were upregulated (Table D.8).
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Figure 7.16: Comparisons of differentially expressed gene transcripts on GD20. Gene tran-
scripts were identified as differentially expressed by Cuffdiff (Cuff), edgeR, and DESeq2 between the (a –
b) decidua and the inner myometrium, (c – d) decidua and the outer myometrium, and (e – f) between
the inner and outer myometrial layers. Agglomerative hierarchical clustering was used to identify the
relationships among the decidua (dec), inner (inn) circular myometrium (myo), and outer longitudi-
nal myometrium (out). The tissues and gene transcripts were represented by the columns and rows,
respectively.
7.5. Gestational Changes in Transcript Abundance
7.4.4 GD22(L)
In labouring samples, gene transcripts that were differentially expressed between uterine
tissues were identified using Cuffdiff, edgeR and DESeq2. The numbers of the DE gene
transcripts are listed in Table 7.6.
Table 7.6: Genes that were differentially expressed in labouring samples at term.
Differentially expressed genes between decidua, inner myometrium and outer myometrium were
identified using Cuffdiff, edgeR and DESeq2. A significance level of 5% as well as a multiple testing
correction threshold of 5% was applied in all cases.
Differential Analysis Method Identified by at
least 2 methods
Comparison between: Cuffdiff DESeq2 edgeR
decidua & inner myometrium 260 21 67 35
decidua & outer myometrium 291 57 103 53
inner myometrium & outer myometrium 125 5 53 27
Between the decidua and the inner myometrium, 35 gene transcripts were differentially
expressed, and 26% of them were upregulated in the inner myometrium (see Table D.9).
Of the 53 gene transcripts that were differentially expressed in the outer myometrium in
comparison to the decidua, 64% were upregulated in the outer myometrium (see Table
D.10). Almost all the 27 gene transcripts that were differentially expressed by between the
myometrial layers were upregulated in the outer myometrium, with only two of the genes
down-regulated (see Table D.11).
7.5 Gestational Changes in Transcript Abundance
The analysis of the differential expression patterns of gene transcripts between consecu-
tive time points in control tissues was conducted using three methods; Cuffdiff, edgeR, and
DESeq2 as described in Section 6.2.2. If the associated p-value of a transcript, after mul-
tiple testing correction, was less than the predefined threshold of 5%, that transcript was
classified as differentially expressed by each of the methods. A final set of transcripts com-
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posed of those transcripts identified by at least two of the three methods, was considered
to be the bona fide set of differentially expressed transcripts. These sets of differentially
expressed transcripts were used for the analysis presented in this section. The numbers of
the gene transcripts that were considered significantly different between consecutive time
points within uterine tissues are shown in the graph in Figure 7.17.
7.5.1 Decidua
In the decidua, the number of transcripts that were differentially expressed between con-
secutive time points increased towards term. There was a 5-fold increase from the period
GD19+6hrs – GD20, to the period GD20 – GD22(NL), followed by a 2.5-fold increase in the
period GD22(NL) – GD22(L). Of the transcripts that were differentially expressed between
GD19+6hrs and GD20, 67% were upregulated as shown in Table 7.7. Less than a third of
the transcripts that were differentially expressed between GD20 and GD22(NL) were upreg-
ulated (see Table D.12), while the majority (91%) of the transcripts that were differentially
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Figure 7.17: Number of genes whose transcripts were differentially expressed between
consecutive time points. Number of genes differentially expressed between A: GD19+6hrs &
GD20, B: GD20 & GD22(NL), and C: GD22(NL) & GD22(L).
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expressed during labour were upregulated (see Supplementary Table D.13).
Table 7.7: Gene transcripts that were differentially expressed in the decidua, between
GD19+6hrs and GD20. Transcript expression levels are shown in transcripts per million (TPM)
values (mean±SD).
GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD 20
Fhl1 four and a half LIM domains 1 16.88 13.42 237.56 380.03
Hrsp12 heat-responsive protein 12 8.70 8.48 66.77 43.98
Klk8 kallikrein related-peptidase 8 0.24 0.42 35.05 60.72
Myf6 myogenic factor 6 0.01 0.01 23.79 41.20
Serpinb12 serpin peptidase inhibitor, 0.00 0.00 20.63 35.71
clade B (ovalbumin), member 12
Defa defensin alpha 0.00 0.00 8.08 13.99
Down-regulated on GD 20
B4galnt3 beta-1,4-N-acetyl-galactosaminyl transferase 3 9.43 5.75 0.03 0.06
Mybpc3 myosin binding protein C, cardiac 9.94 2.49 0.06 0.10
Iffo2 intermediate filament family orphan 2 11.42 4.14 0.11 0.20
7.5.2 Inner Myometrium
Instead of a pure increase or decrease, there was a bi-phasic change in the number of differen-
tially expressed mRNA transcripts in the inner myometrium. The number of differentially
expressed transcripts between consecutive time points in the inner myometrium rose be-
tween GD20 and GD22(NL), then fell between GD22(NL) and GD22(L). Of the transcripts
that were differentially expressed between GD19+6hrs and GD20, three were upregulated
as shown in Table 7.8. The greatest change in the expression pattern of transcripts in the
inner myometrium occurred between GD20 and GD22(NL), where the number of differen-
tially expressed transcripts rose to 102, 43% of which were upregulated (see Table D.14 for
more details). Once labour commenced, the number of differentially expressed transcripts
dropped to 10, with 60% of them being upregulated. Details of the gene transcripts are
given in Table D.15.
Table 7.8: Gene transcripts that were differentially expressed in the inner circular
myometrial layer, between GD19+6hrs and GD20. Transcript expression levels are shown
in transcripts per million (TPM) values (mean±SD).
GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD 20
Prl3a1 Prolactin family 3, subfamily a, member 1 0.08 0.15 47.32 77.57
Tmem37 transmembrane protein 37 22.56 10.44 65.21 31.84
Ascc1 activating signal cointegrator 1 complex subunit 1 5.04 1.17 36.51 23.90
Down-regulated on GD 20
Inmt indolethylamine N-methyltransferase 8.25 1.30 0.00 0.00
Col14a1 collagen, type XIV, alpha 1 13.78 5.92 0.51 0.09
7.5.3 Outer Myometrium
The opposite of the pattern observed in the decidua was observed in the outer myometrium,
with the number of differentially expressed transcripts decreasing towards term. Between
GD19+6hrs and GD20, there were 66 differentially expressed transcripts, while there were
51 and 9 transcripts differentially expressed between GD20 and GD22(NL), and between
GD22(NL) and GD 20 (L), respectively. Of the transcripts that were differentially expressed
between GD19+6hrs and GD20, 71% were upregulated, while 53% and 33% of the differ-
entially expressed transcripts were upregulated on GD22(NL) and GD22(L), respectively,
when compared to the preceding time point. The lists of gene transcripts whose expression
patterns changed significantly in the outer layer of the myometrium with the progression
of pregnancy are given in Table D.16, Table D.17, and Table 7.9, for changes occurring
between GD19+6hrs and GD20, GD20 and GD22(NL), and GD22(NL) and GD22(L), re-
spectively.
Table 7.9: Gene transcripts that were differentially expressed in the outer my-
ometrium, between GD22(NL) and GD22(L). Transcript expression levels are shown in
transcripts per million (TPM) values (mean±SD).
GD22(NL) GD22(L)
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD22(L)
Ano7 anoctamin 7 0.02 0.03 8.19 11.16
Prap1 proline-rich acidic protein 1 0.01 0.01 23.03 32.57
Tac1 tachykinin, precursor 1 0.00 0.00 13.35 17.54
Continued on next page
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Table 7.9 – continued from previous page
GD22(NL) GD22(L)
Gene symbol Gene name TPM ±SD TPM ±SD
Down-regulated on GD22(L)
Np4 defensin NP-4 precursor 106.03 165.90 0.58 0.00
Mpo myeloperoxidase 25.10 43.48 0.00 0.00
Clic3 chloride intracellular channel 3 15.03 7.96 0.00 0.00
Epx eosinophil peroxidase 8.26 13.38 0.04 0.06
Slc22a2 solute carrier family 22 7.63 11.10 0.06 0.03
(organic cation transporter), member 2
C9 complement component 9 5.34 8.19 0.09 0.02
7.6 Summary and Discussion
Previous studies of the uterine transcriptome have provided a wealth of information on the
molecular processes occurring in uterine tissues during late pregnancy and labour (Girotti
& Zingg, 2003; Salomonis et al., 2005; Arthur et al., 2008; Helguera et al., 2009). Most of
these studies, however, used samples that contained both endometrial and myometrial layers
(Girotti & Zingg, 2003; Arthur et al., 2008), or homogenised myometrial layers (Salomonis
et al., 2005; Helguera et al., 2009). In addition to indistinct tissue samples, these studies
employed methods microarray or qRT-PCR in the measurement of mRNA expression. As
such, to enable better understanding of uterine transcriptome within distinct layers of the
myometrium, the present study employed laser-capture microdissection (LCM), a technique
that enables the collection of homogeneous tissue, or individual cells, from heterogeneous
tissues (Murray, 2008). While this improves the specificity with which analyses in complex
tissues may be conducted, great care is required to maintain the integrity of the nucleic
acids, particularly RNA, within samples (Cle´ment-Ziza et al., 2008). To minimise the
degradation of RNA during the LCM process, staining for LCM tissues was conducted
using stains dissolved in ethanol. A combination of eosin yellow and cresyl violet enabled
the distinction of cell types while reducing degradation of RNA during LCM. In addition
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to using ethanol, tissues were stored at −80◦C or kept on dry ice when not in use. It is,
therefore, feasible to obtain RNA of good quality from LCM tissues, provided that the tissue
stains are prepared in a solvent that dehydrates the tissue, such as ethanol, and the tissue
samples are maintained at suitable temperatures.
7.6.1 Why Bother with RNAseq?
In order to improve the accuracy of the measurement of mRNA transcript abundance, and to
detect even those transcripts whose expression is low, a “next-generation” sequencing tech-
nique RNAseq was used to measure the expression of gene transcripts within LCM tissues
in the present study. While microarray technology may be used to generate transcriptomic
data, it has some weaknesses that are overcome by RNAseq. The main disadvantage of
microarrays is that they require that a set of nucleotide sequences be known prior to mea-
suring the abundance of transcripts within tissues, which is not always possible as some
experiments are exploratory. Combining the known set of nucleotides with the RNA ex-
tracted from samples, a process called hybridisation, which is required when conducting
microarray studies, may introduce biases that reduce the sensitivity of the technique (Ba-
ginsky et al., 2010). In addition, high numbers of biological replicates are required in order
to correctly measure the variability within biological replicates and identify differentially
expressed genes with microarrays (Pan et al., 2002; Churchill, 2002). While being rela-
tively expensive in comparison to microarrays, RNAseq does not require prior knowledge of
nucleotide sequences. As such, biases introduced due to hybridisation are avoided through
the use of RNAseq. In addition, using RNAseq enables the concurrent exploration of an
entire transcriptome and measuring of gene expression, which allows the identification of
novel transcripts (Mortazavi et al., 2008). Furthermore, it is possible to identify differen-
tially expressed genes while using low numbers of biological replicates, e.g., n = 2 or n = 3,
with RNAseq (Robinson et al., 2010). A recent study by Schurch et al. (2015), however,
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suggests that at least 20 biological replicates are required for RNAseq studies in order to
achieve a true positive rate of 85%.
To counteract the possibility of incorrectly classifying a gene as differentially expressed, the
work presented in this thesis utilised three differential expression analysis methods, and a
gene was considered differentially expressed only if it had been identified as such by at least
two of the methods. While this approach reduced the numbers of false positives, some gene
transcripts that were differentially expressed may have been ignored.
7.6.2 Can these Data be Trusted?
While only good-quality RNA was used in the preparation of sequencing libraries, the es-
timated transcript abundances in transcripts per million (TPM) showed great variability
among biological replicates. While differences in mRNA expression among biological repli-
cates may be attributed to the inherent biological differences among individuals, the biolog-
ical variability among similarly housed and treated animals is expected to be negligible. To
obtain a better picture of the variation among individuals within the same biological group,
the number of replicates could be increased as suggested by Schurch et al. (2015). How-
ever, the differential expression methods employed in this thesis take the variation among
individuals into account when assessing gene transcripts (Love et al., 2014). In addition,
two of the three methods employed, DESeq and edgeR, have been shown to yield credible
results using low numbers of biological replicates (Robinson et al., 2010). While increasing
biological replicates may improve the accuracy with which distinction may be made between
treatment groups, the results presented in this thesis can be considered to be credible.
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7.6.3 Tissue Specific Expression
A possible decidual marker in late pregnancy was identified in Section 7.2. The gene tran-
scripts encoding thyrotropin releasing hormone (Trh) were predominantly expressed in the
decidua across the four study time-points. Immunohistochemical staining for the Trh pro-
tein showed the localisation of Trh mainly in the decidua. Trh is known to stimulate the
release of prolactin, a known decidual marker, by the pituitary (Molitch, 2009).
A gene transcript that could be used to distinguish the inner myometrium from the outer
myometrium is the tenascin n (Tnn) gene transcript. Expression of Tnn was distinctly lower
in the outer myometrium in comparison to the inner myometrium at both the mRNA and
protein levels. Tenascin proteins are extracellular glycoproteins, which are known to be
expressed in the cervix (Mahendroo, 2012), skeletal tissue (Alford & Hankenson, 2006),
proliferating endometrial cells during the menstrual cycle in humans (Jabbour et al., 2006),
as well as in developing tissues (Neidhardt et al., 2003; Hsia & Schwarzbauer, 2005). There
are six known tenascin proteins; tenascin c, tenascin x, tenascin w, tenascin r, tenascin y,
tenascin r, and Tnn. Although Kida et al. (1997) observed changes in the uterine expression
of tenascin in early pregnancy, it is not clear which of the tenascin proteins was observed.
Thus it is proposed in the present study that Tnn is expressed in the decidual and myometrial
layers of the late-pregnant rat uterus, and that it is predominantly expressed in the inner
circular layer of the myometrium.
7.6.4 Spatial Gene Expression
For the first time, the spatial expression of gene transcripts was assessed and documented
in the present study. In addition, differences in the spatial expression of gene transcripts
between the myometrial layers were identified at all four time-points. The data presented
in Section 7.2 and Section 7.4 indicate that the transcriptional landscape of the inner my-
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ometrium differs significantly from that of the outer myometrium. These observations will
enrich current knowledge of the molecular processes occurring within uterine tissues.
7.6.5 Changes Occurring Towards Term
The pattern of differential expression illustrated in Figure 7.17 suggests that the uterus
begins preparing for labour in the outer layer of the myometrium followed by the inner
myometrium. This would suggest that the signal to prepare for labour emanates from
within the uterus itself, the outer layer in particular, and travels to the inner layer of the
myometrium.
The onset of labour coincides with the significant upregulation of mRNA transcript ex-
pression in the decidua. The gene transcripts upregulated in the decidua encode the fol-
lowing proteins among others: the voltage-dependent L type calcium channel α 1S sub-
unit (Cacna1s), which is a component of channels through which extracellular Ca2+ enters
the cell; gap junction proteins (Gjc2), which increase cell-to-cell coupling; glycoproteins
(Psg16, Psg19, and Psg21); apolipoproteins (Apoa2, Apoh, and Apom); solute carriers
(Slc1a2, Slc2a2, Scl32a1, and Slc7a9); members of the prolactin family (Prl3a1, Prl3b1,
Prl3c1,Prl7a4, and Prl8a4); cyclin dependent kinase (Cdk5r2); and phosphatases (Ptn5).
Gjc2 is expressed in the brain and spinal cord (Molica et al., 2014), the mutation of which
is associated with Pelizaues-Merzbacher-like disease and lymphedema (Molica et al., 2014)
While gap junction proteins are known to increase at term and during labour in the my-
ometrium (Garfield & Maner, 2007), the role of Gjc2 has not been previously described in
the uterus. As such, its role during parturition has not been described. Apolipoproteins
are involved in transporting lipoproteins that are used in the synthesis of steroid hormones
(Schreiber et al., 1985). While some of apolipoproteins are associated with the onset
of labour in humans (Yuan et al., 2012), their role during labour has not been charac-
129
7.6. Summary and Discussion
terised.
7.6.6 Extracellular Matrix Remodelling
The up-regulation of proteins involved in tissue remodelling is expected at term or dur-
ing labour. Matrix metalloproteinases (Mmps) are involved in the degradation of pro-
teins within the extracellular matrix which lead to the rupture of fetal membranes (Epstein
et al., 1998). In the present study, Mmp11 and Mmp12 mRNA transcript were signifi-
cantly upregulated in the inner myometrium at term, while Mmp7 and Mmp9 mRNA levels
were significantly upregulated in the outer myometrium during labour. Previously, Mmp7
(Girotti & Zingg, 2003) and Mmp9 (Chan et al., 2014) expression was found to increase
during labour in the myometrium. The data presented in this study, therefore, are consistent
with published literature. In addition, the observations made in the current study indicate
that the Mmps involved in the remodelling of the extracellular matrix during labour, are
synthesised in the outer myometrium.
7.6.7 Channels and Transporters
Potassium (K+) channels are involved in regulating the contractility of SMCs during preg-
nancy (Wray et al., 2014). In the present study, K+ voltage-gated channel subfamily G
member 1 (Kcng1) mRNA levels were upregulated in the outer myometrium on GD20, an
observation which is in direct contrast to that of Soloff et al. (2011) who observed the upreg-
ulation of Kcng1 mRNA following treatment of human myometrial cells with P4 in culture.
Also significantly upregulated in the outer myometrium on GD20 were mRNA transcripts
encoding hyperpolarisation-activated cyclic nucleotide-gated K+ channel 4 (Hcn4), which
is associated with ventricular myocyte hypertrophy (Lin et al., 2009a). Pregnancy is as-
sociated with myometrial growth as a result of the hypertrophy of uterine smooth muscle
130
7.6. Summary and Discussion
cells (SMCs) (Shynlova et al., 2010). The upregulation of Hcn4 in the outer myometrium,
therefore, is in line with observations made in the heart. At term, large conductance Ca2+-
activated K+ channel subfamily M β member 1 (Kcnmb1) mRNA expression was signifi-
cantly down-regulated in the outer myometrium. The Ca2+-activated K+ (BK) channels,
of which Kcnmb1 is a component, are expressed in myometrial SMCs where the protein and
mRNA expression levels are down-regulated during labour (Song et al., 1999; Matharoo-
Ball, 2002). The data presented in this chapter are in agreement with these findings.
Expression levels of mRNA transcripts encoding various solute carriers changed significantly
with the progression of pregnancy. Solute carrier family 51 α subunit (Slc51a) mRNA levels
were upregulated in outer myometrium on GD20 in comparison to GD19+6hrs. While that
of solute carrier family 22 (organic cation transporter) member 2 (Slc22a2) mRNA decreased
significantly during the same period in the outer myometrium. The genes whose transcripts
encode solute carrier family 17 member 3 (Slc17a3), solute carrier family 17 member 4
(Slc17a4), solute carrier family 1 (neutral amino acid transporter), member 5 (Slc1a5),solute
carrier family 4 member 1 (Slc4a1), solute carrier family 34 member 2 (Slc34a2), and so-
lute carrier family 5 (sodium/myo-inositol co-transporter), member 3 (Slc5a3) were down-
regulated in the inner myometrium at term. In contrast with observations made on GD20,
Slc22a2 mRNA expression levels were significantly upregulated in the outer myometrium at
term, suggesting that Slc22a2 may have a role during labour. While the level of expression
of solute carrier family 2 (facilitated glucose transporter), member 4 (Slc2a4) and solute
carrier family 48 (heme transporter), member 1 (Slc48a1) mRNA were reduced significantly
in the outer myometrium at term. Previously, Slc1a5 has been shown to be upregulated in
the myometrium during pregnancy in comparison to non-pregnant human myometrial sam-
ples (Rehman, 2003). In addition, Jeong (2005) observed the down-regulation of the gene
encoding Slc1a5 in uterine tissues following P4-treatment. The down-regulation of Slc1a5
at term appears to contradict these findings.
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7.6.8 G Protein-coupled Receptors
G protein-coupled receptors (GPCRs) are cell-surface receptors that mediate the effects
of numerous signalling molecules such as growth factors, hormones, and neurotransmitters
through G-proteins, which are composed of three subunits; α, β, and γ, that are attached
to the receptors inside the cell. (Gimpl & Fahrenholz, 2001). Activation of GPCRs such as
the oxytocin receptor (OTR) leads to an increase in intracellular Ca2+, which is favourable
for contraction of SMCs. In the present study, mRNA transcripts encoding G protein-
coupled 5-hydroxytryptamine (serotonin) receptor 2A (Htr2a), and G protein-coupled 5-
hydroxytryptamine (serotonin) receptor 4 (Htr4) were upregulated in the inner myometrium,
while G protein-coupled 5-hydroxytryptamine (serotonin) receptor 1D (Htr1d) mRNA lev-
els were upregulated in both the inner and outer myometrium at term. Serotonin is known
to stimulate contraction of SMCs through the action of Gq-coupled 5-hydroxytryptamine
receptors, the expression of which is upregulated in late pregnancy (Cohen et al., 1985;
Minosyan et al., 2007). The data presented in this study are consistent with published
literature. In addition, only Htr1d is upregulated in the outer myometrium at term as
opposed to the inner myometrium in which Htr1d, Htr2a, and Htr4 were upregulated, in-
dicating that the contractility of the two myometrial layers may be mediated by different
receptors. Significant upregulation of serotonin receptor mRNA indicates that OTR sig-
nalling is not the only GPCR that can mediate uterine SMC contraction. In fact, Nishimori
et al. (1996) observed normal labour in OTR knock-out mice. In contrast to the upregula-
tion of mRNA encoding serotonin receptors, mRNA encoding cannabinoid receptor 1 (Cnr1)
were down-regulated in the outer myometrium at term. Cnr1, which is coupled to Gαi/o,
inhibits adenylyl cyclase, thus increasing K+ conductance and decreasing Ca2+ conductance
(Childers & Deadwyler, 1996). The down-regulation of Cnr1 mRNA, therefore, leads to an
increase Ca2+ conductance and a decrease in K+ conductance, thus facilitating the entry of
extracellular Ca2+ into SMCs leading to contractions.
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7.6.9 Inflammatory Response
During gestation, the expression of pro-inflammatory genes is suppressed while anti-inflammatory
gene expression is elevated. During labour, the tables are turned and the expression of pro-
inflammatory genes is upregulated while that of anti-inflammatory genes is down-regulated
(Stephen et al., 2014). The data presented in the present thesis demonstrate the down-
regulation of anti-inflammatory genes; coagulation factor V (F5) and colony stimulating
factor 1 (Csf1) in the inner myometrium, and Bradykinin receptor B1 (Bdkrb1) in the outer
myometrium at term. The upregulation of pro-inflammatory gene transcripts; interleukin 1
receptor-like 1 in the decidua and interleukin 33 in the inner myometrium, at term was also
observed.
7.7 Conclusion
This chapter set out to study the transcriptional changes occurring in rat uterine tissues
following the systemic withdrawal of P4 on GD19 so as: to document the whole transcrip-
tome of the decidua, the inner myometrium, and the outer myometrium in late pregnancy
and at term; and establish the temporal expression patterns of gene transcripts across four
gestational time-points. To aid the separation of homogeneous decidual, inner myometrial,
and outer myometrial tissues from uterine horns, laser-capture microdissection was em-
ployed. RNA of good quality was successfully extracted from laser-captured tissue samples
and used to prepare sequencing libraries. Sequencing data, consisting of reads that were 51
be in length, were assessed for bias and aligned to the reference genome. The estimated
abundance of transcripts within the uterine tissues were documented and assessed for spatial
and temporal differences. In addition to the identification of the spatio-temporal changes
occurring in the respective myometrial tissues, a protein that may be used to distinguish the
inner layer of the myometrium from the outer layer of the myometrium in late pregnancy
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was identified.
The strength of the current study is in the use of two powerful techniques to interrogate
the transcriptomic changes occurring in uterine tissues in late pregnancy and during labour.
To the author’s knowledge, this is the first time that pure decidual, inner myometrial, and
outer myometrial tissues have been separated and analysed, not just for temporal changes,
but also for spatial differences in the expression of gene transcripts. This study has laid
the foundation for identification of other changes, such as differential splicing, in response
to the systemic withdrawal of progesterone within uterine tissues. A possible drawback
of the data presented here is the high variability among biological replicates. Increasing
the number of biological replicates may better reflect the variability within groups of sim-
ilarly treated tissues as opposed to n = 2 and n = 3. In conclusion, the onset of labour
at term is characterised by numerous changes that still require investigation. The use of
laser-capture microdissection and RNAseq has enabled the distinct separation of myometrial
tissues and allowed the identification of genes whose transcripts change significantly in late
pregnancy and during labour; including genes involved in immune/inflammatory response
and excitation-contraction coupling of smooth muscle cells. The findings in this study will
enrich the current knowledge of the transcriptomic changes associated with late gestation
and labour. the following chapter describes the expression patterns of genes encoding pro-
teins involved in the activation, as well as in the contraction, of smooth muscle.
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Chapter 8
Uterine Smooth Muscle
Contraction
The expression patterns of the genes that code for the proteins involved in the excitation
and subsequent contraction of uterine smooth muscle cells are analysed in this chapter
with the aim of elucidating their expression patterns in the inner myometrium and outer
myometrium.
Transcript expression values that were estimated using Sailfish (TPM values), were used to
assess the expression patterns of contraction-associated protein (CAP) gene transcripts.
Tests for significant differences in gene transcript expression were conducted using the
Kruskal-Wallis test with a significance level of 5%. Dunn’s multiple testing correction ap-
proach was also employed at a 5% level of significance. Expression patterns of some of the
CAP gene transcripts were validated using quantitative real-time PCR (qPCR).
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Figure 8.1: Oxytocin (Oxt) and oxytocin receptor (Oxtr) gene expression in the preg-
nant rat uterus. Expression levels are in transcripts per million (TPM), and the lines show the
mean expression levels ±SD with n = 3 for all time points except GD22(NL) where n = 2.
8.1 Oxytocin and the Oxytocin Receptor
In the inner myometrium, the levels of Oxytocin (Oxt) increased on GD20 but dropped
significantly at term and stayed low during labour as illustrated in Figure 8.1. While there
was a slight decrease in Oxt expression levels during labour, Oxt expression levels were
significantly higher than the Oxt levels at GD19+6hrs. In the outer myometrium, the levels
of oxytocin increased significantly towards labour. Oxytocin receptor (Oxtr) levels increased
gradually towards term and were at their highest during labour, in the inner myometrium
(Figure 8.1). Similarly, Oxtr levels in the outer myometrium increased gradually towards
term and were at their highest during labour.
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Figure 8.2: Ptgs1 mRNA transcript expression in myometrial tissues of the pregnant
rat uterus. Expression levels are in transcripts per million (TPM). The horizontal bars indicate
the mean expression levels. Sample size n = 3 for all time points except GD22(NL) where n = 2.
8.2 Prostaglandin-Endoperoxide Synthase mRNA Tran-
scripts
Ptgs1 mRNA expression fell between GD19+6hrs and GD20 in the inner myometrium (Fig-
ure 8.2). There was a further drop in expression on GD22(NL) which was followed by
a small increase on GD22(L). Despite the increase in expression on GD22(L), Ptgs1 ex-
pression levels were lower on GD22(L) than levels observed on GD19+6hrs. In the outer
myometrium, a sharp increase in Ptgs1 mRNA levels between GD19+6hrs and GD20 pre-
ceded a slight decrease in Ptgs1 expression levels on GD22(NL), which remained unchanged
on GD22(L).
Ptgs2 mRNA levels were relatively unchanged between GD19+6hrs and GD22(NL) followed
by a ten-fold increase in expression on GD22(L) in the inner myometrium (Figure 8.3). The
pattern of Ptgs2 expression in the outer myometrium was similar to that observed in the
inner myometrium where levels of expression were relatively unchanged between GD19+6hrs
and GD22(NL) followed by an increase on GD22(L).
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Figure 8.3: Ptgs2 mRNA transcript expression in myometrial tissues of the pregnant
rat uterus. Expression levels are in transcripts per million (TPM). The horizontal bars indicate
the mean expression levels. Sample size n = 3 for all time points except GD22(NL) where n = 2.
8.3 Expression of Transcripts Encoding Gap Junction
Proteins
Transcripts of 17 genes that encode gap junction proteins were identified in the vehicle
treated myometrial tissues. The mean (±SD) expression levels across the four gestational
time points of all the mRNA transcripts encoding gap junction proteins that were expressed
in myometrial tissues are summarised in Table 8.1.
Of the 17 gap junction protein-encoding genes expressed in myometrial tissues, the gene
encoding Gap junction δ 4 protein (Gjd4) was only expressed in the outer myometrium at
term. In both layers of the myometrium, the top five, in terms of average level of expression,
expressed mRNA transcripts were for the genes encoding the proteins Gap junction α 1
(Gja1), Gap junction β 2 (Gjb2), Gap junction α 5 (Gja5), Gap junction α 4 (Gja4), and
Gap junction α 7 (Gja7). The expression levels of these highly expressed transcripts are
assessed further in the subsequent sections.
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Table 8.1: Messenger RNA transcripts encoding gap junction proteins expressed in
the inner myometrium. Transcripts are expressed in transcripts per million (TPM) values
(mean±SD).
Inner Myometrium Outer Myometrium
Transcripts Transcripts
Gene per million ±SD per million ±SD
Gja1 243.16 154.99 309.86 83.71
Gjb2 230.14 186.63 198.36 124.29
Gja5 25.35 13.06 21.98 12.89
Gja4 19.64 22.70 18.76 18.20
Gja7 6.11 4.60 17.68 17.43
Gjb5 5.58 4.38 9.50 4.43
Gjb1 3.51 4.60 7.68 15.35
Gjb3 2.67 1.63 6.55 4.73
Gja3 1.75 1.29 5.75 8.67
Gjb4 1.07 0.92 4.31 4.43
Gjb6 0.71 0.45 2.28 0.40
Gja6 0.27 0.35 1.62 3.20
Gjc2 0.17 0.31 1.30 1.26
Gja10 0.10 0.16 1.31 0.88
Gjd2 0.01 0.01 0.87 0.91
Gja8 0.01 0.01 0.18 0.30
Gjd4 0.00 0.00 0.01 0.01
8.3.1 Gap junction α 1 (Gja1)
The RNAseq data indicate that there was a drop in the level of expression of Gja1, also
known as connexin 43 (Cx-43), mRNA transcripts between GD19+6hrs and GD20 in the
inner myometrium (Figure 8.4). This was followed by an increase at term, and a drop in
transcript levels during labour. There were no significant changes in the expression of Gja1
mRNA transcripts between GD19+6hrs and GD22(L). Gja1 mRNA expression in the outer
myometrium dropped slightly between GD19+6hrs and GD20, and increased at term as well
as during labour. Gja1 mRNA expression levels in the outer myometrium on GD19+6hrs
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Figure 8.4: Gja1 (Cx-43) mRNA transcript expression in myometrial tissues of the
pregnant rat uterus. Expression levels are in transcripts per million (TPM). The horizontal bars
indicate the mean expression levels. Sample size n = 3 for all time points except GD22(NL) where
n = 2.
and GD22(L) were similar, suggesting that there was negligible change in the levels of Gja1
mRNA expression between GD19+6hrs and GD22(L) as illustrated in Figure 8.4.
8.3.2 Gap junction β 2 (Gjb2)
An initial increase in Gjb2, also known as connexin 26 (Cx-26), mRNA expression be-
tween GD19+6hrs and GD20 was followed by a decrease in expression on GD22(NL) in
the inner myometrium (Figure 8.5). An increase in Gjb2 mRNA during labour led to the
expression levels on GD22(L) being higher than those observed on GD19+6hrs in the inner
myometrium. While Gjb2 expression levels fell between GD19+6hrs and GD20 in the outer
myometrium, there was no change in expression at term, but there was an increase during
labour. As a result, Gjb2 mRNA levels in the outer myometrium were higher in samples
obtained on GD22(L) than in samples acquired on GD19+6hrs (Figure 8.5).
8.3.3 Gap junction α 5 (Gja5)
The average expression of Gja5, also known as connexin 40 (Cx-40), in the inner myometrium
was approximately a tenth of Gja1 and Gjb2 expression in the inner myometrium (Table 8.1).
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Figure 8.5: Gjb2 (Cx-26) mRNA transcript expression in myometrial tissues of the
pregnant rat uterus. Expression levels are in transcripts per million (TPM). The horizontal bars
indicate the mean expression levels. Sample size n = 3 for all time points except GD22(NL) where
n = 2.
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Figure 8.6: Gja5 (Cx-40) mRNA transcript expression in myometrial tissues of the
pregnant rat uterus. Expression levels are in transcripts per million (TPM). The horizontal bars
indicate the mean expression levels. Sample size n = 3 for all time points except GD22(NL) where
n = 2.
Gja5 expression patterns in the inner myometrium were similar to those of Gja1 transcripts
that were observed in the outer myometrium (see Figure 8.6 and Figure 8.4). Outer my-
ometrium levels of Gja5 mRNA were, on average, 10% and 7% of Gjb2 and Gja1 mRNA
levels in the same tissue, respectively (Table 8.1). Between GD19+6hrs and GD20 the
level of Gja5 mRNA expression increased substantially and remained relatively unchanged
between GD20 and GD22(L) in the outer myometrium (Figure 8.6).
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Figure 8.7: Gja4 (Cx-37) mRNA transcript expression in myometrial tissues of the
pregnant rat uterus. Expression levels are in transcripts per million (TPM). The horizontal bars
indicate the mean expression levels. Sample size n = 3 for all time points except GD22(NL) where
n = 2.
8.3.4 Gap junction α 4 (Gja4)
Although the average level of expression of Gja4, also known as connexin-37 (Cx-37), mRNA
was 8% of Gja1 mRNA expression in the inner myometrium (Table 8.1), the patterns of
expression of Gja4 and Gja1 transcripts were similar as illustrated in Figure 8.7 and Fig-
ure 8.4. Gja4 mRNA levels on GD22(NL) were lower than those on GD19+6hrs. In the
outer myometrium, Gja4 transcript expression fell between GD19+6hrs and GD20, and fell
even further at term followed by a slight increase during labour.
8.3.5 Gap junction α 7 (Gja7)
Gja7 mRNA levels fell between GD19+6hrs and GD20, then increased on GD22(NL), and
fell again on GD22(L) in the inner myometrium (Figure 8.8), a pattern of expression that
was observed in the same tissue for Gja1 and Gja4 mRNA. There were more Gja7 transcripts
in both the inner and outer myometrium on GD19+6hrs than on GD22(L).
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Figure 8.8: Gja7 (Cx-45) mRNA transcript expression in myometrial tissues of the
pregnant rat uterus. Expression levels are in transcripts per million (TPM). The horizontal bars
indicate the mean expression levels. Sample size n = 3 for all time points except GD22(NL) where
n = 2.
8.3.6 Quantitative RT-PCR Experiments
Quantitative RT-PCR (qPCR) experiments were conducted for the genes encoding Oxt,
Oxtr, Ptgs1, Ptgs2, Gja1, and Gja7. Data from qPCR experiments (Figure 8.9) showed
an increase in relative Oxt mRNA expression throughout late gestation in the inner my-
ometrium, while in the outer myometrium, Oxt levels decreased on GD20, then increased
during labour. Validation experiments measuring expression of Oxt mRNA by qPCR showed
different patterns of expression to those observed by RNAseq in the inner myometrium. In
the outer myometrium however, the increase in expression detected by qPCR during labour
when compared to GD19+6hrs, is consistent with RNAseq results.
The expression of Oxtr mRNA relative to Actb in the inner myometrium was undetected
on GD19+6hrs and GD20, then increased remarkably at term, but dropped during labour
as shown in Figure 8.10. In the outer myometrium, the relative abundance of Oxtr mRNA
transcripts increased progressively in late pregnancy and reached peak levels at term. The
relative expression pattern of Oxtr mRNA in the outer myometrium matched that which
was observed in RNAseq experiments. In the outer myometrium, however, RNAseq and
qPCR findings did not agree.
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Figure 8.9: Relative abundance (mean±SD) of Oxt mRNA in myometrial tissues in
the pregnant rat. Expression was normalised to the abundance of β-Actin (Actb) mRNA. Here
n = 3 for all time points except GD22(NL) where n = 2.
Increases in Ptgs1 mRNA relative expression on GD20 and during labour were punctuated by
a drop in expression at term (Figure 8.11). In the outer myometrium, relative expression of
Ptgs1 mRNA increased throughout late pregnancy and were highest during labour. Similar
to the pattern of expression observed for Ptgs1 mRNA, inner myometrial expression of
Ptgs2 mRNA expression increased on GD20 then fell at term and increased during labour
(Figure 8.12). During labour, Ptgs2 expression were low in comparison to Ptgs1 levels in
the outer myometrium. RNAseq and qPCR results were different for both Ptgs1 and Ptgs2
in the inner and outer myometrium.
Relative expression of Gja1 mRNA peaked at term and dropped slightly during labour in
the inner myometrium, while expression in the outer myometrium peaked during labour
(Figure 8.13). In contrast, relative expression of Gja7 was at its lowest at term in the
inner myometrium (Figure 8.14), but peaked during labour in the outer myometrium. The
increase in Gja1 mRNA expression from GD20 to GD22(L), is in line with the observations
that were made using RNAseq data. However, the observations in the inner myometrium
for Gja1 and Gja7 mRNA, as well as for Gja7 in the outer myometrium, contradict those
of RNAseq experiments.
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Figure 8.10: Relative abundance (mean±SD) of Oxtr mRNA in myometrial tissues in
the pregnant rat. Expression was normalised to abundance of β-Actin (Actb) mRNA with n = 3
for all time points except GD22(NL) where n = 2.
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Figure 8.11: Relative abundance (mean±SD) of Ptgs1 mRNA in myometrial tissues
in the pregnant rat. Expression was normalised to abundance of β-Actin (Actb) mRNA with
n = 3 for all time points except GD22(NL) where n = 2.
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Figure 8.12: Relative abundance (mean±SD) of Ptgs2 mRNA in myometrial tissues
in the pregnant rat. Expression was normalised to abundance of β-Actin (Actb) mRNA with
n = 3 for all time points except GD22(NL) where n = 2.
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Figure 8.13: Relative abundance (mean±SD) of Gja1 mRNA in myometrial tissues in
the pregnant rat. Expression was normalised to abundance of β-Actin (Actb) mRNA with n = 3
for all time points except GD22(NL) where n = 2.
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Figure 8.14: Relative abundance (mean±SD) of Gja7 mRNA in myometrial tissues in
the pregnant rat. Expression was normalised to abundance of β-Actin (Actb) mRNA with n = 3
for all time points except GD22(NL) where n = 2.
8.4 Smooth Muscle Genes
The expression patterns of mRNA transcripts encoding proteins involved in the activation
and contraction of smooth muscle cells, namely: Actin; Caldesmon; Calmodulin; Calponin;
Myosin; Myosin light-chain kinase; and Tropomyosin were assessed in the inner and outer
layers of the myometrium.
8.4.1 Actin
In the inner myometrium, actin α-2 (Acta2) mRNA expression was at its highest on GD19+6hrs
then it decreased substantially on GD20 and remained relatively unchanged (Figure 8.15).
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Thus, Acta2 expression levels on GD22(L) were lower than levels on GD19+6hrs in the
inner myometrium. In the outer myometrium, Acta2 mRNA expression increased between
GD19+6hrs and GD20. Acta2 mRNA expression levels dropped on GD22(NL) to levels
that were similar to those observed on GD19+6hrs, then dropped even further on GD22(L).
On GD19+6hrs, Acta2 mRNA was more abundant in the inner myometrium than the outer
myometrium in contrast to the abundance observed on GD22(L).
Actin γ-2 (Actg2) mRNA levels in the inner myometrium decreased between GD19+6hrs
and GD20 (Figure 8.15). This decrease was followed by a further decrease in Actg2 mRNA
expression on GD22(NL) and an increase on GD22(L). The expression of Actg2 mRNA tran-
scripts in the inner myometrium was at its peak on GD19+6hrs. In the outer myometrium,
the highest level of Actg2 expression was observed on GD20 with the lowest expression
level on GD22(NL). On GD19+6hrs, Actg2 mRNA expression in the inner myometrium
was higher than that of the outer myometrium. On GD22(L), however, Actg2 mRNA levels
were higher in the outer myometrium compared to the inner myometrium.
8.4.2 Caldesmon 1 (Cald1)
Cald1 mRNA levels in the inner myometrium decreased between GD19+6hrs and GD20
then were relatively unchanged from GD20 through to labour (Figure 8.16). In the outer
myometrium, Cald1 mRNA levels increased on average (mean ± SD) from 92.93 ± 73.19
TPM to 491.70 ± 275.90 TPM between GD19+6hrs and GD20, falling to 118.00 ± 48.74
TPM at term and increasing to 227.40± 175.20 during labour.
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Figure 8.15: Expression of Acta2 and Actg2 mRNA transcripts in myometrial tissues of
the pregnant rat uterus. Expression levels are in transcripts per million (TPM). The horizontal
bars indicate the mean expression levels. Sample size n = 3 for all time points except GD22(NL)
where n = 2. Acta2: Actin α-2; Actg2: Actin γ-2
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Figure 8.16: Caldesmon 1 (Cald1) mRNA transcript expression in myometrial tis-
sues of the pregnant rat uterus. Expression levels are in transcripts per million (TPM). The
horizontal bars indicate the mean expression levels. Sample size n = 3 for all time points except
GD22(NL) where n = 2.
8.4.3 Calmodulin
Calmodulin 1 (Calm1) levels in the inner myometrium were relatively unchanged from
GD19+6hrs through to GD22(NL), with a decrease in expression during labour (Figure 8.17).
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Between GD19+6hrs and GD20, in the outer myometrium, there was an increase in Calm1
expression, followed by a drop in expression at term, and a slight increase during labour. In
the inner myometrium, Calmodulin 2 (Calm2) levels decreased gradually between GD19+6hrs
and GD22(NL), then remained unchanged during labour (Figure 8.17). In the outer my-
ometrium, however, Calm2 levels decreased between GD19+6hrs and GD22(NL), but in-
creased slightly during labour. Calmodulin 3 (Calm3) levels were relatively lower than
Calm1 and Calm2 levels in the inner myometrium, with average expression values of 72.6±
67.87 TPM, 483.1 ± 26.48 TPM, and 119.0 ± 30.63 TPM in the inner myometrium on
GD19+6hrs, respectively (Figure 8.17). Calm3 levels in the inner myometrium dropped
to about 24.66 ± 18.46 TPM on GD20, remained unchanged on GD22(NL), then dropped
further during labour. In the outer myometrium, Calm3 levels dropped between GD19+6hrs
and GD20, increased slightly on GD22(NL), followed by a slight decrease on GD22(NL).
8.4.4 Calponin
Calponin 1 (Cnn1) mRNA expression decreased towards term in the inner myometrium,
with a slight increase during labour (Figure 8.18). In the outer myometrium, however,
Cnn1 expression increased significantly between GD19+6hrs and GD20 (p < 0.05), followed
by a decrease at term and a slight increase during labour. Expression levels of mRNA
transcripts encoding calponin 3 (Cnn3) remained relatively unchanged throughout late ges-
tation and labour in the inner myometrium (Figure 8.18). Similarly, Cnn3 expression lev-
els in the outer myometrium were relatively unchanged across the four gestational time-
points, however, Cnn3 mRNA expression was elevated in one of the biological replicates on
GD19+6hrs.
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Figure 8.17: Calmodulin mRNA expression in the myometrium. Expression levels are in
transcripts per million (TPM). The horizontal bars indicate the mean expression levels. Sample
size n = 3 for all time points except GD22(NL) where n = 2. Calm1: Calmodulin 1; Calm2:
Calmodulin 2; Calm3: Calmodulin 3.
8.4.5 Myosin
In the inner myometrium, myosin light chain 6B (Myl6b) transcript expression levels dropped
on GD20 and GD22(NL) followed by an increase during labour (Figure 8.19). While in the
outer myometrium, there was an increase in Myl6b levels on GD20 and subsequent decreases
on the ensuing gestational days. Myosin light chain 9 (Myl9) gene transcript levels in the
inner myometrium dropped sharply between GD19+6hrs and GD22(NL), then increased
during labour (Figure 8.19). In the outer myometrium, Myl9 transcript expression increased
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Figure 8.18: Expression of Cnn1 and Cnn3 mRNA transcripts in myometrial tissues of
the pregnant rat uterus. Expression levels are in transcripts per million (TPM). The horizontal
bars indicate the mean expression levels. Sample size n = 3 for all time points except GD22(NL)
where n = 2. Cnn1: Calponin 1; Cnn3: Calponin 3.
significantly (p < 0.05) between GD19+6hrs and GD20 form an average of 41.85 ± 36.49
TPM to 4954.08± 3099 TPM. At term, Myl9 expression fell followed by an increase during
labour. Myosin light chain kinase (Mylk) expression patterns were similar to the observed
Myl9 expression patterns in both the inner and the outer myometrium (Figure 8.19). While
Mylk expression increased significantly between GD19+6hrs and GD20 in the outer my-
ometrium as did Myl9, Myl9 expression levels were five times higher than Mylk expression
levels.
8.4.6 Tropomyosin
Expression of Tropomyosin 1α (Tpm1) and Tropomyosin 2β (Tpm2) mRNA transcripts
was similar in the inner myometrium; there was a decrease in expression on GD20, which
was followed by a further decrease at term and slight elevation during labour (Figure 8.20).
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Figure 8.19: Expression of myosin and myosin kinase mRNA in myometrial tissues.
Expression levels are in transcripts per million (TPM). The horizontal bars indicate the mean
expression levels. Sample size n = 3 for all time points except GD22(NL) where n = 2. Myl6b:
Myosin light chain 6B; Myl9: Myosin light chain 9; Mylk: Myosin light chain kinase.
In the outer myometrium, the expression patterns of Tpm1 and Tpm2 were also similar,
with increase in expression on GD20 followed by a decrease at term and increase during
labour. Tpm1 and Tpm2 are, therefore, expressed similarly within myometrial tissues, but
not between the myometrial tissues. There was a slight drop in Tropomyosin 3 (Tpm3)
mRNA levels between GD19+6hrs and GD20 in the inner myometrium, which was followed
by an increase at term and a slight decrease in expression during labour (Figure 8.20). In
the outer myometrium, Tpm3 mRNA levels were unchanged between GD19+6hrs and GD20
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followed by an increase at term and a slight decrease in expression during labour. Average
Tropomyosin 4 (Tpm4) mRNA expression levels were similar on GD19+6hrs and GD22(L)
in the inner myometrium (Figure 8.20). Similarly, Tpm4 mRNA expression levels in the
outer myometrium were similar on GD19+6hrs and GD22(L).
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Figure 8.20: Expression of tropomyosin mRNA in myometrial tissues. Expression levels
are in transcripts per million (TPM). The horizontal bars indicate the mean expression levels.
Sample size n = 3 for all time points except GD22(NL) where n = 2. Tpm1: Tropomyosin 1α;
Tpm2: Tropomyosin 2β; Tpm3: Tropomyosin 3; Tpm4: Tropomyosin 4.
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8.5 Summary and Discussion
8.5.1 Contraction-Associated Proteins
The onset of labour is associated with an increase in the expression of CAPs within the uterus
(Fuchs et al., 1984). As such, it is to be expected that the increase in protein expression is
due to the upregulation of the gene transcripts that code for CAPs. In addition to assessing
the temporal expression of CAP-encoding gene transcripts, the present study assessed the
spatial expression of the genes encoding CAPs. For the first time, the differences, and
similarities, in CAP expression between the inner myometrium and the outer myometrium
have been documented. Data presented in Section 8.1 show that Oxt mRNA levels increases
significantly immediately following the systemic withdrawal of P4, then drops significantly at
term in the inner myometrium. Conversely, in the outer myometrium Oxt mRNA expression
increases significantly between GD19+6hrs and GD22(L). In contrast to published literature,
neither a significant up- (Cook et al., 2000; Helguera et al., 2009) nor down-regulation
(Phaneuf et al., 2000; Mittal et al., 2010; Chan et al., 2014) of mRNA encoding the Oxtr
was observed in the current study. Though not identified as significant, Oxtr mRNA levels
increased throughout late gestation reaching peak expression levels during labour in both
the inner and outer myometrium, which may be considered to be consistent with some of
the published literature.
Labour in the rat is preceded by the systemic withdrawal of P4, which is brought about by
the luteolytic effects of PGF2α, whose synthesis is dependent upon Ptgs1 and Ptgs2 enzymes
(Sugimoto et al., 2015). The expression of both Ptgs1 and Ptgs2 has been previously shown
to increase at term and during labour in rat myometrium (Dong et al., 1996). The data
presented in Section 8.2 indicate that Ptgs1 mRNA expression in the inner myometrium de-
creases following the withdrawal of P4. In addition, Ptgs1 gene transcript expression in the
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outer myometrium decreases following an initial increase on GD20. Ptgs2 mRNA expression
is upregulated during labour in both the inner and the outer myometrium. These observa-
tions are in line with literature, which suggests that the induction of Ptgs2 is responsible
for the increase in PGF2α, which leads to luteolysis and P4 withdrawal in rats (Condon
et al., 2004). While the reduction in the expression of Ptgs1 mRNA in myometrial tissues
may seem contradicting to the findings of Dong et al. (1996), it has been shown that the
lack of Ptgs1 proteins does not inhibit labour. Instead, labour is delayed, indicating that
the inducible Ptgs2 protein plays a larger role in the onset of parturition in the rat than the
constitutive Ptgs1 protein (Ratajczak & Muglia, 2008; Funk et al., 2009).
8.5.2 Gap Junction Proteins
Gap junction proteins, Gja1 in particular, are known to increase in late pregnancy and
during labour (Garfield & Maner, 2007). Ou et al. (1997) demonstrated that Gja1 and
Gjb2 are the most abundant gap junction proteins in the myometrium, an observation that
was also made in the present study. In addition to Gja1 and Gjb2, the gap junction proteins
Gja5, and Gja7 have been previously identified in myometrial tissues (Albrecht et al., 1996;
Garfield & Maner, 2007; Kidder & Winterhager, 2009). The spatial expression of mRNA
encoding gap junction proteins however, had not been described prior to this study. There
was no significant increase in Gja1 mRNA expression within either myometrial layer as was
observed by Helguera et al. (2009). Since Gja1 proteins are synthesised prior to term and
stored within vesicles in the cytoplasm then transported to plasma membranes at the onset
of labour (Hendrix et al., 1992), the absence of a significant increase in Gja1 myometrial
mRNA expression is to be expected. Instead of increasing, Gja1 mRNA levels fell in the inner
myometrium. In the outer myometrium, however, a slight increase in the expression of Gja1
mRNA was observed. The differences in the pattern of Gja1 expression between myometrial
tissues has also been observed in bovine myometrium (Doualla-Bell et al., 1995).
156
8.5. Summary and Discussion
Gjb2, whose expression is induced by P4 treatment, has been shown to decrease significantly
at term prior to labour (Ou et al., 1997; Kidder & Winterhager, 2009). On GD20 and
during labour, Gjb2 mRNA was more abundant than Gja1 mRNA in the inner myometrium,
suggesting that the Gjb2 protein may play a significant role during labour. In the outer
myometrium, however, Gja1 mRNA transcripts were the most abundant among all gap
junction mRNA transcripts. Also in the outer myometrium, Gjb2 mRNA expression levels
dropped on GD20 and at term as has been previously described. While expression patterns
of Gjb2 mRNA in the outer myometrium are consistent with the literature, the pattern of
expression observed in the inner myometrium is somewhat different.
Data presented in Section 8.3.3 indicate that Gja5 mRNA expression in the inner my-
ometrium increases towards term following an initial drop on GD20. In the outer my-
ometrium, however, Gja5 mRNA levels increase on GD20 and remain unchanged during
labour. Since Gja5 knock-out mice are fertile (Simon et al., 1998), the role of Gja5 in
the uterus is unclear. Gja7 mRNA expression in the inner and outer myometrium is down-
regulated between GD19+6hrs and GD22(L), observations that are consistent with those
made by Albrecht et al. (1996) who suggested that the ratio of Gja1 and Gja7 proteins
may be vital to the coupling of SMCs during labour. The data presented in this thesis,
also indicate that other gap junction proteins apart from Gja1, Gjb2, Gja5, and Gja7 are
expressed in rat myometrial tissues
8.5.3 Smooth Muscle Genes
Contraction of SMCs is brought about by the interaction of a host of proteins; calmodulin
(Calm) binds Ca2+ and activates myosin light-chain kinase (Mylk) enzymes, which phospho-
rylate and activate myosin. Filaments, composed of the phosphorylated myosin, slide over
thin filaments, which are composed of actin, caldesmon, and tropomyosin proteins result-
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ing in the contraction of SMCs (Garfield & Maner, 2007). The expression of the proteins
involved in the contraction of SMCs in the two layers of the rat myometrium have been
assessed and documented in the present study, which had not been done previously.
The data presented in Section 8.4.1 indicate that Acta2 (α-actin) mRNA expression was
considerably lower during labour in comparison to levels observed on GD19+6hrs in the
inner myometrium. While in the outer myometrium, Acta2 mRNA levels were relatively
higher than those on GD19+6hrs. These observations seem to contradict the observations
made by Shynlova (2005), whereby α-actin mRNA expression remained high in the my-
ometrium throughout gestation relative to samples obtained from non-pregnant rats. How-
ever, Shynlova (2005) observed a decrease in the relative fold change between gestation day
20 and day 23, suggesting a decrease in expression. Similar to the Acta2 mRNA expression
levels in the inner myometrium, the mRNA expression levels of the Actg2 (γ-actin), in the
inner myometrium were low during labour in comparison to GD19+6hrs expression levels.
In the outer myometrium, however, Acta2 mRNA levels during labour were relatively simi-
lar to those observed on GD19+6hrs. Shynlova (2005), observed significant increases in the
expression of γ-actin protein in the inner myometrium between the 18th and the 21st day
of gestation in the rat, an observation which is contradicted by the findings of the present
study. The only agreement between the data presented in Section 8.4.1 and the observa-
tions made by Shynlova (2005) is that γ-actin is highly expressed throughout late gestation
in comparison to α-actin. Comparison of mRNA expression to protein expression is not
always possible as these data demonstrate. In addition, Shynlova (2005) could not differen-
tiate between smooth muscle γ-actin and cytoplasmic γ-actin due to the non-specific nature
of the antibody that was used, hence it is not possible to refute or confirm their observa-
tions. Furthermore, Arnoldi et al. (2013) observed a significant increase in the expression
of the smooth muscle γ-actin protein on the 18th day of gestation in the myometrium of
the rat using immunoblotting, when compared to non-pregnant rat myometrium. How-
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ever, the specific layer of the myometrium in which these changes were observed was not
determined.
The tissue specific expression patterns of the actin-binding proteins caldesmon and calponin
have been described in the present study. The average expression levels of Cald1 mRNA
in the inner and outer myometrium were relatively similar, however, the patterns of ex-
pression within the tissues were different. Cald1 mRNA levels in the inner myometrium
decreased slightly then remained unchanged whilst outer myometrium levels increased ini-
tially, declined, then increased again. Expression of Cnn1 and Cnn2 mRNA levels in the
inner myometrium were low during labour in comparison to GD19+6hrs levels. There was
significant upregulation of Cnn1 mRNA expression on GD20. While the expression of genes
encoding caldesmon and calponin has been shown to increase in differentiated cultured
SMCs in comparison to dedifferentiated SMCs (Sobue et al., 1999), the tissue specific ex-
pression patterns of calmodulin and calponin mRNA transcripts have not been previously
determined.
Most studies have focused on the regulation of SMC contraction by calmodulin (Walsh, 1994),
the interactions between calmodulin and Ca2+, as well as myosin light chain kinase (Fajmut
et al., 2005), and the effect of calmodulin on the gating kinetics of gap junction channels
(Peracchia et al., 2014). The spatial expression of the mRNA transcripts encoding the
calmodulin isoforms, therefore, are presented in this thesis for the first time. The dynamics
of tropomyosin are discussed in the review by El-Mezgueldi (2014), however, the expression
patterns of the mRNA transcripts encoding various tropomyosin protein isoforms have not
been described. In the present study, the spatial and temporal expression patterns of mRNA
transcripts encoding four tropomyosin protein isoforms; Tpm1, Tpm2, Tpm3, and Tpm4,
were described (Section 8.4.6).
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8.6 Conclusion
The aim of this chapter was to analyse the pattern of expression of genes encoding proteins
involved in excitation-contraction coupling in the inner myometrium and the outer my-
ometrium. As with the previous chapter, the separation of the inner and outer myometrium
enabled the identification of distinct patterns of mRNA expression between the two layers
of the myometrium.
Expression patterns of contraction-associated proteins; Oxtr, Ptgs1, Ptgs2, and numerous
gap junction proteins, were analysed. In addition, 17 gap junction proteins were detected in
myometrial tissues, 5 of which had an average level of expression that was greater than 10
TPM in at least one of the tissues. It was also noted that mRNA transcripts encoding the
gap junction protein Gjb2 are more abundant than Gja1 in the inner myometrium at some
stages during late gestation. While qPCR data largely contradicted the RNAseq data, the
observations made using RNAseq data were found to be consistent with published literature.
The author, therefore, asserts that the RNAseq data are accurate. However, the use of more
than one, or a different, housekeeping gene may yield qPCR results that are more agreeable
with the RNAseq data.
In line with the aim of the chapter, the expression patterns of the “so-called” smooth muscle
genes, i.e., genes encoding smooth muscle actin caldesmon, calmodulin, calponin, myosin,
myosin light-chain kinase, and tropomyosin, were assessed in the inner and outer layers
of the myometrium. As far as the author is aware, the spatial patterns of expression of
smooth muscle gene transcripts are documented in this chapter for the first time. In con-
clusion, identification of the spatio-temporal expression of genes encoding proteins involved
in smooth muscle excitation-contraction coupling will further enrich current knowledge into
the molecular processes occurring in uterine tissues in the run-up to labour, and in preterm
labour. The following chapter describes the changes in expression of mRNA transcripts
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within uterine tissues that occur in response to treatment with a progesterone receptor
antagonist.
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Chapter 9
Transcriptomic Effects of
Progesterone Receptor
Antagonist-Induced
Progesterone Withdrawal
In the work presented in this chapter, the partial PR antagonist Mifepristone described
in Section 2.3.3 was used in the identification and analysis of transcriptomic changes that
occurred in response to the withdrawal of progesterone (P4) in the rat uterus. This chapter
aims to identify the gene transcripts whose expression changed in response to treatment
with Mifepristone in the decidua, inner circular myometrium, and the outer longitudinal
layer of the myometrium; and to further elucidate the transcriptional changes that occur
during preterm labour in uterine tissues.
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9.1 Transcriptomic Landscape of the Mifepristone-Treated
Rat Uterus
A total of 6 pregnant Sprague-Dawley rats were treated with 3 mg of Mifepristone by sub-
cutaneous injection on GD19. Three of the rats were sacrificed 6 hours following treatment,
on GD19+6hrs, and the remaining three were sacrificed 24 hours post-treatment, on GD20.
Mifepristone-treated rats delivered on GD20, however, tissues from labouring rats were
not provided. Professor Robert Garfield, at St. Joseph’s Hospital and Medical Centre in
Phoenix (USA) treated the rats and harvested whole uterine horns which were flash-frozen
in liquid nitrogen, then stored at −80◦C until required. Laser capture microdissection
(LCM), a technique for separating cells from tissues, was used to collect homogenous tissue
samples containing decidua, inner myometrium, or outer myometrium cells as described in
Section 5.4. RNA was isolated from each of the samples, and only RNA with a RIN score
≥6 (see Section 5.5.2 for checking of RNA integrity) was used for library preparation and
sequencing as described in to Section 5.6.
Over 589.56 million reads were sequenced across all the libraries that were generated from
Mifepristone-treated tissues, of which 50.44% were sequenced from GD19+6hrs libraries, and
the remaining 49.56% from GD20 libraries as illustrated in Figure 9.1. Table 9.1 provides
details on the number of reads that were generated per sample. Here, a sample represents
each of the three uterine tissues; decidua, inner circular myometrium, and outer longitu-
dinal myometrium, obtained on both GD19+6hrs and GD20, from three biological repli-
cates. Mifepristone-treated samples from GD19+6hrs generated between 19,597,589 and
51,977,455 reads each, while those from GD20 generated between 21,584,276 and 40,005,053
reads each. On average, 32.75 million paired-end reads were sequenced per sample, 79.96%
of which were aligned to the reference genome. Of the aligned reads, 71.15% were defined as
expressed across the 2 gestational time points, and all the tissues. The expressed transcrip-
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Figure 9.1: Number of reads in sequencing files generated from Mifepristone-treated
tissues. The average number of reads generated from decidua, inner myometrium and outer
myometrium samples obtained on GD19+6hrs, and GD20. The error bars indicate the standard
deviation of the number of reads within a group of biological replicates.
tome was covered 16.09×, and 18.06× on average with respect to GD19+6hrs, and GD20
samples. Details of the sequencing coverage are provided in Table 9.1.
The abundance of transcripts was estimated using three methods: HTSeq, which was used
to estimate the number of transcripts (counts); Cuﬄinks (Section 6.2.1), which was used
to estimate abundance in the form of reads per kilobase per million (RPKM); and Sailfish
(Section 6.2.1), which was used to estimate transcripts per million (TPM) values.
9.1.1 Principal Component Analysis
Principal component analysis (PCA) of the non-zero TPM values estimated using Sailfish
was employed to determine the expression patterns of gene transcripts within Mifepristone-
treated tissues. PCA was conducted as described in Section 6.1 using the princomp function
in R as follows:
myPCA = princomp(∼.,data = myData, na.action = na.exclude, cor = FALSE),
where ∼. indicates that all the Mifepristone-treated tissue samples in the data matrix,
represented by myData, were used in the estimation of principal components (PCs), while
na.action = na.include indicates all transcripts “NA” expression values were not used in the
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Table 9.1: Alignment of sequenced reads to the Rattus norvegicus transcriptome and
coverage statistics of sequences generated from Mifepristone-treated tissues. Gestation
- The day during pregnancy on which the uterine sample was collected. Tissue - The layer of the
uterus that was separated from the other tissues using laser-capture microdissection. The number
illustrates the replicate number. % Aligned - The proportion of the sequenced reads that were
aligned successfully to the Rattus norvegicus transcriptome using Tophat2. % Expressed features
- The proportion of genes to which counts were assigned by HTSeq. Expressed transcriptome
(× covered) - The number of times the expressed transcriptome was covered by the sequenced
reads.
Sample Expressed
% Expressed transcriptome
Gestation Tissue Total reads % Aligned features (× covered)
GD19+6hrs Decidua 1 30,347,943 74.90 64.87 17.97
GD19+6hrs Decidua 2 19,597,589 75.90 58.14 13.30
GD19+6hrs Decidua 3 33,752,940 76.80 86.04 9.44
GD19+6hrs Inner Myo 1 51,977,455 71.30 64.67 16.11
GD19+6hrs Inner Myo 2 25,312,372 77.50 67.38 16.64
GD19+6hrs Inner Myo 3 28,370,936 80.90 64.06 23.05
GD19+6hrs Outer Myo 1 31,354,384 78.00 79.73 7.30
GD19+6hrs Outer Myo 2 41,546,591 82.50 74.44 22.15
GD19+6hrs Outer Myo 3 35,108,356 75.30 54.29 18.86
GD20 Decidua 1 25,280,743 82.60 61.09 11.42
GD20 Decidua 2 22,500,156 80.00 70.62 12.83
GD20 Decidua 3 43,464,337 85.80 81.05 25.56
GD20 Inner Myo 1 30,661,735 78.00 71.08 16.05
GD20 Inner Myo 2 33,480,557 84.20 78.60 12.05
GD20 Inner Myo 3 37,905,128 80.90 67.91 29.06
GD20 Outer Myo 1 37,314,111 86.60 74.15 22.08
GD20 Outer Myo 2 21,584,276 82.80 82.88 8.92
GD20 Outer Myo 3 40,005,053 85.20 79.64 24.60
estimation of PCs, and cor = FALSE indicates that the correlation matrix was not used in
the estimation of PCs. The number of PCs used to assess the relationship among the data
were selected as described in Section 6.1.2.
GD19+6hrs
To determine the number of PCs to retain for analysis, the cumulative proportion of variance
accounted for by the PCs was considered (Table 9.2), as well as a plot of the eigenvalues
(Figure 9.2). The first two PCs, PC1 and PC2, accounted for more than 85% of the variation
within the data. In addition, the plot of variances indicated that the remaining PCs, PC3–
PC9, accounted for a negligible proportion of the variation within the data. As such, two
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Table 9.2: Variance accounted for by principal components. Shown are the proportions of
variance, as well as the cumulative proportion of variance, accounted for by principal components
estimated using transcript expression values for generated from Mifepristone-treated tissue samples
obtained on GD19+6hrs and GD20. PV (%): proportion of variance explained, expressed as
a percentage; CP (%): cumulative variance explained, expressed as a percentage; and Comp.:
principal component.
GD19+6hrs GD20
PV (%) CP (%) PV (%) CP (%)
Comp.1 72.87% 72.87% 66.24% 66.24%
Comp.2 22.24% 95.11% 18.82% 85.06%
Comp.3 2.11% 97.22% 6.18% 91.24%
Comp.4 1.27% 98.49% 4.19% 95.43%
Comp.5 1.11% 99.60% 2.91% 98.34%
Comp.6 0.24% 99.84% 0.90% 99.24%
Comp.7 0.11% 99.95% 0.56% 99.80%
Comp.8 0.03% 99.98% 0.14% 99.94%
Comp.9 0.02% 100.00% 0.06% 100.00%
Comp.1 Comp.3 Comp.5 Comp.7 Comp.9
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Figure 9.2: Plot of the eigenvalues of the covariance matrix of data generated from
Mifepristone-treated tissue samples obtained on GD19+6hrs. The low variance accounted
for by principal component (Comp.) numbers 5–9 suggests that the first two principal components
should be retained for analysis.
PCs were retained for further analysis.
A plot of the retained PCs (Figure 9.3) did not show distinct separation of all the three
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Figure 9.3: Principal component analysis (PCA) of mRNA expression in Mifepristone-
treated tissue samples on GD19+6hrs. Transcripts per million (TPM) abundances were used
for PCA. The variance within the data which is accounted for by each of the principal components
is displayed next to the corresponding principal component. PC1: the first principal component;
and PC2: the second principal component;
uterine tissues on GD19+6hrs. However, there was clear separation of two groups; one con-
sisting of two decidual samples and one inner myometrial sample, and the other composed of
all the outer myometrial tissue samples, as well as one each of decidual and inner myometrial
samples. One of the decidual samples and the inner myometrial sample in the former group,
were obtained from the same uterine sample, suggesting that the inner myometrial sample
may have been contaminated with decidual cells. However, given the care that was taken in
ensuring accurate selection of specific cell types, the similarity between these samples may
indicate that this particular inner myometrial sample and the decidual sample that grouped
with the rest of the samples were mislabelled. Assessment of the laser-capture and RNA
isolation experiments showed that the inner myometrial sample, which was grouped together
with the two decidual samples, was collected on the same day as the decidual samples, and
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RNA was also extracted on the same day. In addition, the quantification or the RNA and
the subsequent checks for integrity, as well as library preparation, were all conducted on the
same day, further pointing to the increased likelihood of mislabelling the samples. Despite
this observation, none of the samples were excluded from further analyses as it was believed
that the methods employed were robust enough to “weed out” any outliers. Furthermore,
there was distinct variability between one of the outer myometrial samples and the other
two outer myometrial samples. Since this particular sample was neither lasered nor have
RNA extracted from it on the same day as the suspected mislabelled samples, the variability
was attributed to inherent biological variability.
GD20
Data generated from Mifepristone-treated tissue samples that were obtained on GD20 were
subjected to PCA as previously described. PC1 and PC2 accounted for a cumulative pro-
portion of 85.06% of the total variation within the GD20 data (Table 9.2). In addition,
the scree plot of the eigenvalues (Figure 9.4) shows that the first two principal components
explain the bulk of the variability within the data. Therefore, PC1 and PC2 were retained
for further analysis.
The plot of the first two PCs in Figure 9.5 shows that there was more variation between
tissues on GD20 in comparison to GD19+6hrs. However, not all samples within the same
biological group were closely associated with their group-mates as one outer myometrial
sample was closely associated with the decidua samples, indicating that mRNA transcript
expression within that sample was similar to the expression within decidual samples.
9.1.2 Spatial Expression Patterns
To assess specific mRNA expression patterns within uterine tissues, the following three
methods were employed: Cuffdiff, which utilises the RPKM values estimated by Cuﬄinks
as input; edgeR; and DESeq2, both of which use the gene transcript counts estimated by
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Figure 9.4: Plot of the eigenvalues of the covariance matrix of data generated from
Mifepristone-treated tissue samples obtained on GD20. The low variance accounted for by
principal component (Comp.) numbers 5–9 suggests that the first two principal components may
be retained for analysis.
HTSeq as input. For each method, a transcript was considered differentially expressed if the
associated q-value (Cuffdiff), false discovery rate (edgeR), or the adjusted p-value (DESeq2)
was less than a threshold of 5%. Transcripts that were identified as differentially expressed
by at least 2 of the 3 methods were used in the analyses presented in this section.
GD19+6hrs
There were 190, 30, and 36 transcripts that were identified as differentially expressed be-
tween the decidua and the inner myometrium by Cuffdiff, edgeR, and DESeq2, respectively
as illustrated in Figure 9.6a. A set of 23 transcripts were identified by at least 2 methods,
78% of these were upregulated in the inner myometrium. A list of the 23 genes that were
differentially expressed together with their levels of expression in the decidua and the inner
myometrium are listed in Supplementary Table E.1. The heat map in Figure 9.6b pointed
to a distinct separation of the decidua and the inner myometrium when agglomerative hier-
archical clustering was employed. The Venn diagram in Figure 9.6c represents the overlap
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Figure 9.5: Principal component analysis (PCA) of mRNA expression in Mifepristone-
treated tissue samples on GD20. Transcripts per million (TPM) abundances were used for
PCA. The variance within the data which is accounted for by each of the principal components is
displayed next to the corresponding principal component. PC1: the first principal component; and
PC2: the second principal component;
between the number of genes identified as differentially expressed between the decidua and
the outer myometrium by Cuffdiff (Cuff), edgeR and DESeq2. A total of 225 genes were iden-
tified by at least 2 methods, of which 64% were upregulated in the outer myometrium, details
of which are provided in Supplementary Table E.2. Agglomerative hierarchical clustering
of the differentially expressed genes separated the tissues and the differentially regulated
genes into distinct clusters as illustrated in Figure 9.6d. Cuffdiff identified 123 transcripts
that were differentially expressed between the inner and the outer myometrium, while edgeR
identified 1, and DESeq identified 6. The genes identified by DESeq2 were not identified by
any of the other methods; the gene encoding for the doublesex and mab-3 related transcrip-
tion factor 2 (Dmrt2), was the only gene identified as differentially expressed by Cuffdiff and
edgeR between the myometrial layers.
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Figure 9.6: Spatial expression of gene transcripts on GD19+6hrs. Gene transcripts
were identified as differentially expressed by Cuffdiff (Cuff), edgeR and DESeq2 between the (a–b)
decidua and the inner myometrium, and between the (c–d) decidua and the outer myometrium.
Agglomerative hierarchical clustering was used to identify the relationships among the decidua
(dec), inner (inn) circular myometrium (myo), and outer longitudinal myometrium (out). The
tissues and gene transcripts are represented by the columns and rows, respectively.
GD20
The decidua and inner myometrial samples on GD20 had 33 differentially expressed tran-
scripts between them as identified by at least two of the three methods (Figure 9.7a). Clus-
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tering of the 33 genes, 15% of which were upregulated in the inner myometrium, segregated
the tissues and genes distinctly as illustrated by the heat map in Figure 9.7b. Figure 9.7c
and Figure 9.7d show that 8 gene transcripts were differentially expressed between the de-
cidua and the outer myometrium, and that clustering of the z-scores of the differentially
expressed TPM values grouped tissues and genes into distinct sets. Between the myome-
trial layers, 36 transcripts were identified as differentially expressed by at least two methods
(Figure 9.7e). The heat map in Figure 9.7f, shows a pattern of expression in one replicate of
the inner myometrium that is different from other inner myometrium replicates. The outer
myometrium replicates, however, are clustered together.
9.1.3 Temporal Expression Patterns
Analysis of the changes in expression with time in Mifepristone-treated tissues was con-
ducted using the Cuffdiff, DESeq2, and edgeR as previously described. The largest change in
transcript expression occurred in the inner myometrium where 59 transcripts were differen-
tially expressed between GD19+6hrs and GD20, with 78% of the transcripts being upreg-
ulated on GD20 (Supplementary Table E.6). The least number of differentially expressed
transcripts was observed in the outer myometrium where 14 transcripts were differentially
expressed, 10 of which were upregulated on GD20 (Supplementary Table E.7). In the de-
cidua, 30 transcripts were differentially expressed, and all but 2 of them were upregulated
on GD20 (Supplementary Table E.8). Illustrations of the numbers of gene transcripts that
were identified as differentially expressed between GD19+6hrs and GD20 in the decidua,
inner myometrium, and outer myometrium by the 3 differential expression analysis methods
are shown in Figure 9.8a, Figure 9.8c, and Figure 9.8e, respectively. Clustering of the non-
zero z-scores that were derived from the TPM values of the differentially expressed genes
is illustrated by the heat maps in Figure 9.8b, Figure 9.8d, and 9.8f, which show distinct
separation of decidua tissues obtained on GD19+6hrs from those obtained on GD20, but
not the inner myometrium or outer myometrium, respectively.
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Figure 9.7: Venn diagrams and heat maps of differentially expressed gene transcripts
between myometrial tissues on GD20. Gene transcripts were identified as differentially expressed by
Cuffdiff (Cuff), edgeR and DESeq2 between the (a–b) decidua and the inner myometrium, (c–d) decidua
and the outer myometrium, and between the (e–f) inner and outer myometrial layers. Agglomerative
hierarchical clustering was used to identify the relationships among the decidua (dec), inner (inn) circular
myometrium (myo), and outer longitudinal myometrium (out). The tissues and gene transcripts are
represented by the columns and rows, respectively.
a) Decidua b) Decidua
d1
9.
de
c.
2
d1
9.
de
c.
1
d1
9.
de
c.
3
d2
0.
de
c.
2
d2
0.
de
c.
1
d2
0.
de
c.
3
−1 0 1 2
Value
0
40
80
Color Key
and Histogram
Co
un
t
c) Inner myometrium d) Inner myometrium
d1
9.
in
n.
2
d1
9.
in
n.
3
d2
0.
in
n.
3
d2
0.
in
n.
1
d1
9.
in
n.
1
d2
0.
in
n.
2
−1 0 1 2
Value
0
50
15
0
Color Key
and Histogram
Co
un
t
c) Outer myometrium d) Outer myometrium
d2
0.
ou
t.2
X2
d0
.o
ut
.1
d1
9.
ou
t.3
d1
9.
ou
t.2
d1
9.
ou
t.1
d2
0.
ou
t.3
−0.5 0.5 1.5
Value
0
5
15
Color Key
and Histogram
Co
un
t
Figure 9.8: Venn diagrams and heat maps of differentially expressed gene transcripts be-
tween GD19+6hrs and GD20 in Mifepristone-treated tissues. Gene transcripts were identified
as differentially expressed by Cuffdiff (Cuff), edgeR and DESeq2 in the (a–b) decidua, (c–d) inner my-
ometrium, and the (e–f) outer myometrium. Agglomerative hierarchical clustering was used to identify
the relationships among the genes and gestational time points. The tissues and gene transcripts are
represented by the columns and rows, respectively.
9.2. Effects of Mifepristone
9.2 Effects of Mifepristone
To determine the transcriptomic effects of Mifepristone on rat uterine tissues in late preg-
nancy, the expression of transcripts obtained from Mifepristone-treated tissues was com-
pared with that of the control tissues that were obtained in Chapter 7. Comparisons were
made between tissues obtained 6 hours after treatment (GD19+6hrs), and on the 20th day
of gestation (GD). To determine the transcriptional changes that occur during preterm
labour in distinct uterine tissues, further comparisons were made between tissues obtained
at term (GD22) before labour (NL) in control tissues with Mifepristone-treated tissues ob-
tained on GD20. Cuffdiff, edgeR, and DESeq2 were used to identify transcripts that were
differentially expressed between tissues from different treatment groups as described in Sec-
tion 6.2.2.
9.2.1 GD19+6hrs
When compared to the expression in control tissues obtained on GD19+6hrs, a total of 100,
2, and 22 gene transcripts were identified as differentially expressed by at least two methods
in Mifepristone-treated decidua, inner myometrium, and outer myometrium, respectively
(Figure 9.9). In the outer myometrium, DESeq2 identified only one transcript as differen-
tially expressed between control and Mifepristone-treated tissues on GD19+6hrs. This one
transcript was, however, not discovered by either Cuffdiff or edgeR. A major proportion of
the transcripts that were differentially expressed between control and Mifepristone-treated
tissues were down-regulated with 92% down-regulated in the decidua, 1 out of 2 in the inner
myometrium, and 59% in the outer myometrium. Details of the specific gene transcripts
and their mean expression levels, in TPM values (±SD), are given in Supplementary Tables
E.9, E.10, and E.11. Clustering of the non-zero z-scores calculated from the TPM values of
the differentially expressed transcripts separated the control from the Mifepristone-treated
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tissues distinctly in the decidua and inner myometrium, but failed to segregate the tissues
by treatment in the outer myometrium as illustrated by the heat maps in Figure 9.9.
9.2.2 GD20
On the GD20, both of the gene transcripts that were differentially expressed between con-
trol and Mifepristone-treated decidua samples were down-regulated in response to treatment
with Mifepristone (see Supplementary Table E.12). In this case, DESeq2 identified 3, edgeR
5, and Cuffdiff 148 differentially expressed transcripts as illustrated in Figure 9.11a. None
of the genes identified by edgeR were identified by the other two methods. In inner my-
ometrium tissue samples, 117 transcripts were identified as differentially expressed between
control and Mifepristone-treated samples by at least 2 methods (Figure 9.11c and Supple-
mentary Table E.13), 56% of which were down-regulated in RU486-treated tissues. Of the 54
transcripts that were identified as differentially expressed between control and Mifepristone-
treated outer myometrium tissues by at least 2 methods as illustrated in Figure 9.11e, 54%
were down-regulated in Mifepristone-treated samples (Supplementary Table E.14). Clus-
tering analysis using non-zero z-scores of the expression levels of differentially expressed
transcripts, in transcripts per million (TPM) values, did not separate the tissue treatments
distinctly (see Figures 9.11b, 9.11d, and 9.11f for illustrations).
9.2.3 Term vs Pre-term
Pregnant rats that were treated with Mifepristone on GD19, went into labour and deliv-
ered on GD20, two days pre-term. The expression of transcripts in non-labouring GD20
Mifepristone-treated samples was compared to that of tGD22(NL) control samples to iden-
tify transcriptomic differences therein.
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Differential expression analysis between term and pre-term decidua samples identified 133,
82, and 9 significantly different transcripts using Cuffdiff, edgeR, and DESeq2, respectively.
As illustrated in Figure 9.11a, three transcripts were detected by all three methods, and a
total of 29 gene transcripts were detected by at least two of the differential analysis methods
as being significantly different between pre-term and term decidua samples, 93% of which
were upregulated in pre-term decidua samples (details in Supplementary Table E.15).
In the inner myometrium, five transcripts were detected by all three differential expres-
sion analysis methods as being significantly different between pre-term and term samples.
In total, 95 transcripts were detected by at least 2 methods of analysis as being differen-
tially expressed as illustrated in Figure 9.11c. The majority of the differentially expressed
transcripts (65%) were upregulated in pre-term samples.
The illustration in Figure 9.11e shows that the least number of differentially expressed
transcripts were identified between the pre-term and term outer myometrium samples, where
97 transcripts were detected by Cuffdiff, 38 by edgeR, and 20 by DESeq 2 as significantly
different. Only one of these transcripts was identified by all methods, and a robust set of 14
transcripts consisted of transcripts that were detected by at least 2 of the analysis methods.
In contrast to the decidua and the inner myometrium, the majority of the differentially
expressed transcripts in outer myometrium tissues (85%) were down-regulated in the pre-
term samples. Clustering analysis of the pre-term and term non-labouring samples did not
segregate the tissues.
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Figure 9.9: Venn diagrams and heatmaps of gene transcripts that were differentially ex-
pressed in GD19+6hrs RU486-treated tissues in comparison with GD19+6hrs control tis-
sues. Gene transcripts were identified as differentially expressed by Cuffdiff (Cuff), edgeR and DESeq2
in the (a – b) decidua , (c – d) inner myometrium, and the (e – f) outer myometrium. Agglomerative
hierarchical clustering was used to identify the relationships among the differentially expressed genes
and gestational time points. The tissues and gene transcripts are represented by the columns and rows,
respectively.
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Figure 9.10: Venn diagrams and heatmaps of gene transcripts that were differentially
expressed in GD20 RU486-treated tissues in comparison with GD20 control tissues. Gene
transcripts were identified as differentially expressed by Cuffdiff (Cuff), edgeR and DESeq2 in the (a –
b) decidua , (c – d) inner myometrium, and the (e – f) outer myometrium. Agglomerative hierarchical
clustering was used to identify the relationships among the differentially expressed genes and gestational
time points. The tissues and gene transcripts are represented by the columns and rows, respectively.
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Figure 9.11: Venn diagrams and heatmaps of gene transcripts that were differentially ex-
pressed in GD20 RU486-treated tissues in comparison with non-labouring control tissues at
term. Gene transcripts were identified as differentially expressed by Cuffdiff (Cuff), edgeR and DESeq2
in the (a – b) decidua , (c – d) inner myometrium, and the (e – f) outer myometrium. Agglomerative
hierarchical clustering was used to identify the relationships among the differentially expressed genes
and gestational time points. The tissues and gene transcripts are represented by the columns and rows,
respectively.
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9.3 Summary and Discussion
Preterm labour is a major cause for concern as babies born too early are faced with numerous
challenges (Goldenberg et al., 2008). In this chapter, preterm labour was induced through
the use of the progesterone receptor antagonist Mifepristone. The data presented in this
chapter were obtained from non-labouring animals.
9.3.1 Spatial Expression
The transcripts of typical myometrium genes such as myosin light chain 9 (Myl9) and
actin α 2 (Acta2) exhibited higher expression in myometrial tissues in comparison to the
decidua. In addition, mRNA encoding Toll-like receptor 8 (Tlr8) were highly expressed in
the inner myometrium in comparison to the outer myometrium. Toll-like receptors have
been implicated in the onset of labour at term in rodents (Condon et al., 2004) and their
presence in myometrial tissues may be an indication of the preparation of the uterus for
labour. There were more differences in mRNA expression between the outer myometrium
and the decidua, than there were between the inner myometrium and decidua, as evi-
denced by the numbers of differentially express mRNA transcripts. There was significantly
higher expression in the outer myometrium of mRNA transcripts encoding proteins involved
in smooth muscle excitation-contraction coupling such as: actin α 1 (Acta1) and Acta2
(Arnoldi et al., 2013); transgelin (Tagln), a member of the calponin family which binds
actin (Assinder et al., 2009); tropomyosin 2 beta (Tpm2), basic smooth muscle calponin 1
(Cnn1), Myl9, oxytocin (Oxt), and the oxytocin receptor (Aguilar & Mitchell, 2010; Michal
& Schomburg, 2012; El-Mezgueldi, 2014). Only one transcript was significantly different
between the inner circular and outer longitudinal layers of the myometrium, suggesting that
mRNA expression patterns in both tissues was similar. This, however, is contradicted by
the differences in mRNA expression between the respective myometrial layers and the de-
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cidua. If expression patterns were indeed similar, one would expect the expression of mRNA
transcripts within the myometrial tissues relative to that of the decidua to be similar.
Decidua
Comparison of mRNA expression on GD19+6hrs to that on GD20 in Mifepristone-treated
tissues showed an upregulation of genes encoding high density lipoproteins (Apoa1 and
Apof), myometrial proteins (Acta2 and Myh11), glycoproteins (Fgb, Fgg, Psg16, and
Psg19), haptoglobin (Hp), and histidine decarboxylase (Hdc) among others. The upreg-
ulation of Apoa1 in Mifepristone-treated tissues is in line with published literature; Saladin
et al. (1996) demonstrated that Apoa1 mRNA is inhibited by mifepristone treatment after
treatment with dexamethasone, but is elevated by treatment with Mifepristone alone in the
liver. In addition, Kojima et al. (2001) observed that P4 inhibits a Apoa1 action in-vitro,
and Apoa1 has been identified in endometrial tissues where upregulation of the protein is
associated with implantation failure and endometriosis (Brosens et al., 2010). The with-
drawal of P4, therefore, leads to the upregulation of Apoa1, whose role in pregnancy and
during labour requires investigation. Apof regulates the metabolism of high-density lipopro-
tein (Paromov & Morton, 2003), but has not been previously identified in uterine tissues.
It is reasonable to expect the upregulation of genes encoding Acta2 and Myh11 due to the
withdrawal of P4. Their upregulation in the decidua is in line with the published literature;
Oliver et al. (1999) smooth-muscle actin is present in decidual stromal cells. Additionally,
Winn et al. (2007) observed that Myh11 mRNA expression was upregulated at term in
biopsies of the maternal-fetal interface basal plate. The Hdc gene is regulated by P4 in mice
(Khatua et al., 2006), and is expressed in uterine tissues (Wood et al., 2000). However,
the specific uterine tissue in which the Hdc is expressed had not been previously identified.
The data presented in this chapter not only confirms that Hdc is regulated by P4, but also
demonstrates that Hdc mRNA is expressed in the decidua in rats. Berkova et al. (2001)
182
9.3. Summary and Discussion
demonstrated that Hp levels are elevated in the decidua. As such, the data presented here
support this observation. Hp protein expression has been shown to increase in response to
inflammation (Wang et al., 2001). Since preterm labour is associated with inflammation
(Goldenberg et al., 2008), the upregulation of Hp mRNA is consistent with an inflammatory
response.
9.3.2 Myometrium
Channels and Transporters
The expression of solute carriers has been shown to decrease in response to treatment with
Mifepristone in human endometrial biopsies (Catalano et al., 2007). However, non of
the solute carriers identified by Catalano et al. (2007) were differentially expressed in the
Mifepristone-treated tissues used in the present study. Instead, solute carrier family 13,
member 3 (Slc13a3) mRNA was upregulated in preterm decidual samples, while solute
carrier family 14 member 1 (Slc14a1) and solute carrier family 17 member 1 (Slc17a1)
mRNA expression was upregulated in preterm inner myometrial tissues. In addition, solute
carrier family 22, member 3 (Slc22a3) transcripts were upregulated, while solute carrier
family 4, sodium borate transporter, member 11 (Slc14a11) transcripts were down-regulated
in preterm outer myometrium.
Extracellular Matrix Remodelling
The rupture of fetal membranes prior to the completion of 37 weeks of gestation in hu-
mans, known as preterm pre-labour rupture of membranes (PPROM),is known to cause
preterm labour (Vadillo-Ortega & Estrada-Gutierrez, 2005). In the present study in which
a preterm labour was induced through treatment with Mifepristone, expression of Mmp11
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mRNA increased in preterm inner myometrial tissues. An observation which was also made
in the myometrium of control samples. In preterm outer myometrial samples, matrix met-
allopeptidase 1 (Mmp1a), also known as interstitial collagenase, mRNA expression was
down-regulated. The down-regulation of Mmp1a contradicts observations made by Lee
et al. (2012) and Chan et al. (2014) in which Mmp1 expression was upregulated by PR-
knock-down and during labour at term, respectively.
G Protein-coupled Receptors and other Receptors
G protein-coupled receptor 68 (Gpr68) mRNA expression was upregulated in preterm inner
myometrial tissues when compared to control tissues of a similar gestational age. Upreg-
ulation of Gpr68 mRNA has been previously observed in the human basal plate at term
(Winn et al., 2007). As the preterm samples may exhibit some mRNA expression patterns
similar to those of samples at term, the observations made in this study are consistent with
those of Winn et al. (2007). The data presented here, therefore, indicate that Gpr68 is also
expressed in myometrial tissues, specifically in the inner myometrium. Htr1d mRNA levels
were upregulated in preterm outer myometrial samples when compared with control GD20
samples, an observation which is inline with observations in control tissues at term (Cohen
et al., 1985; Minosyan et al., 2007), indicating that P4 inhibits the expression of Htr1d.
When compared to outer myometrial samples at term, Htr2a mRNA levels in preterm inner
myometrial samples were low.
Inflammation Response
Apoa1, which is upregulated in Mifepristone-treated tissues is involved in the negative reg-
ulation of cytokine secretion involved in immune response, more specifically in the negative
regulation of interleukin-1 β secretion. There was upregulation of coagulation factor X
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(F10), coagulation factor XI (F11), and coagulation factor XIII, B polypeptide in the inner
myometrium preterm (F13b) mRNA in the inner myometrium preterm, a sign of the upreg-
ulation of anti-inflammatory molecules. In the decidua, however, coagulation factor II (F2)
expression was down-regulated.
9.4 Conclusion
In this chapter, the transcriptome of laser-captured Mifepristone-treated uterine tissues are
described, for the first time. Laser-capture microdissection enabled the separation of pure
cell samples from heterogenous tissues, thus allowing for the extraction and sequencing of
RNA from the decidua, inner circular myometrium, and outer longitudinal myometrium of
Mifepristone-treated animals. Mifepristone (RU486) was administered on the 19th day of
gestation to induce the withdrawal of progesterone in order enable the identification of those
genes whose mRNA transcripts were regulated during the withdrawal of progesterone (P4),
and in the events preceding pre-term labour. The first aim of this chapter was to identify the
gene transcripts whose expression changed in response to treatment with Mifepristone in the
decidua, inner circular myometrium, and the outer longitudinal layer of the myometrium.
Distinct spatial patterns of mRNA expression were observed between uterine tissues on
GD19+6hrs, as well as on GD20. In addition, changes in transcript expression in response
to treatment with Mifepristone in each of the three tissues has been documented in this
chapter. The second aim of this chapter was to further elucidate the transcriptional changes
that occur during preterm labour in uterine tissues. While data from animals undergoing
preterm labour are not presented in this chapter, observations made using animals at the
preterm time point augment current knowledge of the processes underlying the onset of
pre-term tabour, and will be useful in identifying genes that are regulated by progesterone.
As such, the following chapter assesses the effect of treatment with progesterone on the
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transcriptomes of uterine tissues, and integrates that information with the data obtained
in this chapter, together with data from Chapter 7, to identify progesterone-responsive
genes.
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Chapter 10
Identification of Progesterone
Responsive Genes
In this chapter, the steroid hormone progesterone is used to maintain gestation in rats with
the aim of identifying genes whose expression responds to treatment with progesterone. In
addition, this chapter aims to identify progesterone-responsive through the integration of
sets of genes that are differentially expressed in control tissues, Mifepristone-treated tissues,
and P4-treated tissues, as well as regulatory features that are common among the identified
P4-responsive genes.
10.1 Transcriptomic Landscape
Approximately 254 million reads were sequenced across libraries from progesterone-treated
tissues (Table 10.1), of which 35.36%, 26.37%, and 38.27% were sequenced from decidua, in-
ner myometrium, and outer myometrium libraries, respectively. An average of 14.12 million
paired-end reads were sequenced per sample, 82.01% of which were aligned to the reference
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Table 10.1: Alignment of sequenced reads to the Rattus norvegicus transcriptome and
coverage statistics of sequences generated from Progesterone-treated tissues. Gesta-
tion - The day during pregnancy on which the uterine sample was collected. Tissue - The layer
of the uterus that was separated from the other tissues using laser-capture microdissection. The
number illustrates the replicate number. % Aligned - The proportion of the sequenced reads that
were aligned successfully to the Rattus norvegicus transcriptome using Tophat2. % Expressed
features - The proportion of genes to which counts were assigned by HTSeq. Expressed tran-
scriptome (× covered) - The number of times the expressed transcriptome was covered by the
sequenced reads.
Expressed
% Expressed transcriptome
Tissue Total reads % Aligned features (× covered)
Decidua 1 34,722,902 80.60 68.17 10.14
Decidua 2 35,752,903 86.80 68.89 20.26
Decidua 3 19,414,800 83.60 79.43 7.87
Inner Myo 1 23,564,748 84.90 68.98 10.02
Inner Myo 2 19,230,640 78.10 75.45 4.72
Inner Myo 3 24,221,162 82.40 69.53 8.99
Outer Myo 1 47,866,362 83.90 75.11 29.05
Outer Myo 2 25,298,650 83.60 72.33 14.80
Outer Myo 3 24,093,937 74.20 73.49 11.63
genome. Of the aligned reads, 72.37% were assigned a count by HTSeq, and were considered
expressed. On average, the expressed transcriptome was covered 13.05× per sample.
10.2 Tissue-dependent Gene Expression
Principal component analysis (PCA) was employed to assess of the variability among P4-
treated samples using non-zero mRNA transcript abundances, in transcripts per million
(TPM) values as estimated by Sailfish. PCA was conducted as described in Section 6.1
using the princomp function in R. The number of PCs used to assess the relationship among
the data were selected as described in Section 6.1.2. The first two PCs, whose cumulative
proportion of variance exceeds 85%, were plotted to assess the relationships among the
mRNA expression patterns within the decidua, inner myometrium, and outer myometrium
(Figure 10.1). The myometrial tissues were separated distinctly, however, one of the decidual
samples was not grouped together with the other decidual samples.
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Figure 10.1: Principal component analysis (componentPCA) of P4-treated tissues.
PCA was performed on P4-treated samples using transcript per million (TPM) abundances. The
variance explained by each of the first three PCs is displayed next to the corresponding PC.
Further analysis was carried out on the sequencing data to determine the expression patterns
of gene transcripts in uterine tissues. The Tophat-Cuﬄinks pipeline was used to generate
transcript abundances, in the form of reads per kilo-base per million (RPKM), that were
used for differential expression analysis in Cuffdiff. Two other differential expression analysis
methods, edgeR and DESeq2, were used in the analysis of count data generated through the
Tophat-HTSeq pipeline. To determine significant differential expression of gene transcript, a
5% significance level, a q-value of 5% (Cuffdiff), a false discovery rate (FDR) of 5% (edgeR),
or an adjusted p-value of 5% (DESeq2), were used as thresholds. Compared to the decidua,
380, 323, and 258 mRNA transcripts were identified as differentially expressed in the inner
myometrium by Cuffdiff, edgeR, and DESeq2, respectively (Figure 10.2). Between the de-
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cidua and the outer myometrium, Cuffdiff identified 332 mRNA transcripts as differentially
expressed, in comparison to 221, and 114 gene transcripts that were identified by edgeR
and DESeq2, respectively. The two myometrial layers had 215, 297, and 58 genes whose
transcripts were identified as differentially expressed between them by Cuffdiff, edgeR, and
DESeq2, respectively. A final set of differentially expressed genes, which consisted of genes
whose transcripts were identified by at least two of the differential analysis methods, are
presented in Supplementary Table F.1, Supplementary Table F.2, and Supplementary Ta-
ble F.3. One hundred and fifty genes were upregulated, while 101 genes were down-regulated
in the inner myometrium compared to the decidua. In the outer myometrium, 148 genes
were differentially expressed in comparison to the decidua, of which 121 genes were upregu-
lated. Of the 146 genes that were differentially expressed between the myometrial tissues, 92
were upregulated in the outer layer of the myometrium compared to the inner layer.
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10.3 Early Response to Progesterone Withdrawal
Systemic withdrawal of P4 occurs naturally on GD19. At the first experimental time point,
GD19+6hrs, early responses to the withdrawal of P4 may have occurred. To identify the
early-response genes, as well as genes that changed due to the progression in pregnancy,
but not due to the effects of P4, comparisons of expression levels of genes in control tissues,
collected on GD19+6hrs, and P4-treated tissues were made. Analyses were performed using
the methods described in Section 10.2. Principal component analysis of the expression
values of transcripts (TPM) could not distinguish control samples obtained on GD19+6hrs
from P4-treated samples (Figure 10.3), indicating that not many distinguishable changes
in mRNA expression had occurred in GD19+6hrs samples even though P4 withdrawal had
commenced on GD19.
Further analyses were carried out on the data to identify differential expression of gene
transcripts between control samples obtained on GD19+6hrs and P4-treated samples. In
the decidua, Cuffdiff, edgeR, and DESeq2 identified 76, 65, and 47 differentially expressed
genes, respectively. In the inner myometrium, 115 genes were identified as differentially
expressed by Cuffdiff, while edgeR and DESeq2 identified 47 and 34 genes, respectively.
Cuffdiff identified the highest number of differentially expressed in the outer layer of the
myometrium, 119, in comparison to the 15 genes identified by edgeR, and the 7 genes that
were identified by DESeq2 (Figure 10.4).
The three methods: Cuffdiff, edgeR, and DESeq2, identified varying numbers of genes that
were differentially expressed. To create sets of genes for further analysis, final sets of differ-
entially expressed genes were created from only those genes that had been identified by at
least 2 of the 3 methods (Figure 10.5). The set of genes that were differentially expressed
in the decidua contained 49 genes, most of which were down-regulated in the P4-treated
decidual tissues (Supplementary Table F.4). There were 62 GO terms were overrepresented
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Figure 10.4: Number of differentially expressed between control (GD19+hrs) and P4-
treated tissues. Genes were identified in the decidua (blue), inner myometrium (green), and outer
myometrium (red) by Cuffdiff, edgeR, and DESeq2.
within the set of upregulated genes (Supplementary Table F.7). Gene ontology analysis
of the down-regulated genes identified 371 overrepresented GO terms (Supplementary Ta-
ble F.8). In the inner myometrium, 31 genes were common among the methods, and 5 of
these genes were upregulated in P4-treated tissues (Supplementary Table F.5). GO term
analysis of the upregulated genes identified 8 overrepresented GO terms (Supplementary
Table F.9), while analysis of the down-regulated genes identified 89 overrepresented GO
terms (Supplementary Table F.10). Ten genes were differentially expressed in the outer my-
ometrium, of which 6 were upregulated in response to treatment with P4. GO term analysis
of the up- and down-regulated genes did not yield results.
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10.4 Response to Treatment with Progesterone
Genes that responded to P4 treatment were identified by comparing the levels of expression
of genes in control and P4-treated tissues on GD22(NL). PCA analysis was performed as
described in Section 6.1 using the princomp function in R. Plots of the PC coefficients did
not indicate complete separation of the control samples from the P4-treated samples in the
decidua, inner myometrium, and outer myometrium (Figure 10.6).
Genes that were differentially expressed between control GD22(NL) and P4-treated tissues
were identified using 3 methods as described in Section 10.2. In the decidua, 142 genes were
identified as differentially expressed by Cuffdiff, whereas 149 and 15 genes were identified by
edgeR and DESeq2, respectively (Figure 10.7). EdgeR also identified the highest numbers
of differentially expressed genes in the inner and outer myometrial tissues of 163 and 283, re-
spectively. Cuffdiff identified 141 differentially expressed genes in the inner myometrium and
261 genes in the outer myometrium, while DESeq2 identified 42 and 135 genes, respectively.
On average, more genes were differentially expressed in the outer myometrium (226 ± 80),
in comparison to the inner myometrium (115± 65), and the decidua (102± 75).
Forty-eight genes were identified as differentially expressed by at least two methods in the
decidua (Figure 10.8). Of the 48 differentially expressed genes in the decidua, 75% of
the genes were upregulated in P4-treated samples (Supplementary Table F.11). Gene on-
tology analysis of the upregulated genes identified 37 GO terms that were significantly
overrepresented, including maternal process involved in female pregnancy (Supplementary
Table F.14). The 12 genes that were down-regulated in P4-treated decidua tissues were
involved in signalling, regulation of cell migration, and the regulation of action potentials
(Supplementary Table F.15).
In the inner myometrium, 78 differentially expressed genes were identified by at least
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10.4. Response to Treatment with Progesterone
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Figure 10.7: Number of genes differentially expressed in response to progesterone
treatment. Genes were identified in the decidua (blue), inner myometrium (green), and outer
myometrium (red) by Cuffdiff, edgeR and DESeq2.
two methods, 19 of which were upregulated in P4-treated tissues. There were no signif-
icantly overrepresented GO terms identified for the up- or down-regulated gene sets. How-
ever, the combined set of up- and down-regulated genes identified 2 overrepresented GO
terms: female pregnancy (corrected p-value=0.0097), and tissue development (corrected
p-value=0.0097).
In the outer myometrium, a final set of 164 genes was considered for further analysis. The
set of genes consisted of 41 up- and 123 down-regulated genes (Supplementary Table F.13).
The upregulated genes were involved in muscle tissue development, muscle contraction,
muscle system process, and the regulation of release of sequestered calcium ions into the
cytosol by the sarcoplasmic reticulum (Supplementary Table F.16). A subset of 85 down-
regulated genes was used as the test set for GO analysis. Seven overrepresented GO terms
were identified (Supplementary Table F.17).
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10.5. Regulation of P4 differentially Expressed Genes in Control Tissues
10.5 Regulation of P4 differentially Expressed Genes in
Control Tissues
To identify genes that were differentially regulated in P4 and Control treatment groups,
genes that were differentially expressed (DE) in P4-treated tissues (P4-DE genes) were
compared to the genes that were differentially expressed in control tissues (Control-DE
genes).
The number of common genes between Control-DE genes and P4-DE genes in the decidua
increased with the progression of gestation in control tissues. There were no genes that were
common in the decidua between P4 and GD19+6hrs-GD20 differentially expressed gene
sets (Figure 10.9). Unlike the trend of common genes in the decidua, there were biphasic
changes in the number of common genes in the inner myometrium, with no common genes
between P4-DE genes and GD19+6hrs-GD20 Control-DE genes. Similar to the trend in the
inner myometrium, the number of common genes between Control-DE genes and P4-DE
genes in the outer myometrium increased between GD20 and GD22(NL), but decreased
between GD22(NL) and GD22(L). These data indicate that not all changes that occur at
the transcriptomic level during late pregnancy are due to steroid hormone effects.
10.5.1 Regulation Patterns of Differentially Expressed Genes
For each tissue, Control-DE genes at consecutive gestational time points were grouped by
their pattern of regulation, such that there were two sets of differentially expressed genes
per tissue, i.e., up- and down-regulated gene sets, at each time point. These sets of grouped
genes were compared to P4-DE gene sets that were also split into groups of up- and down-
regulated genes (Figure 10.10).
In the decidua, three genes were regulated differently between P4-treated samples and con-
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Figure 10.9: Number of differentially expressed genes that are common between P4-
treated and control tissues. Comparisons were made between genes that were differentially
expressed between GD22(NL) control and P4-treated tissues, and genes that were differentially
expressed between consecutive time points in control tissues.
trol samples (Figure 10.10a). The three genes were down-regulated in control samples and
up-regulated in P4-treated samples (Table 10.2), and are involved in the positive regulation
of biological processes (Supplementary Table F.18).
Table 10.2: Differentially regulated genes in the decidua. Genes that were differentially
regulated in the P4-DE gene set and the Control-DE gene set in the decidua.
P4 Control
Symbol Description regulation regulation
GD20-GD22(NL)
Plagl1 pleiomorphic adenoma gene-like 1 UP DOWN
Alb albumin UP DOWN
Cdh1 cadherin 1 UP DOWN
In the inner myometrium, 8 genes were differentially regulated in P4-treated samples com-
pared to control samples (Figure 10.10b). The majority of the genes were up-regulated in
control samples, while genes encoding cadherin 16 (Cdh16) and collagen type II alpha 1
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(Col2a1) were down-regulated in control samples (Table 10.3).
Table 10.3: Differentially regulated genes in the inner myometrium. Genes that were
differentially regulated in the P4-DE gene set and the Control-DE gene set in the inner layer of the
myometrium.
P4 Control
Symbol Description regulation regulation
GD20-GD22(NL)
LOC685544 hypothetical protein LOC685544 DOWN UP
Oasl 2’-5’-oligoadenylate synthetase-like DOWN UP
Htr2a 5-hydroxytryptamine receptor 2A DOWN UP
Tssk6 testis-specific serine kinase 6 DOWN UP
Cdh16 cadherin 16 UP DOWN
Col2a1 collagen, type II, alpha 1 UP DOWN
Cd70 Cd70 molecule DOWN UP
Cilp cartilage intermediate layer protein DOWN UP
The highest number of genes that displayed different patterns of regulation between P4-
DE genes and Control-DE genes was observed in the outer myometrium (Figure 10.10c).
Three genes were down-regulated in control samples but up-regulated in P4-treated sam-
ples, while 17 genes were up-regulated in control and down-regulated in P4-treated samples
(Table 10.4). The outer myometrium was the only tissue that displayed differing patterns
of gene regulation between P4-DE genes and GD19+6hrs - GD20 Control-DE genes.
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10.6. Regulation of P4 Differentially Expressed Genes in Mifepristone-treated
Tissues
Table 10.4: Differentially regulated genes in the outer myometrium. Genes that were
differentially regulated in the P4-DE gene set and the Control-DE gene set in the outer layer of the
myometrium.
Symbol Description P4 Control
regulation regulation
GD19+6hrs-GD20
Zim1 zinc finger, imprinted 1 UP DOWN
Alcam activated leukocyte cell adhesion molecule DOWN UP
F5 coagulation factor V (proaccelerin, labile factor) DOWN UP
Slc10a1 solute carrier family 10 (sodium/bile acid cotransporter), member 1 DOWN UP
Aadac arylacetamide deacetylase DOWN UP
GD20-GD22(NL)
Itm2a integral membrane protein 2A UP DOWN
Sgcd sarcoglycan, delta (dystrophin-associated glycoprotein) UP DOWN
Cndp1 carnosine dipeptidase 1 (metallopeptidase M20 family) DOWN UP
Ehhadh enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase DOWN UP
Lgals12 lectin, galactoside-binding, soluble, 12 DOWN UP
LOC691352 similar to Robo-1 DOWN UP
Mmp7 matrix metallopeptidase 7 DOWN UP
Prl3a1 Prolactin family 3, subfamily a, member 1 DOWN UP
RGD1309676 similar to RIKEN cDNA 5730469M10 DOWN UP
Slc26a4 solute carrier family 26 (anion exchanger), member 4 DOWN UP
Tcerg1l transcription elongation regulator 1-like DOWN UP
Cftr cystic fibrosis transmembrane conductance regulator DOWN UP
Cuzd1 CUB and zona pellucida-like domains 1 DOWN UP
Prom1 prominin 1 DOWN UP
Wnt7a wingless-type MMTV integration site family, member 7A DOWN UP
10.6 Regulation of P4 Differentially Expressed Genes
in Mifepristone-treated Tissues
To identify genes that were regulated differently in response to P4 and Mifepristone treat-
ment, P4-DE genes were compared to genes that were differentially expressed in Mifepristone-
treated (RU486-DE) samples (Figure 10.11).
In the decidua, three genes displayed different regulation patterns between P4-treated sam-
ples and Mifepristone-treated samples (Figure 10.11a. The genes were up-regulated in P4
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Tissues
and down-regulated in Mifepristone samples (Table 10.5). Gene ontology analysis showed
that the gene cadherin 1 (Cdh1) is involved in the regulation of transcription factor import
into the nucleus, while the gene erythrocyte membrane protein band 4.1-like 3 (Epb41l3)
is involved in cortical actin cytoskeleton organisation, and the gene solute carrier family
4 member 1 (Slco4a1) is involved in thyroid hormone metabolic process (Supplementary
Table F.21).
Table 10.5: Differentially regulated genes in the decidua. Genes that exhibited different
patterns of regulation between P4-treated and Mifepristone-treated decidua samples.
Symbol Description P4 Mifepristone
GD19+6hrs
Cdh1 cadherin 1 UP DOWN
Epb41l3 erythrocyte membrane protein band 4.1-like 3 UP DOWN
Slco4a1 solute carrier family 4(organic cation transporter), member 1 UP DOWN
There were no genes that exhibited different patterns of regulation between P4 and Mifepri-
stone in the inner layer of the myometrium (Figure 10.11b). In the outer layer of the my-
ometrium, 8 genes were regulated differently in P4 and Mifepristone samples (Figure 10.11c).
The genes were up-regulated in Mifepristone-treated samples and down-regulated in P4-
treated samples (Table 10.6).
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10.7. Identification of Common Regulatory Features
Table 10.6: Differentially regulated genes in the outer myometrium. Genes that exhibited
different patterns of regulation between P4-treated and Mifepristone-treated samples from the outer
layer of the myometrium.
Symbol Description P4 Mifepristone
CTR GD19+6hrs vs Mifepristone GD16+6hrs
Kap kidney androgen regulated protein DOWN UP
Lcn2 lipocalin 2 DOWN UP
CTR GD20 vs Mifepristone GD20
Cftr cystic fibrosis transmembrane conductance regulator DOWN UP
LOC171573 spleen protein 1 precursor DOWN UP
Prl3a1 Prolactin family 3, subfamily a, member 1 DOWN UP
Mifepristone GD19+6hrs vs Mifepristone GD20
Apoa1 apolipoprotein A-I DOWN UP
Psg29 pregnancy-specific glycoprotein 29 DOWN UP
Cldn4 claudin 4 DOWN UP
10.7 Identification of Common Regulatory Features
The P4-responsive genes identified in the preceding sections were compared to the list of
genes whose upstream regions were predicted to contain PR-binding sites as described in
Section 6.5 and Section 6.6 to determine whether they contained predicted PR-binding
sites. However, non of the P4-responsive genes identified in the present study were found
to contain predicted PR-binding sites.
To determine whether common regulatory features, apart from the PR-sites, were present
within the groups of P4-responsive genes, upstream regions of the genes, 500, 1000, and
2000 base pairs in length, were analysed. MEME-LaB was used to identify motifs that were
enriched within the promoters of P4-responsive genes whose sequences were downloaded
from Biomart and repeat masked using RepeatMasker. The repeat-masked sequences were
then used as input in MEME-LaB and the results were filtered so that only those motifs that
were enriched in at least 25% of the promoter sequences were displayed.
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10.7.1 Motifs in 500 bp Promoters
Within the set of decidua promoter sequences, three motifs were enriched (Figure 10.12).
Motifs similar to specificity protein 1 (SP1) were present in 84.3% of the regulatory regions
of genes that responded to P4-treatment or P4-withdrawal, while the Drosophila Hunchback
(hb) binding motif was associated with motifs found in 27.7% of the decidual P4-responsive
gene promoter sequences. A motif without similarities to any known binding sites was also
identified in 29.6% of the regulatory sequences of genes that were responsive to P4 in the
decidua. In the inner myometrium, two motifs were enriched in gene promoter sequences,
namely the SP1 binding motif in 57.3% of the genes, and the KLF4 binding motif in 55.9%
of the genes (Figure 10.13). Two motifs were also identified in the promoter sequences of
P4-responsive genes in the outer myometrium (Figure 10.14). Of the two motifs, one was
present 64.9% of the regulatory sequences and was found to be similar to two known motifs,
i.e., the complementary sequence of the SP1 binding motif, and the Kru¨ppel-like factor 4
(KLF4) binding motif. The second motif was present in 54.3% of the genes, however, no
known motifs with similarities to the second motif were identified.
10.7.2 Motifs in 1000 bp Promoters
In promoter sequences that were 1000 base-pairs in length, motifs similar to inhibitor of
DNA-binding 1 (ID1) binding, T-box, and hb motifs were present in 55.4% of the promoter
sequences of decidua P4-responsive genes (Supplementary Figure F.1). The SP1 binding site
was identified in 57.8% of the decidua regulatory sequences while in 43.3% of the sequences,
the same motif was present with a higher E-value, 7× 10−18 compared to 7.7× 10−46, and
a smaller distance score of 2.9 compared to 8.1. The KLF4 motif was also enriched in 35%
of the decidua sequences (E-value = 3.4 × 10−7). In the inner myometrium, the SP1 and
KLF4 binding motifs were enriched in 97.9% of the promoter regions of P4-responsive genes
208
10.7. Identification of Common Regulatory Features
	  
	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Enriched	  mo,f	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Similar	  known	  mo,f	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Associated	  genes	  
Speciﬁcity	  protein	  1	  (SP1)	  
	  
	  	  
	  
(E-­‐value	  =	  7	  x	  10-­‐45)	  
	   (Distance	  score	  =	  3.2)	  
84.3%	  
Hunchback	  (hb)	  
27.7%	  
(E-­‐value	  =	  4	  x	  10-­‐30)	  
	  
(Distance	  score	  =	  8.9)	  
(E-­‐value	  =	  8.1	  x	  10-­‐10)	  
	  
(None)	   29.6%	  
Figure 10.12: Motifs identified in genes that were responsive to progesterone in the
decidua. MEME-LaB was used to identify motifs that were enriched within promoter regions of
P4-responsive genes in the decidua. The promoter regions were 500 nucleotides in length.
(Supplementary Figure F.2). Motifs similar to SP1 and KLF4 were detected in regulatory
sequences of P4-responsive genes in the outer myometrium, with SP1 and KLF4 motifs con-
tained in 55.2% and 64.9% of the sequences, respectively (Supplementary Figure F.3).
10.7.3 Motifs in 2000 bp Promoters
When 2000 bp promoter regions of P4-responsive genes were assessed for motif enrichment,
motifs similar to ID1, hb, SP1, and Spi-1 proto oncogene (SPI1) were identified in the
promoter regions of decidual P4-responsive genes (Supplementary Figure F.4). In the set
of promoter regions of inner myometrial P4-responsive genes, motifs similar to SP1 and
KLF4 were identified in 52.4% of the genes with an E-value of 1.5× 10−35 and 1.5× 10−14
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Figure 10.13: Motifs identified in genes that were P4-responsive in the inner my-
ometrium. MEME-LaB was used to identify motifs that were enriched within promoter regions
of P4-responsive genes in the inner myometrium. The promoter regions were 500 nucleotides in
length.
(Supplementary Figure F.5). In the promoter regions of 97.9% of the outer myometrial P4-
responsive genes, motifs similar to SP1 and KLF4 were also identified, but with an E-value
of 1.3× 10−8 (Supplementary Figure F.6).
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Figure 10.14: Motifs identified in genes that were responsive to progesterone in the
outer myometrium. MEME-LaB was used to identify motifs that were enriched within promoter
regions of P4-responsive genes in the outer myometrium. The promoter regions were 500 nucleotides
in length.
10.8 Random Occurrence of Motifs in the Uterus
To check whether the enrichment of motifs was due to P4-response and not random oc-
currence, 10 sets of genes were selected at random and analysed for motif enrichment. A
total of 125 genes per set were selected at random from the whole set of genes that were
expressed in the uterine transcriptome. Sequences of the upstream regions of the selected
genes were obtained and masked for repeats as described in Section 6.7.1, and analysed in
MEME-LaB. Motifs that occurred in at least 25% of the genes in a set were counted. The
SP1 motif was enriched in 9 of the 10 sets of genes, while the KLF4 motif was enriched in 5
and ID1 motifs were not enriched in any of the gene sets (Supplementary Figure F.7). These
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findings suggest that the SP1 motif may be present in the regulatory regions of numerous
genes and is, therefore, not unique in P4-responsive genes. Additionally, the presence of the
KLF4 motif in half the sets of randomly selected genes may indicate that this motif is also
present in numerous regulatory regions. Since ID1 was not found in any of the randomly
selected gene sets, it may be a good candidate for the common regulatory factor among
P4-responsive genes.
10.9 Significance Testing of Motifs
Motifs in the promoter regions of P4-responsive genes, which had been masked for repeats,
were tested for significant enrichment as described in Section 6.7.3. The overrepresented
motifs identified within the regulatory regions of the P-4 responsive genes are summarised
in Table 10.7. Of the motifs that were identified in Section 10.7, only KLF4 was identified as
statistically significant in P4-responsive decidual genes with 1000 bp- and 2000 bp-promoter
regions. In addition, motifs similar to hepatocyte nuclear factor 4 alpha (Hnf4a), Nuclear
Receptor Subfamily 1, Group H, Member 2: Retinoid X receptor alpha (NR1H2:RXRA),
Nuclear Receptor Subfamily 2 Group F Member 1 (Nr2f1) were identified in promoter regions
that were 500 bp, 1000 bp, and 2000 bp of decidual P4-responsive genes, respectively. Motifs
similar to heart and neural crest derivatives-expressed protein 1: transcription factor E2A
(Hand1:Tcfe2a) and peroxisome proliferator-activated receptor γ (Pparg) were identified
in 500 bp- and 1000 bp-promoters of inner myometrial P4-responsive genes, respectively.
While motifs similar to Hnf4a and macrophage-1 antigen (Mac1) were significant in outer
myometrial regulatory regions that were 500 bp and 1000 bp long, respectively.
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Table 10.7: Statistically significant motifs identified within groups of progesterone-
responsive genes. The hypergeometric test was used to assess the statistical significance of motif
enrichment. myo: myometrium.
Promoter
length Tissue Statistically significant motif
500 bp
Decidua Hepatocyte nuclear factor 4 alpha (Hnf4a)
Inner myo Heart and neural crest derivatives-expressed protein 1:
transcription factor E2A (Hand1:Tcfe2a)
Outer myo Hepatocyte nuclear factor 4 alpha (Hnf4a)
1000 bp
Decidua
Hepatocyte nuclear factor 4 alpha (Hnf4a)
Nuclear Receptor Subfamily 1, Group H, Member 2:
Retinoid X receptor alpha (NR1H2:RXRA)
Kru¨ppel-like factor 4 (KLF4)
Inner myo Peroxisome proliferator-activated receptor γ (Pparg)
Outer myo Macrophage-1 antigen (Mac1)
2000 bp Decidua
Nuclear Receptor Subfamily 2 Group F Member 1 (Nr2f1)
Nuclear Receptor Subfamily 1, Group H, Member 2:
Retinoid X receptor alpha (NR1H2:RXRA)
Kru¨ppel-like factor 4 (KLF4)
10.10 Summary and Discussion
P4 plays a major role in the maintenance of pregnancy in mammals (Blanks & Brosens, 2012).
To help identify those gene transcripts whose expression is modulated by P4, pregnant rats
were treated with P4. Pregnancy in P4-treated animals was maintained beyond term, pro-
viding further credence to the role of P4 in the maintenance of pregnancy.
10.10.1 Extracellular Matrix Remodelling
P4 has been shown to suppress matrix metalloproteinase (Mmp) activity in uterine tissues
(Epstein et al., 1998), as such, the regulation of Mmps in P4-treated tissues is expected to
differ from that of control tissues. In the decidua, Mmp11 mRNA levels were down-regulated
in P4-treated samples. Mmp11 has not been previously associated with the onset of labour,
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however, this may be due to Mmp11 levels in the decidua dropping prior to term. Analysis
of earlier time-points during gestation may provide more information on the expression
patterns of Mmp11 mRNA. In line with the observations made in control tissues (Girotti
& Zingg, 2003; Salomonis et al., 2005), the gene encoding Mmp7 was down-regulated in
P4-treated outer myometrium samples as opposed to the upregulation observed in control
tissues of a similar gestational age. The expression of Mmp16 mRNA was upregulated in the
outer myometrium in comparison to control tissues. While Catalano et al. (2007) observed
an increase in Mmp16 expression following treatment with Mifepristone, these observations
are incomparable with those made in the current study as the observations of Catalano et al.
(2007) were made in endometrial samples.
10.10.2 Channels and Transporters
Potassium (K+) channels are involved in regulating the contractility of SMCs during preg-
nancy (Wray et al., 2014). As such, their expression was expected to be regulated by
treatment with P4. In the present study, upregulation of K+ channel subfamily K mem-
ber 2 (Kcnk2), also known as Trek-1, mRNA expression was observed in P4-treated inner
myometrial tissues when compared with control tissues. Since pregnancy in P4-treated an-
imals is maintained while the pups continue to grow, even if the pregnancy is left to persist
beyond GD25, the uterine walls in these animals are subjected to immense stretch. Thus
upregulation of Kcnk2 channels that were shown to be upregulated by stretch (Monaghan
et al., 2011; Heyman et al., 2013) and down-regulated during labour (Buxton et al., 2010)
the myometrium, is consistent with the literature. In addition, the data presented in this
thesis shows that Kcnk2 channels are expressed in the inner myometrium. Conversely, K+
intermediate/small conductance Ca2+-activated channel subfamily N member 2 (Kcnn2)
mRNA levels were significantly down-regulated in P4-treated myometrial tissues, indicating
that Kcnn2 proteins are required for SMC contraction. This is consistent with the expres-
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sion of Kcnn2 protein observed in pregnant rats by Noble et al. (2010), whereby Kcnn2
protein expression increased between GD21 and term-labouring samples.
The expression of mRNA encoding solute carrier was significantly different in P4-treated
tissues in comparison to control tissues. Solute carrier family 26 (anion exchanger), member
4 (Slc26a4) mRNA expression was down-regulated in P4-treated tissues and upregulated
in control tissues at term in the outer myometrium. The gene encoding solute carrier
family 4 member 1 (Slc4a1), which is involved in thyroid hormone metabolic process, was
upregulated in P4-treated but down-regulated in GD19+6hrs control decidual samples. In
line with the observed down-regulation of aquaporin 8 (Aqp8) in the uterus at term and
during labour (Helguera et al., 2009), a decrease in the expression of Aqp8 mRNA was
observed in Mifepristone-treated decidual samples in comparison to control samples. In
addition, Aqp8 mRNA levels decreased significantly on GD19+6hrs in control tissues when
compared to P4-treated tissues. Thus Aqp8 responds early to the withdrawal of P4.
10.10.3 G Protein-coupled Receptors
Since serotonin receptors are upregulated in the myometrium of control tissues at term,
It is reasonable to expect that treatment with P4 will result in a decrease in serotonin
receptor mRNA expression. Htr1d and Htr2a mRNA expression levels were down-regulated
in P4-treated inner myometrial samples when compared with control tissues of the same
gestational age as expected.
10.10.4 P4-responsive Genes
P4-responsive genes were identified by integrating groups of genes whose transcripts were
identified as differently expressed with the progression of pregnancy, in response to treat-
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ment with P4, and treatment with Mifepristone. Genes that were differentially regulated
between P4-treated and Mifepristone-treated tissues, as well as those genes that were dif-
ferently regulated between control tissues and Mifepristone-treated tissues, were considered
P4-responsive. The identified genes were involved in the regulation of transcription factor
import into the nucleus, cortical actin cytoskeleton organisation, and the positive regulation
of intracellular transport among others. Within the groups of P4-responsive genes, motifs
similar to SP1, hb, ID1,T-box, KLF4 , and SPI1 binding motifs were found in at least 25% of
P4-responsive genes in the decidua. However, of these motifs, only the KLF4 binding motif
was identified as significantly enriched in decidual P4-responsive genes. It is proposed, there-
fore, that KLF4 mediates the action of PR in the decidua during late pregnancy. There
are no agreements between motif-search results and significant overrepresentation results
in either the inner or outer myometrial layers, indicating that the transcriptional changes
occurring in myometrial tissues during late pregnancy are not driven entirely by P4-PR
signalling.
10.11 Conclusion
This chapter set out to identify and document the effects of progesterone treatment on
the transcriptome of uterine tissues during late pregnancy. Gene transcripts that tend to
be upregulated in late pregnancy and at term, were down-regulated in P4-treated tissues,
while the same was observed for those transcripts whose expression is down-regulated in
late pregnancy and at term. In addition, this chapter brought together work that was
presented in previous chapters, Chapter 7 and Chapter 9, in the identification of transcripts
that were differentially regulated between P4-treated and control tissues, as well as between
P4- and Mifepristone-treated tissues. These transcripts, were identified and documented,
as per the second aim of this thesis. Regions that are upstream of genes whose transcripts
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were differentially regulated, were assessed for common regulatory features, and a candidate
was identified as regulating the signalling of progesterone in decidual tissues. The following
chapter is a general discussion of this thesis.
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Chapter 11
General Discussion
Preterm birth remains one of the major causes of health problems in infants, and infant
death (Goldenberg et al., 2008). The steroid hormone progesterone is known to play a ma-
jor role in maintenance of pregnancy in mammals. Progesterone exerts its effects through
both genomic and non-genomic mechanisms. Following on from the work conducted by
Garfield et al. (2012), it was hypothesised that the effect of progesterone on the uterus are
genomic. As such, an analysis of the effects of progesterone, and its withdrawal, on the preg-
nant expression of genes in uterine tissues will augment current knowledge of the processes
preceding the onset of labour at term and preterm. To investigate the effect of progesterone
on the uterus, a rat model of the pregnant uterus was utilised. Animals were treated with
progesterone and Mifepristone, and the changes resulting from treatments were analysed.
Laser capture microdissection was used to isolate homogeneous decidual and myometrial
tissues. High-throughput sequencing was used to measure the abundance of transcripts
within laser-captured tissues, which were subsequently analysed for differential expression
in late pregnancy, during labour, and in response to progesterone and Mifepristone treat-
ment.
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While transcriptomic studies of rat uterine tissues have been conducted in the past (Girotti
& Zingg, 2003; Arthur et al., 2008; Helguera et al., 2009), the work presented in this
thesis differs in that: the decidual, inner myometrial, and outer myometrial layers of the
uterus were separated by laser-capture microdissection, and transcriptional changes occur-
ring therein analysed separately; spatial assessment of transcript abundance was assessed;
and a deep (high-throughput) sequencing technique was used to determine the abundance
of transcripts within tissues. Sequencing of the transcriptome is one of the high-throughput
sequencing methods that can be used to expand the knowledge on the underlying molecular
processes of a system. The combination of high-throughput sequencing and the profiling of
expressed gene transcripts was used to identify those genes whose transcription changes in
response to progesterone withdrawal and treatment. The use of high-throughput sequenc-
ing technologies not only enables the understanding of the processes that underlie the onset
of labour at term, or preterm, but also allows the identification of potential therapeutic
targets.
Working under the hypothesis that the effects of progesterone on uterine tissues are genomic,
this thesis began by assessing the transcriptional landscape of control tissues in late preg-
nancy in Chapter 7. Of particular interest were those changes that occurred following the
natural systemic withdrawal of progesterone, hence tissues obtained after the time-point at
which progesterone withdrawal commences were utilised in the study. The expressed tran-
scriptome was covered 14-times on average, indicative of sequencing depth that is sufficient
for the detection of all the mRNA transcripts within tissues. Unique transcript expression
patterns within uterine tissues were identified with one particular transcript being expressed
predominantly in the inner myometrium. As such, it was hypothesised that the protein
coded for by this transcript, tenascin n, was inner myometrial-specific and could be used
to differentiate the inner layer of the myometrium from the outer layer of the myometrium.
Immunohistochemical staining for the tenascin n protein provided further evidence support-
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ing this hypothesis. Another hypothesis, proposing that thyrotropin-releasing hormone is a
decidual marker in late pregnancy, was put forward based on the spatial expression patterns
of transcripts encoding thyrotropin-releasing hormone. While this hypothesis was supported
by immunohistochemical staining for thyrotropin-releasing hormone in late pregnancy, at
term and during labour, the hormone was expressed in all the three tissues under study. As
such, thyrotropin hormone, which stimulates the release of the decidual marker prolactin
by the pituitary (Molitch, 2009), may be considered to be a decidual marker during late
pregnancy but not at term or during labour. In addition to uniquely expressed mRNA
transcripts, transcripts whose expression is spatially different were identified. Furthermore,
within each uterine tissue, changes in mRNA expression patterns were identified. While
some of the differential expression findings were consistent with published literature, com-
parisons were not easy to make as this is the first study in which the uterine layers have
been studied separately.
Further assessment of mRNA transcript expression was conducted in Chapter 8, whereby the
expression of transcripts encoding contraction-associated proteins and myometrial proteins
were delineated. Here it was also noted that mRNA transcript expression patterns in the
two myometrial layers were different. While some of the patterns of expression in the
myometrial layers are consistent with published literature, the fact that previous studies
have tended to assess mRNA expression while treating both layers of the myometrium as a
single unit makes it difficult to draw any meaningful conclusions. An attempt to validate
the RNAseq data with qPCR was unsuccessful as the majority of the mRNA expression
patterns observed relative to β-actin were inconsistent with RNAseq findings. This calls for
further investigation and perhaps the use of more than one housekeeping gene.
The next chapter in the thesis identified and documented the transcriptional changes that
occurred due to induced progesterone withdrawal. Here, a time-point at which animals
went into labour preterm was used to assess the transcriptional changes preceding preterm
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labour. While mRNA transcripts were differentially expressed in response to treatment
with the progesterone receptor antagonist Mifepristone, these changes cannot be attributed
to the withdrawal of progesterone alone as Mifepristone is also a glucocorticoid receptor
antagonist. As such, the data generated in this chapter, and that from Chapter 7 were used
in Chapter 10 to identify a set of “true” progesterone-responsive genes in late pregnancy
and during labour.
Chapter 10 began by identifying and assessing the differences in mRNA expression between
progesterone-treated and control tissues. The genes whose transcripts were differentially ex-
pressed between progesterone-treated and control samples were then compared to the sets of
genes identified in Chapter 7 and Chapter 9. Those differentially expressed genes that were
regulated differently in Chapter 7 and Chapter 9, in comparison to the regulation pattern of
genes in progesterone-treated tissues were proposed to be the set of progesterone-responsive
genes in late pregnancy. While the proposed progesterone-responsive genes were found not
to contain predicted progesterone receptor binding sites within their regulatory regions, con-
ducting chromatin immunoprecipitation experiments on the rat uterine tissues will provide
a more comprehensive list of decidua-, inner myometrium-, and outer myometrium-specific
genes whose regulatory regions are bound by the progesterone receptor.
The identification of genes within the progesterone-responsive gene sets in this study that
are bound by the progesterone will support the hypothesis that progesterone effects in the
uterus during late pregnancy are genomic. Since the progesterone receptor interacts with
numerous other factors when regulating gene transcription (Leonhardt et al., 2003), the
upstream regions of progesterone-responsive genes were assessed for the presence of common
regulatory features. A combination of motif searching and testing for overrepresentation
identified the Kru¨ppel-like factor 4 binding site within the regulatory regions of p4-responsive
genes in the decidua. Kru¨ppel-like factor 4 has been linked to endometrial, cervical, and
ovarian cancer, as well as endometriosis , and has been previously shown to mediate the
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genomic effects of progesterone in human endometrial epithelial cells (Shimizu et al., 2010).
It is, therefore, proposed that the effects of progesterone in the decidua are genomic and
are mediated by Kru¨ppel-like factor 4. Further investigations into the factors regulating the
expression of the progesterone-responsive genes identified in this thesis such as chromatin
immunoprecipitation experiments are required.
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Chapter 12
Conclusions
This thesis aimed to identify and analyse the effects of progesterone withdrawal on the
transcriptome of the rat uterus. This was achieved through combining the power of laser
capture microdissection with that of RNAseq in the identification of the tissue-specific tran-
scriptomic changes that occurred during the transition of the uterus from a quiescent to a
contractile state. A ramping-up of stimulus in the decidua at term supports the hypothesis
that the signal for the onset of labour emanates from the decidua. In addition, mRNA
expression within myometrial tissues was shown to change prior to ramping-up of stimulus
in the decidua, and indication that a separate signal within the uterus induces the tissues to
prepare for labour. Further information on the transcriptomic changes preceding pre-term
labour was obtained. In addition, differences between pre-term and term mRNA expression
were identified and documented. Furthermore, comparisons of the observations made in
this thesis to those made in other studies were conducted. This thesis documents observa-
tions obtained from snapshots of the transcriptomic landscape of uterine tissues at specific
time-points in late pregnancy. The novelty of the work presented in this thesis is in the
segregation of the decidua from the myometrial tissues, and that of the inner myometrium
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from the outer myometrium, using laser capture microdissection to allow for the separate
investigation of transcriptomic changes in these tissues. In conclusion, the data presented in
this thesis paves the way for further inroads into identifying the underlying cause of preterm
labour and labour at term.
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Appendix A
Nuclear Receptor
Nomenclature
Table A.1: Proposed Nomenclature for Nuclear Receptors.
Subfamily and Group NR/Gene Trivial Names Accession Number
Group 1
1A NR1A1 TRα, c-erbA-1, THRA M24748
NR1A2 TRβ, c-erbA-2, THRB X04707
1B NR1B1 RARα X06538
NR1B2 RARβ, HAP Y00291
NR1B3 RAR?, RARD M57707
1C NR1C1 PPARα L02932
NR1C2 PPARβ, NUC1, PPAR?, FAAR L07592
NR1C3 PPAR? L40904
1D NR1D1 REVERBα, EAR1, EAR1A M24898
NR1D2 REVERBβ, EAR1β, BD73, RVR, HZF2 L31785
NR1D3 E75 X51548
1E NR1E1 E78, DR-78 U01087
1F NR1F1 RORα, RZRα U04897
NR1F2 RORβ, RZRβ Y08639
NR1F3 ROR, TOR U16997
NR1F4 HR3, DHR3, MHR3, GHR3, CNR3, M90806
CHR3 U13075
1G NR1G1 CNR14 U13074
1H NR1H1 ECR M74078
NR1H2 UR, OR-1, NER1, RIP15, LXRβ U07132
NR1H3 RLD1, LXR, LXRα U22662
NR1H4 FXR, RIP14, HRR1 U09416
1I NR1I1 VDR J03258
NR1I2 ONR1, PXR, SXR, BXR X75163
NR1I3 MB67, CAR1, CARα Z30425
NR1I4 CAR2, CARβ AF00932
1J NR1J1 DHR96 U36792
1K NR1K1 NHR1 U19360
Group 2
Continued on next page
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Subfamily and Group NR/Gene Trivial Names Accession Number
2A NR2A1 HNF4 X76930
NR2A2 HNF4G Z49826
NR2A3 HNF4B Z49827
NR2A4 DHNF4, HNF4D U70874
2B NR2B1 RXRA X52773
NR2B2 RXRB, H-2RIIBP, RCoR-1 M84820
NR2B3 RXRG X66225
NR2B4 USP, Ultraspiracle, 2C1, CF1 X52591
2C NR2C1 TR2, TR2-11 M29960
NR2C2 TR4, TAK1 L27586
2D NR2D1 DHR78 U36791
2E NR2E1 TLL, TLX, XTLL S72373
NR2E2 TLL, Tailless M34639
2F NR2F1 COUP-TFI, COUPTFA, EAR3, SVP44 X12795
NR2F2 COUP-TFII, COUPTFB, ARP1, SVP40 M64497
NR2F3 SVP, COUP-TF M28863
NR2F4 COUP-TFIII, COUPTFG X63092
NR2F5 SVP46 X70300
NR2F6 EAR2 X12794
Group 3
3A NR3A1 ERα X03635
NR3A2 ERβ U57439
3B NR3B1 ERR1, ERRα X51416
NR3B2 ERR2, ERRβ X51417
3C NR3C1 GR X03225
NR3C2 MR M16801
NR3C3 PR M15716
NR3C4 AR M20132
Group 4
4A NR4A1 NGFIB, TR3, N10, NUR77, NAK1 L13740
NR4A2 NURR1, NOT, RNR1, HZF-3, TINOR X75918
NR4A3 NOR1, MINOR D38530
NR4A4 DHR38, NGFIB U36762
CNR8, C48D5 U13076
Group 5
5A NR5A1 SF1, ELP, FTZ-F1, AD4BP D88155
NR5A2 LRH1, xFF1rA, xFF1rB, FFLR, PHR, FTF U93553
NR5A3 FTZ-F1 M63711
5B NR5B1 DHR39, FTZF1B L06423
Group 6
6A NR6A1 GCNF1, RTR U14666
Group 0
0A NR0A1 KNI, Knirps X13331
NR0A2 KNRL, Knirps related X14153
NR0A3 EGON, Embryonic gonad, EAGLE X16631
NR0A4 ODR7 U16708
NR0A5 Trithorax M31617
0B NR0B1 DAX1, AHCH S74720
NR0B2 SHP L76571
256
Appendix B
Animals Used in the Study
Table B.1: Animals used in the study. GD indicates the gestational day.
Treatment Collection Day Number of Animals
Control GD19+6hrs 3
RU486 GD19+6hrs 3
Control GD20 3
RU486 GD20 3
Control GD22 2
Control GD22 ( NL) 3
P4 GD22 3
Figure B.1: Visual checking of samples. Six frozen whole uterus samples being checked
visually to make sure they are still frozen.
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Table B.2: Whole uterine samples for the research. The samples were catalogued and
weighed after 24h of receipt.
Sample ID Treatment Day of Sacrifice Weight (in g)
1 Vehicle GD22 40.4
2 Vehicle GD22 64.7
3 Vehicle GD22 43.7
7 P4 (×3 days, 4mg) GD22 61.1
8 P4 (×3 days, 4mg) GD22 62.5
9 P4 (×3 days, 4mg) GD22 65.3
R1 Vehicle GD19 + 6h 25.9
R2 Vehicle GD19 + 6h 29.9
R3 Vehicle GD19 + 6h 26.6
R4 Vehicle GD20 30.6
R5 Vehicle GD20 23.4
R6 Vehicle GD20 32.8
R7 RU486 (3mg) GD19 + 6h 14.4
R8 RU486 (3mg) GD19 + 6h 22.2
R9 RU486 (3mg) GD19 + 6h 31.5
R10 RU486 (3mg) GD20 + 6h 33.6
R11 RU486 (3mg) GD20 + 6h 33.6
R12 RU486 (3mg) GD20 + 6h 39.9
A-CTR Vehicle GD22 4
B-CTR Vehicle GD22 38.9
C-CTR Vehicle GD22 49.1
Table B.3: Quantitation of total RNA using the NanoDrop®.
Sample ID Concentration (ng/µl) 260/280 260/230
1 2651.165 2.04 2.16
2 676.415 2.15 1.4
3 1464.56 2.08 1.76
7 775.615 2.16 1.22
8 1407.735 2.14 1.86
9 803.595 2.28 1.24
R1 3832.835 1.83 1.92
R2 2735.875 1.86 1.93
R3 3375.49 1.95 2.06
R4 2024.57 2.05 1.78
R5 2739.56 2.01 2.19
R6 2583.53 1.94 2.22
R7 3779.27 1.85 1.98
R8 3311.345 1.97 2.08
R9 4069.135 1.67 1.78
R10 2958.995 1.93 2.14
R11 3966.2 1.78 1.78
R12 3585.295 1.73 1.84
A-CTR 3442.875 1.92 2.09
B-CTR 3985.61 1.77 1.87
C-CTR 2503.64 1.97 2.15
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Instrument Name: DE34903137 Firmware:
Serial#:
Assay Information:
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Figure B.2: Bioanalyzer traces. The RIN indicates the integrity of the RNA, where 10 is the
most intact and 1 is the most degraded. RIN: RNA integrity number.
Appendix C
Inspection for Bias
Table C.1: Inspection of FASTQ files. FASTQ files were inspected for contamination and
sequencing errors. A pass (green) indicated that a file passed a test, while a warning (orange) was
issued if the test result result was borderline, and a fail (red) indicated that the file had not passed
the test. GD19q: 6 hours after the 19th day of gestation; GD20: 20th day of gestation; GD22:
22nd day of gestation - not in labour; GD22L): 22nd day of gestation - in labour; CTR: control;
RU486: mifepristone-treated; P4: progesterone treated; DEC: decidua; INN: inner myometrium;
OUT: outer myometrium.
Base Seq Overre-
Basic Seq Quality Seq GC GC N Seq Seq presented Kmer
File Stats Quality Scores Content Content Content Content Length Duplicates Seqs Content
GD19q-CTR-DEC-r1a PASS PASS PASS WARN PASS FAIL PASS PASS FAIL FAIL FAIL
GD19q-CTR-DEC-r1a PASS PASS PASS WARN PASS FAIL PASS PASS FAIL FAIL FAIL
GD19q-CTR-DEC-r2a PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN FAIL
GD19q-CTR-DEC-r2a PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN FAIL
GD19q-CTR-DEC-r3a PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN WARN
GD19q-CTR-DEC-r3a PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN WARN
GD19q-CTR-INN-r1b PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN FAIL
GD19q-CTR-INN-r1b PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN FAIL
GD19q-CTR-INN-r2b PASS PASS PASS PASS PASS PASS PASS PASS WARN WARN WARN
GD19q-CTR-INN-r2b PASS PASS PASS PASS PASS PASS PASS PASS WARN WARN WARN
GD19q-CTR-INN-r3b PASS PASS PASS PASS PASS PASS PASS PASS WARN WARN WARN
GD19q-CTR-INN-r3b PASS PASS PASS PASS PASS PASS PASS PASS WARN WARN WARN
GD19q-CTR-OUT-r1c PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD19q-CTR-OUT-r1c PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD19q-CTR-OUT-r2c PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN FAIL
GD19q-CTR-OUT-r2c PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN FAIL
GD19q-CTR-OUT-r3c PASS PASS PASS WARN PASS WARN PASS PASS FAIL WARN WARN
GD19q-CTR-OUT-r3c PASS PASS PASS WARN PASS WARN PASS PASS FAIL WARN FAIL
GD19q-RU486-DEC-r7a PASS PASS PASS WARN WARN PASS PASS PASS FAIL WARN WARN
GD19q-RU486-DEC-r7a PASS PASS PASS WARN WARN PASS PASS PASS FAIL WARN WARN
GD19q-RU486-DEC-r8a PASS PASS PASS WARN WARN WARN PASS PASS FAIL PASS WARN
GD19q-RU486-DEC-r8a PASS PASS PASS PASS WARN WARN PASS PASS FAIL WARN WARN
GD19q-RU486-INN-r8b PASS PASS PASS PASS WARN PASS PASS PASS FAIL PASS WARN
GD19q-RU486-INN-r8b PASS PASS PASS PASS WARN PASS PASS PASS FAIL WARN WARN
GD19q-RU486-INN-r9b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN FAIL
GD19q-RU486-INN-r9b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN FAIL
GD19q-RU486-OUT-r7c PASS PASS PASS WARN WARN PASS PASS PASS WARN WARN FAIL
GD19q-RU486-OUT-r7c PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN FAIL
GD19q-RU486-OUT-r8c PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD19q-RU486-OUT-r8c PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
Continued on next page
260
Table C.1 – continued from previous page
Base Seq Overre-
Basic Seq Quality Seq GC GC N Seq Seq presented Kmer
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GD19q-RU486-OUT-r9c PASS PASS PASS WARN PASS WARN PASS PASS FAIL WARN FAIL
GD19q-RU486-OUT-r9c PASS PASS PASS WARN PASS WARN PASS PASS FAIL WARN FAIL
GD20-CTR-DEC-r4a PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD20-CTR-DEC-r4a PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD20-CTR-DEC-r5a PASS PASS PASS FAIL WARN FAIL PASS PASS FAIL FAIL FAIL
GD20-CTR-DEC-r5a PASS PASS PASS FAIL WARN FAIL PASS PASS FAIL FAIL FAIL
GD20-CTR-DEC-r6a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN FAIL
GD20-CTR-DEC-r6a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN FAIL
GD20-CTR-INN-r4b PASS PASS PASS PASS WARN PASS PASS PASS FAIL WARN FAIL
GD20-CTR-INN-r4b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN FAIL
GD20-CTR-INN-r5b PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD20-CTR-INN-r5b PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD20-CTR-INN-r6b PASS PASS PASS WARN WARN WARN PASS PASS FAIL WARN FAIL
GD20-CTR-INN-r6b PASS PASS PASS WARN WARN WARN PASS PASS FAIL WARN FAIL
GD20-CTR-INN-r6b PASS PASS PASS WARN WARN WARN PASS PASS FAIL WARN FAIL
GD20-CTR-INN-r6b PASS PASS PASS WARN WARN WARN PASS PASS FAIL WARN FAIL
GD20-CTR-INN-r6b PASS PASS PASS WARN WARN WARN PASS PASS FAIL WARN FAIL
GD20-CTR-OUT-r4c PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN WARN
GD20-CTR-OUT-r4c PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN WARN
GD20-CTR-OUT-r5c PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN WARN
GD20-CTR-OUT-r5c PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD20-CTR-OUT-r6c PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD20-CTR-OUT-r6c PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD20-RU486-DEC-r10a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD20-RU486-DEC-r10a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN FAIL
GD20-RU486-DEC-r11a PASS PASS PASS WARN PASS WARN PASS PASS FAIL WARN FAIL
GD20-RU486-DEC-r11a PASS PASS PASS WARN PASS WARN PASS PASS FAIL WARN FAIL
GD20-RU486-DEC-r12a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD20-RU486-DEC-r12a PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD20-RU486-INN-r10b PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN FAIL
GD20-RU486-INN-r10b PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN FAIL
GD20-RU486-INN-r11b PASS PASS PASS WARN PASS PASS PASS PASS FAIL PASS WARN
GD20-RU486-INN-r11b PASS PASS PASS WARN PASS PASS PASS PASS FAIL PASS WARN
GD20-RU486-INN-r11b PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD20-RU486-INN-r11b PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD20-RU486-INN-r12b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN FAIL
GD20-RU486-INN-r12b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN FAIL
GD20-RU486-OUT-r10c PASS PASS PASS WARN PASS PASS PASS PASS FAIL PASS WARN
GD20-RU486-OUT-r10c PASS PASS PASS WARN PASS PASS PASS PASS FAIL PASS WARN
GD20-RU486-OUT-r11c PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD20-RU486-OUT-r11c PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD20-RU486-OUT-r12c PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD20-RU486-OUT-r12c PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD22-CTR-DEC-1a PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD22-CTR-DEC-1a PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN FAIL
GD22-CTR-DEC-2a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN FAIL
GD22-CTR-DEC-2a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN FAIL
GD22-CTR-DEC-3a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22-CTR-DEC-3a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22-CTR-INN-1b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22-CTR-INN-1b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22-CTR-INN-2b PASS PASS PASS WARN PASS WARN PASS PASS FAIL WARN FAIL
GD22-CTR-INN-2b PASS PASS PASS WARN PASS WARN PASS PASS FAIL WARN FAIL
GD22-CTR-INN-3b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22-CTR-INN-3b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22L-CTR-DEC-b-ctr-a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22L-CTR-DEC-b-ctr-a PASS PASS PASS PASS PASS WARN PASS PASS FAIL WARN WARN
GD22L-CTR-DEC-c PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD22L-CTR-DEC-c PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD22L-CTR-INN-b-ctr-b PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD22L-CTR-INN-b-ctr-b PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD22L-CTR-INN-c PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22L-CTR-INN-c PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22L-CTR-OUT-b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22L-CTR-OUT-b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22L-CTR-OUT-c-ctr-c PASS PASS PASS WARN WARN WARN PASS PASS FAIL WARN WARN
GD22L-CTR-OUT-c-ctr-c PASS PASS PASS WARN WARN WARN PASS PASS FAIL WARN WARN
GD22-CTR-OUT-1c PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
Continued on next page
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GD22-CTR-OUT-1c PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22-CTR-OUT-3c PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD22-CTR-OUT-3c PASS PASS PASS PASS PASS PASS PASS PASS WARN WARN WARN
GD22-CTR-PP-DEC PASS PASS PASS WARN WARN PASS PASS PASS WARN PASS FAIL
GD22-CTR-PP-DEC PASS PASS PASS WARN PASS PASS PASS PASS WARN PASS FAIL
GD22-CTR-PP-INN PASS PASS PASS PASS PASS WARN PASS PASS FAIL PASS WARN
GD22-CTR-PP-INN PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD22-CTR-PP-OUT PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD22-CTR-PP-OUT PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD22-P4-DEC-7a PASS PASS PASS WARN PASS PASS PASS PASS WARN PASS WARN
GD22-P4-DEC-7a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22-P4-DEC-7a PASS PASS PASS WARN PASS PASS PASS PASS WARN PASS WARN
GD22-P4-DEC-7a PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22-P4-DEC-9a PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD22-P4-DEC-9a PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD22-P4-INN-7b PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN WARN
GD22-P4-INN-7b PASS PASS PASS PASS PASS PASS PASS PASS FAIL WARN WARN
GD22-P4-INN-8b PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD22-P4-INN-8b PASS PASS PASS WARN PASS PASS PASS PASS WARN WARN WARN
GD22-P4-INN-9b PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN WARN
GD22-P4-INN-9b PASS PASS PASS WARN PASS PASS PASS PASS FAIL WARN WARN
GD22-P4-OUT-8c PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
GD22-P4-OUT-8c PASS PASS PASS PASS PASS PASS PASS PASS FAIL PASS WARN
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Appendix D
Transcriptomic Landscape of
the Rat Uterus in Late
Pregnancy and at Term
D.1 GD19 + 6 hours
Table D.1: Genes that were differentially expressed in the inner myometrium com-
pared to the decidua on GD19+6hrs. Transcript expression levels are shown in transcripts
per million values (mean±SD).
Decidua Inner myometrium
Gene
symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Akap12 A kinase (PRKA) anchor protein 12 4.53 1.80 58.94 46.29
Lrrc4b leucine rich repeat containing 4B 1.99 0.25 27.59 40.52
Mrvi1 murine retrovirus integration site 1 homolog 3.15 0.48 70.63 52.25
Sult1a1 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 2.26 1.32 69.09 58.78
Olr303 olfactory receptor 303 0.06 0.11 39.59 68.26
Aoc3 amine oxidase, copper containing 3 2.92 0.80 148.63 120.24
Meox1 mesenchyme homeobox 1 0.19 0.06 4.77 5.32
Popdc2 popeye domain containing 2 2.77 1.94 40.97 33.48
Lmod1 leiomodin 1 (smooth muscle) 4.36 2.72 91.61 82.28
Dpt dermatopontin 1.44 0.80 67.59 55.44
Crp C-reactive protein, pentraxin-related 0.01 0.01 5.87 9.78
Ppp1r12b protein phosphatase 1, regulatory subunit 12B 28.84 19.70 104.21 72.45
Sorcs2 sortilin-related VPS10 domain containing receptor 2 1.11 0.36 50.80 41.11
C1qtnf9 C1q and tumor necrosis factor related protein 9 0.01 0.01 4.08 6.08
Continued on next page
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Decidua Inner myometrium
Gene
symbol Gene name TPM ±SD TPM ±SD
Isyna1 inositol-3-phosphate synthase 1 17.38 14.26 718.80 625.89
Pdlim3 PDZ and LIM domain 3 18.64 17.83 226.33 206.87
Acta1 actin, alpha 1, skeletal muscle 10.77 1.79 2208.48 2003.48
Vtcn1 V-set domain containing T cell activation inhibitor 1 1.51 0.42 54.06 59.22
Cpa3 carboxypeptidase A3, mast cell 0.00 0.00 3.19 5.52
Glrb glycine receptor, beta 0.01 0.02 2.50 1.93
Lrat lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-acyltransferase) 2.88 2.35 120.84 118.41
Csf1 colony stimulating factor 1 (macrophage) 5.88 8.46 159.80 202.04
Ptgs1 prostaglandin-endoperoxide synthase 1 7.53 6.51 115.41 100.00
Slc24a3 solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 2.35 1.27 44.63 33.68
Slc4a11 solute carrier family 4, sodium borate transporter, member 11 3.24 3.60 125.33 110.33
Bpi bactericidal/permeability-increasing protein 0.02 0.03 2.91 4.27
Cxcl12 chemokine (C-X-C motif) ligand 12 1.69 0.51 69.61 59.34
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B 6.74 3.23 129.18 118.61
Ptn pleiotrophin 33.07 52.75 191.90 204.81
Crhr2 corticotropin releasing hormone receptor 2 0.02 0.03 7.59 12.90
Kif12 kinesin family member 12 0.96 1.66 5.78 8.34
Guca2b guanylate cyclase activator 2B 15.16 25.37 1329.53 1960.71
C1qc complement component 1, q subcomponent, C chain 4.13 2.94 196.15 166.18
Mchr1 melanin-concentrating hormone receptor 1 0.07 0.11 17.12 19.70
Olr894 olfactory receptor 894 0.07 0.11 78.02 135.13
Krt83 keratin 83 0.67 0.79 10.00 8.98
Cnn1 calponin 1, basic, smooth muscle 16.49 18.28 1955.91 1586.11
Crabp1 cellular retinoic acid binding protein 1 0.00 0.00 35.65 60.11
Abcg4 ATP-binding cassette, subfamily G (WHITE), member 4 1.09 0.44 134.92 115.13
Tagln transgelin 47.17 10.26 2038.89 1613.39
RGD1562136 similar to D1Ertd622e protein 10.11 7.63 48.96 40.45
Mrgprf MAS-related GPR, member F 0.78 0.30 44.82 37.99
Bcam basal cell adhesion molecule (Lutheran blood group) 9.18 1.83 89.57 73.51
Bcl3 B-cell CLL/lymphoma 3 3.14 1.99 70.42 112.00
Ltbp4 latent transforming growth factor beta binding protein 4 0.58 0.20 29.47 30.97
Fut2 fucosyltransferase 2 (secretor status included) 3.39 2.21 39.70 35.35
Pgm5 phosphoglucomutase 5 2.74 3.92 143.59 119.34
Clec10a C-type lectin domain family 10, member A 29.21 32.75 209.17 111.03
Lpo lactoperoxidase 2.41 0.46 31.16 34.21
Itfg3 integrin alpha FG-GAP repeat containing 3 18.11 17.34 161.02 143.13
Myocd myocardin 5.34 2.67 35.81 34.08
Slc5a3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 3.32 2.27 38.84 38.06
Eln elastin 2.07 0.67 35.00 31.86
Mrc1 mannose receptor, C type 1 2.40 1.61 20.31 19.23
Egr1 early growth response 1 13.37 5.89 126.07 120.74
Rasd2 RASD family, member 2 16.34 20.72 40.12 39.71
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) 10.72 14.27 78.42 71.42
Thbs4 thrombospondin 4 35.78 36.75 701.39 634.49
Mecom MDS1 and EVI1 complex locus 0.81 0.34 10.08 7.72
Rxfp1 relaxin/insulin-like family peptide receptor 1 10.62 10.57 44.82 43.30
Oxt oxytocin/neurophysin 1 prepropeptide 17.92 11.92 207.67 226.00
Pax8 paired box 8 3.44 5.00 68.56 65.21
Myl9 myosin, light chain 9, regulatory 132.69 126.93 10272.75 8708.75
Atp6v0a4 ATPase, H+ transporting, lysosomal V0 subunit A4 0.74 0.53 25.42 21.81
Fam13a family with sequence similarity 13, member A 2.05 0.39 20.96 23.16
Kap kidney androgen regulated protein 23.68 12.26 682.17 1078.09
Mgp matrix Gla protein 68.27 49.59 545.96 646.80
Fgr feline Gardner-Rasheed sarcoma viral oncogene 2.00 1.43 27.50 41.65
Prkaa2 protein kinase, AMP-activated, alpha 2 catalytic subunit 5.31 6.67 20.40 17.33
C1qa complement component 1, q subcomponent, A chain 3.39 1.92 213.84 178.11
Igfbp6 insulin-like growth factor binding protein 6 79.47 124.30 810.09 660.39
Mmp3 matrix metallopeptidase 3 5.81 9.25 113.39 138.29
Slc9a9 solute carrier family 9, subfamily A (NHE9, cation proton antiporter 9), member 9 2.21 2.02 10.22 10.51
C3 complement component 3 8.75 2.09 120.89 163.61
Figf c-fos induced growth factor 7.53 11.98 151.41 121.46
Igfbp4 insulin-like growth factor binding protein 4 42.20 12.56 92.64 30.17
Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 13.49 8.63 58.99 11.88
Hip1 huntingtin interacting protein 1 33.66 37.12 47.47 8.72
Sgcb sarcoglycan, beta (dystrophin-associated glycoprotein) 2.44 3.55 22.68 11.99
Lix1l Lix1 homolog (mouse)-like 14.69 16.13 95.56 21.84
Pygb phosphorylase, glycogen; brain 12.73 5.24 60.87 40.33
Nod1 nucleotide-binding oligomerization domain containing 1 3.60 2.15 23.77 12.48
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Suclg2 succinate-CoA ligase, GDP-forming, beta subunit 13.21 7.11 63.55 15.30
Ston1 stonin 1 19.30 3.24 76.90 22.71
Apol9a apolipoprotein L 9a 17.47 5.61 81.51 42.62
Tmem47 transmembrane protein 47 15.18 9.90 71.33 37.53
Mill1 MHC I like leukocyte 1 2.89 0.52 36.28 8.50
Spon1 spondin 1, extracellular matrix protein 13.08 20.67 160.06 65.31
Ifitm1 interferon induced transmembrane protein 1 8.48 5.25 90.42 5.05
Ptprcap protein tyrosine phosphatase, receptor type, C-associated protein 0.55 0.80 9.70 10.13
Synm synemin, intermediate filament protein 7.34 5.43 56.14 39.38
Bgn biglycan 76.41 33.31 1370.81 886.27
Ifitm2 interferon induced transmembrane protein 2 28.97 15.72 461.16 188.59
Slit3 slit homolog 3 (Drosophila) 14.88 8.84 108.08 39.54
Col1a1 collagen, type I, alpha 1 29.68 19.91 858.18 406.81
Serpinf1 serpin peptidase inhibitor, clade F , member 1 87.68 64.69 634.33 287.77
Mx1 myxovirus (influenza virus) resistance 1 3.64 0.67 53.07 30.97
Atp2b4 ATPase, Ca++ transporting, plasma membrane 4 3.07 2.12 49.80 36.69
Fmod fibromodulin 5.12 4.67 76.89 70.56
Tnn tenascin N 5.55 4.77 86.47 39.28
Spp1 secreted phosphoprotein 1 19.31 16.55 607.02 435.91
Phf11 PHD finger protein 11 9.08 11.60 42.93 32.24
Rbpms RNA binding protein with multiple splicing 10.35 5.03 229.42 58.03
Pdlim7 PDZ and LIM domain 7 122.62 17.09 568.90 71.58
Svil supervillin 10.82 6.95 85.24 55.33
Cd74 Cd74 molecule, major histocompatibility complex, class II invariant chain 4.70 2.97 160.00 113.58
Nfix nuclear factor I/X (CCAAT-binding transcription factor) 12.03 8.93 200.84 27.11
Fam198b family with sequence similarity 198, member B 0.70 0.21 26.12 14.38
Col11a1 collagen, type XI, alpha 1 0.97 1.02 23.94 13.60
F3 coagulation factor III (thromboplastin, tissue factor) 23.81 1.81 308.08 246.32
Gbp2 guanylate binding protein 2, interferon-inducible 7.28 4.79 72.47 59.84
Vcan versican 3.14 1.66 41.59 23.76
Ptgfrn prostaglandin F2 receptor inhibitor 11.60 9.03 166.59 102.79
Gpr88 G-protein coupled receptor 88 2.90 1.90 51.02 45.46
Ier3 immediate early response 3 24.97 16.91 241.00 101.82
Cfb complement factor B 3.86 1.44 77.92 53.61
Lcn2 lipocalin 2 2.43 2.87 221.06 177.26
Frzb frizzled-related protein 3.14 1.40 105.08 52.79
Ptgis prostaglandin I2 (prostacyclin) synthase 2.03 2.23 140.19 82.43
Cav1 caveolin 1, caveolae protein 15.58 2.29 269.86 198.87
Tmem176a transmembrane protein 176A 24.45 20.53 849.07 590.52
C1r complement component 1, r subcomponent 13.08 7.26 153.14 50.13
Cacna2d1 calcium channel, voltage-dependent, alpha2/delta subunit 1 1.21 0.98 51.60 39.60
Tmem176b transmembrane protein 176B 23.31 8.30 261.90 39.39
Inmt indolethylamine N-methyltransferase 0.00 0.00 8.25 1.30
Antxr1 anthrax toxin receptor 1 25.45 16.64 277.48 223.08
C1s complement component 1, s subcomponent 5.54 2.80 141.14 61.93
Abcc9 ATP-binding cassette, subfamily C (CFTR/MRP), member 9 1.51 1.26 22.91 15.25
Sdc3 syndecan 3 9.88 13.29 46.60 30.19
Bnc2 basonuclin 2 1.96 0.38 28.46 9.45
C1qb complement component 1, q subcomponent, B chain 3.33 1.74 108.99 78.62
Vwa1 von Willebrand factor A domain containing 1 3.53 2.10 78.35 47.33
Slc8a1 solute carrier family 8 (sodium/calcium exchanger), member 1 4.44 4.59 20.42 14.41
Fbln5 fibulin 5 4.08 3.01 67.25 43.40
Igf1 insulin-like growth factor 1 4.16 4.20 73.30 30.07
Col14a1 collagen, type XIV, alpha 1 0.70 0.51 13.78 5.92
Ly6e lymphocyte antigen 6 complex, locus E 35.02 3.22 530.44 339.82
Col3a1 collagen, type III, alpha 1 50.32 26.71 1091.52 272.63
Bok BCL2-related ovarian killer 8.16 3.62 188.81 103.11
Igfbp5 insulin-like growth factor binding protein 5 7.33 6.61 135.79 124.66
Fhl1 four and a half LIM domains 1 16.88 13.42 858.68 631.95
Enpp3 ectonucleotide pyrophosphatase/phosphodiesterase 3 6.80 3.10 60.66 61.32
Ssc5d scavenger receptor cysteine rich domain containing (5 domains) 8.02 10.06 33.16 14.08
Dact3 dishevelled-binding antagonist of beta-catenin 3 3.64 3.66 58.36 42.05
Rgma repulsive guidance molecule family member A 3.06 1.93 64.25 30.48
Pde3b phosphodiesterase 3B, cGMP-inhibited 3.30 2.25 17.84 10.09
Tgfb1i1 transforming growth factor beta 1 induced transcript 1 29.18 21.16 227.16 139.43
Mpeg1 macrophage expressed 1 4.64 4.32 61.03 39.44
Ehd2 EH-domain containing 2 17.98 13.99 123.83 90.57
Ifitm3 interferon induced transmembrane protein 3 245.64 245.12 3474.50 648.65
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Irf7 interferon regulatory factor 7 23.36 14.11 156.06 70.44
Gda guanine deaminase 26.48 20.26 146.59 75.49
Acta2 actin, alpha 2, smooth muscle, aorta 51.44 43.99 2331.00 1806.03
Ifi47 interferon gamma inducible protein 47 13.38 11.35 90.95 63.47
Anxa6 annexin A6 19.42 6.78 107.82 47.27
Lpp LIM domain containing preferred translocation partner in lipoma 21.48 9.23 166.83 130.05
Pla1a phospholipase A1 member A 4.32 0.87 39.01 28.88
Mylk myosin light chain kinase 16.67 5.04 892.90 611.27
Oasl2 2’-5’ oligoadenylate synthetase-like 2 8.05 6.78 57.24 39.14
Rgs5 regulator of G-protein signaling 5 7.25 8.97 100.30 34.49
Bcl2 B-cell CLL/lymphoma 2 4.10 2.28 48.67 52.83
Prelp proline/arginine-rich end leucine-rich repeat protein 85.16 135.79 1433.10 1165.88
Fcer1g Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide 19.97 23.06 185.60 146.71
Ifi204 myeloid cell nuclear differentiation antigen 6.35 4.76 52.10 25.21
Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 29.57 23.65 215.59 27.39
Aebp1 AE binding protein 1 20.34 15.02 150.44 42.82
Pcdh7 protocadherin 7 0.39 0.40 25.81 11.50
Smtn smoothelin 25.44 15.60 174.71 45.11
Wnt5a wingless-type MMTV integration site family, member 5A 1.18 0.33 20.46 22.13
Tlr3 toll-like receptor 3 5.55 2.32 33.82 12.19
Zfp521 zinc finger protein 521 0.83 0.19 10.72 4.54
Dclk1 doublecortin-like kinase 1 3.97 1.33 35.06 24.70
Kcnd3 potassium voltage-gated channel, Shal-related subfamily, member 3 0.19 0.19 7.97 5.11
Adh1 alcohol dehydrogenase 1 (class I) 10.83 12.42 79.74 51.54
Lmo4 LIM domain only 4 12.75 12.09 79.74 46.57
Col6a2 collagen, type VI, alpha 2 57.77 41.62 466.26 316.67
Susd2 sushi domain containing 2 24.94 12.09 143.79 64.68
Aif1 allograft inflammatory factor 1 4.11 2.65 83.32 66.60
Thbs1 thrombospondin 1 7.50 1.13 40.28 12.68
Rassf2 Ras association (RalGDS/AF-6) domain family member 2 6.39 8.05 27.38 12.95
Prkag2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit 9.16 4.67 53.85 23.61
Dbf4 DBF4 homolog (S. cerevisiae) 1.24 0.43 24.77 26.86
Tnfrsf1a tumor necrosis factor receptor superfamily, member 1a 16.56 6.17 80.10 29.81
Steap4 STEAP family member 4 4.40 0.94 29.13 14.23
Cnr1 cannabinoid receptor 1 (brain) 8.94 9.45 28.93 10.99
Nfia nuclear factor I/A 3.70 1.08 32.54 20.08
Flrt2 fibronectin leucine rich transmembrane protein 2 2.47 2.09 32.72 16.29
Pld4 phospholipase D family, member 4 18.78 28.08 66.28 53.73
Csf2rb colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 3.69 1.71 40.11 19.75
Slc2a13 solute carrier family 2 (facilitated glucose transporter), member 13 3.19 3.85 9.61 7.83
Mcam melanoma cell adhesion molecule 16.18 2.30 135.38 103.87
Plod2 procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 22.64 14.20 162.90 69.38
Rexo2 RNA exonuclease 2 37.22 26.05 273.82 163.92
Cd276 Cd276 molecule 16.91 9.03 88.55 35.72
Filip1 filamin A interacting protein 1 2.64 1.59 17.20 7.58
Gls glutaminase 13.78 6.61 93.60 60.74
Klf7 Kruppel-like factor 7 (ubiquitous) 42.97 31.40 137.39 39.30
Sp110 SP110 nuclear body protein 10.34 5.31 48.98 37.83
Ar androgen receptor 2.79 2.72 24.83 16.68
Kcnmb1 potassium large conductance calcium-activated channel, subfamily M, beta member 1 0.80 0.65 174.59 134.24
Rprm reprimo, TP53 dependent G2 arrest mediator candidate 2.83 4.07 40.31 24.32
Car12 carbonic anyhydrase 12 1.27 0.46 58.75 38.73
Mmp17 matrix metallopeptidase 17 0.53 0.10 19.98 6.66
Penk proenkephalin 0.66 0.72 33.28 41.82
C4a complement component 4A (Rodgers blood group) 2.95 2.23 87.49 71.46
Pla2g2d phospholipase A2, group IID 0.90 0.87 17.97 14.26
Wbscr17 Williams-Beuren syndrome chromosome region 17 1.20 0.79 36.68 23.62
RT1-Da RT1 class II, locus Da 1.33 1.19 36.72 23.40
RT1-Ba RT1 class II, locus Ba 1.56 0.97 21.30 14.27
RT1-Db1 RT1 class II, locus Db1 0.71 0.48 17.45 7.15
Cacna1c calcium channel, voltage-dependent, L type, alpha 1C subunit 0.62 0.62 14.89 3.84
Acy3 aspartoacylase (aminocyclase) 3 0.45 0.50 27.76 22.74
Tlr8 toll-like receptor 8 0.30 0.22 9.23 8.77
LOC100910940 ecotropic viral integration site 2B 1.81 0.65 26.77 7.49
Tlr2 toll-like receptor 2 0.32 0.32 9.77 1.71
Dio3 deiodinase, iodothyronine, type III 1.78 1.15 32.23 19.05
Klrk1 killer cell lectin-like receptor subfamily K, member 1 0.43 0.63 14.29 12.88
Cx3cr1 chemokine (C-X3-C motif) receptor 1 1.28 0.87 33.14 18.50
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Tm4sf1 transmembrane 4 L six family member 1 0.35 0.25 10.29 3.99
Six4 SIX homeobox 4 3.15 2.08 9.47 2.80
Hoxb7 homeo box B7 0.98 0.09 20.87 16.09
Cd180 CD180 molecule 1.73 1.55 22.91 18.96
Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1 0.48 0.16 10.65 10.64
Fas Fas cell surface death receptor 0.34 0.24 10.02 7.51
Osr2 odd-skipped related transciption factor 2 3.43 4.55 59.53 47.50
Lmo2 LIM domain only 2 1.93 1.72 25.23 13.96
Ociad2 OCIA domain containing 2 7.95 11.02 22.71 14.80
Gpm6b glycoprotein m6b 0.73 0.57 15.83 12.48
Tmem252 transmembrane protein 252 1.70 0.47 20.62 14.85
Nptx2 neuronal pentraxin II 0.09 0.15 11.63 4.47
Gstt1 glutathione S-transferase theta 1 17.53 21.55 187.75 195.71
Cd37 CD37 molecule 0.60 0.68 19.19 17.79
Astn1 astrotactin 1 0.20 0.18 3.74 1.59
Gpc4 glypican 4 2.59 1.08 22.77 5.31
Kctd15 potassium channel tetramerization domain containing 15 3.84 1.80 35.17 5.62
Arsj arylsulfatase family, member J 0.40 0.34 10.72 8.61
Tpm2 tropomyosin 2, beta 338.24 143.17 6114.96 4999.49
Sema4a sema domain, (semaphorin) 4A 2.48 1.86 34.62 21.47
Cacna1g calcium channel, voltage-dependent, T type, alpha 1G subunit 0.41 0.39 6.98 3.28
Unc93b1 unc-93 homolog B1 (C. elegans) 4.87 3.25 43.94 18.23
Oasl 2’-5’-oligoadenylate synthetase-like 2.47 1.80 25.90 16.40
Fjx1 four jointed box 1 (Drosophila) 0.72 0.48 20.16 8.24
Tifa TRAF-interacting protein with forkhead-associated domain 1.31 0.47 17.94 9.38
Oas1a 2’-5’ oligoadenylate synthetase 1A 2.15 2.63 34.01 9.52
Cyp7b1 cytochrome P450, family 7, subfamily b, polypeptide 1 0.32 0.32 7.13 5.37
C1qtnf7 C1q and tumor necrosis factor related protein 7 1.93 1.64 27.81 18.03
Arhgef25 Rho guanine nucleotide exchange factor (GEF) 25 1.87 0.45 26.84 22.18
Vcam1 vascular cell adhesion molecule 1 0.67 0.47 7.59 4.55
Gja5 gap junction protein, alpha 5 13.57 17.96 34.03 28.97
Has2 hyaluronan synthase 2 0.36 0.48 2.79 2.25
Tnfaip8l2 tumor necrosis factor, alpha-induced protein 8-like 2 1.31 1.50 20.16 9.11
Foxs1 forkhead box S1 2.66 2.29 40.14 39.21
Fam20c family with sequence similarity 20, member C 4.45 2.69 37.39 23.92
Pltp phospholipid transfer protein 71.18 67.34 598.66 551.87
Gem GTP binding protein overexpressed in skeletal muscle 2.13 1.75 23.18 12.83
Cndp1 carnosine dipeptidase 1 (metallopeptidase M20 family) 1.01 0.72 12.24 12.83
Xk X-linked Kx blood group (McLeod syndrome) 0.28 0.25 3.48 2.44
Il13ra1 interleukin 13 receptor, alpha 1 2.46 2.35 25.44 5.25
Limd2 LIM domain containing 2 13.24 19.61 32.50 26.90
Sulf1 sulfatase 1 1.24 1.35 12.92 13.42
MGC108823 similar to interferon-inducible GTPase 13.47 14.09 78.38 70.41
Ltbp1 latent transforming growth factor beta binding protein 1 18.25 11.25 165.89 164.13
Atp1b2 ATPase, Na+/K+ transporting, beta 2 polypeptide 1.63 1.38 14.68 3.16
Meis1 Meis homeobox 1 5.15 0.97 29.28 7.13
Folr2 folate receptor 2 (fetal) 1.62 1.60 28.14 31.02
Cnrip1 cannabinoid receptor interacting protein 1 0.93 0.14 13.07 6.84
Tnfaip6 tumor necrosis factor alpha induced protein 6 6.22 5.15 43.39 42.05
Ism1 isthmin 1, angiogenesis inhibitor 4.58 7.75 62.25 17.77
Igfbp2 insulin-like growth factor binding protein 2 174.41 187.05 1386.43 515.28
Cd24 CD24 molecule 105.48 19.18 789.11 703.67
Ddx52 DEAD (Asp-Glu-Ala-Asp) box polypeptide 52 5.40 1.00 33.44 14.53
Tnfrsf26 tumor necrosis factor receptor superfamily, member 26 4.18 0.86 17.92 3.43
Clic2 chloride intracellular channel 2 3.74 3.18 29.09 12.24
Flna filamin A, alpha 112.68 80.13 997.33 645.61
Rxfp2 relaxin/insulin-like family peptide receptor 2 3.08 3.26 11.57 5.86
Pde7b phosphodiesterase 7B 2.00 2.61 8.73 2.37
Ccl6 chemokine (C-C motif) ligand 6 0.59 0.90 14.99 10.06
Tmem119 transmembrane protein 119 5.34 3.15 38.34 21.66
Ror2 receptor tyrosine kinase-like orphan receptor 2 0.71 0.39 13.38 6.48
RT1-S3 RT1 class Ib, locus S3 11.35 10.02 64.22 31.23
Tmem200a transmembrane protein 200A 0.14 0.07 0.92 0.56
Car14 carbonic anhydrase 14 1.83 1.06 56.26 50.21
Ppp1r36 protein phosphatase 1, regulatory subunit 36 7.90 9.23 20.92 7.22
Tmem45b transmembrane protein 45b 1.96 0.40 8.40 5.22
Acp5 acid phosphatase 5, tartrate resistant 2.14 1.04 20.44 4.81
Clec4a1 C-type lectin domain family 4, member A1 26.68 26.57 64.50 54.32
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Krt75 keratin 75 2.24 3.03 19.69 15.79
Itgb8 integrin, beta 8 0.42 0.49 3.97 1.17
RT1-T24-3 RT1 class I, locus T24, gene 3 5.36 1.79 39.41 9.71
Gal3st4 galactose-3-O-sulfotransferase 4 0.80 0.67 10.09 11.65
Zbed3 zinc finger, BED-type containing 3 5.37 1.11 34.66 6.09
Casq2 calsequestrin 2 (cardiac muscle) 0.42 0.18 4.05 2.94
Rab38 RAB38, member RAS oncogene family 0.19 0.00 4.16 1.08
Synpo2 synaptopodin 2 55.74 59.63 418.19 355.70
S1pr3 sphingosine-1-phosphate receptor 3 7.93 12.45 8.55 5.53
Lysmd2 LysM, putative peptidoglycan-binding, domain containing 2 2.81 3.13 27.02 17.51
Tlr1 toll-like receptor 1 0.42 0.27 6.13 4.09
Plac8 placenta-specific 8 26.44 20.79 163.90 86.49
Plac9 placenta-specific 9 15.78 24.55 16.02 8.80
Apol3 apolipoprotein L, 3 2.76 1.21 19.65 4.95
Pik3r1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 18.63 14.34 49.89 32.35
Dennd1c DENN/MADD domain containing 1C 1.16 0.38 10.12 6.60
Ogfrl1 opioid growth factor receptor-like 1 5.54 2.85 30.56 24.18
Slc44a1 solute carrier family 44 (choline transporter), member 1 30.78 28.66 204.19 124.35
Irf2bpl interferon regulatory factor 2 binding protein-like 4.69 2.81 41.85 20.75
Map4k1 mitogen activated protein kinase kinase kinase kinase 1 0.46 0.28 9.42 5.83
Grid2 glutamate receptor, ionotropic, delta 2 0.13 0.12 1.54 0.66
Downregulated genes
Psg16 pregnancy specific glycoprotein 16 198.37 219.18 2.57 3.19
Psg29 pregnancy-specific glycoprotein 29 389.64 390.73 5.07 8.19
Tex36 testis expressed 36 5.20 9.01 0.00 0.00
Sparcl1 SPARC-like 1 (hevin) 324.73 557.73 159.00 126.33
Sftpc surfactant protein C 0.16 0.15 0.02 0.04
Atp4b ATPase, H+/K+ exchanging, beta polypeptide 3.82 5.47 0.00 0.00
Prl3a1 Prolactin family 3, subfamily a, member 1 110.97 136.74 0.08 0.15
Prl3d4 prolactin family 3, subfamily d, member 4 854.67 1382.74 7.83 9.29
Trib3 tribbles pseudokinase 3 5.31 5.99 0.02 0.04
Snhg11 small nucleolar RNA host gene 11 (non-protein coding) 15.74 20.19 4.71 2.64
Reln reelin 32.68 51.74 2.68 1.25
Slc46a2 solute carrier family 46, member 2 0.47 0.80 0.00 0.00
Serpina12 serpin peptidase inhibitor, clade A , member 12 0.60 0.64 0.00 0.00
Slc38a4 solute carrier family 38, member 4 125.54 192.17 7.97 6.11
Ucn2 urocortin 2 2.66 2.75 0.19 0.08
Gpbar1 G protein-coupled bile acid receptor 1 14.60 15.29 0.00 0.00
Mreg melanoregulin 6.81 9.10 0.00 0.00
Alpi alkaline phosphatase, intestinal 2.96 2.75 0.01 0.02
Rrm1 ribonucleotide reductase M1 129.70 207.42 23.32 1.21
Nsg2 neuron specific gene family member 2 44.26 55.60 0.78 0.87
Cldn4 claudin 4 65.29 77.05 1.48 1.08
Fga fibrinogen alpha chain 78.63 39.83 13.85 21.64
Apom apolipoprotein M 87.18 33.70 10.27 15.16
Mmp9 matrix metallopeptidase 9 1.99 2.83 0.04 0.03
Pgf placental growth factor 445.84 758.60 22.05 13.19
Sema3b sema domain, (semaphorin) 3B 104.43 169.48 13.83 5.81
Utf1 undifferentiated embryonic cell transcription factor 1 7.59 2.39 0.00 0.00
Tcp11l2 t-complex 11, testis-specific-like 2 70.19 26.42 17.62 7.50
Mllt4 myeloid/lymphoid or mixed-lineage leukemia translocated to, 4 37.28 23.79 11.07 1.87
Tjp2 tight junction protein 2 31.15 12.84 9.39 1.22
F11r F11 receptor 161.64 79.66 51.47 7.94
Cd55 Cd55 molecule 114.51 37.56 44.26 22.20
Lamc2 laminin, gamma 2 157.00 157.65 13.91 8.07
Irs2 insulin receptor substrate 2 45.93 34.10 25.19 7.74
Socs6 suppressor of cytokine signaling 6 44.04 51.76 18.56 2.14
Phf17 jade family PHD finger 1 51.38 50.73 29.32 14.66
Prdm1 PR domain containing 1, with ZNF domain 41.67 34.78 11.34 3.93
Procr protein C receptor, endothelial 53.45 46.12 14.77 6.28
Emp1 epithelial membrane protein 1 122.02 93.43 38.30 10.50
Slc6a6 solute carrier family 6 (neurotransmitter transporter), member 6 74.57 104.90 22.21 8.83
Lbh limb bud and heart development 68.68 77.72 28.54 6.21
Kif3c kinesin family member 3C 65.60 77.76 19.93 13.33
Rps6ka5 ribosomal protein S6 kinase, polypeptide 5 9.40 8.77 3.09 0.47
Uaca uveal autoantigen with coiled-coil domains and ankyrin repeats 51.69 1.35 13.04 1.93
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Lama1 laminin, alpha 1 5.89 6.47 1.67 0.60
Slc40a1 solute carrier family 40 (iron-regulated transporter), member 1 62.84 77.00 4.98 3.79
Ptprm protein tyrosine phosphatase, receptor type, M 13.79 9.67 3.70 1.19
Bcor BCL6 co-repressor 45.68 9.93 16.15 3.07
RGD1564534 similar to CHCHD4 protein 20.58 26.35 6.81 3.40
Efnb1 ephrin B1 42.77 5.54 12.61 4.91
Plagl1 pleiomorphic adenoma gene-like 1 20.40 20.57 4.08 2.22
Sbsn suprabasin 547.12 821.99 24.58 17.84
Rtn4rl1 reticulon 4 receptor-like 1 61.54 91.74 6.23 0.94
Pla2g10 phospholipase A2, group X 3.62 2.67 0.00 0.01
Slc22a5 solute carrier family 22 (organic cation/carnitine transporter), member 5 31.07 47.36 3.55 0.94
Gap43 growth associated protein 43 5.02 2.30 3.44 1.79
Tfrc transferrin receptor 146.78 58.21 15.35 7.60
Tmem37 transmembrane protein 37 174.04 45.70 22.56 10.44
Pkp1 plakophilin 1 28.19 33.75 3.98 4.17
Tgfb2 transforming growth factor, beta 2 211.97 173.93 31.23 10.87
Hopx HOP homeobox 643.48 925.76 93.71 72.66
Prom1 prominin 1 22.79 30.13 3.68 1.37
Anxa3 annexin A3 100.05 91.01 11.82 1.63
Kit v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 22.82 23.71 3.49 3.34
Cpe carboxypeptidase E 221.20 191.35 26.01 14.03
Ctsr cathepsin R 955.05 500.72 83.06 86.91
Ctsq cathepsin Q 206.52 82.99 11.77 15.51
Ctsj cathepsin J 660.36 372.10 53.08 59.67
Prl8a2 prolactin family 8, subfamily a, member 2 787.71 816.32 29.84 35.98
Prl3b1 Prolactin family 3, subfamily b, member 1 938.94 1457.12 77.21 96.93
Cdh3 cadherin 3 151.40 144.60 11.94 2.94
Fa2h fatty acid 2-hydroxylase 3.44 1.88 0.03 0.04
Lpar3 lysophosphatidic acid receptor 3 6.34 1.63 0.22 0.26
Usp53 ubiquitin specific peptidase 53 85.04 96.12 9.28 4.18
Aif1l allograft inflammatory factor 1-like 245.86 176.45 32.09 14.64
Rnf128 ring finger protein 128, E3 ubiquitin protein ligase 68.91 76.56 9.21 7.18
Slc6a13 solute carrier family 6 (neurotransmitter transporter), member 13 194.59 331.90 0.06 0.10
Slc6a12 solute carrier family 6 (neurotransmitter transporter), member 12 492.76 783.27 11.46 4.59
Acer2 alkaline ceramidase 2 255.36 295.41 27.52 13.16
Aqp7 aquaporin 7 2.46 1.37 0.00 0.00
Ehd3 EH-domain containing 3 696.47 821.12 18.94 14.74
Slc5a6 solute carrier family 5 (sodium/multivitamin and iodide cotransporter), member 6 98.95 133.93 13.22 8.26
Flvcr2 feline leukemia virus subgroup C cellular receptor family, member 2 33.92 33.82 15.09 13.65
Mfsd12 major facilitator superfamily domain containing 12 125.81 136.81 10.79 2.33
Fndc3c1 fibronectin type III domain containing 3C1 63.47 44.76 7.83 7.87
Itm2a integral membrane protein 2A 22.48 29.82 5.60 3.24
Arhgef6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 49.62 27.71 5.47 3.62
Vnn1 vanin 1 17.52 3.75 1.32 1.02
Wdr62 WD repeat domain 62 19.01 6.73 3.33 1.47
Cdhr5 cadherin-related family member 5 74.25 99.68 6.42 7.34
Car4 carbonic anhydrase 4 72.54 35.73 13.91 10.90
Dlx3 distal-less homeobox 3 35.93 24.35 0.80 0.15
Tmem204 transmembrane protein 204 101.81 92.12 20.45 5.19
Tlr5 toll-like receptor 5 52.00 54.27 9.47 6.56
Ctsql2 cathepsin Q-like 2 996.54 599.53 67.21 73.38
Wfdc1 WAP four-disulfide core domain 1 242.67 277.12 28.42 0.84
Cdc14a cell division cycle 14A 46.50 32.52 7.99 4.43
Hyal4 hyaluronoglucosaminidase 4 3.13 2.89 0.27 0.07
Slc13a4 solute carrier family 13 (sodium/sulfate symporter), member 4 33.43 16.92 3.19 2.97
Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 52.02 23.82 7.37 10.90
Rp1 retinitis pigmentosa 1 (human) 7.12 10.96 0.83 0.67
Tgfb3 transforming growth factor, beta 3 865.90 904.04 74.01 60.51
Ston2 stonin 2 23.23 2.01 3.63 2.87
RGD1310507 similar to RIKEN cDNA 1300017J02 25.76 23.50 4.56 3.09
Efhc2 EF-hand domain (C-terminal) containing 2 1.34 0.35 0.02 0.03
Dlg3 discs, large homolog 3 (Drosophila) 18.54 9.42 1.79 0.74
MGC114529 similar to melanoma antigen family A, 10 36.14 18.27 2.73 3.53
Trh thyrotropin releasing hormone 553.73 372.47 1.55 2.06
Dsc3 desmocollin 3 9.79 8.39 0.03 0.05
Alpk3 alpha-kinase 3 19.37 15.48 0.39 0.45
Anxa8 annexin A8 146.94 141.90 4.17 4.15
Cst6 cystatin E/M 29.93 22.72 0.31 0.51
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Tns4 tensin 4 29.34 16.37 1.05 1.27
Snap91 synaptosomal-associated protein 91 7.04 6.22 0.33 0.26
MGC114246 similar to cathepsin R 33.80 20.69 1.28 0.68
Nkd2 naked cuticle homolog 2 (Drosophila) 22.42 9.54 1.57 0.84
Slc9b2 solute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2 6.70 4.29 0.23 0.24
Scara3 scavenger receptor class A, member 3 17.87 30.03 17.05 8.30
Irx4 iroquois homeobox 4 10.44 5.92 0.24 0.09
Ins2 insulin 2 27.87 35.55 3.19 4.94
B4galnt3 beta-1,4-N-acetyl-galactosaminyl transferase 3 9.43 5.75 0.12 0.16
Slc30a2 solute carrier family 30 (zinc transporter), member 2 1.61 1.64 0.14 0.03
Plg plasminogen 2.54 2.01 0.14 0.21
Csrp3 cysteine and glycine-rich protein 3 (cardiac LIM protein) 10.24 6.67 0.08 0.15
Fgb fibrinogen beta chain 33.96 11.46 3.40 4.54
Klhl40 kelch-like family member 40 21.37 27.20 1.40 1.92
Prl2b1 Prolactin family 2, subfamily b, member 1 1070.25 1736.94 4.69 6.28
Exoc3l4 exocyst complex component 3-like 4 5.36 2.08 0.05 0.09
Afm afamin 5.95 5.10 0.26 0.46
Fmo1 flavin containing monooxygenase 1 16.56 6.65 1.47 2.12
Aadat aminoadipate aminotransferase 20.54 12.08 1.90 2.39
Fhod3 formin homology 2 domain containing 3 3.29 0.82 0.23 0.24
Cryab crystallin, alpha B 4544.38 2993.44 469.59 192.83
Otud3 OTU domain containing 3 19.45 27.48 2.54 2.48
Mrgprg MAS-related GPR, member G 8.83 6.81 0.23 0.38
Gpc3 glypican 3 25.97 15.46 3.54 4.50
Serpinb9d serine (or cysteine) peptidase inhibitor, clade B, member 9d 15.17 10.20 0.19 0.33
Adora1 adenosine A1 receptor 7.21 5.25 0.03 0.05
Arid3a AT rich interactive domain 3A (Bright like) 29.50 2.52 5.49 2.51
Tceanc transcription elongation factor A (SII) N-terminal and central domain containing 9.92 3.12 0.47 0.39
Ces4a carboxylesterase 4A 2.50 1.51 0.03 0.04
Pc pyruvate carboxylase 48.04 36.51 6.35 4.38
Elovl4 ELOVL fatty acid elongase 4 27.64 23.55 3.01 2.26
Ghrl ghrelin/obestatin prepropeptide 28.12 20.63 1.06 0.99
Rassf8 Ras association (RalGDS/AF-6) domain family (N-terminal) member 8 21.88 11.70 4.32 1.74
Gata4 GATA binding protein 4 3.42 0.84 0.05 0.05
Pax1 paired box 1 7.38 7.86 0.05 0.09
Tmeff1 transmembrane protein with EGF-like and two follistatin-like domains 1 7.09 8.46 0.35 0.40
Mettl7b methyltransferase like 7B 18.00 16.05 1.68 1.52
Slc6a3 solute carrier family 6 (neurotransmitter transporter), member 3 1.48 1.33 0.00 0.00
LOC691083 hypothetical protein LOC691083 9.83 9.94 0.61 0.55
Shisa7 shisa family member 7 0.98 0.88 0.06 0.07
Tm4sf20 transmembrane 4 L six family member 20 6.12 3.31 0.31 0.07
Phlda2 pleckstrin homology-like domain, family A, member 2 15.88 18.86 1.79 1.01
Rgcc regulator of cell cycle 38.12 33.62 5.12 3.96
Duoxa1 dual oxidase maturation factor 1 4.15 2.73 0.11 0.01
Ccnjl cyclin J-like 9.82 4.06 4.89 3.59
Rasgrf2 RAS protein-specific guanine nucleotide-releasing factor 2 10.17 14.61 0.88 0.79
Smim1 small integral membrane protein 1 11.88 15.19 2.31 0.88
Kng2 kininogen 2 5.80 1.70 0.50 0.71
Gata3 GATA binding protein 3 55.02 8.58 6.18 3.62
Angpt2 angiopoietin 2 14.72 14.29 1.81 0.40
Rps6ka6 ribosomal protein S6 kinase polypeptide 6 9.10 3.19 1.04 1.20
Adhfe1 alcohol dehydrogenase, iron containing, 1 2.52 1.52 0.07 0.13
Shisa3 shisa family member 3 0.72 0.36 0.00 0.00
Pard6b par-6 family cell polarity regulator beta 11.96 13.69 4.33 2.56
Afap1l1 actin filament associated protein 1-like 1 10.31 3.97 0.85 0.80
Espn espin 1.66 0.40 0.17 0.10
Mical1 microtubule associated monooxygenase, calponin and LIM domain containing 1 27.15 11.64 4.99 2.51
Sptb spectrin, beta, erythrocytic 26.14 42.30 0.09 0.08
RGD1562726 similar to Putative protein C21orf62 homolog 5.02 7.92 0.72 0.53
Osbp2 oxysterol binding protein 2 8.90 8.86 0.36 0.06
Pvrl4 poliovirus receptor-related 4 27.22 16.82 4.24 2.56
D.1. GD19 + 6 hours
Table D.2: Genes that were differentially expressed in the outer myometrium com-
pared to the decidua on GD19+6hrs. Transcript expression levels are shown in transcripts
per million values (mean±SD).
Decidua Outer myometrium
Gene
symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Myod1 myogenic differentiation 1 1.32 1.05 13.91 12.33
Myh8 myosin, heavy chain 8, skeletal muscle, perinatal 1.33 1.66 27.64 47.77
Aoc3 amine oxidase, copper containing 3 2.92 0.80 6.80 4.23
Meox1 mesenchyme homeobox 1 0.19 0.06 19.54 26.93
Myog myogenin 0.05 0.02 13.35 11.65
Dpt dermatopontin 1.44 0.80 11.18 15.76
Sparcl1 SPARC-like 1 (hevin) 324.73 557.73 1713.69 2941.03
Cabs1 calcium-binding protein, spermatid-specific 1 0.10 0.06 0.15 0.15
Acta1 actin, alpha 1, skeletal muscle 10.77 1.79 249.16 212.72
Tmem176a transmembrane protein 176A 24.45 20.53 654.65 1001.41
Cxcl12 chemokine (C-X-C motif) ligand 12 1.69 0.51 7.56 7.13
Ptn pleiotrophin 33.07 52.75 73.28 75.41
Abcc9 ATP-binding cassette, subfamily C (CFTR/MRP), member 9 1.51 1.26 18.58 26.10
Slc46a2 solute carrier family 46, member 2 0.47 0.80 2.92 5.05
C1qc complement component 1, q subcomponent, C chain 4.13 2.94 32.07 16.50
Col14a1 collagen, type XIV, alpha 1 0.70 0.51 5.15 8.42
Cntn1 contactin 1 0.03 0.02 1.07 1.01
Crabp1 cellular retinoic acid binding protein 1 0.00 0.00 13.04 22.57
Abcg4 ATP-binding cassette, subfamily G (WHITE), member 4 1.09 0.44 81.12 139.98
Actc1 actin, alpha, cardiac muscle 1 1.53 1.27 87.83 146.54
Aebp1 AE binding protein 1 20.34 15.02 216.48 331.30
C1qb complement component 1, q subcomponent, B chain 3.33 1.74 70.54 94.04
Cd163 CD163 molecule 0.47 0.30 30.26 50.99
Figf c-fos induced growth factor 7.53 11.98 123.46 199.82
Ltbp4 latent transforming growth factor beta binding protein 4 0.58 0.20 17.94 19.81
Mrgprf MAS-related GPR, member F 0.78 0.30 4.10 5.84
Myh3 myosin, heavy chain 3, skeletal muscle, embryonic 2.71 4.39 76.52 132.23
Pla2g2a phospholipase A2, group IIA (platelets, synovial fluid) 1.02 0.85 17.13 17.42
Ptgis prostaglandin I2 (prostacyclin) synthase 2.03 2.23 65.89 72.52
Zfhx4 zinc finger homeobox 4 0.41 0.14 5.07 8.35
Sema5a sema domain, (semaphorin) 5A 2.60 2.25 7.67 3.83
Dclk1 doublecortin-like kinase 1 3.97 1.33 18.26 21.12
Vcan versican 3.14 1.66 22.72 20.93
Ly6e lymphocyte antigen 6 complex, locus E 35.02 3.22 177.18 225.33
Col5a1 collagen, type V, alpha 1 16.29 4.43 34.30 37.89
Fbln5 fibulin 5 4.08 3.01 34.22 17.63
Fkbp10 FK506 binding protein 10 5.33 0.67 49.87 35.17
Gpc4 glypican 4 2.59 1.08 48.14 46.75
Hip1 huntingtin interacting protein 1 33.66 37.12 47.29 42.59
Nfix nuclear factor I/X (CCAAT-binding transcription factor) 12.03 8.93 56.45 34.93
Tgfbi transforming growth factor, beta induced 5.17 1.49 35.05 21.70
Thbs2 thrombospondin 2 1.14 0.73 14.04 5.72
Zfp521 zinc finger protein 521 0.83 0.19 11.92 7.34
Col11a1 collagen, type XI, alpha 1 0.97 1.02 32.09 37.99
Dpp4 dipeptidylpeptidase 4 0.69 0.08 17.13 16.75
Acp5 acid phosphatase 5, tartrate resistant 2.14 1.04 39.62 19.99
Fam198b family with sequence similarity 198, member B 0.70 0.21 9.64 6.57
Pcdh7 protocadherin 7 0.39 0.40 8.22 4.44
Scara5 scavenger receptor class A, member 5 (putative) 0.39 0.16 12.59 13.02
Col3a1 collagen, type III, alpha 1 50.32 26.71 215.00 196.84
Scara3 scavenger receptor class A, member 3 17.87 30.03 33.15 37.61
Downregulated genes
Nox4 NADPH oxidase 4 55.68 73.79 3.47 3.04
Rtn4rl1 reticulon 4 receptor-like 1 61.54 91.74 12.03 9.48
Slc44a5 solute carrier family 44, member 5 2.79 2.48 2.54 4.40
Trh thyrotropin releasing hormone 553.73 372.47 37.31 63.06
Zc2hc1c zinc finger, C2HC-type containing 1C 6.87 7.80 0.00 0.00
Grem1 gremlin 1 31.14 48.11 5.16 6.05
Mfap5 microfibrillar associated protein 5 77.49 65.13 51.57 80.47
Nov nephroblastoma overexpressed 62.93 75.26 7.11 6.01
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Nsg2 neuron specific gene family member 2 44.26 55.60 3.54 2.98
Scg5 secretogranin V (7B2 protein) 41.58 67.69 2.37 2.32
Slpi secretory leukocyte peptidase inhibitor 14.06 12.06 3.07 2.53
Trpc4 transient receptor potential cation channel, subfamily C, member 4 21.69 31.29 1.81 1.52
Kcnj16 potassium inwardly-rectifying channel, subfamily J, member 16 1.42 0.78 0.06 0.06
Lbh limb bud and heart development 68.68 77.72 10.94 12.54
Hopx HOP homeobox 643.48 925.76 60.32 37.46
Cpe carboxypeptidase E 221.20 191.35 20.09 11.80
Ppp1r14c protein phosphatase 1, regulatory (inhibitor) subunit 14c 30.45 24.46 1.06 0.54
Gnat2 guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide 2 14.18 13.88 0.85 0.79
Table D.3: Genes that were differentially expressed in the outer myometrium com-
pared to the inner myometrium on GD19+6hrs. Transcript expression levels are shown in
transcripts per million values (mean±SD).
Inner myometrium Outer myometrium
Gene
symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Ibsp integrin-binding sialoprotein 0.71 0.43 52.10 73.90
LOC641520 popeye domain containing 3 0.00 0.00 1.49 1.67
Fam26e family with sequence similarity 26, member E 6.16 6.43 19.36 33.53
Atg9b autophagy related 9B 16.12 18.50 26.36 45.65
Grhl3 grainyhead-like 3 (Drosophila) 0.01 0.01 1.26 1.38
Itm2a integral membrane protein 2A 5.60 3.24 125.71 207.64
Cldn4 claudin 4 1.48 1.08 87.02 144.75
Efnb1 ephrin B1 12.61 4.91 45.01 43.14
Tmem37 transmembrane protein 37 22.56 10.44 133.19 41.23
Vnn1 vanin 1 1.32 1.02 24.26 14.46
Down-regulated genes
Cldn10 claudin 10 28.56 25.43 1.01 1.41
Slc17a3 solute carrier family 17 (organic anion transporter), member 3 4.32 5.38 0.20 0.16
Vtcn1 V-set domain containing T cell activation inhibitor 1 54.06 59.22 0.65 0.38
Lrat lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-acyltransferase) 120.84 118.41 1.56 1.26
Lcn2 lipocalin 2 221.06 177.26 9.09 12.62
Hcn4 hyperpolarization activated cyclic nucleotide-gated potassium channel 4 15.05 15.60 0.00 0.00
Inmt indolethylamine N-methyltransferase 8.25 1.30 0.01 0.01
Mill1 MHC I like leukocyte 1 36.28 8.50 4.03 1.77
Csf2rb colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 40.11 19.75 8.78 10.10
Tnn tenascin N 86.47 39.28 0.41 0.33
Hoxb7 homeo box B7 20.87 16.09 0.65 0.79
Nptx2 neuronal pentraxin II 11.63 4.47 1.36 2.24
D.2 GD20
Table D.4: Genes that were differentially expressed in the inner myometrium com-
pared to the decidua on GD20. Transcript expression levels are shown in transcripts per million
values (mean±SD).
Decidua Inner myometrium
Gene
symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Fut2 fucosyltransferase 2 (secretor status included) 1.09 1.14 175.95 215.98
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Gngt2 guanine nucleotide binding protein (G protein), 0.00 0.00 12.34 16.81
gamma transducing activity polypeptide 2
Gabrp gamma-aminobutyric acid (GABA-A) receptor, pi 0.31 0.53 128.25 141.85
Slc4a11 solute carrier family 4, sodium borate transporter, member 11 0.14 0.13 392.42 478.35
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B 0.36 0.32 448.31 578.32
Hpgds hematopoietic prostaglandin D synthase 0.03 0.03 31.75 42.30
B4galnt3 beta-1,4-N-acetyl-galactosaminyl transferase 3 0.03 0.06 19.00 32.72
Kif12 kinesin family member 12 0.03 0.03 46.13 55.08
Smc1b structural maintenance of chromosomes 1B 0.18 0.31 8.44 14.55
Prtg protogenin 0.64 0.52 75.81 109.07
Cldn7 claudin 7 7.21 7.49 165.01 94.28
Slc5a3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 2.11 2.99 57.11 54.54
Slc7a7 solute carrier family 7 (amino acid transporter light chain, y+L system), member 7 4.49 1.55 55.91 12.50
Cdh1 cadherin 1 8.88 4.99 126.93 45.69
Emb embigin 0.99 1.01 60.60 42.02
Mab21l3 mab-21-like 3 (C. elegans) 2.21 2.41 38.50 33.49
Fjx1 four jointed box 1 (Drosophila) 0.00 0.00 21.16 20.38
Slco4a1 solute carrier organic anion transporter family, member 4a1 8.95 13.28 277.95 180.45
Epcam epithelial cell adhesion molecule 26.28 11.66 434.22 324.52
Wdr72 WD repeat domain 72 0.00 0.01 4.19 2.15
Ehf ets homologous factor 0.26 0.14 45.68 35.58
Igfbp2 insulin-like growth factor binding protein 2 92.67 80.49 1481.23 943.51
Fkbp11 FK506 binding protein 11 2.61 3.38 41.52 27.93
Downregulated genes
LOC171161 common salivary protein 1 30.39 37.35 0.00 0.00
Matn1 matrilin 1, cartilage matrix protein 48.13 83.36 0.02 0.03
Tmem204 transmembrane protein 204 80.44 69.90 5.41 4.05
Pkp1 plakophilin 1 56.99 75.54 0.32 0.38
Anxa3 annexin A3 86.79 89.23 9.26 4.62
Mamdc4 MAM domain containing 4 2.24 2.41 0.05 0.06
Slc6a12 solute carrier family 6 (neurotransmitter transporter), member 12 591.70 520.75 4.51 4.45
Slc6a6 solute carrier family 6 (neurotransmitter transporter), member 6 71.23 72.75 8.48 6.05
Ehd3 EH-domain containing 3 389.61 348.12 11.80 10.06
Tgfb3 transforming growth factor, beta 3 375.47 353.65 13.03 18.12
RGD1307554 similar to CG16812-PA 32.43 34.23 2.95 1.35
Table D.5: Genes that were differentially expressed in the outer myometrium com-
pared to the decidua on GD20. Transcript expression levels are shown in transcripts per million
values (mean±SD).
Decidua Outer myometrium
Gene
symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Cox6b2 cytochrome c oxidase subunit VIb polypeptide 2 0.00 0.00 6.96 7.43
Nmb neuromedin B 0.00 0.00 10.73 13.90
Trim58 tripartite motif-containing 58 0.03 0.02 5.51 8.68
Hoxb7 homeo box B7 0.05 0.08 16.99 16.46
Csf3 colony stimulating factor 3 (granulocyte) 0.00 0.00 11.61 14.94
Alox15b arachidonate 15-lipoxygenase, type B 0.02 0.03 7.92 11.60
Lmod1 leiomodin 1 (smooth muscle) 2.58 3.19 196.29 111.88
Crp C-reactive protein, pentraxin-related 0.00 0.00 10.39 15.09
Btc betacellulin 0.00 0.00 23.60 24.84
Isyna1 inositol-3-phosphate synthase 1 7.80 7.03 1052.83 1069.36
Defb1 defensin beta 1 0.00 0.00 36.69 36.60
Ppp2r2b protein phosphatase 2, regulatory subunit B, beta 0.29 0.40 2.70 2.83
Marveld3 MARVEL domain containing 3 0.00 0.00 14.12 12.05
Tmem171 transmembrane protein 171 0.02 0.03 7.55 11.06
Gzmk granzyme K 0.05 0.08 5.55 6.55
Lypd6b LY6/PLAUR domain containing 6B 0.15 0.14 4.46 5.49
Foxa2 forkhead box A2 0.04 0.04 4.25 4.94
Gfi1b growth factor independent 1B transcription repressor 0.01 0.01 9.06 11.09
RGD1564114 similar to FLJ46082 protein 0.25 0.22 3.11 4.92
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Slc4a11 solute carrier family 4, sodium borate transporter, member 11 0.14 0.13 268.24 284.96
Cd8a CD8a molecule 0.00 0.00 4.26 4.21
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B 0.36 0.32 271.55 265.10
Hpgds hematopoietic prostaglandin D synthase 0.03 0.03 28.67 36.58
Ttc22 tetratricopeptide repeat domain 22 0.01 0.02 7.97 7.89
Nr0b2 nuclear receptor subfamily 0, group B, member 2 0.00 0.00 9.14 8.06
Fhl5 four and a half LIM domains 5 0.02 0.03 5.18 4.55
Kif12 kinesin family member 12 0.03 0.03 9.89 13.86
Sostdc1 sclerostin domain containing 1 0.00 0.00 21.60 19.70
Krtcap3 keratinocyte associated protein 3 0.40 0.44 7.59 8.57
Tac2 tachykinin 2 0.03 0.06 9.01 11.67
Zfpm2 zinc finger protein, multitype 2 3.61 6.10 3.68 3.98
Arc activity-regulated cytoskeleton-associated protein 0.20 0.11 4.45 3.96
Wdr72 WD repeat domain 72 0.00 0.01 4.52 5.94
Epor erythropoietin receptor 0.01 0.02 10.83 15.08
Faim2 Fas apoptotic inhibitory molecule 2 0.02 0.04 12.28 12.70
Ctxn1 cortexin 1 0.81 0.84 355.51 189.63
Akap12 A kinase (PRKA) anchor protein 12 4.54 4.46 111.25 63.31
Rgma repulsive guidance molecule family member A 2.24 2.63 110.40 74.97
Slc35g1 solute carrier family 35, member G1 0.02 0.04 5.81 5.84
Hpn hepsin 0.02 0.03 12.21 4.51
Synm synemin, intermediate filament protein 4.07 3.11 125.90 55.14
P2ry6 pyrimidinergic receptor P2Y, G-protein coupled, 6 0.46 0.41 4.13 3.68
Rasl11a RAS-like family 11 member A 0.04 0.07 11.02 6.25
Chi3l1 chitinase 3-like 1 (cartilage glycoprotein-39) 0.02 0.04 2.91 0.91
Cd84 CD84 molecule 0.01 0.01 3.67 0.56
Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 10.93 9.47 495.45 406.14
Ldb2 LIM domain binding 2 3.97 2.75 38.86 10.07
Pdlim2 PDZ and LIM domain 2 0.15 0.16 12.87 10.92
Pdlim3 PDZ and LIM domain 3 14.51 12.99 187.43 105.57
Zdhhc2 zinc finger, DHHC-type containing 2 0.04 0.04 9.89 3.39
Fgf2 fibroblast growth factor 2 0.00 0.00 8.27 3.06
Dusp15 dual specificity phosphatase 15 0.31 0.38 4.79 2.80
Napepld N-acyl phosphatidylethanolamine phospholipase D 0.01 0.02 7.08 6.67
Gp9 glycoprotein IX (platelet) 0.00 0.00 4.70 1.54
Clec4a C-type lectin domain family 4, member A 0.00 0.01 4.49 3.14
C1r complement component 1, r subcomponent 12.05 11.96 188.05 90.13
Ptn pleiotrophin 19.10 15.89 362.30 217.46
Kcnj8 potassium inwardly-rectifying channel, subfamily J, member 8 3.48 4.14 116.24 87.86
Sh3d21 SH3 domain containing 21 1.92 1.70 5.45 1.77
Arhgap5 Rho GTPase activating protein 5 11.34 9.68 97.15 49.22
Slc8a1 solute carrier family 8 (sodium/calcium exchanger), member 1 0.86 1.27 31.14 17.33
Igfbp6 insulin-like growth factor binding protein 6 16.21 17.29 1256.56 759.01
Slc25a23 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 0.05 0.06 9.50 1.09
Pdcl3 phosducin-like 3 5.88 6.21 72.75 38.97
Figf c-fos induced growth factor 4.36 2.54 148.41 97.87
Gnaq guanine nucleotide binding protein (G protein), q polypeptide 5.06 8.06 170.63 87.88
Serpinb9 serpin peptidase inhibitor, clade B (ovalbumin), member 9 10.03 6.38 72.38 21.66
Svil supervillin 6.34 5.93 82.99 50.62
Sqrdl sulfide quinone reductase-like (yeast) 4.97 4.96 72.45 51.51
Fam83d family with sequence similarity 83, member D 0.01 0.02 2.32 0.23
Prkag2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit 2.07 2.66 39.28 16.66
Tes testis derived transcript 25.83 6.38 102.47 35.95
Prkaa2 protein kinase, AMP-activated, alpha 2 catalytic subunit 1.40 0.63 35.48 25.78
Ppp1r12a protein phosphatase 1, regulatory subunit 12A 11.22 9.81 205.11 111.00
RGD1562136 similar to D1Ertd622e protein 6.74 5.99 56.64 30.27
Il13ra1 interleukin 13 receptor, alpha 1 1.62 1.40 26.43 8.26
Lilrb3 leukocyte immunoglobulin-like receptor, subfamily B 0.09 0.12 2.54 1.75
(with TM and ITIM domains), member 3
Slc8a2 solute carrier family 8 (sodium/calcium exchanger), member 2 0.04 0.05 6.32 3.01
Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 0.03 0.05 7.13 2.41
Ppp1r14a protein phosphatase 1, regulatory (inhibitor) subunit 14A 0.03 0.04 10.88 6.76
Sh3gl3 SH3-domain GRB2-like 3 0.01 0.01 3.71 1.65
Tppp tubulin polymerization promoting protein 0.00 0.00 9.55 8.09
Scn1b sodium channel, voltage-gated, type I, beta subunit 0.16 0.14 20.86 13.18
Siglec5 sialic acid binding Ig-like lectin 5 0.07 0.13 3.48 3.32
Folr2 folate receptor 2 (fetal) 0.14 0.25 23.53 11.68
Gria1 glutamate receptor, ionotropic, AMPA 1 0.07 0.12 4.09 2.06
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Gngt2 guanine nucleotide binding protein (G protein), 0.00 0.00 14.25 13.53
gamma transducing activity polypeptide 2
gamma transducing activity polypeptide 2
Aoc3 amine oxidase, copper containing 3 3.94 2.62 199.44 120.89
Fn3k fructosamine 3 kinase 0.02 0.03 5.95 0.81
Alox15 arachidonate 15-lipoxygenase 0.00 0.00 14.83 8.44
Ccl6 chemokine (C-C motif) ligand 6 0.00 0.00 13.80 4.85
Krt13 keratin 13 2.51 4.35 15.56 12.22
Chaf1b chromatin assembly factor 1, subunit B (p60) 0.02 0.03 3.26 2.31
Selplg selectin P ligand 0.00 0.00 25.76 8.23
Faim3 Fas apoptotic inhibitory molecule 3 0.08 0.08 16.74 18.87
Sult1d1 sulfotransferase family 1D, member 1 0.01 0.01 7.68 5.09
Gata4 GATA binding protein 4 0.02 0.04 8.10 6.50
Efnb2 ephrin B2 0.02 0.02 4.64 3.20
Adrb2 adrenoceptor beta 2, surface 5.12 6.96 13.51 8.89
Slc14a1 solute carrier family 14 (urea transporter), member 1 0.00 0.00 5.43 4.05
Lyl1 lymphoblastic leukemia derived sequence 1 0.00 0.00 17.90 6.75
Prss12 protease, serine, 12 neurotrypsin (motopsin) 0.01 0.01 5.27 2.37
Fcrls Fc receptor-like S, scavenger receptor 0.00 0.00 7.17 1.74
Ptger3 prostaglandin E receptor 3 (subtype EP3) 0.00 0.00 7.08 3.90
Gstt1 glutathione S-transferase theta 1 1.97 3.25 17.88 4.01
Tspyl4 TSPY-like 4 0.09 0.08 2.65 1.22
Slc24a3 solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 4.89 4.28 93.47 89.76
Fjx1 four jointed box 1 (Drosophila) 0.00 0.00 12.43 4.65
C1rl complement component 1, r subcomponent-like 0.00 0.00 5.04 2.59
Fam180a family with sequence similarity 180, member A 1.14 1.33 9.01 7.35
Alox5 arachidonate 5-lipoxygenase 0.00 0.01 5.39 3.97
Iffo2 intermediate filament family orphan 2 0.11 0.20 6.57 3.84
Pigv phosphatidylinositol glycan anchor biosynthesis, class V 2.71 2.30 6.82 1.80
Mdga2 MAM domain containing glycosylphosphatidylinositol anchor 2 0.03 0.03 1.82 0.82
Itgb8 integrin, beta 8 0.00 0.00 6.19 2.33
Mchr1 melanin-concentrating hormone receptor 1 0.00 0.00 15.32 11.55
Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase 0.00 0.00 6.51 4.35
Pdgfb platelet-derived growth factor beta polypeptide 0.44 0.32 9.23 4.38
Hyal3 hyaluronoglucosaminidase 3 0.10 0.17 34.77 20.21
Abcg4 ATP-binding cassette, subfamily G (WHITE), member 4 1.14 1.58 124.24 46.42
Il1rl2 interleukin 1 receptor-like 2 0.19 0.24 3.65 2.20
Adam23 ADAM metallopeptidase domain 23 0.01 0.02 5.76 3.49
Lepr leptin receptor 1.78 2.10 64.87 28.80
Begain brain-enriched guanylate kinase-associated 0.02 0.04 4.47 3.21
Nmur2 neuromedin U receptor 2 0.38 0.51 18.42 11.50
RT1-Ba RT1 class II, locus Ba 0.04 0.04 59.90 47.52
RT1-Db1 RT1 class II, locus Db1 0.06 0.04 25.53 20.53
Tpd52l1 tumor protein D52-like 1 0.02 0.02 29.50 9.18
Ppp1r36 protein phosphatase 1, regulatory subunit 36 0.00 0.01 19.73 11.09
Fez1 fasciculation and elongation protein zeta 1 (zygin I) 0.13 0.21 30.69 15.80
Lgals5 lectin, galactose binding, soluble 5 0.26 0.35 59.63 32.23
Rgs1 regulator of G-protein signaling 1 0.00 0.00 20.40 13.84
Tenm2 teneurin transmembrane protein 2 0.08 0.09 11.44 5.65
Bnc1 basonuclin 1 0.18 0.23 2.53 1.05
Mgll monoglyceride lipase 0.03 0.03 16.73 17.45
Gimap4 GTPase, IMAP family member 4 0.79 0.44 17.02 10.49
Lilrb3l leukocyte immunoglobulin-like receptor, subfamily B 0.22 0.17 16.10 8.89
(with TM and ITIM domains), member 3-like
Id4 inhibitor of DNA binding 4 0.47 0.50 35.05 32.05
Dmbt1 deleted in malignant brain tumors 1 0.13 0.03 13.26 5.17
Ociad2 OCIA domain containing 2 0.33 0.38 34.19 1.17
Bves blood vessel epicardial substance 0.21 0.24 34.28 12.26
Kcnb1 potassium voltage gated channel, Shab-related subfamily, member 1 0.03 0.05 9.57 6.62
Mst1r macrophage stimulating 1 receptor (c-met-related tyrosine kinase) 0.01 0.02 7.14 2.94
Astn1 astrotactin 1 0.02 0.04 5.09 2.52
Hyal1 hyaluronoglucosaminidase 1 0.10 0.09 13.10 10.16
Slc2a13 solute carrier family 2 (facilitated glucose transporter), member 13 0.14 0.16 12.41 3.78
Slc6a9 solute carrier family 6 (neurotransmitter transporter, glycine), member 9 7.15 12.20 11.37 5.25
Gata6 GATA binding protein 6 0.46 0.55 25.10 14.52
Cdca7 cell division cycle associated 7 0.06 0.06 5.43 2.45
Wnt5a wingless-type MMTV integration site family, member 5A 0.27 0.07 17.42 14.74
Cnp 2’,3’-cyclic nucleotide 3’ phosphodiesterase 0.43 0.16 25.99 8.56
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Emb embigin 0.99 1.01 65.08 69.41
Nrxn2 neurexin 2 13.28 16.18 25.61 7.95
Pla2g2d phospholipase A2, group IID 0.62 0.77 12.61 6.91
Rad51 RAD51 recombinase 0.10 0.09 10.50 1.95
Arhgap26 Rho GTPase activating protein 26 0.21 0.14 7.64 5.36
Nek11 NIMA-related kinase 11 0.08 0.13 1.98 0.91
Ogn osteoglycin 22.79 38.12 235.09 159.09
Downregulated genes
Klk8 kallikrein related-peptidase 8 35.05 60.72 0.00 0.00
Dmrt2 doublesex and mab-3 related transcription factor 2 9.39 16.09 0.21 0.07
Lrtomt O-methyltransferase domain containing 13.00 22.52 0.02 0.03
LOC171161 common salivary protein 1 30.39 37.35 0.00 0.00
Myh3 myosin, heavy chain 3, skeletal muscle, embryonic 219.70 380.48 2.17 2.16
Tprg1 tumor protein p63 regulated 1 7.50 12.97 0.15 0.09
Enam enamelin 1.92 3.32 0.00 0.00
Mcpt2 mast cell protease 2 6.76 9.86 1.23 2.13
Prl8a2 prolactin family 8, subfamily a, member 2 354.83 439.23 3.19 2.34
Olr1667 olfactory receptor 1667 75.53 130.83 0.00 0.00
Ces4a carboxylesterase 4A 2.57 4.45 0.01 0.02
Vgll2 vestigial like 2 (Drosophila) 6.94 12.02 0.00 0.00
Trim10 tripartite motif-containing 10 5.77 4.68 3.81 4.29
Cst5 cystatin D 4.00 6.93 0.00 0.00
Bpifa2 BPI fold containing family A, member 2 16.21 27.86 0.01 0.01
Bpifa2f BPI fold containing family A, member 2F 27.98 48.46 0.00 0.00
Pck1 phosphoenolpyruvate carboxykinase 1 (soluble) 15.88 22.33 1.54 1.24
Pbp2 phosphatidylethanolamine binding protein 2 6.34 10.49 0.00 0.00
Htr1d 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled 9.84 8.53 0.00 0.00
LOC682102 hypothetical protein LOC682102 4.07 6.90 0.20 0.05
RGD1305627 hypothetical LOC314467 27.17 32.06 0.00 0.00
Smgc submandibular gland protein C 18.50 32.01 0.00 0.00
Myf6 myogenic factor 6 23.79 41.20 0.00 0.00
Gldn gliomedin 5.03 8.69 0.00 0.00
Dmrtc1c DMRT-like family C1c 13.50 20.83 0.00 0.00
Rhox4g reproductive homeobox 4G 8.16 12.75 0.00 0.00
Krt10 keratin 10 264.25 457.37 2.02 1.70
Ceacam11 carcinoembryonic antigen-related cell adhesion molecule 11 2156.53 2749.06 7.53 8.09
Dkk1 dickkopf WNT signaling pathway inhibitor 1 7.13 6.37 0.60 0.29
Zfp39 zinc finger protein 39 9.17 6.51 4.71 0.17
Pkp1 plakophilin 1 56.99 75.54 4.78 5.71
Limch1 LIM and calponin homology domains 1 31.83 35.76 3.44 2.22
Slc10a2 solute carrier family 10 (sodium/bile acid cotransporter), member 2 36.80 49.68 12.43 4.33
Tpbpa trophoblast specific protein alpha 1358.04 1781.76 5.35 5.44
Prl3b1 Prolactin family 3, subfamily b, member 1 144.12 132.01 19.98 33.39
Inhba inhibin beta-A 165.88 160.51 14.43 9.31
LOC682105 receptor accessory protein 2 83.10 72.74 26.19 10.36
Wfdc1 WAP four-disulfide core domain 1 193.06 215.95 36.20 11.50
Aif1l allograft inflammatory factor 1-like 165.43 128.55 35.79 21.68
Tfpi tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 487.67 411.14 48.33 14.87
Slc6a12 solute carrier family 6 (neurotransmitter transporter), member 12 591.70 520.75 6.15 7.59
Slc6a6 solute carrier family 6 (neurotransmitter transporter), member 6 71.23 72.75 12.36 5.55
Smim1 small integral membrane protein 1 32.07 30.11 8.94 4.94
Ehd3 EH-domain containing 3 389.61 348.12 80.84 27.36
Slc5a6 solute carrier family 5 (sodium/multivitamin and iodide cotransporter), member 6 129.12 22.80 14.70 2.44
Tgfb3 transforming growth factor, beta 3 375.47 353.65 39.59 17.73
Cpm carboxypeptidase M 28.44 32.14 12.37 2.41
Slc38a4 solute carrier family 38, member 4 70.46 78.45 5.69 2.11
Ncam1 neural cell adhesion molecule 1 10.27 10.55 5.33 3.39
Ptk7 protein tyrosine kinase 7 44.15 42.11 7.01 4.56
Slc29a1 solute carrier family 29 (equilibrative nucleoside transporter), member 1 58.98 51.11 6.02 2.08
Fndc3c1 fibronectin type III domain containing 3C1 54.74 74.41 1.07 1.62
Tmem204 transmembrane protein 204 80.44 69.90 20.57 11.69
Serpine1 serpin peptidase inhibitor, clade E 838.81 856.95 36.01 19.61
(nexin, plasminogen activator inhibitor type 1), member 1
Prom1 prominin 1 22.65 20.02 4.60 4.59
Kdm1b lysine (K)-specific demethylase 1B 22.27 33.35 3.71 2.12
Gadd45g growth arrest and DNA-damage-inducible, gamma 166.58 144.85 84.32 2.27
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S100a4 S100 calcium-binding protein A4 274.82 394.40 65.11 4.28
Traf3 Tnf receptor-associated factor 3 40.80 18.50 15.63 4.51
Cmtm7 CKLF-like MARVEL transmembrane domain containing 7 54.57 47.24 31.32 8.93
Pttg1 pituitary tumor-transforming 1 10.34 17.92 10.31 4.25
Prl7a4 prolactin family 7, subfamily a, member 4 121.86 177.85 0.00 0.00
Prl8a5 prolactin family 8, subfamily a, member 5 2011.73 742.77 6.02 8.05
Prl8a7 prolactin family 8, subfamily a, member 7 8949.40 8357.04 4.74 5.05
Prl8a4 prolactin family 8, subfamily a, member 4 967.13 784.32 3.57 3.17
Ticam2 toll-like receptor adaptor molecule 2 91.23 138.75 4.47 0.24
Ceacam3 carcinoembryonic antigen-related cell adhesion molecule 3 36.70 39.13 0.13 0.08
Psg16 pregnancy specific glycoprotein 16 50.94 45.68 0.10 0.11
Cgm4 carcinoembryonic antigen gene family 4 220.61 181.00 0.50 0.38
Psgb1 pregnancy-specific beta 1-glycoprotein 1513.64 2597.60 0.05 0.08
Pik3r5 phosphoinositide-3-kinase, regulatory subunit 5 15.76 27.07 4.14 1.09
Phf11 PHD finger protein 11 2238.65 3875.68 20.10 4.08
Psg29 pregnancy-specific glycoprotein 29 115.70 140.20 0.11 0.04
Srpx sushi-repeat-containing protein, X-linked 457.14 787.56 88.71 61.11
D.3 GD22(NL)
Table D.6: Genes that were differentially expressed in the inner myometrium com-
pared to the decidua on GD22(NL). Transcript expression levels are shown in transcripts per
million values (mean±SD).
Decidua Inner myometrium
Gene
symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Abcc9 ATP-binding cassette, subfamily C (CFTR/MRP), member 9 8.03 8.57 18.88 28.39
Adcyap1r1 adenylate cyclase activating polypeptide 1 receptor 1 2.09 1.91 30.49 47.47
Aoc3 amine oxidase, copper containing 3 5.62 3.61 32.63 27.88
Apbb1ip amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 3.74 2.74 60.28 69.49
Asgr1 asialoglycoprotein receptor 1 0.14 0.13 6.06 4.98
Ass1 argininosuccinate synthase 1 5.55 4.61 56.19 84.75
B3gnt7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 1.62 0.28 28.18 39.84
Cd53 Cd53 molecule 3.59 3.25 26.31 22.03
Cdh1 cadherin 1 2.09 1.21 21.35 36.08
Cdkn1c cyclin-dependent kinase inhibitor 1C 54.14 35.49 462.85 190.55
Cenpf centromere protein F 0.65 0.47 8.55 2.89
Cldn4 claudin 4 5.35 5.09 248.75 405.09
Cldn7 claudin 7 2.53 2.67 56.65 97.63
Cmbl carboxymethylenebutenolidase homolog (Pseudomonas) 2.44 1.76 45.50 38.94
Creb3l1 cAMP responsive element binding protein 3-like 1 29.59 14.62 215.34 89.87
Ctsm cathepsin M 4.68 5.20 224.42 353.44
Ctxn1 cortexin 1 6.35 4.54 71.27 31.12
Cxcl13 chemokine (C-X-C motif) ligand 13 3.90 2.63 47.32 50.10
Dhrs3 dehydrogenase/reductase (SDR family) member 3 19.50 6.55 110.95 100.97
Dlx3 distal-less homeobox 3 0.81 0.38 26.97 46.14
Ebf3 early B-cell factor 3 0.86 0.80 18.63 21.52
Ednrb endothelin receptor type B 48.74 20.61 346.91 137.08
Enpp3 ectonucleotide pyrophosphatase/phosphodiesterase 3 5.42 4.00 60.16 53.61
Epcam epithelial cell adhesion molecule 5.48 5.31 42.27 70.02
Eps8l2 EPS8-like 2 5.21 2.40 37.79 61.61
Fam110c family with sequence similarity 110, member C 21.32 32.11 21.58 26.48
Fbln1 fibulin 1 26.41 17.99 62.05 107.47
Fmod fibromodulin 3.07 1.01 50.99 81.26
Folr1 folate receptor 1 (adult) 2.35 1.50 41.98 70.89
Gfpt2 glutamine-fructose-6-phosphate transaminase 2 3.73 0.61 31.56 33.54
Gpm6a glycoprotein m6a 1.14 0.76 22.82 38.91
Gprc5b G protein-coupled receptor, family C, group 5, member B 3.24 2.15 42.10 70.08
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Hgd homogentisate 1, 2-dioxygenase 2.06 2.19 65.02 96.01
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) 2.87 3.79 27.14 36.72
Htr2a 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled 1.63 0.18 86.91 148.90
Ifi204 myeloid cell nuclear differentiation antigen 8.18 9.36 151.67 157.03
Itm2a integral membrane protein 2A 1.77 0.47 27.31 44.56
Kcnmb1 potassium large conductance calcium-activated channel, subfamily M, beta member 1 3.83 2.68 69.93 74.90
Kctd15 potassium channel tetramerization domain containing 15 11.78 9.19 167.92 261.06
Lcn2 lipocalin 2 8.24 3.36 160.85 170.17
LOC498662 testis development related protein 0.98 0.37 16.31 24.61
Lrrc63 leucine rich repeat containing 63 0.67 0.44 12.33 20.81
Mgst1 microsomal glutathione S-transferase 1 32.50 19.07 185.45 187.57
Mpeg1 macrophage expressed 1 9.54 7.41 117.83 96.74
Mx1 myxovirus (influenza virus) resistance 1 13.22 10.17 116.26 117.87
Npl N-acetylneuraminate pyruvate lyase 4.35 2.45 50.87 59.27
Oasl 2’-5’-oligoadenylate synthetase-like 9.29 8.88 131.13 159.32
Olr1590 olfactory receptor 1590 0.00 0.00 9.87 17.10
Pcdh7 protocadherin 7 3.82 1.72 38.60 47.61
Pde4a phosphodiesterase 4A, cAMP-specific 3.25 2.03 50.95 80.06
Pdpn podoplanin 13.45 11.62 114.37 67.08
Perp PERP, TP53 apoptosis effector 1.29 1.77 33.53 29.26
Pla1a phospholipase A1 member A 9.61 6.37 85.68 70.17
Pnoc prepronociceptin 0.01 0.02 9.91 16.24
Podxl podocalyxin-like 4.13 1.33 27.00 26.85
Ppp1r12b protein phosphatase 1, regulatory subunit 12B 29.13 27.84 70.35 75.76
Prl3a1 Prolactin family 3, subfamily a, member 1 0.00 0.00 12.10 15.73
Psg16 pregnancy specific glycoprotein 16 3.63 2.07 754.24 1242.57
Psg29 pregnancy-specific glycoprotein 29 3.08 2.60 662.38 1056.85
Ptch2 patched homolog 2 (Drosophila) 0.14 0.15 5.76 4.42
Ptprc protein tyrosine phosphatase, receptor type, C 6.65 7.50 24.65 23.22
Rfx5 regulatory factor X, 5 (influences HLA class II expression) 3.27 1.66 27.97 39.93
Rhox12 reproductive homeobox 12 0.06 0.03 1.85 2.77
Rsad2 radical S-adenosyl methionine domain containing 2 9.52 7.00 50.42 21.61
Sdc1 syndecan 1 12.47 9.29 75.09 40.71
Sgce sarcoglycan, epsilon 8.75 5.76 119.44 79.72
Slco4a1 solute carrier organic anion transporter family, member 4a1 2.74 2.31 23.45 39.85
Ssc5d scavenger receptor cysteine rich domain containing (5 domains) 5.45 4.38 64.46 91.68
St3gal5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 5.49 1.68 47.33 57.02
Tlr7 toll-like receptor 7 1.41 1.35 18.00 16.68
Tpx2 TPX2, microtubule-associated 2.29 0.69 18.00 22.08
Vav3 vav 3 guanine nucleotide exchange factor 1.94 1.52 12.17 8.20
Downregulated genes
Abp1 amiloride binding protein 1 (amine oxidase copper-containing) 13476.76 10528.29 482.48 348.16
Acer2 alkaline ceramidase 2 230.07 184.92 22.06 13.17
Ampd3 adenosine monophosphate deaminase 3 182.62 141.49 23.00 16.60
Angpt2 angiopoietin 2 14.94 11.93 0.80 0.49
Arsg arylsulfatase G 65.63 52.38 2.95 0.66
Bmp6 bone morphogenetic protein 6 181.20 146.39 11.10 13.15
Cdhr5 cadherin-related family member 5 275.61 307.44 6.77 9.62
Cdon cell adhesion associated, oncogene regulated 28.39 22.57 2.46 0.46
Ceacam9 carcinoembryonic antigen-related cell adhesion molecule 9 514.25 886.25 12.94 7.58
Clic5 chloride intracellular channel 5 674.00 544.53 56.52 26.64
Cmah cytidine monophospho-N-acetylneuraminic acid hydroxylase 84.99 111.17 1.83 2.81
Cryab crystallin, alpha B 3593.53 2550.04 182.84 163.06
Cspg4 chondroitin sulfate proteoglycan 4 117.16 95.35 7.53 3.13
Csrp3 cysteine and glycine-rich protein 3 (cardiac LIM protein) 3.82 4.10 0.00 0.00
Ctgf connective tissue growth factor 1562.03 1121.93 126.87 83.31
Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 228.05 216.17 13.11 4.48
Doxl2 diamine oxidase-like protein 2 3.62 3.84 0.04 0.05
Dync1i1 dynein cytoplasmic 1 intermediate chain 1 11.42 8.95 0.54 0.56
Ehd3 EH-domain containing 3 335.34 257.89 22.93 23.33
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 114.74 91.63 8.97 6.01
Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 479.19 443.48 23.16 18.54
Gnat2 guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide 2 115.07 94.43 4.69 7.88
Hopx HOP homeobox 415.16 372.91 32.65 17.32
Hspb7 heat shock protein family, member 7 (cardiovascular) 71.83 69.41 4.71 5.10
Hyal4 hyaluronoglucosaminidase 4 4.27 3.09 0.13 0.09
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Il1rl1 interleukin 1 receptor-like 1 21.84 30.81 1.60 0.67
Itgbl1 integrin, beta-like 1 286.33 219.40 28.82 16.44
Kcna1 potassium voltage-gated channel, shaker-related subfamily, member 1 2.13 3.46 0.06 0.03
LOC691083 hypothetical protein LOC691083 9.65 7.32 0.12 0.08
Mboat2 membrane bound O-acyltransferase domain containing 2 25.06 22.58 2.07 1.95
Mdfic MyoD family inhibitor domain containing 42.72 28.55 9.39 2.66
Mfsd12 major facilitator superfamily domain containing 12 256.78 221.05 13.65 17.23
Mogat1 monoacylglycerol O-acyltransferase 1 2.04 0.26 0.09 0.16
Nalcn sodium leak channel, non-selective 9.11 6.55 0.33 0.11
Nsg2 neuron specific gene family member 2 53.53 45.75 4.82 3.69
Pgf placental growth factor 752.54 615.73 19.21 7.28
Phactr3 phosphatase and actin regulator 3 5.60 6.44 0.00 0.00
Pkp1 plakophilin 1 59.31 49.85 3.46 3.96
Plcxd2 phosphatidylinositol-specific phospholipase C, X domain containing 2 7.76 6.74 0.66 0.26
Prdm1 PR domain containing 1, with ZNF domain 66.53 50.45 6.68 2.43
Prom1 prominin 1 32.99 33.17 3.62 3.47
Prss35 protease, serine, 35 26.84 27.76 0.47 0.19
Ptprn2 protein tyrosine phosphatase, receptor type, N polypeptide 2 7.84 6.14 0.27 0.11
Ptprr protein tyrosine phosphatase, receptor type, R 2.65 1.84 0.11 0.03
Ramp3 receptor (G protein-coupled) activity modifying protein 3 624.16 692.21 58.80 31.50
Reln reelin 42.64 35.74 3.00 2.26
Rrm2 ribonucleotide reductase M2 141.53 185.22 13.40 4.06
S100a4 S100 calcium-binding protein A4 624.60 421.62 41.13 31.11
Scg5 secretogranin V (7B2 protein) 58.11 52.30 2.25 1.96
Sema3b (semaphorin) 3B 206.03 188.52 9.99 10.27
Slc6a12 solute carrier family 6 (neurotransmitter transporter), member 12 824.03 675.56 20.29 30.55
Slc6a6 solute carrier family 6 (neurotransmitter transporter), member 6 139.81 93.01 16.32 8.16
Sostdc1 sclerostin domain containing 1 1.71 2.95 0.00 0.00
Syt4 synaptotagmin IV 0.79 1.19 0.05 0.02
Tgfa transforming growth factor alpha 28.15 25.42 3.25 2.91
Tgfb2 transforming growth factor, beta 2 171.44 142.67 19.19 11.63
Tmeff1 transmembrane protein with EGF-like and two follistatin-like domains 1 11.41 10.34 0.26 0.16
Tmem204 transmembrane protein 204 200.68 162.41 8.95 10.82
Uck2 uridine-cytidine kinase 2 201.50 164.04 6.50 5.87
Usp53 ubiquitin specific peptidase 53 57.82 47.14 4.88 0.71
Vldlr very low density lipoprotein receptor 123.50 110.20 14.10 9.93
Vom2r34 vomeronasal 2 receptor, 34 130.98 203.13 8.51 1.50
Wfdc1 WAP four-disulfide core domain 1 577.72 535.36 22.16 21.11
Zc2hc1c zinc finger, C2HC-type containing 1C 5.20 4.47 0.01 0.02
Table D.7: Genes that were differentially expressed in the outer myometrium com-
pared to the decidua on GD22(NL). Transcript expression levels are shown in transcripts per
million values (mean±SD).
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symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
A1i3 alpha-1-inhibitor 3 0.38 0.06 39.68 68.23
Aadac arylacetamide deacetylase 0.04 0.06 8.90 15.32
Aadat aminoadipate aminotransferase 2.05 1.67 41.93 42.22
Abcc8 ATP-binding cassette, subfamily C (CFTR/MRP), member 8 0.02 0.04 8.44 7.39
Abcg2 ATP-binding cassette, subfamily G (WHITE), member 2 0.60 0.66 15.93 11.24
Acot12 acyl-CoA thioesterase 12 0.08 0.13 7.75 12.35
Acsl1 acyl-CoA synthetase long-chain family member 1 3.22 1.41 49.13 67.79
Adra1b adrenoceptor alpha 1B 0.00 0.00 3.37 5.29
Adtrp androgen-dependent TFPI-regulating protein 0.41 0.12 26.74 20.75
Afm afamin 0.06 0.11 11.40 18.78
Afp alpha-fetoprotein 1.87 2.01 3683.71 2943.42
Agxt2 alanine-glyoxylate aminotransferase 2 0.06 0.10 21.84 37.20
Ahr aryl hydrocarbon receptor 0.83 1.00 10.27 5.58
Akr1c14 aldo-keto reductase family 1, member C14 23.80 22.00 465.31 410.16
Alas1 aminolevulinate, delta-, synthase 1 15.45 6.64 206.45 197.01
Alas2 aminolevulinate, delta-, synthase 2 2.36 0.44 28.53 41.56
Aldh1b1 aldehyde dehydrogenase 1 family, member B1 0.00 0.00 3.85 6.59
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Alox15b arachidonate 15-lipoxygenase, type B 0.05 0.08 6.34 8.35
Alpl alkaline phosphatase, liver/bone/kidney 3.22 0.62 34.71 48.23
Amdhd1 amidohydrolase domain containing 1 0.00 0.00 11.24 19.04
Amy1a amylase, alpha 1A (salivary) 0.01 0.03 6.14 10.62
Ankrd22 ankyrin repeat domain 22 0.02 0.03 2.63 2.26
Apcs amyloid P component, serum 0.00 0.01 28.50 49.18
Apoa2 apolipoprotein A-II 0.00 0.00 104.68 178.40
Apof apolipoprotein F 0.12 0.22 5.50 8.93
Apol3 apolipoprotein L, 3 1.91 0.58 30.76 24.35
Apon apolipoprotein N 0.44 0.09 9.62 11.96
Arl5c ADP-ribosylation factor-like 5C 0.00 0.01 2.34 4.04
Arsb arylsulfatase B 15.57 8.84 181.41 222.54
As3mt arsenic (+3 oxidation state) methyltransferase 5.61 4.13 40.56 54.29
Asgr1 asialoglycoprotein receptor 1 0.14 0.13 42.89 59.49
Aspm asp (abnormal spindle) homolog, microcephaly associated (Drosophila) 0.50 0.16 5.86 5.27
Ass1 argininosuccinate synthase 1 5.55 4.61 223.08 184.38
Atp7b ATPase, Cu++ transporting, beta polypeptide 0.09 0.08 13.36 17.33
Azgp1 alpha-2-glycoprotein 1, zinc-binding 0.06 0.11 59.58 103.10
B3gnt7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 1.62 0.28 42.13 61.50
Baiap2l1 BAI1-associated protein 2-like 1 1.39 0.99 26.26 31.70
Bcam basal cell adhesion molecule (Lutheran blood group) 4.22 4.08 44.66 36.97
Brca1 breast cancer 1, early onset 0.40 0.30 3.48 2.18
Bub1 BUB1 mitotic checkpoint serine/threonine kinase 1.26 0.37 8.13 6.38
Bucs1 acyl-CoA synthetase medium-chain family member 1 0.01 0.01 35.57 61.34
C3 complement component 3 11.31 17.57 1199.02 1226.91
C4bpa complement component 4 binding protein, alpha 0.01 0.03 13.12 22.58
C4bpb complement component 4 binding protein, beta 0.09 0.10 52.51 90.75
Camp cathelicidin antimicrobial peptide 0.11 0.18 37.38 64.73
Car1 carbonic anhydrase I 0.00 0.00 7.42 12.84
Ccdc64b coiled-coil domain containing 64B 0.00 0.00 3.01 3.04
Ccl21 chemokine (C-C motif) ligand 21 0.13 0.13 19.05 22.06
Ccna2 cyclin A2 1.96 0.64 22.59 15.09
Ccnb2 cyclin B2 1.30 0.40 16.63 13.60
Cd4 Cd4 molecule 1.00 0.62 16.06 17.75
Cd79b Cd79b molecule, immunoglobulin-associated beta 0.01 0.01 4.80 8.20
Cdh1 cadherin 1 2.09 1.21 179.51 198.89
Ceacam1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 12.81 17.33 55.77 36.10
Cenpf centromere protein F 0.65 0.47 23.52 18.14
Cfb complement factor B 2.73 3.71 157.75 97.41
Cfh complement factor H 1.24 0.90 37.81 42.05
Cfhr1 complement factor H-related 1 0.02 0.04 5.63 9.20
Cfi complement factor I 4.05 2.86 48.20 53.03
Cftr cystic fibrosis transmembrane conductance regulator 0.82 0.59 22.54 29.22
Cideb cell death-inducing DFFA-like effector b 7.17 9.12 47.99 34.09
Cit citron (rho-interacting, serine/threonine kinase 21) 0.47 0.38 8.30 5.80
Ckmt1b creatine kinase, mitochondrial 1B 0.44 0.32 19.76 13.85
Cldn1 claudin 1 0.64 0.57 20.50 25.59
Cldn2 claudin 2 1.65 2.71 135.04 114.17
Cldn4 claudin 4 5.35 5.09 367.31 529.47
Cldn7 claudin 7 2.53 2.67 72.57 79.21
Cldn8 claudin 8 0.00 0.01 4.29 5.87
Clmn calmin 0.62 0.56 23.05 26.47
Cndp1 carnosine dipeptidase 1 (metallopeptidase M20 family) 0.83 0.53 35.15 22.93
Col2a1 collagen, type II, alpha 1 0.10 0.05 8.56 14.79
Coro2a coronin, actin binding protein 2A 0.16 0.19 6.53 6.43
Cpn1 carboxypeptidase N, polypeptide 1 0.02 0.04 10.15 10.54
Cpn2 carboxypeptidase N, polypeptide 2 0.01 0.02 10.27 16.58
Creb3l1 cAMP responsive element binding protein 3-like 1 29.59 14.62 165.27 175.08
Creb3l3 cAMP responsive element binding protein 3-like 3 0.62 0.34 33.39 41.91
Crip1 cysteine-rich protein 1 (intestinal) 14.15 9.71 171.22 132.17
Csf1r colony stimulating factor 1 receptor 14.57 5.08 100.47 85.43
Ctsg cathepsin G 0.00 0.00 4.11 6.75
Ctsm cathepsin M 4.68 5.20 107.27 182.78
Ctxn1 cortexin 1 6.35 4.54 75.65 19.18
Cubn cubilin (intrinsic factor-cobalamin receptor) 0.14 0.03 25.73 21.78
Cuzd1 CUB and zona pellucida-like domains 1 10.68 17.89 492.78 409.84
Cx3cl1 chemokine (C-X3-C motif) ligand 1 0.71 0.66 17.66 18.54
Cxcl16 chemokine (C-X-C motif) ligand 16 8.86 6.79 68.94 68.02
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Cyp2c22 cytochrome P450, family 2, subfamily c, polypeptide 22 0.00 0.01 6.25 10.51
Cyp2d1 cytochrome P450, family 2, subfamily d, polypeptide 1 0.52 0.91 5.86 6.24
Cyp3a62 cytochrome P450, family 3, subfamily a, polypeptide 62 0.00 0.01 2.27 3.11
Cyp4a2 cytochrome P450, family 4, subfamily a, polypeptide 2 0.02 0.03 5.48 9.19
Dcdc2 doublecortin domain containing 2 2.48 3.19 18.15 13.93
Defa defensin alpha 0.07 0.12 76.90 132.33
Dhrs11 dehydrogenase/reductase (SDR family) member 11 2.57 0.65 18.39 10.30
Dhtkd1 dehydrogenase E1 and transketolase domain containing 1 1.81 1.20 11.63 14.38
Dmbt1 deleted in malignant brain tumors 1 0.65 0.45 18.86 13.45
Dpp4 dipeptidylpeptidase 4 0.15 0.01 4.48 3.25
Dsc2 desmocollin 2 1.96 0.75 42.35 53.92
Ehf ets homologous factor 1.06 1.23 29.02 34.55
Ehhadh enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase 1.89 1.28 21.25 16.87
Elf3 E74-like factor 3 1.75 2.37 70.44 73.54
Emb embigin 2.99 3.75 32.47 27.92
Entpd2 ectonucleoside triphosphate diphosphohydrolase 2 16.36 6.45 151.88 111.70
Epb41l3 erythrocyte membrane protein band 4.1-like 3 0.66 0.13 17.60 11.00
Epcam epithelial cell adhesion molecule 5.48 5.31 352.04 262.99
Epha2 Eph receptor A2 1.44 0.30 14.75 9.18
Eps8l1 EPS8-like 1 0.12 0.02 5.83 3.71
Eps8l2 EPS8-like 2 5.21 2.40 73.65 82.21
Epsti1 epithelial stromal interaction 1 (breast) 2.25 0.63 24.95 26.49
Epx eosinophil peroxidase 0.03 0.04 8.26 13.38
Ercc6l excision repair cross-complementing rodent repair 0.28 0.16 3.25 2.19
deficiency complementation group 6 - like
Exoc6 exocyst complex component 6 1.12 0.43 19.85 16.30
Eya2 eyes absent homolog 2 (Drosophila) 1.02 1.45 37.63 37.38
F11 coagulation factor XI 0.02 0.02 5.03 6.70
F2rl1 coagulation factor II (thrombin) receptor-like 1 7.48 3.58 39.54 16.00
F5 coagulation factor V (proaccelerin, labile factor) 0.82 0.67 39.50 32.53
Fabp1 fatty acid binding protein 1, liver 0.00 0.00 91.57 158.60
Faim3 Fas apoptotic inhibitory molecule 3 0.60 0.45 13.33 7.74
Fam167a family with sequence similarity 167, member A 1.49 1.10 15.38 11.67
Fam84a family with sequence similarity 84, member A 0.05 0.05 3.90 2.47
Fcgbp Fc fragment of IgG binding protein 0.52 0.59 20.48 25.88
Fgd4 FYVE, RhoGEF and PH domain containing 4 0.78 0.48 5.08 3.78
Fhdc1 FH2 domain containing 1 1.32 0.72 9.59 5.01
Fhl1 four and a half LIM domains 1 46.77 43.41 291.70 108.06
Fmod fibromodulin 3.07 1.01 21.12 6.88
Folr1 folate receptor 1 (adult) 2.35 1.50 162.60 159.02
Fxyd4 FXYD domain-containing ion transport regulator 4 0.22 0.14 9.49 5.19
Gabrp gamma-aminobutyric acid (GABA-A) receptor, pi 0.00 0.00 3.76 4.09
Gatsl2 GATS protein-like 2 21.24 6.98 71.36 34.62
Gca grancalcin 0.59 0.30 12.74 8.91
Gckr glucokinase (hexokinase 4) regulator 0.00 0.00 6.79 11.66
Gcnt1 glucosaminyl (N-acetyl) transferase 1, core 2 2.15 0.32 12.87 7.82
Ghrl ghrelin/obestatin prepropeptide 0.09 0.08 14.37 19.54
Gnmt glycine N-methyltransferase 0.01 0.02 107.74 186.61
Gpa33 glycoprotein A33 (transmembrane) 0.40 0.36 24.22 28.58
Gpc3 glypican 3 0.82 0.62 44.34 31.72
Gpx2 glutathione peroxidase 2 5.29 6.55 160.81 81.14
Gramd1b GRAM domain containing 1B 3.13 0.57 26.96 20.74
Grik2 glutamate receptor, ionotropic, kainate 2 0.29 0.26 6.42 2.72
Gsta3 glutathione S-transferase alpha 3 7.75 1.03 71.62 93.58
Haao 3-hydroxyanthranilate 3,4-dioxygenase 0.01 0.01 17.24 29.68
Hao1 hydroxyacid oxidase (glycolate oxidase) 1 0.05 0.08 10.21 17.58
Hemgn hemogen 1.05 0.93 55.11 91.97
Hgfac HGF activator 0.29 0.48 23.55 23.19
Hjurp Holliday junction recognition protein 0.30 0.21 4.92 3.13
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) 2.87 3.79 100.87 169.45
Hnf1b HNF1 homeobox B 0.34 0.35 10.65 12.63
Hnf4a hepatocyte nuclear factor 4, alpha 0.02 0.03 36.88 22.69
Hook1 hook microtubule-tethering protein 1 0.23 0.11 3.14 2.13
Hoxb8 homeo box B8 1.83 0.60 18.48 28.79
Hp haptoglobin 2.65 0.74 511.81 885.89
Hpd 4-hydroxyphenylpyruvate dioxygenase 0.02 0.03 69.38 119.72
Hpx hemopexin 1.12 0.52 82.09 136.29
Ifitm1 interferon induced transmembrane protein 1 27.54 18.87 236.37 143.09
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Igfals insulin-like growth factor binding protein, acid labile subunit 0.00 0.00 4.22 5.21
Igsf5 immunoglobulin superfamily, member 5 0.03 0.05 8.04 7.70
Il1a interleukin 1 alpha 0.16 0.20 9.88 10.42
Ildr1 immunoglobulin-like domain containing receptor 1 0.11 0.09 4.74 3.34
Irf6 interferon regulatory factor 6 0.47 0.41 20.26 14.60
Itga6 integrin, alpha 6 2.19 1.54 23.89 18.92
Itgb4 integrin, beta 4 1.81 1.77 31.49 25.12
Itih1 inter-alpha trypsin inhibitor, heavy chain 1 0.02 0.03 44.95 77.65
Itpr2 inositol 1,4,5-trisphosphate receptor, type 2 2.28 0.68 10.99 7.00
Kap kidney androgen regulated protein 17.01 28.41 1514.85 999.61
Kazn kazrin, periplakin interacting protein 4.02 1.89 21.73 21.97
Kcnj16 potassium inwardly-rectifying channel, subfamily J, member 16 0.10 0.03 6.87 6.70
Keg1 glycine-N-acyltransferase-like 2 0.04 0.01 7.44 12.04
Kif11 kinesin family member 11 1.11 0.79 9.36 6.68
Kif23 kinesin family member 23 1.32 1.16 26.13 22.56
Krt19 keratin 19 33.21 26.87 396.19 327.46
Lad1 ladinin 1 1.25 0.43 149.58 221.93
Lamb3 laminin, beta 3 0.29 0.38 22.91 17.10
Lcn2 lipocalin 2 8.24 3.36 126.31 66.72
Lcn5 lipocalin 5 0.06 0.11 7.34 12.71
Lgals2 lectin, galactoside-binding, soluble, 2 0.02 0.02 30.51 23.52
Lgr4 leucine-rich repeat-containing G protein-coupled receptor 4 2.08 1.00 13.51 10.12
Llgl2 lethal giant larvae homolog 2 (Drosophila) 1.04 0.64 15.11 11.65
LOC360228 WDNM1 homolog 0.04 0.04 27.85 15.10
LOC498222 similar to specifically androgen-regulated protein 0.24 0.07 3.18 1.89
LOC498368 similar to RIKEN cDNA 0610040J01 0.30 0.16 6.81 5.47
LOC500797 mitotic spindle positioning 0.49 0.24 24.58 20.86
LOC641520 popeye domain containing 3 0.00 0.00 2.45 2.66
LOC684112 SIK family kinase 3 9.48 5.23 27.45 12.17
LOC689064 beta-globin 39.69 29.70 1489.39 2365.58
Lpcat4 lysophosphatidylcholine acyltransferase 4 4.60 2.60 67.64 67.55
Lpo lactoperoxidase 3.18 5.50 99.94 125.95
Lrp2 low density lipoprotein receptor-related protein 2 0.28 0.26 17.89 15.16
Lrrc66 leucine rich repeat containing 66 0.06 0.05 2.23 0.85
Lsr lipolysis stimulated lipoprotein receptor 3.48 1.82 82.74 68.07
Lurap1l leucine rich adaptor protein 1-like 0.14 0.22 9.97 3.17
Lypd3 Ly6/Plaur domain containing 3 0.21 0.28 6.86 0.81
Macc1 metastasis associated in colon cancer 1 0.20 0.34 4.52 3.27
Mal2 mal, T-cell differentiation protein 2 0.38 0.41 32.51 32.69
Manba mannosidase, beta A, lysosomal 7.45 1.87 26.17 10.74
Map7 microtubule-associated protein 7 1.12 0.36 11.82 10.71
Mat1a methionine adenosyltransferase I, alpha 1.35 1.18 38.17 64.94
Mecom MDS1 and EVI1 complex locus 1.42 0.79 13.64 12.88
Met met proto-oncogene 0.73 0.65 12.53 7.83
Mgst1 microsomal glutathione S-transferase 1 32.50 19.07 181.62 249.08
Mki67 marker of proliferation Ki-67 1.85 1.26 36.01 32.97
Mlxipl MLX interacting protein-like 1.74 2.18 17.63 23.88
Mmp17 matrix metallopeptidase 17 2.18 2.30 16.35 1.74
Mmp7 matrix metallopeptidase 7 9.86 17.00 131.36 56.43
Mpzl2 myelin protein zero-like 2 5.47 4.65 47.52 40.78
Mrc1 mannose receptor, C type 1 0.73 0.62 6.95 8.45
Ms4a8a membrane-spanning 4-domains, subfamily A, member 8A 0.00 0.00 3.12 4.14
Msx1 msh homeobox 1 0.53 0.37 20.51 21.33
Myh14 myosin, heavy chain 14, non-muscle 1.31 1.40 40.59 36.09
Napsa napsin A aspartic peptidase 1.06 0.82 42.31 33.89
Ngp neutrophilic granule protein 0.00 0.00 24.71 41.14
Npl N-acetylneuraminate pyruvate lyase 4.35 2.45 62.26 58.25
Nr1i2 nuclear receptor subfamily 1, group I, member 2 0.01 0.03 6.49 11.16
Nt5e 5’ nucleotidase, ecto 1.61 0.65 16.60 11.38
Nusap1 nucleolar and spindle associated protein 1 1.39 0.59 11.88 8.84
P2ry4 pyrimidinergic receptor P2Y, G-protein coupled, 4 0.00 0.00 2.09 1.93
Pah phenylalanine hydroxylase 0.01 0.01 27.06 46.80
Paqr9 progestin and adipoQ receptor family member IX 0.42 0.73 18.69 31.80
Parm1 prostate androgen-regulated mucin-like protein 1 12.75 7.34 112.71 107.20
Pax8 paired box 8 1.23 0.92 33.09 38.30
Pbld1 phenazine biosynthesis-like protein domain containing 1 0.06 0.05 7.87 11.31
Pced1b PC-esterase domain containing 1B 5.63 2.35 64.02 83.06
Pdpn podoplanin 13.45 11.62 335.56 393.33
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Perp PERP, TP53 apoptosis effector 1.29 1.77 98.98 97.77
Phlda1 pleckstrin homology-like domain, family A, member 1 7.74 1.76 54.13 54.73
Pigr polymeric immunoglobulin receptor 1.26 1.04 55.40 69.41
Pip5k1b phosphatidylinositol-4-phosphate 5-kinase, type I, beta 0.26 0.19 5.70 3.97
Pklr pyruvate kinase, liver and RBC 2.23 0.65 27.71 27.58
Pkp2 plakophilin 2 4.27 3.71 44.33 42.76
Plcb1 phospholipase C, beta 1 (phosphoinositide-specific) 0.63 0.27 6.10 6.28
Plekhd1 pleckstrin homology domain containing, family D (with coiled-coil domains) member 1 0.85 0.22 18.19 13.33
Plekhh1 pleckstrin homology domain containing, family H (with MyTH4 domain) member 1 4.43 0.60 53.21 49.26
Plk5 polo-like kinase 5 0.04 0.06 6.15 9.11
Plvap plasmalemma vesicle associated protein 8.69 4.43 46.28 47.64
Plxnb2 plexin B2 13.91 10.76 69.59 50.50
Pnoc prepronociceptin 0.01 0.02 120.54 147.72
Podxl podocalyxin-like 4.13 1.33 53.81 49.43
Ppp1r12b protein phosphatase 1, regulatory subunit 12B 29.13 27.84 60.32 23.04
Prc1 protein regulator of cytokinesis 1 3.51 0.98 36.80 31.76
Prkaa2 protein kinase, AMP-activated, alpha 2 catalytic subunit 0.97 0.71 10.40 8.88
Prkcb protein kinase C, beta 0.17 0.12 5.27 5.05
Prkcz protein kinase C, zeta 0.38 0.36 7.52 6.61
Prl3a1 Prolactin family 3, subfamily a, member 1 0.00 0.00 16.33 5.06
Prl3d4 prolactin family 3, subfamily d, member 4 16.49 23.55 826.10 1424.54
Prodh2 proline dehydrogenase (oxidase) 2 0.00 0.01 21.12 36.49
Prrt1 proline-rich transmembrane protein 1 1.15 0.35 12.05 12.18
Prss30 protease, serine, 30 0.00 0.00 2.31 3.00
Psat1 phosphoserine aminotransferase 1 1.54 1.77 21.17 18.95
Psg16 pregnancy specific glycoprotein 16 3.63 2.07 716.10 1237.31
Psg29 pregnancy-specific glycoprotein 29 3.08 2.60 648.04 1117.62
Ptgs1 prostaglandin-endoperoxide synthase 1 2.31 1.14 45.52 44.58
Ptprf protein tyrosine phosphatase, receptor type, F 4.36 2.69 23.40 17.48
Ptprh protein tyrosine phosphatase, receptor type, H 0.98 1.06 49.37 42.47
Rab11fip1 RAB11 family interacting protein 1 (class I) 6.06 4.10 47.84 41.67
Rab17 RAB17, member RAS oncogene family 0.27 0.47 17.60 13.99
Rarres1 retinoic acid receptor responder (tazarotene induced) 1 5.94 2.27 46.29 45.43
Rbp4 retinol binding protein 4, plasma 1.96 1.58 593.30 896.31
RGD1309313 transmembrane protein 180 7.14 6.94 53.18 40.76
RGD1309821 similar to KIAA1161 protein 1.93 0.27 18.70 13.63
RGD1310507 similar to RIKEN cDNA 1300017J02 1.90 1.50 133.95 103.79
RGD1310587 similar to hypothetical protein FLJ14146 2.98 3.55 28.51 18.14
RGD1563547 small integral membrane protein 22 0.32 0.14 28.31 20.33
RGD1564614 similar to complement factor H-related protein 0.01 0.02 6.67 11.20
RGD1564894 similar to glycine-N-acyltransferase isoform a 0.00 0.00 17.76 30.66
Rgs20 regulator of G-protein signaling 20 0.04 0.05 6.40 9.52
Rhox12 reproductive homeobox 12 0.06 0.03 4.18 3.34
Rnf208 ring finger protein 208 0.00 0.00 6.23 5.14
Rtp3 receptor (chemosensory) transporter protein 3 2.00 0.38 21.09 20.82
Sdc3 syndecan 3 3.46 3.67 22.41 16.45
Sema4a (semaphorin) 4A 1.30 0.93 30.26 33.24
Sema4g (semaphorin) 4G 0.30 0.30 17.71 18.35
Sepp1 selenoprotein P, plasma, 1 45.60 23.88 865.70 728.25
Sgce sarcoglycan, epsilon 8.75 5.76 92.76 117.09
Sgms1 sphingomyelin synthase 1 1.42 0.65 25.90 24.57
Sgms2 sphingomyelin synthase 2 1.12 1.09 13.94 13.37
Sipa1l3 signal-induced proliferation-associated 1 like 3 7.84 4.21 51.75 50.62
Slc16a14 solute carrier family 16, member 14 1.14 0.91 28.20 33.75
Slc1a1 solute carrier family 1 (neuronal/epithelial high affinity 0.07 0.03 8.19 7.64
glutamate transporter, system Xag), member 1
Slc22a23 solute carrier family 22, member 23 3.98 1.69 33.68 24.39
Slc25a37 solute carrier family 25 (mitochondrial iron transporter), member 37 2.62 1.97 27.89 31.46
Slc26a4 solute carrier family 26 (anion exchanger), member 4 1.26 2.07 69.38 68.87
Slc27a5 solute carrier family 27 (fatty acid transporter), member 5 0.00 0.00 9.51 16.01
Slc28a2 solute carrier family 28 (sodium-coupled nucleoside transporter), member 2 5.56 0.33 36.76 11.80
Slc2a2 solute carrier family 2 (facilitated glucose transporter), member 2 0.03 0.01 22.17 22.06
Slc34a2 solute carrier family 34 (type II sodium/phosphate contransporter), member 2 1.46 2.13 24.89 23.72
Slc38a4 solute carrier family 38, member 4 14.54 13.24 202.40 309.79
Slc39a8 solute carrier family 39 (zinc transporter), member 8 4.88 1.32 28.25 13.92
Slc44a4 solute carrier family 44, member 4 0.91 0.59 38.47 42.57
Slc45a3 solute carrier family 45, member 3 0.59 0.50 8.03 7.58
Slc4a1 solute carrier family 4 (anion exchanger), member 1 1.73 0.66 92.03 153.87
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Slc5a3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 1.85 0.80 16.42 14.05
Slc6a14 solute carrier family 6 (amino acid transporter), member 14 0.09 0.15 5.53 4.79
Slc7a9 solute carrier family 7 (amino acid transporter light chain, bo,+ system), member 9 0.00 0.00 10.30 8.64
Slc9a3r1 solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), 45.15 12.76 311.36 201.25
member 3 regulator 1
Slco1a1 solute carrier organic anion transporter family, member 1a1 0.01 0.01 2.91 4.91
Slco4c1 solute carrier organic anion transporter family, member 4C1 0.03 0.05 4.11 2.71
Smlr1 small leucine-rich protein 1 0.00 0.00 9.12 12.15
Snhg11 small nucleolar RNA host gene 11 (non-protein coding) 2.34 1.16 7.20 6.89
Sort1 sortilin 1 3.15 2.13 23.31 16.87
Spint1 serine peptidase inhibitor, Kunitz type 1 0.97 0.46 45.26 38.51
Spint2 serine peptidase inhibitor, Kunitz type, 2 36.22 24.98 203.59 229.62
Spns2 spinster homolog 2 2.94 2.31 14.41 9.66
Spp1 secreted phosphoprotein 1 22.43 21.05 177.65 144.31
Sprr1a small proline-rich protein 1A 0.04 0.07 32.13 49.80
St14 suppression of tumorigenicity 14 (colon carcinoma) 1.64 2.21 59.10 42.80
St8sia3 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 0.00 0.00 5.65 9.16
Stard4 StAR-related lipid transfer (START) domain containing 4 3.00 2.99 12.40 4.39
Stat5b signal transducer and activator of transcription 5B 1.87 1.18 22.59 20.44
Stfa3 stefin A3 0.98 0.32 19.76 29.44
Sult1b1 sulfotransferase family, cytosolic, 1B, member 1 0.00 0.00 6.82 9.63
Taok3 TAO kinase 3 6.36 3.50 31.35 2.88
Tcf7l1 transcription factor 7-like 1 (T-cell specific, HMG-box) 7.21 4.00 54.92 50.46
Tf transferrin 1.63 0.72 1446.88 1856.73
Timd2 T-cell immunoglobulin and mucin domain containing 2 3.93 1.52 56.86 42.93
Tmc4 transmembrane channel-like 4 0.87 0.97 62.03 69.32
Tmem171 transmembrane protein 171 0.65 0.48 12.98 11.29
Tmem246 transmembrane protein 246 0.13 0.05 3.91 1.51
Tmem252 transmembrane protein 252 2.33 1.90 25.70 13.93
Tmem30b transmembrane protein 30B 0.08 0.10 14.20 15.23
Tnfaip6 tumor necrosis factor alpha induced protein 6 14.57 13.29 101.61 108.15
Tonsl tonsoku-like, DNA repair protein 1.05 0.40 8.62 9.51
Top2a topoisomerase (DNA) II alpha 1.50 1.10 24.51 19.83
Tpx2 TPX2, microtubule-associated 2.29 0.69 19.68 15.15
Trpv6 transient receptor potential cation channel, subfamily V, member 6 0.29 0.13 16.66 18.45
Tspan1 tetraspanin 1 1.60 2.18 67.06 39.29
Tspan13 tetraspanin 13 4.23 1.48 36.33 22.37
Ttc22 tetratricopeptide repeat domain 22 0.01 0.01 2.79 4.08
Ugt1a1 UDP glucuronosyltransferase 1 family, polypeptide A1 0.02 0.03 7.75 9.17
Ugt1a5 UDP glucuronosyltransferase 1 family, polypeptide A5 0.60 0.50 23.36 39.08
Ugt1a7c UDP glucuronosyltransferase 1 family, polypeptide A7C 2.68 1.60 49.66 42.40
Uhrf1 ubiquitin-like with PHD and ring finger domains 1 0.50 0.38 5.92 2.46
Unc5cl unc-5 homolog C (C. elegans)-like 0.13 0.18 17.36 9.72
Upb1 ureidopropionase, beta 0.02 0.04 16.36 28.14
Upk1b uroplakin 1B 0.24 0.14 26.98 14.78
Vax2 ventral anterior homeobox 2 0.00 0.00 5.06 8.30
Vtcn1 V-set domain containing T cell activation inhibitor 1 0.65 0.09 14.37 16.06
Vtn vitronectin 1.75 1.28 196.99 333.38
Wnt7a wingless-type MMTV integration site family, member 7A 0.20 0.14 11.54 9.93
Zmynd12 zinc finger, MYND-type containing 12 0.04 0.07 5.37 5.94
Downregulated genes
Acer2 alkaline ceramidase 2 230.07 184.92 20.19 7.40
Adamts12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 40.54 32.29 3.41 3.78
Ampd3 adenosine monophosphate deaminase 3 182.62 141.49 14.90 7.90
Atg4al1 autophagy related 4A, cysteine peptidase-like 1 198.54 149.16 17.08 9.57
Bdnf brain-derived neurotrophic factor 8.64 8.34 1.54 0.33
Bmp6 bone morphogenetic protein 6 181.20 146.39 13.61 12.44
Btbd3 BTB (POZ) domain containing 3 197.51 148.67 28.89 9.33
Camk2a calcium/calmodulin-dependent protein kinase II alpha 5.91 5.77 0.14 0.15
Cdh3 cadherin 3 173.14 134.14 15.36 16.24
Cdhr5 cadherin-related family member 5 275.61 307.44 17.67 14.49
Ceacam9 carcinoembryonic antigen-related cell adhesion molecule 9 514.25 886.25 40.76 22.98
Chodl chondrolectin 57.86 49.01 0.81 1.17
Clic5 chloride intracellular channel 5 674.00 544.53 28.98 13.51
Cmah cytidine monophospho-N-acetylneuraminic acid hydroxylase 84.99 111.17 1.36 1.17
Cpe carboxypeptidase E 794.87 666.43 26.39 20.83
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Crim1 cysteine rich transmembrane BMP regulator 1 (chordin like) 245.45 201.55 34.23 3.97
Cryab crystallin, alpha B 3593.53 2550.04 133.57 92.52
Cryl1 crystallin, lambda 1 52.98 44.63 7.19 2.32
Ctgf connective tissue growth factor 1562.03 1121.93 68.87 32.78
Cyp26b1 cytochrome P450, family 26, subfamily b, polypeptide 1 228.05 216.17 7.11 2.18
Ehd3 EH-domain containing 3 335.34 257.89 35.29 28.12
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 114.74 91.63 6.59 1.51
Epdr1 ependymin related 1 78.10 53.63 10.73 8.34
Fam134b family with sequence similarity 134, member B 219.76 184.81 17.42 4.41
Fam25a family with sequence similarity 25, member A 210.52 129.46 6.87 4.86
Gadd45g growth arrest and DNA-damage-inducible, gamma 915.00 747.80 111.74 65.34
Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 479.19 443.48 15.04 1.72
Gnat2 guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide 2 115.07 94.43 0.38 0.29
Grem1 gremlin 1 103.82 84.95 4.44 2.83
Hopx HOP homeobox 415.16 372.91 33.35 20.48
Inhba inhibin beta-A 1234.68 972.39 37.05 24.34
Irx4 iroquois homeobox 4 35.59 38.50 0.14 0.10
Itgb5 integrin, beta 5 566.31 459.64 53.43 20.75
Itgbl1 integrin, beta-like 1 286.33 219.40 14.49 21.29
Kcnmb4 potassium large conductance calcium-activated channel, subfamily M, beta member 4 3.77 1.19 0.00 0.00
Krt23 keratin 23 (histone deacetylase inducible) 46.49 56.70 3.78 3.91
Larp6 La ribonucleoprotein domain family, member 6 49.58 37.18 3.57 1.68
LOC680549 PBX/knotted 1 homeobox 2 55.93 41.23 6.10 4.93
LOC682105 receptor accessory protein 2 85.90 69.12 8.27 1.31
Map1a microtubule-associated protein 1A 105.65 83.02 10.71 6.47
Mfap5 microfibrillar associated protein 5 92.69 69.59 9.37 8.18
Mfsd12 major facilitator superfamily domain containing 12 256.78 221.05 19.71 4.57
Mgp matrix Gla protein 508.86 346.75 89.38 73.40
Mrgprg MAS-related GPR, member G 79.26 93.25 0.20 0.34
Mustn1 musculoskeletal, embryonic nuclear protein 1 618.94 531.20 45.31 32.81
Nbl1 neuroblastoma 1, DAN family BMP antagonist 1771.85 1383.23 116.24 57.97
Nkd2 naked cuticle homolog 2 (Drosophila) 66.57 72.34 4.64 6.11
Nox4 NADPH oxidase 4 67.01 59.69 5.38 1.18
Npr2 natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B) 34.07 23.58 4.51 1.13
Olig1 oligodendrocyte transcription factor 1 4.03 3.18 0.12 0.09
Pde4dip phosphodiesterase 4D interacting protein 101.42 82.96 13.21 3.40
Pea15 phosphoprotein enriched in astrocytes 15 571.28 443.95 65.53 6.03
Pgf placental growth factor 752.54 615.73 9.08 3.96
Pkp1 plakophilin 1 59.31 49.85 1.17 0.91
Pla2g16 phospholipase A2, group XVI 247.85 177.76 36.28 28.46
Plk2 polo-like kinase 2 347.65 246.92 49.71 12.24
Ppp1r14c protein phosphatase 1, regulatory (inhibitor) subunit 14c 31.69 28.48 3.16 1.96
Pqlc3 PQ loop repeat containing 3 73.78 52.78 12.09 8.39
Praf2 PRA1 domain family, member 2 214.85 136.42 31.82 9.12
Prdm1 PR domain containing 1, with ZNF domain 66.53 50.45 8.04 4.38
Prl7d1 prolactin family 7, subfamily d, member 1 39.70 63.54 2.37 1.48
Procr protein C receptor, endothelial 85.61 75.90 7.46 1.86
Pros1 protein S (alpha) 103.77 79.71 13.46 7.53
Prss35 protease, serine, 35 26.84 27.76 0.76 0.27
Ramp3 receptor (G protein-coupled) activity modifying protein 3 624.16 692.21 35.15 30.65
Rasd1 RAS, dexamethasone-induced 1 216.96 206.58 19.31 10.70
RGD1563441 similar to RIKEN cDNA A030009H04 4.70 3.29 0.04 0.07
Rtn4rl1 reticulon 4 receptor-like 1 41.76 49.66 2.59 0.76
S100a4 S100 calcium-binding protein A4 624.60 421.62 33.96 17.13
Scg5 secretogranin V (7B2 protein) 58.11 52.30 1.79 1.81
Sema3b (semaphorin) 3B 206.03 188.52 4.77 1.72
Sema3e (semaphorin) 3E 23.59 18.12 3.20 1.50
Sipa1l2 signal-induced proliferation-associated 1 like 2 68.27 40.93 11.78 5.50
Slc29a1 solute carrier family 29 (equilibrative nucleoside transporter), member 1 154.98 129.23 7.42 3.43
Slc5a6 solute carrier family 5 (sodium/multivitamin and iodide cotransporter), member 6 103.83 80.92 10.30 4.20
Slc6a12 solute carrier family 6 (neurotransmitter transporter), member 12 824.03 675.56 6.65 4.52
Slc6a6 solute carrier family 6 (neurotransmitter transporter), member 6 139.81 93.01 17.11 8.51
Smoc2 SPARC related modular calcium binding 2 56.00 76.77 4.85 2.62
St8sia2 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 2.77 4.80 0.00 0.00
Stmn4 stathmin-like 4 57.94 54.63 5.33 3.77
Tac1 tachykinin, precursor 1 9.63 8.51 0.00 0.00
Tgfb2 transforming growth factor, beta 2 171.44 142.67 12.88 12.22
Tgfb3 transforming growth factor, beta 3 1372.94 1188.02 40.26 6.08
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Tmeff1 transmembrane protein with EGF-like and two follistatin-like domains 1 11.41 10.34 0.04 0.05
Tmem204 transmembrane protein 204 200.68 162.41 7.27 3.44
Tnfaip2 tumor necrosis factor, alpha-induced protein 2 83.77 67.43 8.83 4.41
Tnfaip8 tumor necrosis factor, alpha-induced protein 8 47.03 24.75 9.66 2.32
Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b 130.76 102.38 15.86 9.11
Trpc4 transient receptor potential cation channel, subfamily C, member 4 25.84 19.51 1.19 0.80
Tshz3 teashirt zinc finger homeobox 3 19.48 14.80 2.40 0.77
Tspan5 tetraspanin 5 95.74 67.25 15.71 7.08
Uap1 UDP-N-acteylglucosamine pyrophosphorylase 1 62.65 41.35 12.85 2.85
Uck2 uridine-cytidine kinase 2 201.50 164.04 8.40 2.43
Usp53 ubiquitin specific peptidase 53 57.82 47.14 7.09 5.15
Vamp5 vesicle-associated membrane protein 5 19.01 13.90 0.36 0.53
Vldlr very low density lipoprotein receptor 123.50 110.20 9.57 2.77
Wfdc1 WAP four-disulfide core domain 1 577.72 535.36 11.82 10.67
Wt1 Wilms tumor 1 61.54 46.12 7.09 2.80
Table D.8: Genes that were differentially expressed in the outer myometrium com-
pared to the inner myometrium on GD22(NL). Transcript expression levels are shown in
transcripts per million values (mean±SD).
Inner myometrium Outer myometrium
Gene
symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Aass aminoadipate-semialdehyde synthase 0.00 0.00 3.50 4.38
Acadm acyl-CoA dehydrogenase, C-4 to C-12 straight chain 10.04 5.15 82.00 62.41
Acot4 acyl-CoA thioesterase 4 4.64 6.51 21.26 23.04
Acsl1 acyl-CoA synthetase long-chain family member 1 3.98 1.18 49.13 67.79
Acsm5 acyl-CoA synthetase medium-chain family member 5 0.00 0.00 2.70 4.68
Ahsg alpha-2-HS-glycoprotein 2.99 4.87 1290.62 2231.35
Aldh1a1 aldehyde dehydrogenase 1 family, member A1 0.00 0.00 13.84 11.51
Aldh1a7 aldehyde dehydrogenase family 1, subfamily A7 0.02 0.04 9.44 9.53
Aldh2 aldehyde dehydrogenase 2 family (mitochondrial) 24.87 8.28 99.32 47.79
Alox15b arachidonate 15-lipoxygenase, type B 0.00 0.00 6.34 8.35
Als2cr12 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 12 0.00 0.00 4.59 6.03
Amdhd1 amidohydrolase domain containing 1 0.01 0.02 11.24 19.04
Amy1a amylase, alpha 1A (salivary) 0.00 0.00 6.14 10.62
Apcs amyloid P component, serum 0.00 0.00 28.50 49.18
Apoa1 apolipoprotein A-I 2.43 3.93 1327.79 1142.31
Apoa4 apolipoprotein A-IV 7.88 13.51 432.20 376.34
Aspdh aspartate dehydrogenase domain containing 0.00 0.00 30.44 52.32
Bhmt betaine-homocysteine S-methyltransferase 1.04 1.40 236.57 407.41
Bspry B-box and SPRY domain containing 0.21 0.29 15.94 16.72
C3 complement component 3 11.78 14.87 1199.02 1226.91
C9 complement component 9 0.07 0.03 5.34 8.19
Camp cathelicidin antimicrobial peptide 0.00 0.00 37.38 64.73
Ceacam1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 4.95 2.69 55.77 36.10
Cfhr1 complement factor H-related 1 0.00 0.00 5.63 9.20
Cfi complement factor I 2.19 1.94 48.20 53.03
Ckmt1b creatine kinase, mitochondrial 1B 0.34 0.51 19.76 13.85
Clca4 chloride channel accessory 4 0.20 0.10 7.93 6.15
Cldn1 claudin 1 1.31 1.20 20.50 25.59
Cldn8 claudin 8 0.00 0.00 4.29 5.87
Col2a1 collagen, type II, alpha 1 0.05 0.05 8.56 14.79
Cpamd8 C3 and PZP-like, alpha-2-macroglobulin domain containing 8 0.00 0.00 11.58 19.93
Crp C-reactive protein, pentraxin-related 0.00 0.00 23.28 40.33
Cubn cubilin (intrinsic factor-cobalamin receptor) 0.76 0.87 25.73 21.78
Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 0.00 0.00 4.99 5.35
Cyp2b2 cytochrome P450, family 2, subfamily b, polypeptide 2 0.00 0.00 3.90 3.83
Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 0.02 0.01 2.68 4.16
Cyp2c12 cytochrome P450, family 2, subfamily c, polypeptide 12 0.00 0.00 5.90 9.84
Cyp4a8 cytochrome P450, family 4, subfamily a, polypeptide 8 8.34 6.93 85.73 103.28
Cyp7a1 cytochrome P450, family 7, subfamily a, polypeptide 1 0.13 0.00 12.58 21.00
Cyp8b1 cytochrome P450, family 8, subfamily b, polypeptide 1 0.00 0.00 35.09 60.67
Dcdc2 doublecortin domain containing 2 1.28 0.86 18.15 13.93
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Defa defensin alpha 0.00 0.00 76.90 132.33
Dhcr24 24-dehydrocholesterol reductase 1.00 1.02 42.97 56.93
Dpy19l3 dpy-19-like 3 (C. elegans) 2.92 2.02 13.84 8.78
Ehf ets homologous factor 0.03 0.06 29.02 34.55
Ehhadh enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase 1.31 1.46 21.25 16.87
Elf3 E74-like factor 3 2.65 3.07 70.44 73.54
Emp1 epithelial membrane protein 1 21.37 5.48 191.08 170.45
Etnk2 ethanolamine kinase 2 0.01 0.01 4.38 7.04
Eya2 eyes absent homolog 2 (Drosophila) 0.15 0.20 37.63 37.38
Fam84a family with sequence similarity 84, member A 0.04 0.05 3.90 2.47
Fcer2 Fc fragment of IgE, low affinity II, receptor for (CD23) 0.77 1.07 3.65 5.74
Fgb fibrinogen beta chain 1.40 2.16 651.41 993.37
Fgg fibrinogen gamma chain 1.81 2.45 797.41 1172.83
Fgl1 fibrinogen-like 1 0.00 0.00 18.93 32.71
Glrx glutaredoxin (thioltransferase) 14.09 7.43 135.84 123.07
Gpc3 glypican 3 2.87 3.95 44.34 31.72
Gpr151 G protein-coupled receptor 151 0.00 0.00 2.57 4.35
Gpx2 glutathione peroxidase 2 6.70 11.45 160.81 81.14
Grik2 glutamate receptor, ionotropic, kainate 2 0.02 0.04 6.42 2.72
Gucy2c guanylate cyclase 2C 0.47 0.46 11.04 8.82
H6pd hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) 8.63 3.03 40.43 29.93
Haao 3-hydroxyanthranilate 3,4-dioxygenase 0.00 0.00 17.24 29.68
Hao1 hydroxyacid oxidase (glycolate oxidase) 1 0.00 0.00 10.21 17.58
Hdc histidine decarboxylase 0.70 0.71 212.31 366.46
Hemgn hemogen 1.12 1.68 55.11 91.97
Hgfac HGF activator 0.07 0.12 23.55 23.19
Hnf4a hepatocyte nuclear factor 4, alpha 0.27 0.44 36.88 22.69
Hp haptoglobin 9.33 11.73 511.81 885.89
Igfals insulin-like growth factor binding protein, acid labile subunit 0.00 0.00 4.22 5.21
Il24 interleukin 24 0.00 0.00 2.37 2.59
Itih4 inter-alpha-trypsin inhibitor heavy chain family, member 4 1.13 0.81 55.77 96.37
Kap kidney androgen regulated protein 18.99 31.19 1514.85 999.61
Kif23 kinesin family member 23 1.61 1.23 26.13 22.56
Klkb1 kallikrein B, plasma 1 0.00 0.00 16.45 28.23
Kntc1 kinetochore associated 1 0.74 0.47 5.68 3.53
Lad1 ladinin 1 9.33 15.34 149.58 221.93
Lamb3 laminin, beta 3 0.08 0.08 22.91 17.10
Lcn12 lipocalin 12 0.00 0.01 3.97 6.62
Lgals12 lectin, galactoside-binding, soluble, 12 0.08 0.02 4.37 4.30
Lgr5 leucine rich repeat containing G protein coupled receptor 5 0.02 0.02 4.06 4.83
LOC500797 mitotic spindle positioning 0.15 0.07 24.58 20.86
Lpcat4 lysophosphatidylcholine acyltransferase 4 9.85 4.31 67.64 67.55
Lpo lactoperoxidase 1.03 0.85 99.94 125.95
Lrp2 low density lipoprotein receptor-related protein 2 1.06 0.62 17.89 15.16
Lypd6b LY6/PLAUR domain containing 6B 0.23 0.15 5.67 4.55
Macc1 metastasis associated in colon cancer 1 0.02 0.02 4.52 3.27
Mfi2 antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5 0.14 0.06 29.61 25.59
Mug2 murinoglobulin 2 0.02 0.03 4.06 7.02
Myh14 myosin, heavy chain 14, non-muscle 0.59 0.33 40.59 36.09
Mylk2 myosin light chain kinase 2 0.00 0.00 3.16 5.46
Npbwr1 neuropeptides B/W receptor 1 0.02 0.03 21.42 27.19
Nr1i2 nuclear receptor subfamily 1, group I, member 2 0.00 0.00 6.49 11.16
Olr1662 olfactory receptor 1662 0.11 0.12 81.48 140.60
Olr1748 olfactory receptor 1748 0.00 0.00 0.00 0.00
Olr299 olfactory receptor 299 0.00 0.00 45.82 79.37
Oxt oxytocin/neurophysin 1 prepropeptide 15.25 23.58 1094.37 1644.29
Pah phenylalanine hydroxylase 0.00 0.00 27.06 46.80
Pla2g4c phospholipase A2, group IVC 0.00 0.00 4.57 4.58
Plg plasminogen 1.14 1.10 202.16 329.93
Ppl periplakin 4.80 6.72 46.99 34.96
Prodh2 proline dehydrogenase (oxidase) 2 0.00 0.00 21.12 36.49
Prom1 prominin 1 3.62 3.47 105.22 100.68
Prox1 prospero homeobox 1 1.83 1.36 26.74 41.19
Ptgs1 prostaglandin-endoperoxide synthase 1 2.84 1.79 45.52 44.58
Pzp pregnancy-zone protein 0.93 0.35 127.17 219.61
Rab11fip4 RAB11 family interacting protein 4 (class II) 0.12 0.05 6.95 3.63
Rbp4 retinol binding protein 4, plasma 1.62 1.80 593.30 896.31
RGD1309313 transmembrane protein 180 4.68 3.44 53.18 40.76
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RGD1310507 similar to RIKEN cDNA 1300017J02 5.20 5.95 133.95 103.79
RGD1559600 RGD1559600 0.00 0.00 10.97 18.78
RGD1564614 similar to complement factor H-related protein 0.06 0.07 6.67 11.20
Rtp3 receptor (chemosensory) transporter protein 3 0.72 0.57 21.09 20.82
S100a9 S100 calcium binding protein A9 5.41 4.32 157.30 267.66
Scnn1a sodium channel, nonvoltage-gated 1 alpha 4.93 6.80 63.50 75.41
Serpina1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 2.88 4.83 1295.37 2065.82
member 1
Serpina3k serine (or cysteine) peptidase inhibitor clade A member 3K 0.00 0.00 169.13 292.60
Serpinb11 serpin peptidase inhibitor, clade B (ovalbumin), member 11 0.00 0.00 1.51 1.20
Slc16a14 solute carrier family 16, member 14 0.71 0.40 28.20 33.75
Slc17a1 solute carrier family 17 (organic anion transporter), member 1 0.00 0.00 3.70 6.08
Slc17a3 solute carrier family 17 (organic anion transporter), member 3 0.04 0.04 1.74 2.21
Slc26a3 solute carrier family 26 (anion exchanger), member 3 0.00 0.00 3.36 2.23
Slc30a10 solute carrier family 30, member 10 0.00 0.00 6.05 10.27
Slc34a2 solute carrier family 34 (type II sodium/phosphate contransporter), 0.96 1.30 24.89 23.72
member 2
Slc36a2 solute carrier family 36 (proton/amino acid symporter), member 2 0.05 0.06 3.36 5.66
Slc4a1 solute carrier family 4 (anion exchanger), member 1 3.65 4.40 92.03 153.87
Slc5a1 solute carrier family 5 (sodium/glucose cotransporter), member 1 0.00 0.00 2.26 3.41
Slc6a14 solute carrier family 6 (amino acid transporter), member 14 0.02 0.03 5.53 4.79
Slco1a1 solute carrier organic anion transporter family, member 1a1 0.00 0.00 2.91 4.91
Spp2 secreted phosphoprotein 2 2.27 3.53 166.71 195.06
Stard4 StAR-related lipid transfer (START) domain containing 4 1.68 1.06 12.40 4.39
Sult1b1 sulfotransferase family, cytosolic, 1B, member 1 0.00 0.00 6.82 9.63
Tfcp2l1 transcription factor CP2-like 1 1.87 0.43 8.81 1.55
Tmc4 transmembrane channel-like 4 5.07 7.67 62.03 69.32
Tmem171 transmembrane protein 171 0.03 0.04 12.98 11.29
Tppp3 tubulin polymerization-promoting protein family member 3 8.12 8.38 193.38 163.72
Tspan1 tetraspanin 1 0.20 0.34 67.06 39.29
Ttpa tocopherol (alpha) transfer protein 0.00 0.00 8.13 10.52
Ugt1a1 UDP glucuronosyltransferase 1 family, polypeptide A1 0.06 0.08 7.75 9.17
Ugt1a5 UDP glucuronosyltransferase 1 family, polypeptide A5 0.06 0.07 23.36 39.08
Ugt1a7c UDP glucuronosyltransferase 1 family, polypeptide A7C 1.80 2.36 49.66 42.40
Ugt2b1 UDP glucuronosyltransferase 2 family, polypeptide B1 0.00 0.00 3.36 5.80
Ugt8 UDP glycosyltransferase 8 0.00 0.00 2.18 2.87
Upk1b uroplakin 1B 1.75 0.90 26.98 14.78
Ush1c Usher syndrome 1C 0.00 0.00 4.20 6.12
Usp43 predicted ubiquitin specific peptidase 43 0.04 0.07 9.24 9.55
Vnn3 vanin 3 0.00 0.00 1.97 3.32
Vom2r34 vomeronasal 2 receptor, 34 8.51 1.50 221.27 337.86
Vtn vitronectin 2.20 1.63 196.99 333.38
Wnt7a wingless-type MMTV integration site family, member 7A 0.24 0.15 11.54 9.93
Zfhx4 zinc finger homeobox 4 0.16 0.03 1.56 1.11
Dmbt1 deleted in malignant brain tumors 1 0.64 0.51 18.86 13.45
Cuzd1 CUB and zona pellucida-like domains 1 3.16 4.53 492.78 409.84
Gabrp gamma-aminobutyric acid (GABA-A) receptor, pi 0.00 0.00 3.76 4.09
Alcam activated leukocyte cell adhesion molecule 5.57 2.35 86.39 83.80
Pigr polymeric immunoglobulin receptor 0.22 0.22 55.40 69.41
F5 coagulation factor V (proaccelerin, labile factor) 1.34 0.48 39.50 32.53
Lrrc66 leucine rich repeat containing 66 0.00 0.00 2.23 0.85
Adcy1 adenylate cyclase 1 (brain) 0.17 0.20 2.88 2.72
Fignl1 fidgetin-like 1 0.01 0.02 1.26 0.73
Thrb thyroid hormone receptor beta 3.04 1.85 18.52 11.57
Adam28 ADAM metallopeptidase domain 28 0.00 0.00 2.68 2.07
Cndp1 carnosine dipeptidase 1 (metallopeptidase M20 family) 1.35 0.80 35.15 22.93
Cdh16 cadherin 16 0.00 0.00 12.25 12.69
Fa2h fatty acid 2-hydroxylase 0.01 0.02 3.28 1.53
Galnt5 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 0.00 0.00 1.76 1.06
N-acetylgalactosaminyltransferase 5 (GalNAc-T5)
Myo3b myosin IIIB 0.10 0.13 1.99 1.89
Cldn2 claudin 2 3.34 5.26 135.04 114.17
Cftr cystic fibrosis transmembrane conductance regulator 0.14 0.17 22.54 29.22
Tmem88b transmembrane protein 88B 0.84 0.36 4.62 1.99
Slc26a4 solute carrier family 26 (anion exchanger), member 4 0.73 0.80 69.38 68.87
Gnat1 guanine nucleotide binding protein (G protein), 0.00 0.00 4.64 0.69
alpha transducing activity polypeptide 1
Rab17 RAB17, member RAS oncogene family 0.04 0.04 17.60 13.99
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Mal2 mal, T-cell differentiation protein 2 0.55 0.79 32.51 32.69
Down-regulated genes
Ccdc82 coiled-coil domain containing 82 17.74 21.28 1.95 0.68
Ebf3 early B-cell factor 3 18.63 21.52 1.02 0.79
Htr2a 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled 86.91 148.90 3.04 1.75
Kctd15 potassium channel tetramerization domain containing 15 167.92 261.06 9.16 7.71
LOC685544 hypothetical protein LOC685544 106.53 184.51 0.17 0.16
LOC686999 M phase phosphoprotein 6 78.19 90.38 10.76 2.21
Lrrc63 leucine rich repeat containing 63 12.33 20.81 0.02 0.02
Nudt18 nudix (nucleoside diphosphate linked moiety X)-type motif 18 54.02 74.12 4.11 1.79
Syt13 synaptotagmin XIII 8.71 14.99 0.03 0.02
Tatdn3 TatD DNase domain containing 3 61.33 66.95 6.76 4.98
Tnn tenascin N 61.51 30.36 5.69 4.16
Tssk6 testis-specific serine kinase 6 42.14 72.99 0.02 0.03
Prl7a3 prolactin family 7, subfamily a, member 3 153.98 51.71 20.37 21.81
D.4 GD22(L)
Table D.9: Gene transcripts that were differentially expressed in the inner my-
ometrium compared to the decidua on GD22(L). Transcript expression levels are shown
in transcripts per million (TPM) values (mean±SD).
Decidua Inner myometrium
Gene
symbol Gene name TPM ±SD TPM ±SD
Upregulated in inner myometrium
Upk1b uroplakin 1B 0.00 0.00 84.52 119.01
Msr1 macrophage scavenger receptor 1 0.00 0.00 15.22 0.72
C3ar1 complement component 3a receptor 1 0.00 0.00 11.69 10.15
LOC300308 similar to hypothetical protein 4930509O22 0.00 0.00 4.67 2.87
Tmem182 transmembrane protein 182 0.03 0.04 0.12 0.03
Lrguk leucine-rich repeats and guanylate kinase domain containing 0.04 0.06 9.29 11.01
Ctse cathepsin E 0.06 0.02 10.10 0.95
Pla2g2a phospholipase A2, group IIA (platelets, synovial fluid) 0.13 0.18 51.29 27.03
Trpc3 transient receptor potential cation channel, subfamily C, member 3 1.20 0.33 30.75 40.68
Down-regulated in inner myometrium
Khdrbs2 KH domain containing, RNA binding, signal transduction associated 2 16.46 22.61 0.71 0.03
St8sia3 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 17.21 24.34 0.00 0.00
Plin1 perilipin 1 21.91 30.52 0.33 0.23
Sfrp2 secreted frizzled-related protein 2 23.45 9.83 1.92 0.36
Fabp7 fatty acid binding protein 7, brain 26.75 36.60 0.06 0.08
B3gat1 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) 27.82 39.35 0.00 0.00
Scg3 secretogranin III 31.24 44.18 0.00 0.00
S100a3 S100 calcium binding protein A3 31.47 12.25 0.15 0.21
Fezf2 Fez family zinc finger 2 31.53 44.59 0.05 0.04
Map2 microtubule-associated protein 2 31.80 35.73 0.35 0.28
Ankrd34a ankyrin repeat domain 34A 39.62 49.23 6.76 7.28
Cpa3 carboxypeptidase A3, mast cell 45.50 64.34 0.01 0.01
Vamp5 vesicle-associated membrane protein 5 49.68 56.04 1.11 0.51
Cma1 chymase 1, mast cell 51.79 73.24 0.04 0.05
Sec1 secretory blood group 1 52.51 74.26 0.00 0.00
Nrsn2 neurensin 2 52.59 74.37 0.01 0.01
Gng3 guanine nucleotide binding protein (G protein), gamma 3 69.26 82.49 0.28 0.21
Rln1 relaxin 1 78.52 111.05 0.01 0.01
Stfa3 stefin A3 81.53 113.02 2.95 0.49
Crmp1 collapsin response mediator protein 1 90.47 127.49 0.03 0.04
Continued on next page
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Decidua Inner myometrium
Gene
symbol Gene name TPM ±SD TPM ±SD
Stmn2 stathmin-like 2 93.83 132.69 0.00 0.00
Alb albumin 121.74 60.53 1.51 0.87
Aqp5 aquaporin 5 121.83 172.20 0.00 0.00
Trh thyrotropin releasing hormone 188.66 66.99 0.92 0.23
Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 313.84 258.39 11.70 6.30
S100a4 S100 calcium-binding protein A4 525.50 638.03 13.55 9.65
Table D.10: Gene transcripts that were differentially expressed in the outer my-
ometrium compared to the decidua on GD22(L). Transcript expression levels are shown
in transcripts per million (TPM) values (mean±SD)
Gene Decidua Outer myometrium
symbol Gene name TPM ±SD TPM ±SD
Upregulated in outer myometrium
Cuzd1 CUB and zona pellucida-like domains 1 1.83 2.28 483.46 526.98
Mmp7 matrix metallopeptidase 7 0.05 0.07 121.68 79.93
Slc26a4 solute carrier family 26 (anion exchanger), member 4 0.05 0.08 119.61 138.16
Cxcl17 chemokine (C-X-C motif) ligand 17 0.00 0.00 96.32 126.04
Pck1 phosphoenolpyruvate carboxykinase 1 (soluble) 1.24 0.46 42.93 31.50
Myh14 myosin, heavy chain 14, non-muscle 2.64 0.24 40.26 30.07
Slc44a4 solute carrier family 44, member 4 0.06 0.08 34.99 2.65
Trpc3 transient receptor potential cation channel, subfamily C, member 3 1.20 0.33 28.15 33.60
Slc16a14 solute carrier family 16, member 14 0.43 0.16 26.79 33.08
RGD1563547 small integral membrane protein 22 0.12 0.11 23.40 11.27
Akr1cl aldo-keto reductase family 1, member C-like 0.00 0.00 22.86 29.97
B3gnt3 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 0.14 0.20 22.62 23.60
Wisp2 WNT1 inducible signaling pathway protein 2 0.00 0.00 22.22 29.01
Mep1a meprin 1 alpha 0.00 0.00 21.09 29.83
Rgn regucalcin 0.03 0.04 20.58 25.92
Chi3l1 chitinase 3-like 1 (cartilage glycoprotein-39) 0.00 0.00 20.57 25.35
Slc26a3 solute carrier family 26 (anion exchanger), member 3 0.00 0.00 19.92 25.56
G6pc glucose-6-phosphatase, catalytic subunit 0.00 0.00 19.04 19.56
Cyp2c23 cytochrome P450, family 2, subfamily c, polypeptide 23 0.02 0.03 17.61 20.70
Upk1b uroplakin 1B 0.00 0.00 17.54 24.20
Ehf ets homologous factor 0.05 0.07 17.40 19.87
Bhmt2 betaine-homocysteine S-methyltransferase 2 0.00 0.00 17.18 23.55
Ccdc65 coiled-coil domain containing 65 0.00 0.00 16.02 22.56
Cbs cystathionine beta synthase 0.00 0.00 15.36 20.26
Them6 thioesterase superfamily member 6 0.10 0.01 15.18 1.01
P2ry6 pyrimidinergic receptor P2Y, G-protein coupled, 6 0.13 0.03 15.11 19.07
Cacna1c calcium channel, voltage-dependent, L type, alpha 1C subunit 0.11 0.03 14.66 14.40
Tmprss4 transmembrane protease, serine 4 0.03 0.04 14.21 0.87
Igsf5 immunoglobulin superfamily, member 5 0.01 0.02 13.83 12.27
Klkb1 kallikrein B, plasma 1 0.02 0.03 13.56 6.60
Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1 0.00 0.00 13.38 17.11
Itih4 inter-alpha-trypsin inhibitor heavy chain family, member 4 0.00 0.00 12.66 11.04
Clec7a C-type lectin domain family 7, member A 0.51 0.20 12.22 12.86
Lingo4 leucine rich repeat and Ig domain containing 4 0.29 0.08 9.56 11.84
Down-regulated in outer myometrium
Atp2a3 ATPase, Ca++ transporting, ubiquitous 0.00 0.00 7.94 0.01
C8b complement component 8, beta polypeptide 0.00 0.00 7.80 3.55
Emr1 EGF-like module containing, mucin-like, hormone receptor-like 1 0.00 0.00 6.81 7.74
Khdrbs2 KH domain containing, RNA binding, signal transduction associated 2 16.46 22.61 0.51 0.18
Nefl neurofilament, light polypeptide 75.27 106.36 0.30 0.24
Map2 microtubule-associated protein 2 31.80 35.73 0.23 0.24
Nell2 NEL-like 2 (chicken) 31.91 42.68 0.11 0.01
Tmem182 transmembrane protein 182 0.03 0.04 0.10 0.03
Actn3 actinin alpha 3 36.52 51.06 0.09 0.12
Sln sarcolipin 98.09 138.64 0.05 0.02
Ebf2 early B-cell factor 2 12.64 17.83 0.05 0.01
Nrsn2 neurensin 2 52.59 74.37 0.05 0.07
Sec1 secretory blood group 1 52.51 74.26 0.00 0.00
Rln1 relaxin 1 78.52 111.05 0.00 0.00
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Gene Decidua Outer myometrium
symbol Gene name TPM ±SD TPM ±SD
Myog myogenin 110.43 156.11 0.00 0.00
Adprhl1 ADP-ribosylhydrolase like 1 23.25 32.87 0.00 0.00
B3gat1 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) 27.82 39.35 0.00 0.00
Trpc5 transient receptor potential cation channel, subfamily C, member 5 12.93 18.28 0.00 0.00
S100a3 S100 calcium binding protein A3 31.47 12.25 0.00 0.00
Table D.11: Gene transcripts that were differentially expressed in the outer my-
ometrium compared to the inner myometrium on GD22 (L). Transcript expression levels
are shown in transcripts per million (TPM) values (mean±SD).
Gene Inner Outer
symbol Gene name TPM ±SD TPM ±SD
Upregulated in outer myometrium
Alb albumin 1.51 0.87 1558.24 1728.57
Cuzd1 CUB and zona pellucida-like domains 1 6.24 8.65 483.46 526.98
Ahsg alpha-2-HS-glycoprotein 0.69 0.42 346.92 343.38
Mmp7 matrix metallopeptidase 7 1.29 1.23 121.68 79.93
Serpina3k serine (or cysteine) peptidase inhibitor, clade A, member 3K 0.00 0.00 61.88 80.69
Fabp1 fatty acid binding protein 1, liver 0.22 0.11 36.87 38.24
Hdc histidine decarboxylase 0.00 0.00 36.33 28.05
Lgals4 lectin, galactoside-binding, soluble, 4 0.00 0.00 26.44 37.39
Prap1 proline-rich acidic protein 1 0.01 0.01 23.03 32.57
B3gnt3 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 0.07 0.10 22.62 23.60
Hpd 4-hydroxyphenylpyruvate dioxygenase 0.00 0.00 18.19 13.90
LOC299282 Serine protease inhibitor 0.12 0.02 17.42 23.54
Bhmt2 betaine-homocysteine S-methyltransferase 2 0.00 0.01 17.18 23.55
Apoc4 apolipoprotein C-IV 0.03 0.05 16.12 7.00
Fgl1 fibrinogen-like 1 0.01 0.01 16.02 22.66
Anxa13 annexin A13 0.00 0.00 15.44 21.83
Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 0.03 0.04 14.99 17.37
Klkb1 kallikrein B, plasma 1 0.01 0.02 13.56 6.60
Cpb2 carboxypeptidase B2 (plasma) 0.15 0.01 13.49 9.25
Tfr2 transferrin receptor 2 0.02 0.03 12.58 12.92
Azgp1 alpha-2-glycoprotein 1, zinc-binding 0.00 0.00 12.53 16.27
Aqp9 aquaporin 9 2.10 0.08 11.67 5.24
Itih1 inter-alpha trypsin inhibitor, heavy chain 1 0.00 0.00 11.65 16.08
Clca1 chloride channel accessory 1 0.01 0.01 11.52 16.29
Pah phenylalanine hydroxylase 0.00 0.00 10.31 12.29
Cytl1 cytokine like 1 0.01 0.01 9.25 13.09
C8b complement component 8, beta polypeptide 0.00 0.00 7.80 3.55
Bucs1 acyl-CoA synthetase medium-chain family member 1 0.02 0.02 7.43 9.98
Down-regulated in outer myometrium
Acan aggrecan 26.33 37.11 0.07 0.01
Hapln1 hyaluronan and proteoglycan link protein 1 51.51 72.68 0.02 0.02
D.5 Temporal Expression of Transcripts in Control Tis-
sues
Table D.12: Gene transcripts that were differentially expressed in the decidua, between
GD20 and GD22(NL). Transcript expression levels are shown in transcripts per million (TPM)
values (mean±SD).
Gene GD20 GD22(NL)
symbol Gene name TPM ±SD TPM ±SD
Continued on next page
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Gene GD20 GD22 (NL)
symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD22 (NL)
Chac1 ChaC, cation transport regulator homolog 1 (E. coli) 0.05 0.09 7.16 3.18
Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 1.43 1.13 30.73 6.24
Cpe carboxypeptidase E 46.27 38.46 794.87 666.43
Gadd45a growth arrest and DNA-damage-inducible, alpha 21.27 15.72 245.03 73.24
Gngt2 guanine nucleotide binding protein (G protein), 0.00 0.00 7.14 4.48
gamma transducing activity polypeptide 2
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 8.42 8.23 107.34 93.98
Il1rl1 interleukin 1 receptor-like 1 0.66 1.05 21.84 30.81
Pigv phosphatidylinositol glycan anchor biosynthesis, class V 2.71 2.30 5.56 0.65
Plk2 polo-like kinase 2 12.99 16.54 347.65 246.92
Ramp3 receptor (G protein-coupled) activity modifying protein 3 7.65 11.15 624.16 692.21
Slc7a7 solute carrier family 7 (amino acid transporter light chain, y+L system), 4.49 1.55 50.55 34.04
member 7
Sox4 SRY (sex determining region Y)-box 4 9.61 8.67 83.89 50.35
Down-regulated on GD22 (NL)
Afp alpha-fetoprotein 1324.86 1254.26 1.87 2.01
Alb albumin 2322.68 4019.70 0.98 0.19
Apoa1 apolipoprotein A-I 216.98 146.74 0.71 0.59
Apoa2 apolipoprotein A-II 22.33 31.31 0.00 0.00
Apob apolipoprotein B 826.54 986.55 0.69 0.69
Apoc2 apolipoprotein C-II 33.14 29.69 0.14 0.14
Apoh apolipoprotein H (beta-2-glycoprotein I) 46.38 68.47 0.05 0.07
Ass1 argininosuccinate synthase 1 19.93 20.56 5.55 4.61
Car1 carbonic anhydrase I 57.50 99.53 0.00 0.00
Cdh1 cadherin 1 8.88 4.99 2.09 1.21
Cgm4 carcinoembryonic antigen gene family 4 220.61 181.00 12.45 12.42
Clec3a C-type lectin domain family 3, member A 7.19 12.31 0.00 0.00
Creb3l3 cAMP responsive element binding protein 3-like 3 4.57 4.03 0.62 0.34
Creg1 cellular repressor of E1A-stimulated genes 1 324.75 268.19 36.21 43.63
Cubn cubilin (intrinsic factor-cobalamin receptor) 4.19 4.59 0.14 0.03
Cyp2c22 cytochrome P450, family 2, subfamily c, polypeptide 22 25.48 44.13 0.00 0.01
Defb4 defensin beta 4 4.93 8.47 0.00 0.00
Doc2b double C2-like domains, beta 36.26 61.37 0.01 0.01
Fabp1 fatty acid binding protein 1, liver 6.86 11.72 0.00 0.00
Fga fibrinogen alpha chain 391.13 608.42 0.21 0.06
Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 35.25 42.91 12.76 7.71
Hnf4a hepatocyte nuclear factor 4, alpha 6.38 7.17 0.02 0.03
Hrsp12 heat-responsive protein 12 66.77 43.98 22.11 10.74
Klk8 kallikrein related-peptidase 8 35.05 60.72 0.00 0.01
Lypd5 Ly6/Plaur domain containing 5 31.88 55.22 0.00 0.00
Mki67 marker of proliferation Ki-67 18.94 30.58 1.85 1.26
Myf6 myogenic factor 6 23.79 41.20 0.01 0.01
Plagl1 pleiomorphic adenoma gene-like 1 22.01 31.38 2.10 2.32
Prl3b1 Prolactin family 3, subfamily b, member 1 144.12 132.01 34.85 12.31
Prl8a4 prolactin family 8, subfamily a, member 4 967.13 784.32 38.99 16.72
Psg16 pregnancy specific glycoprotein 16 50.94 45.68 3.63 2.07
Sepp1 selenoprotein P, plasma, 1 161.72 179.46 45.60 23.88
Sftpb surfactant protein B 14.24 24.45 0.00 0.00
Stfa3 stefin A3 38.29 64.79 0.98 0.32
Ttr transthyretin 165.81 155.62 0.59 0.54
Table D.13: Gene transcripts that were differentially expressed in the decidua, between
GD22(NL) and GD22(L). Transcript expression levels are shown in transcripts per million
(TPM) values (mean±SD).
GD22(NL) GD22(L)
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD22 (L)
Aard alanine and arginine rich domain containing protein 0.10 0.02 13.55 18.75
Abi3 ABI family, member 3 4.39 0.85 222.75 308.93
Adrb3 adrenoceptor beta 3 0.01 0.02 6.62 9.36
Alb albumin 0.98 0.19 121.74 60.53
Continued on next page
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GD22 (NL) GD22 (L)
Gene symbol Gene name TPM ±SD TPM ±SD
Angptl1 angiopoietin-like 1 0.47 0.34 32.36 45.00
Apoa2 apolipoprotein A-II 0.00 0.00 8.38 11.85
Apobec2 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 0.02 0.04 82.50 116.67
Apoh apolipoprotein H (beta-2-glycoprotein I) 0.05 0.07 22.35 28.48
Apom apolipoprotein M 0.18 0.14 133.79 188.19
Asgr1 asialoglycoprotein receptor 1 0.14 0.13 10.20 14.35
Ass1 argininisuccinate synthase 1 5.55 4.61 94.88 112.79
Cacna1s calcium channel, voltage-dependent, L type, alpha 1S subunit 0.05 0.08 6.60 9.33
Calb1 calbindin 1 0.01 0.02 6.93 9.81
Casq1 calsequestrin 1 (fast-twitch, skeletal muscle) 3.47 0.40 132.31 184.84
Cdk5r2 cyclin-dependent kinase 5, regulatory subunit 2 (p39) 0.00 0.00 15.68 22.18
Cdo1 cysteine dioxygenase type 1 1.73 0.34 100.33 125.59
Ceacam1 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 12.81 17.33 225.82 306.33
Cgm4 carcinoembryonic antigen gene family 4 12.45 12.42 736.55 925.96
Chrnd cholinergic receptor, nicotinic, delta (muscle) 0.00 0.00 5.28 7.46
Ckmt2 creatine kinase, mitochondrial 2, sarcomeric 0.00 0.01 89.98 127.25
Cldn6 claudin 6 2.26 0.14 51.10 69.03
Clec3a C-type lectin domain family 3, member A 0.00 0.00 8.54 12.07
Clstn3 calsyntenin 3 0.08 0.14 13.42 18.97
Cma1 chymase 1, mast cell 0.41 0.71 51.79 73.24
Col2a1 collagen, type II, alpha 1 0.10 0.05 34.55 48.43
Cox8b cytochrome c oxidase, subunit VIIIb 0.25 0.29 25.91 32.94
Cpn1 carboxypeptidase N, polypeptide 1 0.02 0.04 6.84 9.67
Defa defensin alpha 0.07 0.12 18.08 25.57
Dpp6 dipeptidylpeptidase 6 0.04 0.08 10.10 14.29
Dpysl5 dihydropyrimidinase-like 5 1.58 1.75 59.90 83.74
Eno3 enolase 3, beta, muscle 2.66 1.55 188.24 248.17
Epb42 erythrocyte membrane protein band 4.2 2.09 0.85 7.66 7.79
Eps8l2 EPS8-like 2 5.21 2.40 61.62 59.16
Espl1 extra spindle pole bodies homolog 1 (S. cerevisiae) 0.68 0.36 18.66 21.48
Fam5c/Brinp3 bone morphogenetic protein/retinoic acid inducible neural-specific 3 0.06 0.01 6.66 9.36
Fezf2 Fez family zinc finger 2 0.01 0.01 31.53 44.59
Fga fibrinogen alpha chain 0.21 0.06 115.82 150.55
Fgb fibrinogen beta chain 0.22 0.13 12.38 1.72
Fitm1 fat storage-inducing transmembrane protein 1 0.00 0.00 23.47 33.19
Fxyd3 FXYD domain-containing ion transport regulator 3 0.26 0.16 12.57 13.92
Gabrp gamma-aminobutyric acid (GABA-A) receptor, pi 0.00 0.00 17.14 23.83
Ggt6 gamma-glutamyl transferase 6 0.17 0.30 15.06 21.10
Gjc2 gap junction protein, gamma 2 0.01 0.02 7.95 11.25
Gng3 guanine nucleotide binding protein (G protein), gamma 3 2.14 1.31 69.26 82.49
Grxcr2 glutaredoxin, cysteine rich 2 0.01 0.01 8.31 11.75
Hand1 heart and neural crest derivatives expressed 1 4.73 1.60 137.03 150.83
Hoxb5 homeo box B5 1.04 0.71 83.47 116.62
Hspb3 heat shock protein B3 0.01 0.01 6.09 8.61
Ifnk interferon kappa 22.55 9.57 310.55 372.27
Itgb1bp2 integrin beta 1 binding protein 2 0.59 0.67 28.49 36.78
Khdrbs2 KH domain containing, RNA binding, signal transduction associated 2 0.50 0.12 16.46 22.61
Krt14 keratin 14 0.04 0.07 42.70 60.39
Krt15 keratin 15 0.01 0.01 20.35 28.77
Krt17 keratin 17 0.06 0.10 36.85 51.77
Lamp5 lysosomal-associated membrane protein family, member 5 0.00 0.01 14.90 21.07
Letm2 leucine zipper-EF-hand containing transmembrane protein 2 1.78 1.61 43.45 50.54
LOC641520/Popdc3 popeye domain containing 3 0.00 0.00 5.73 8.10
LOC685612/Col26a1 collagen, type XXVI, alpha 1 0.00 0.01 19.99 28.26
Map2 microtubule-associated protein 2 0.68 0.56 31.80 35.73
Mest mesoderm specific transcript 2.78 1.99 200.32 274.18
Mybph myosin binding protein H 0.60 0.31 43.09 54.71
Myf6 myogenic factor 6 0.01 0.01 6.47 9.14
Myl3 myosin, light chain 3, alkali; ventricular, skeletal, slow 0.04 0.03 187.19 264.73
Myl4 myosin, light chain 4 2.53 0.86 160.44 219.46
Myog myogenin 0.02 0.03 110.43 156.11
Nefl neurofilament, light polypeptide 0.47 0.76 75.27 106.36
Neurod1 neuronal differentiation 1 0.03 0.03 8.60 12.16
Nrsn2 neurensin 2 0.02 0.03 52.59 74.37
P2ry4 pyrimidinergic receptor P2Y, G-protein coupled, 4 0.00 0.00 12.03 16.82
Panx3 pannexin 3 0.02 0.03 9.82 10.13
Plekhd1 pleckstrin homology domain containing, family D 0.85 0.22 4.68 5.29
(with coiled-coil domains) member 1
Plekhh1 pleckstrin homology domain containing, family H 4.43 0.60 41.68 48.95
Continued on next page
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GD22 (NL) GD22 (L)
Gene symbol Gene name TPM ±SD TPM ±SD
(with MyTH4 domain) member 1
Pnoc prepronociceptin 0.01 0.02 10.34 14.62
Pou3f4 POU class 3 homeobox 4 0.01 0.02 7.35 10.40
Prl3a1 Prolactin family 3, subfamily a, member 1 0.00 0.00 35.52 50.23
Prl3b1 Prolactin family 3, subfamily b, member 1 34.85 12.31 888.44 1110.55
Prl3c1 Prolactin family 3, subfamily c, member 1 0.04 0.07 13.80 19.26
Prl7a4 prolactin family 7, subfamily a, member 4 9.01 13.53 114.39 112.85
Prl8a4 prolactin family 8, subfamily a, member 4 38.99 16.72 2989.87 3569.19
Prox1 prospero homeobox 1 1.09 1.09 19.76 27.11
Psg16 pregnancy specific glycoprotein 16 3.63 2.07 138.63 173.62
Psg19 pregnancy specific glycoprotein 19 27.38 18.58 645.27 621.10
Psg29 pregnancy-specific glycoprotein 29 3.08 2.60 243.08 335.75
Ptpn5 protein tyrosine phosphatase, non-receptor type 5 0.01 0.01 16.67 23.58
Rbfox1 RNA binding protein, fox-1 homolog (C. elegans) 1 2.89 1.05 13.15 13.60
Rln1 relaxin 1 0.00 0.00 78.52 111.05
Rnase13 ribonuclease, RNase A family, 13 (non-active) 0.00 0.00 4.18 5.91
Rnf144a ring finger protein 144A 2.77 0.43 64.54 76.77
Rnf208 ring finger protein 208 0.00 0.00 46.24 65.40
Rxrg retinoid X receptor gamma 0.00 0.01 12.31 17.40
Sec1 secretory blood group 1 0.00 0.01 52.51 74.26
Siah3 siah E3 ubiquitin protein ligase family member 3 0.00 0.00 21.45 30.34
Slc1a2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 0.01 0.02 9.61 13.41
Slc2a2 solute carrier family 2 (facilitated glucose transporter), member 2 0.03 0.01 19.57 26.73
Slc32a1 solute carrier family 32 (GABA vesicular transporter), member 1 0.24 0.21 6.95 9.38
Slc7a9 solute carrier family 7 (amino acid transporter light chain, bo,+ system), 0.00 0.00 6.21 8.79
member 9
Sln sarcolipin 0.36 0.41 98.09 138.64
Smpx small muscle protein, X-linked 0.00 0.00 43.94 62.14
Snhg11 small nucleolar RNA host gene 11 (non-protein coding) 2.34 1.16 7.76 7.58
Spns2 spinster homolog 2 2.94 2.31 70.62 94.74
Sptb spectrin, beta, erythrocytic 0.12 0.12 19.97 20.98
Sst somatostatin 0.05 0.02 14.12 19.94
St8sia3 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 0.00 0.00 17.21 24.34
Stfa3 stefin A3 0.98 0.32 81.53 113.02
Stmn3 stathmin-like 3 0.07 0.06 16.13 22.81
Tf transferrin 1.63 0.72 230.61 309.81
Tmem151b transmembrane protein 151B 0.00 0.00 35.60 50.34
Tnnt1 troponin T type 1 (skeletal, slow) 0.17 0.08 257.97 361.74
Tppp3 tubulin polymerization-promoting protein family member 3 1.83 1.32 71.21 92.79
Trim3 tripartite motif-containing 3 20.37 13.67 154.24 96.95
Tspyl4 TSPY-like 4 0.24 0.05 12.21 11.41
Vgll2 vestigial-like family member 2 0.00 0.01 30.08 42.54
Zfp575 zinc finger protein 575 0.01 0.02 14.47 20.47
Down-regulated on GD22 (L)
Car13 carbonic anhydrase 13 2.33 2.24 0.00 0.00
Ccdc65 coiled-coil domain containing 65 2.61 1.97 0.00 0.00
Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1 4.47 5.30 0.00 0.00
Ercc2 excision repair cross-complementation group 2 5.42 2.82 0.00 0.00
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 107.34 93.98 2.69 1.10
Nppa natriuretic peptide A 22.21 7.17 0.47 0.67
Nppb natriuretic peptide B 890.97 937.67 31.66 26.48
Nupr1l nuclear protein, transcriptional regulator, 1-like 3.36 0.99 0.03 0.03
Rnase1l1 ribonuclease, RNase A family, 1-like 1 (pancreatic) 11.86 11.55 0.00 0.00
Rnf113a1 ring finger protein 113A1 4.53 2.43 0.00 0.00
Tmem26 Tmem26 7.04 4.49 0.23 0.01
Table D.14: Gene transcripts that were differentially expressed in the inner my-
ometrium, between GD20 and GD22 (NL). Transcript expression levels are shown in tran-
scripts per million (TPM) values (mean±SD).
GD20 GD22 (NL)
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD22 (NL)
LOC685544 hypothetical protein LOC685544 0.00 0.01 106.53 184.51
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GD20 GD22 (NL)
Gene symbol Gene name TPM ±SD TPM ±SD
Angptl4 angiopoietin-like 4 5.08 8.46 148.90 145.71
Apbb1ip amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 3.47 3.34 60.28 69.49
Apod apolipoprotein D 0.20 0.25 17.56 17.10
Ccrl2 chemokine (C-C motif) receptor-like 2 0.01 0.03 6.63 8.93
Cd70 Cd70 molecule 0.00 0.01 16.60 27.92
Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 0.19 0.33 46.49 28.93
Cp ceruloplasmin (ferroxidase) 15.71 7.09 182.13 147.67
Csgalnact1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 2.00 1.41 42.79 34.06
Cst7 cystatin F (leukocystatin) 0.02 0.03 4.97 8.48
Fbln5 fibulin 5 9.18 9.11 111.98 71.43
Fcrl6 Fc receptor-like 6 4.99 4.47 105.72 104.53
G0s2 G0/G1switch 2 1.41 2.38 5.48 2.38
Htr2a 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled 3.21 3.85 86.91 148.90
Ifi204 interferon activated gene 204 11.37 2.46 151.67 157.03
Ifit3 interferon-induced protein with tetratricopeptide repeats 3 15.27 19.75 184.38 151.78
Igfbp4 insulin-like growth factor binding protein 4 16.16 22.00 191.54 123.83
Igsf10 immunoglobulin superfamily, member 10 1.10 1.18 100.94 90.15
Il33 interleukin 33 2.15 1.93 53.08 81.72
Klhl10 kelch-like family member 10 0.00 0.01 5.36 8.95
LOC686539 hypothetical protein LOC686539 11.98 12.18 175.95 115.20
Lrrc63 leucine rich repeat containing 63 0.00 0.01 12.33 20.81
Mgp matrix Gla protein 20.07 18.84 231.75 194.45
Mmp11 matrix metallopeptidase 11 58.99 63.71 2574.78 1613.84
Mmp12 matrix metallopeptidase 12 4.03 2.63 66.61 28.87
Nav3 neuron navigator 3 1.24 1.13 16.45 11.66
Ncam1 neural cell adhesion molecule 1 4.34 2.93 60.56 54.77
Neu2 sialidase 2 1.82 2.60 120.24 72.79
Nov nephroblastoma overexpressed 0.83 0.88 28.92 19.13
Nppb natriuretic peptide B 16.44 25.42 1134.81 598.98
Oasl 2’-5’-oligoadenylate synthetase-like 7.14 6.36 131.13 159.32
Pla1a phospholipase A1 member A 4.00 4.32 85.68 70.17
Prl2c1 Prolactin family 2, subfamily c, member 1 2.79 3.18 805.52 591.09
Prl5a1 prolactin family 5, subfamily a, member 1 9.59 13.49 1092.25 866.74
Prl5a2 prolactin family 5, subfamily a, member 2 31.40 32.14 1024.67 644.50
Prl7b1 prolactin family 7, subfamily b, member 1 100.18 168.57 7866.18 3998.27
RGD1562284 glutaminyl-peptide cyclotransferase 9.65 15.60 95.85 106.99
Rnase1 ribonuclease, RNase A family, 1 (pancreatic) 4.73 4.61 277.71 449.07
Sema6d sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D 15.60 10.65 342.72 385.81
Sox4 SRY (sex determining region Y)-box 4 7.56 3.47 91.46 66.89
Thbs1 thrombospondin 1 8.68 9.40 129.58 94.92
Tssk6 testis-specific serine kinase 6 0.00 0.00 42.14 72.99
Vcan versican 3.19 3.61 70.64 57.12
Zc3h10 zinc finger CCCH type containing 10 0.65 0.61 48.80 61.47
Down-regulated on GD22 (NL)
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B 448.31 578.32 7.46 9.93
Abcc4 ATP-binding cassette, subfamily C (CFTR/MRP), member 4 12.98 10.12 1.28 0.43
Adcy1 adenylate cyclase 1 (brain) 33.29 32.47 0.17 0.20
Alcam activated leukocyte cell adhesion molecule 117.22 128.91 5.57 2.35
Aldh2 aldehyde dehydrogenase 2 family (mitochondrial) 97.80 12.61 24.87 8.28
Apoa1 apolipoprotein A-I 270.94 466.59 2.43 3.93
Atp7b ATPase, Cu++ transporting, beta polypeptide 28.06 24.15 0.06 0.10
C3 complement component 3 529.32 659.41 11.78 14.87
Cdh16 cadherin 16 21.19 35.86 0.00 0.00
Cfb complement factor B 437.51 470.37 23.60 29.95
Chdh choline dehydrogenase 90.27 132.12 4.58 5.37
Cldn8 claudin 8 8.70 8.89 0.00 0.00
Col2a1 collagen, type II, alpha 1 20.34 34.51 0.05 0.05
Csf1 colony stimulating factor 1 (macrophage) 346.31 424.63 4.21 3.77
Csf3 colony stimulating factor 3 (granulocyte) 14.54 11.15 0.00 0.00
Cubn cubilin (intrinsic factor-cobalamin receptor) 12.35 19.70 0.76 0.87
Cyb561 cytochrome b-561 67.28 100.58 2.28 1.33
Defb1 defensin beta 1 12.55 12.39 0.00 0.00
Dio3 deiodinase, iodothyronine, type III 356.99 417.12 9.75 16.62
Ehf ets homologous factor 45.68 35.58 0.03 0.06
Emb embigin 60.60 42.02 2.35 2.21
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 57.85 13.55 8.97 6.01
Eya2 eyes absent homolog 2 (Drosophila) 36.18 4.77 0.15 0.20
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GD20 GD22 (NL)
Gene symbol Gene name TPM ±SD TPM ±SD
F5 coagulation factor V (proaccelerin, labile factor) 13.39 8.88 1.34 0.48
Gabrp gamma-aminobutyric acid (GABA-A) receptor, pi 128.25 141.85 0.00 0.00
Gpx2 glutathione peroxidase 2 160.83 111.13 6.70 11.45
Htr4 5-hydroxytryptamine (serotonin) receptor 4, G protein-coupled 13.82 23.25 0.00 0.00
Iapp islet amyloid polypeptide 37.67 55.80 0.00 0.00
Isyna1 inositol-3-phosphate synthase 1 1489.69 1669.42 18.66 6.69
Itfg3 integrin alpha FG-GAP repeat containing 3 581.32 748.48 15.04 3.41
Kif12 kinesin family member 12 46.13 55.08 0.00 0.00
Lifr leukemia inhibitory factor receptor alpha 127.37 84.77 21.74 11.02
LOC688553 hypothetical protein LOC688553 20.63 15.17 0.21 0.36
Lpo lactoperoxidase 98.90 75.56 1.03 0.85
Lrat lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-acyltransferase) 308.27 357.79 2.25 1.90
Lrp2 low density lipoprotein receptor-related protein 2 69.42 63.47 1.06 0.62
Nr0b2 nuclear receptor subfamily 0, group B, member 2 10.58 13.18 0.00 0.00
Oxt oxytocin/neurophysin 1 prepropeptide 435.40 359.58 15.25 23.58
Pax8 paired box 8 161.20 170.81 10.21 16.38
Pinlyp phospholipase A2 inhibitor and LY6/PLAUR domain containing 151.15 123.87 5.71 8.38
Ppl periplakin 63.45 32.27 4.80 6.72
Psph phosphoserine phosphatase 85.84 117.51 3.62 2.15
Rbp4 retinol binding protein 4, plasma 93.46 159.64 1.62 1.80
RGD1559493 similar to Hypothetical protein MGC58608 9.61 16.64 0.00 0.00
RGD1562136 similar to D1Ertd622e protein 43.70 17.64 6.59 0.98
Sctr secretin receptor 39.67 23.41 0.38 0.52
Sema4a sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) 112.00 130.43 2.09 2.61
and short cytoplasmic domain, (semaphorin) 4A
Slc17a3 solute carrier family 17 (organic anion transporter), member 3 14.03 12.11 0.04 0.04
Slc17a4 solute carrier family 17, member 4 19.05 29.87 0.00 0.00
Slc1a5 solute carrier family 1 (neutral amino acid transporter), member 5 65.52 53.64 2.81 0.66
Slc34a2 solute carrier family 34 (type II sodium/phosphate contransporter), member 2 81.71 78.36 0.96 1.30
Slc4a1 solute carrier family 4 (anion exchanger), member 1 60.90 69.47 3.65 4.40
Slc5a3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 57.11 54.54 2.62 2.43
Tf transferrin 138.84 193.37 10.31 6.22
Thbs4 thrombospondin 4 289.73 348.89 4.53 3.79
Tshr thyroid stimulating hormone receptor 15.08 15.69 0.22 0.10
Vtcn1 V-set domain containing T cell activation inhibitor 1 34.64 25.88 1.32 0.91
Wfs1 Wolfram syndrome 1 (wolframin) 142.57 163.66 13.54 6.05
Table D.15: Gene transcripts that were differentially expressed in the inner my-
ometrium, between GD22 (NL) and GD22 (L). Transcript expression levels are shown in
transcripts per million (TPM) values (mean±SD).
GD22 (NL) GD22 (L)
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD22 (L)
Acan aggrecan 0.20 0.30 26.33 37.11
Col11a2 collagen, type XI, alpha 2 0.00 0.00 18.89 26.42
Col2a1 collagen, type II, alpha 1 0.05 0.05 264.17 373.25
Col9a1 collagen, type IX, alpha 1 0.00 0.00 18.12 25.47
Myh7 myosin, heavy chain 7, cardiac muscle, beta 0.08 0.09 9.95 12.56
Vom2r34 vomeronasal 2 receptor, 34 8.51 1.50 391.32 499.84
Down-regulated on GD22 (L)
A2m alpha-2-macroglobulin 1284.66 917.60 453.92 574.31
Fam150b family with sequence similarity 150, member B 21.86 36.95 0.00 0.00
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 191.56 144.00 5.88 4.59
Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 21.11 33.92 0.03 0.04
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GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Table D.16: Gene transcripts that were differentially expressed in the outer my-
ometrium, between GD19+6hrs and GD20. Transcript expression levels are shown in tran-
scripts per million (TPM) values (mean±SD).
GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD 20
Isyna1 inositol-3-phosphate synthase 1 25.10 12.58 1052.83 1069.36
Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 43.36 51.25 495.45 406.14
Lyz2 lysozyme 2 64.28 60.28 499.34 307.16
Lrat lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-acyltransferase) 1.56 1.26 220.09 219.89
Itfg3 integrin alpha FG-GAP repeat containing 3 14.39 6.71 223.82 245.87
Alcam activated leukocyte cell adhesion molecule 5.28 3.99 112.37 106.09
Aldob aldolase B, fructose-bisphosphate 1.09 1.23 105.04 166.77
Igfbp1 insulin-like growth factor binding protein 1 4.04 5.77 94.70 69.66
Ptgs1 prostaglandin-endoperoxide synthase 1 9.32 11.66 73.66 65.33
Slc5a3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 3.20 1.12 52.64 58.26
Defb1 defensin beta 1 0.00 0.00 36.69 36.60
Art3 ADP-ribosyltransferase 3 2.60 3.00 37.89 18.94
Cfi complement factor I 1.22 0.96 34.83 24.27
Upk3bl uroplakin 3B-like 0.00 0.00 31.40 28.63
Pon3 paraoxonase 3 0.38 0.56 31.69 16.67
Cldn10 claudin 10 1.01 1.41 29.12 35.23
Ly6c Ly6-C antigen 1.89 1.08 28.22 15.11
Csf2rb colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 8.78 10.10 34.86 10.68
C4bpb complement component 4 binding protein, beta 0.00 0.00 22.68 38.19
F5 coagulation factor V (proaccelerin, labile factor) 12.06 20.69 32.97 18.54
Alox15 arachidonate 15-lipoxygenase 0.02 0.03 14.83 8.44
Marveld3 MARVEL domain containing 3 0.00 0.00 14.12 12.05
Tnfaip8l2 tumor necrosis factor, alpha-induced protein 8-like 2 1.36 0.59 14.69 7.25
Faim2 Fas apoptotic inhibitory molecule 2 1.04 1.81 12.28 12.70
Krt83 keratin 83 0.16 0.20 10.80 7.10
Slc17a4 solute carrier family 17, member 4 0.06 0.10 9.88 12.47
Nptx2 neuronal pentraxin II 1.36 2.24 10.94 6.45
Paqr9 progestin and adipoQ receptor family member IX 0.35 0.61 9.72 7.63
Fam5b/Brinp2 bone morphogenetic protein/retinoic acid inducible neural-specific 2 0.26 0.14 7.97 7.79
Clec1b C-type lectin domain family 1, member B 2.74 4.50 9.81 4.12
Inmt indolethylamine N-methyltransferase 0.01 0.01 6.04 8.52
Slc10a1 solute carrier family 10 (sodium/bile acid cotransporter), member 1 1.39 2.38 7.29 6.82
Klkb1 kallikrein B, plasma 1 0.00 0.00 5.67 9.70
Gp9 glycoprotein IX (platelet) 0.14 0.24 4.70 1.54
Kcng1 potassium voltage-gated channel, subfamily G, member 1 0.00 0.00 4.39 1.66
Aadac arylacetamide deacetylase 0.00 0.00 4.06 5.90
Bucs1 acyl-CoA synthetase medium-chain family member 1 8.65 14.96 12.49 21.49
Nmb neuromedin B 6.89 11.94 10.73 13.90
Itih1 inter-alpha trypsin inhibitor, heavy chain 1 4.09 7.09 7.47 12.87
LOC308990 hypothetical protein LOC308990 0.00 0.00 2.37 1.50
Plekhg4 pleckstrin homology domain containing, family G (with RhoGef domain) member 4 0.25 0.44 1.95 1.57
Nccrp1 non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) 13.37 23.15 14.52 16.16
F11 coagulation factor XI 3.96 6.83 4.98 2.84
C3 complement component 3 6.39 1.02 510.34 168.32
Hcn4 hyperpolarization activated cyclic nucleotide-gated potassium channel 4 0.00 0.00 6.11 4.02
Scn2b sodium channel, voltage-gated, type II, beta 2.39 4.15 4.29 1.82
Slc17a3 solute carrier family 17 (organic anion transporter), member 3 0.20 0.16 16.58 16.57
Down-regulated on GD 20
LOC171573 spleen protein 1 precursor 1612.19 2779.47 4.43 4.96
Prl8a9 prolactin family 8, subfamily a, member 9 1217.52 2033.12 5.07 6.08
S100a8 S100 calcium binding protein A8 482.62 835.31 14.45 4.90
Prl8a2 prolactin family 8, subfamily a, member 2 370.32 587.96 3.19 2.34
Dusp9 dual specificity phosphatase 9 254.03 262.39 8.21 6.96
Cited1 Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 231.66 296.75 40.05 23.43
Sbsn suprabasin 174.88 220.49 7.90 1.60
Col4a3 collagen, type IV, alpha 3 152.17 263.41 3.42 1.25
Prl7a4 prolactin family 7, subfamily a, member 4 139.64 208.43 0.00 0.00
Pparg peroxisome proliferator-activated receptor gamma 51.39 43.27 3.01 1.11
Continued on next page
297
Table D.16 – continued from previous page
GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Hic2 hypermethylated in cancer 2 50.49 42.29 6.92 0.34
Ncam1 neural cell adhesion molecule 1 42.05 38.32 5.33 3.39
Idi1 isopentenyl-diphosphate delta isomerase 1 34.92 56.39 34.15 26.13
Atg9b autophagy related 9B 26.36 45.65 8.64 7.98
Lpar2 lysophosphatidic acid receptor 2 26.19 24.53 7.81 0.71
Zim1 zinc finger, imprinted 1 25.92 16.42 2.57 0.94
Sh3gl3 SH3-domain GRB2-like 3 21.96 37.89 3.71 1.65
Htr1d 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled 21.69 30.92 0.00 0.00
Tmem132e transmembrane protein 132E 20.32 17.38 1.92 0.87
Dmrtc1c DMRT-like family C1c1 19.87 34.26 0.00 0.00
Fam26e family with sequence similarity 26, member E 19.36 33.53 2.99 2.22
Otc ornithine carbamoyltransferase 18.62 32.26 11.05 18.86
Cd79b Cd79b molecule, immunoglobulin-associated beta 17.40 30.14 2.97 0.58
Mybph myosin binding protein H 10.01 12.77 0.00 0.00
Cd244 Cd244 molecule, natural killer cell receptor 2B4 6.39 11.05 2.60 0.85
Ggt1 gamma-glutamyltransferase 1 6.10 10.29 5.83 2.09
Rimbp2 RIMS binding protein 2 5.56 1.23 0.58 0.14
Mmp9 matrix metallopeptidase 9 3.20 5.24 0.00 0.00
Myh6 myosin, heavy chain 6, cardiac muscle, alpha 1.04 0.89 0.02 0.03
Table D.17: Gene transcripts that were differentially expressed in the outer my-
ometrium, between GD20 and GD22 (NL). Transcript expression levels are shown in tran-
scripts per million (TPM) values (mean±SD).
GD20 GD22 (NL)
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD22 (NL)
Prl8a2 prolactin family 8, subfamily a, member 2 3.19 2.34 676.30 1155.28
Cuzd1 CUB and zona pellucida-like domains 1 4.68 7.25 492.78 409.84
Serpine1 serpin peptidase inhibitor, clade E 36.01 19.61 297.03 107.48
(nexin, plasminogen activator inhibitor type 1), member 1
RGD1309676 family with sequence similarity 213, member A 34.40 26.96 178.41 127.27
Cited1 Cbp/p300-interacting transactivator with 40.05 23.43 156.19 51.56
Glu/Asp-rich carboxy-terminal domain 1
Mmp7 matrix metallopeptidase 7 0.22 0.31 131.36 56.43
Taf7l TAF7-like RNA polymerase II, 0.61 0.77 112.99 113.12
TATA box binding protein (TBP)-associated factor
Prl7a4 prolactin family 7, subfamily a, member 4 0.00 0.00 106.52 174.73
Prom1 prominin 1 4.60 4.59 105.22 100.68
Fndc3c1 fibronectin type III domain containing 3C1 1.07 1.62 96.35 148.44
Slc26a4 solute carrier family 26 (anion exchanger), member 4 2.87 2.80 69.38 68.87
Cndp1 carnosine dipeptidase 1 (metallopeptidase M20 family) 8.94 6.27 35.15 22.93
Sfmbt2 Scm-like with four mbt domains 2 4.54 2.69 32.45 32.63
Apobr apolipoprotein B receptor 4.62 2.62 28.31 14.70
Htr1d 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled 0.00 0.00 25.53 41.90
Igsf9 immunoglobulin superfamily, member 9 2.51 1.39 23.02 8.12
Cftr cystic fibrosis transmembrane conductance regulator 0.42 0.49 22.54 29.22
Ehhadh enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase 2.67 0.62 21.25 16.87
Prl3a1 Prolactin family 3, subfamily a, member 1 0.00 0.00 16.33 5.06
Wnt7a wingless-type MMTV integration site family, member 7A 0.12 0.03 11.54 9.93
Dmrtc1c DMRT-like family C1c1 0.00 0.00 9.79 15.09
Slc22a2 solute carrier family 22 (organic cation transporter), member 2 0.06 0.01 7.63 11.10
Mmp9 matrix metallopeptidase 9 0.00 0.00 7.42 11.32
Tcerg1l transcription elongation regulator 1-like 0.00 0.00 7.00 11.83
LOC691352 similar to Robo-1 0.51 0.14 6.84 5.45
Lgals12 lectin, galactoside-binding, soluble, 12 0.09 0.04 4.37 4.30
Myo3b myosin IIIB 0.00 0.00 1.99 1.89
Down-regulated on GD22 (NL)
Endou endonuclease, poly(U)-specific 4.99 4.47 0.00 0.00
Bdkrb1 bradykinin receptor B1 2.12 2.71 0.02 0.04
Gp9 glycoprotein IX (platelet) 4.70 1.54 0.04 0.07
Rprml reprimo-like 15.31 4.91 0.07 0.12
Mfrp membrane frizzled-related protein 3.55 1.93 0.07 0.08
Tacr2 tachykinin receptor 2 3.10 2.32 0.17 0.13
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GD20 GD22 (NL)
Gene symbol Gene name TPM ±SD TPM ±SD
Slc2a4 solute carrier family 2 (facilitated glucose transporter), member 4 6.73 3.29 0.22 0.01
Fam5b/Brinp2 bone morphogenetic protein/retinoic acid inducible neural-specific 2 7.97 7.79 0.22 0.19
Vamp5 vesicle-associated membrane protein 5 6.76 3.56 0.36 0.53
Tenm2 teneurin transmembrane protein 2 11.44 5.65 0.60 0.36
Il13ra2 interleukin 13 receptor, alpha 2 47.43 37.17 1.02 0.87
Galnt18 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 18 51.82 38.88 1.71 1.20
N-acetylgalactosaminyltransferase
Sgcd sarcoglycan, delta (dystrophin-associated glycoprotein) 16.96 10.50 2.11 2.52
Sema3e sema domain, immunoglobulin domain (Ig), 28.78 18.94 3.20 1.50
short basic domain, secreted, (semaphorin) 3E
Srpx sushi-repeat-containing protein, X-linked 88.71 61.11 3.23 3.97
C1qtnf2 C1q and tumor necrosis factor related protein 2 18.83 7.20 3.29 1.16
Pkia protein kinase (cAMP-dependent, catalytic) inhibitor alpha 30.81 15.68 3.31 1.13
Bves blood vessel epicardial substance 34.28 12.26 3.83 2.44
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B 271.55 265.10 3.84 2.13
Lepr leptin receptor 64.87 28.80 5.37 2.84
Car12 carbonic anyhydrase 12 87.79 38.69 5.40 1.46
Enpp1 ectonucleotide pyrophosphatase/phosphodiesterase 1 62.78 43.28 6.59 1.51
Abcg4 ATP-binding cassette, subfamily G (WHITE), member 4 124.24 46.42 8.10 4.12
Adam15 ADAM metallopeptidase domain 15 77.74 16.13 8.72 4.70
Thbs4 thrombospondin 4 261.53 327.27 9.47 4.85
Itm2a integral membrane protein 2A 117.15 133.34 9.51 6.30
Dact3 dishevelled-binding antagonist of beta-catenin 3 70.03 28.97 9.60 0.74
Sorcs2 sortilin-related VPS10 domain containing receptor 2 69.58 34.16 10.24 2.41
Cnr1 cannabinoid receptor 1 (brain) 25.19 12.26 10.47 12.48
Pdlim3 PDZ and LIM domain 3 187.43 105.57 11.58 10.89
Akap12 A kinase (PRKA) anchor protein 12 111.25 63.31 11.78 7.34
Svil supervillin 82.99 50.62 11.98 9.34
Cxcl13 chemokine (C-X-C motif) ligand 13 115.60 61.69 13.35 5.26
Atp2b4 ATPase, Ca++ transporting, plasma membrane 4 84.20 50.52 13.84 9.43
Tsc22d3 TSC22 domain family, member 3 84.81 36.62 14.59 5.40
Cercam cerebral endothelial cell adhesion molecule 83.11 51.82 14.83 5.25
Synm synemin, intermediate filament protein 125.90 55.14 15.06 7.14
Rgma repulsive guidance molecule family member A 110.40 74.97 15.17 10.20
Slc48a1 solute carrier family 48 (heme transporter), member 1 90.88 47.10 16.46 3.92
Aoc3 amine oxidase, copper containing 3 199.44 120.89 24.84 9.72
Ehd2 EH-domain containing 2 266.01 157.37 35.35 17.11
Isyna1 inositol-3-phosphate synthase 1 1052.83 1069.36 35.48 20.29
Lims2 LIM and senescent cell antigen like domains 2 235.85 120.37 38.53 11.27
Kcnmb1 potassium large conductance calcium-activated channel, 219.14 110.71 40.07 17.77
subfamily M, beta member 1
Ptn pleiotrophin 362.30 217.46 47.91 25.16
Acta1 actin, alpha 1, skeletal muscle 1253.59 735.94 87.43 35.62
Prkcdbp protein kinase C, delta binding protein 376.06 76.79 92.45 90.97
Hspb1 heat shock protein 1 752.54 365.52 126.15 47.87
Igfbp6 insulin-like growth factor binding protein 6 1256.56 759.01 131.92 42.01
Prelp proline/arginine-rich end leucine-rich repeat protein 1401.54 973.40 155.55 66.39
Actg2 actin, gamma 2, smooth muscle, enteric 16313.36 9336.30 1552.40 497.02
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Appendix E
RU486-treated Tissues
Table E.1: Gene transcripts that were differentially expressed following treatment with
RU486 in the inner myometrium compared to the decidua on GD19+6hrs. Transcript
expression levels are shown in transcripts per million (TPM) values (mean±SD).
Decidua Inner myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in inner myometrium
Acta2 actin, alpha 2, smooth muscle, aorta 6.78 5.26 416.51 411.72
Apob apolipoprotein B 0.97 0.24 19.99 24.51
Atp2b4 ATPase, Ca++ transporting, plasma membrane 4 1.07 1.13 48.68 44.27
C1qb complement component 1, q subcomponent, 0.15 0.20 44.23 60.93
B chain
Cdh1 cadherin 1 1.45 0.80 70.46 55.53
Csf1 colony stimulating factor 1 (macrophage) 1.22 0.45 28.60 28.95
Gpr56 G protein-coupled receptor 56 0.50 0.16 17.76 11.65
Itsn1 intersectin 1 (SH3 domain protein) 4.01 3.04 58.05 32.49
Kcnb1 potassium voltage gated channel, 0.03 0.04 7.47 6.86
Shab-related subfamily, member 1
Mtss1l metastasis suppressor 1-like 1.62 1.37 46.40 13.36
Myl9 myosin, light chain 9, regulatory 29.60 44.99 2389.83 3530.97
Pde3a phosphodiesterase 3A, cGMP inhibited 2.86 0.58 17.37 20.39
Plat plasminogen activator, tissue 8.72 4.57 67.37 57.58
Ppp1r12b protein phosphatase 1, regulatory subunit 12B 21.91 29.33 44.85 28.65
Rgma repulsive guidance molecule family member A 1.84 0.92 26.83 11.25
Rgs1 regulator of G-protein signaling 1 0.01 0.02 0.37 0.64
Tlr8 toll-like receptor 8 0.01 0.01 2.69 4.66
Tns3 tensin 3 3.72 1.48 35.96 22.30
Down-regulated in inner myometrium
Ephb1 Eph receptor B1 2.47 0.88 0.30 0.11
Gpr1 G protein-coupled receptor 1 5.50 3.40 0.00 0.00
Hapln1 hyaluronan and proteoglycan link protein 1 29.42 50.95 1.50 2.60
Pdyn prodynorphin 2.12 1.14 0.10 0.17
Tsx testis specific X-linked gene 4.01 0.58 0.00 0.00
Table E.2: Gene transcripts that were differentially expressed following treatment with
RU486 in the outer myometrium compared to the decidua on GD19+6hrs. Transcript
expression levels are shown in transcripts per million (TPM) values (mean±SD).
Decidua Outer myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in outer myometrium
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), 0.49 0.30 101.85 88.70
member 1B
Acta1 actin, alpha 1, skeletal muscle 18.96 27.53 699.89 747.97
Acta2 actin, alpha 2, smooth muscle, aorta 6.78 5.26 1036.93 1086.75
Adcy1 adenylate cyclase 1 (brain) 0.01 0.02 11.40 10.33
Aebp1 AE binding protein 1 15.32 12.63 127.34 57.56
Alcam activated leukocyte cell adhesion molecule 2.34 1.65 40.54 38.02
Ankh ANKH inorganic pyrophosphate transport 3.99 2.94 17.83 16.96
regulator
Anxa6 annexin A6 7.21 6.46 80.90 67.09
Aoc3 amine oxidase, copper containing 3 3.01 2.18 77.20 68.19
Apob apolipoprotein B 0.97 0.24 22.12 19.74
Ar androgen receptor 0.29 0.33 8.33 5.68
Asb2 ankyrin repeat and SOCS box-containing 2 0.00 0.00 7.09 10.08
Atp2b4 ATPase, Ca++ transporting, plasma membrane 4 1.07 1.13 39.37 28.60
Bgn biglycan 60.10 78.77 677.18 554.77
Bok BCL2-related ovarian killer 4.64 2.70 149.61 98.68
C1r complement component 1, r subcomponent 7.13 3.53 71.14 59.95
C1s complement component 1, s subcomponent 1.89 1.79 53.46 45.99
C3 complement component 3 4.91 2.58 328.78 314.39
C4a complement component 4A 2.03 1.95 83.13 53.95
(Rodgers blood group)
C4b complement component 4B (Chido blood group) 0.76 0.92 21.97 8.25
Ca2 carbonic anhydrase 2 1.23 0.71 23.69 2.45
Cacna1c calcium channel, voltage-dependent, L type, 0.47 0.20 13.06 12.91
alpha 1C subunit
Car12 carbonic anyhydrase 12 0.21 0.26 20.90 13.02
Cav1 caveolin 1, caveolae protein 1.75 1.74 158.10 147.13
Ccl21 chemokine (C-C motif) ligand 21 0.00 0.00 30.34 29.68
Cd24 CD24 molecule 110.82 53.44 1292.54 89.57
Cdh1 cadherin 1 1.45 0.80 49.99 35.37
Cdh16 cadherin 16 0.00 0.00 8.02 7.33
Cfb complement factor B 2.87 3.09 162.21 140.33
Chchd10 coiled-coil-helix-coiled-coil-helix domain 3.42 1.49 35.99 24.56
containing 10
Cnn1 calponin 1, basic, smooth muscle 5.21 3.93 1291.98 1106.88
Col3a1 collagen, type III, alpha 1 14.42 15.69 632.82 499.55
Col6a2 collagen, type VI, alpha 2 31.09 26.72 416.47 317.12
Crip1 cysteine-rich protein 1 (intestinal) 1.14 1.58 27.22 14.30
Csf1 colony stimulating factor 1 (macrophage) 1.22 0.45 109.08 130.17
Ctsc cathepsin C 1.27 1.07 34.60 29.15
Cxcl12 chemokine (C-X-C motif) ligand 12 0.66 0.78 25.24 24.24
Defb1 defensin beta 1 0.03 0.05 31.84 38.48
Dhrs11 dehydrogenase/reductase (SDR family) member 11 1.04 0.57 28.04 42.13
Dpep1 dipeptidase 1 (renal) 0.11 0.19 22.53 18.48
Ehd2 EH-domain containing 2 4.48 3.63 73.18 70.97
Emb embigin 0.87 0.96 35.79 27.40
Epb41l3 erythrocyte membrane protein band 4.1-like 3 0.44 0.33 12.86 11.00
Fam20c family with sequence similarity 20, member C 1.12 0.46 27.78 23.59
Fam46b family with sequence similarity 46, member B 0.00 0.00 7.12 8.50
Fcrl6 Fc receptor-like 6 2.43 1.88 255.78 441.53
Fhl1 four and a half LIM domains 1 6.51 5.59 573.19 572.86
Fhl3 four and a half LIM domains 3 2.84 2.40 88.97 106.18
Fut2 fucosyltransferase 2 (secretor status included) 2.78 2.55 51.18 43.44
Gabbr1 gamma-aminobutyric acid (GABA) B receptor 1 4.26 3.49 51.81 72.74
Gls glutaminase 5.95 3.62 101.89 89.84
Gpr56 G protein-coupled receptor 56 0.50 0.16 15.51 7.59
Gpt glutamic-pyruvate transaminase 0.20 0.34 21.34 11.24
(alanine aminotransferase)
Gpx1 glutathione peroxidase 1 54.59 42.37 642.55 278.44
Gpx2 glutathione peroxidase 2 9.49 13.86 370.37 356.33
Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 6.54 6.51 262.11 169.49
Iapp islet amyloid polypeptide 0.00 0.00 22.93 36.23
Continued on next page
301
Table E.2 – continued from previous page
Decidua Outer myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
Ifi204 myeloid cell nuclear differentiation antigen 3.17 3.75 14.85 15.01
Igfbp5 insulin-like growth factor binding protein 5 8.00 8.60 110.71 109.05
Igfbp6 insulin-like growth factor binding protein 6 8.59 6.65 612.72 621.51
Isyna1 inositol-3-phosphate synthase 1 18.03 9.01 684.90 600.84
Itfg3 integrin alpha FG-GAP repeat containing 3 10.04 6.17 139.06 127.15
Jrk jerky homolog (mouse) 1.49 1.32 34.78 52.09
Kap kidney androgen regulated protein 11.57 16.48 713.32 665.47
Kb23 type II keratin 23 0.01 0.01 5.84 5.59
Kcnf1 potassium voltage-gated channel, subfamily F, 0.00 0.00 7.64 6.81
member 1
Kcnmb1 potassium large conductance calcium-activated 1.06 0.94 79.84 58.57
channel, subfamily M, beta member 1
Lamb3 laminin, beta 3 0.16 0.29 10.94 2.99
Lcn2 lipocalin 2 8.33 11.49 366.02 435.02
Lpo lactoperoxidase 1.10 1.10 63.04 54.71
Lrat lecithin-retinol acyltransferase 1.42 1.18 101.55 97.13
(phosphatidylcholine-retinol-O-acyltransferase)
Lrp2 low density lipoprotein receptor-related protein 2 0.57 0.14 25.45 27.31
Ltbp4 latent transforming growth factor beta binding 0.39 0.34 21.06 12.94
protein 4
Lurap1l leucine rich adaptor protein 1-like 0.01 0.02 11.50 10.39
Lyz2 lysozyme 2 23.38 32.13 402.51 528.49
MGC114464 similar to expressed sequence AI836003 1.42 2.07 25.12 41.41
Mmp17 matrix metallopeptidase 17 0.28 0.17 15.97 13.41
Mmp1a matrix metallopeptidase 1a (interstitial collagenase) 0.83 0.53 95.74 165.74
Mtss1l metastasis suppressor 1-like 1.62 1.37 31.53 24.60
Myh11 myosin, heavy chain 11, smooth muscle 4.39 3.36 847.62 784.51
Myh3 myosin, heavy chain 3, skeletal muscle, embryonic 0.35 0.16 14.24 24.47
Myl9 myosin, light chain 9, regulatory 29.60 44.99 3006.63 2580.67
Mylk myosin light chain kinase 7.63 6.28 456.88 468.29
Net1 neuroepithelial cell transforming 1 12.31 6.76 102.90 19.48
Neu2 sialidase 2 1.77 0.53 62.56 106.60
Nnat neuronatin 2.65 2.96 61.26 100.89
Nsmf NMDA receptor synaptonuclear signaling and 2.01 2.55 61.45 91.04
neuronal migration factor
Ociad2 OCIA domain containing 2 0.52 0.82 17.43 11.38
Odz4 teneurin transmembrane protein 4 0.45 0.36 8.84 4.62
Oxt oxytocin/neurophysin 1 prepropeptide 40.50 68.42 399.04 345.77
Oxtr oxytocin receptor 0.00 0.00 8.19 8.45
Pcdh7 protocadherin 7 0.12 0.17 24.82 11.72
Pcsk7 proprotein convertase subtilisin/kexin type 7 10.47 1.40 74.61 54.10
Pdzk1ip1 PDZK1 interacting protein 1 0.06 0.06 33.68 27.09
Phlda3 pleckstrin homology-like domain, family A, 0.60 0.55 24.93 15.05
member 3
Plxnb2 plexin B2 5.82 4.68 35.51 23.02
Ppl periplakin 6.07 3.62 81.34 60.80
Ppp1r12b protein phosphatase 1, regulatory subunit 12B 21.91 29.33 62.80 53.78
Prelp proline/arginine-rich end leucine-rich repeat 24.26 27.08 518.67 559.42
protein
Prkag2 protein kinase, AMP-activated, gamma 2 5.80 0.24 39.63 22.67
non-catalytic subunit
Prl2c1 Prolactin family 2, subfamily c, member 1 6.16 6.61 131.43 219.04
Psmb8 proteasome (prosome, macropain) subunit, 0.33 0.50 16.38 11.97
beta type, 8
Ptch2 patched homolog 2 (Drosophila) 0.00 0.00 4.48 6.65
Ptn pleiotrophin 3.81 3.93 121.50 134.86
Rexo2 RNA exonuclease 2 29.79 7.67 199.55 106.97
RGD1563547 small integral membrane protein 22 0.41 0.24 9.94 3.65
RGD1564664 similar to LOC387763 protein 3.17 2.62 160.81 131.96
Rgma repulsive guidance molecule family member A 1.84 0.92 33.18 39.49
Rgs1 regulator of G-protein signaling 1 0.01 0.02 6.64 7.68
S100a16 S100 calcium binding protein A16 1.27 1.71 28.28 23.49
Sepp1 selenoprotein P, plasma, 1 8.85 9.59 296.52 215.44
Serpina1 serpin peptidase inhibitor, clade A 4.31 2.68 78.15 100.04
(alpha-1 antiproteinase, antitrypsin), member 1
Sgk1 serum/glucocorticoid regulated kinase 1 28.86 17.25 219.14 149.87
Slc34a2 solute carrier family 34, member 2 0.68 0.57 69.45 60.39
(type II sodium/phosphate contransporter)
Slc6a14 solute carrier family 6, member 14 0.05 0.09 5.31 4.94
Continued on next page
302
Table E.2 – continued from previous page
Decidua Outer myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
(amino acid transporter)
Slc8a1 solute carrier family 8, member 1 1.05 1.13 14.13 13.03
(sodium/calcium exchanger)
Slco2b1 solute carrier organic anion transporter family, 0.13 0.22 5.53 3.00
member 2b1
Socs2 suppressor of cytokine signaling 2 3.59 3.67 28.30 24.25
Sparcl1 SPARC-like 1 (hevin) 0.90 0.82 105.00 93.02
Spns2 spinster homolog 2 1.47 1.01 16.90 3.15
Spp1 secreted phosphoprotein 1 16.17 13.05 889.53 771.63
Srpx sushi-repeat-containing protein, X-linked 0.18 0.10 25.26 27.81
Stbd1 starch binding domain 1 1.15 0.39 16.46 6.95
Svil supervillin 2.75 1.05 34.19 20.63
Synm synemin, intermediate filament protein 1.20 1.02 46.93 40.43
Synpo2 synaptopodin 2 14.23 11.79 234.22 205.03
Tagln transgelin 11.26 12.61 1410.37 1261.54
Taok3 TAO kinase 3 3.85 4.68 60.38 86.65
Thbs2 thrombospondin 2 2.08 2.00 21.80 18.70
Tlr8 toll-like receptor 8 0.01 0.01 4.51 4.27
Tmem176a transmembrane protein 176A 3.35 5.64 114.05 63.59
Tmem229b transmembrane protein 229B 0.62 0.91 17.77 9.01
Tnfsf13 tumor necrosis factor (ligand) superfamily, member 13 0.61 0.47 24.07 12.35
Tnnt2 troponin T type 2 (cardiac) 0.95 1.22 36.41 25.81
Tns3 tensin 3 3.72 1.48 30.35 26.29
Top1mt topoisomerase (DNA) I, mitochondrial 1.86 1.46 32.89 51.00
Tpm2 tropomyosin 2, beta 234.29 208.77 2765.58 2225.69
Trem2 triggering receptor expressed on myeloid cells 2 0.04 0.07 8.39 7.78
Tshr thyroid stimulating hormone receptor 0.51 0.17 2.14 1.79
Tubb2a tubulin, beta 2A class IIa 9.90 7.54 86.98 56.56
Ugt1a1 UDP glucuronosyltransferase 1 family, polypeptide A1 0.27 0.41 25.69 25.98
Upk3bl uroplakin 3B-like 0.00 0.00 22.32 26.61
Usp43 predicted ubiquitin specific peptidase 43 0.00 0.00 11.98 17.25
Down-regulated in outer myometrium
Acad11 acyl-CoA dehydrogenase family, member 11 20.13 8.55 3.36 2.28
Arhgef6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 59.50 44.85 3.97 3.78
Atp4b ATPase, H+/K+ exchanging, beta polypeptide 13.93 19.94 0.00 0.00
Bcor BCL6 co-repressor 115.37 101.57 5.18 2.45
Brd3 bromodomain containing 3 111.80 94.38 11.52 3.31
Ccin calicin 1.43 1.43 0.06 0.04
Cdc14a cell division cycle 14A 45.54 13.87 3.72 1.90
Cdh3 cadherin 3 115.25 13.91 2.52 1.80
Chrna3 cholinergic receptor, nicotinic, alpha 3 (neuronal) 1.84 2.19 0.00 0.00
Cilp2 cartilage intermediate layer protein 2 4.42 3.47 0.02 0.04
Cldn4 claudin 4 472.76 531.31 2.68 2.35
Cln8 ceroid-lipofuscinosis, neuronal 8 59.51 38.33 5.99 1.48
(epilepsy, progressive with mental retardation)
Col2a1 collagen, type II, alpha 1 85.93 148.44 1.27 0.93
Comp cartilage oligomeric matrix protein 12.91 22.31 0.08 0.03
Creg1 cellular repressor of E1A-stimulated genes 1 2259.82 1605.20 78.17 20.36
Creld2 cysteine-rich with EGF-like domains 2 70.81 42.18 8.33 5.15
Cyp11a1 cytochrome P450, family 11, subfamily a, 76.73 79.78 0.06 0.10
polypeptide 1
Defb36 defensin beta 36 17.48 30.28 0.02 0.04
Dmrtc1c DMRT-like family C1c 21.97 17.61 0.04 0.07
Ednrb endothelin receptor type B 516.74 507.39 10.85 9.38
Ehd3 EH-domain containing 3 171.34 158.14 6.69 3.47
Eva1a eva-1 homolog A 27.63 22.13 2.05 1.16
Fam46a family with sequence similarity 46, member A 80.48 50.59 9.07 6.09
Flvcr2 feline leukemia virus subgroup C cellular receptor 40.77 9.82 11.03 13.67
family, member 2
Fndc3c1 fibronectin type III domain containing 3C1 334.61 283.17 4.27 5.95
Fosl1 fos-like antigen 1 122.48 105.33 3.17 2.78
Gadd45b growth arrest and DNA-damage-inducible, beta 62.71 27.29 6.81 1.75
Gata3 GATA binding protein 3 55.22 42.65 0.23 0.17
Gstm7 glutathione S-transferase, mu 7 1.73 0.99 0.17 0.04
Hap1 huntingtin-associated protein 1 3.11 2.73 0.17 0.25
Hdac5 histone deacetylase 5 51.48 39.33 3.17 4.37
Hs3st6 heparan sulfate (glucosamine) 3-O-sulfotransferase 6 50.63 52.92 0.00 0.00
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Hsd17b3 hydroxysteroid (17-beta) dehydrogenase 3 13.06 11.37 0.07 0.11
Il17f interleukin 17F 28.40 22.11 0.01 0.01
Il2rg interleukin 2 receptor, gamma 143.59 102.85 7.46 3.01
Inhba inhibin beta-A 364.85 331.45 19.58 13.86
Kcnh6 potassium voltage-gated channel, subfamily H 6.49 8.92 0.00 0.00
(eag-related), member 6
Lamc2 laminin, gamma 2 62.78 23.21 9.20 7.10
Limk2 LIM domain kinase 2 85.59 22.40 8.30 4.86
LOC171573 spleen protein 1 precursor 8126.30 5720.53 11.65 16.42
LOC690326 hypothetical protein LOC690326 32.78 31.45 0.29 0.34
Lpcat1 lysophosphatidylcholine acyltransferase 1 26.31 11.26 3.67 1.08
Matn1 matrilin 1, cartilage matrix protein 10.55 18.27 0.03 0.02
Mmd monocyte to macrophage differentiation-associated 43.19 14.97 7.46 5.59
Mycbpap Mycbp associated protein 25.23 20.91 0.58 0.55
Nhs Nance-Horan syndrome 20.20 14.59 1.24 0.55
(congenital cataracts and dental anomalies)
Prl3b1 Prolactin family 3, subfamily b, member 1 1101.88 1204.17 8.37 7.25
Prl3d2 Prolactin family 3, subfamily d, member 2 159.94 10.16 0.01 0.01
Prl3d4 prolactin family 3, subfamily d, member 4 3699.29 2139.84 2.97 3.25
Prl7a3 prolactin family 7, subfamily a, member 3 1082.68 833.63 8.12 11.71
Prl8a2 prolactin family 8, subfamily a, member 2 2395.37 1633.06 9.43 14.20
Prl8a5 prolactin family 8, subfamily a, member 5 14633.75 9552.24 33.75 47.10
Prl8a7 prolactin family 8, subfamily a, member 7 32217.60 12642.42 75.88 92.91
Prl8a9 prolactin family 8, subfamily a, member 9 12359.02 5600.73 130.85 214.95
RGD1563945 jade family PHD finger 3 29.69 19.24 2.65 0.80
RGD1564534 similar to CHCHD4 protein 42.37 29.80 1.02 1.12
Rilpl1 Rab interacting lysosomal protein-like 1 70.36 40.96 9.34 6.72
Rnf128 ring finger protein 128, E3 ubiquitin protein ligase 218.27 152.89 5.15 5.61
Sdf2l1 stromal cell-derived factor 2-like 1 83.98 28.92 12.36 5.93
Sfmbt2 Scm-like with four mbt domains 2 166.02 166.99 8.09 12.08
Sftpa1 surfactant protein A1 52.11 34.85 0.08 0.09
Sgce sarcoglycan, epsilon 167.09 141.12 11.00 12.27
Sipa1l2 signal-induced proliferation-associated 1 like 2 62.47 38.98 5.78 2.87
Slc25a25 solute carrier family 25, member 25 26.37 15.61 4.76 0.85
(mitochondrial carrier, phosphate carrier)
Slc29a1 solute carrier family 29, member 1 52.80 25.15 3.28 2.13
(equilibrative nucleoside transporter)
Slc38a4 solute carrier family 38, member 4 874.15 742.95 7.88 8.64
Slc6a2 solute carrier family 6 (neurotransmitter transporter), 28.18 10.80 0.83 0.71
member 2
Slco5a1 solute carrier organic anion transporter family, 36.21 29.99 3.16 1.49
member 5A1
Syn3 synapsin III 11.33 8.29 0.05 0.05
Tbc1d2 TBC1 domain family, member 2 69.99 58.57 7.81 3.59
Tgfb3 transforming growth factor, beta 3 237.04 127.64 19.51 3.51
Thrsp thyroid hormone responsive 8.09 6.06 0.24 0.19
Tmem37 transmembrane protein 37 277.58 197.93 4.03 2.88
Trh thyrotropin releasing hormone 412.51 442.62 1.49 1.31
Unc5b unc-5 homolog B (C. elegans) 97.07 85.26 6.70 1.38
Utf1 undifferentiated embryonic cell transcription factor 1 21.73 21.43 0.00 0.00
Vmo1 vitelline membrane outer layer 1 homolog (chicken) 12.23 8.87 0.00 0.00
Wdr62 WD repeat domain 62 38.11 30.64 2.43 1.16
Wdr7 WD repeat domain 7 16.83 15.34 1.65 1.66
Wfdc6a WAP four-disulfide core domain 6A 3.74 3.27 0.01 0.01
Zbtb44 zinc finger and BTB domain containing 44 35.77 20.54 6.53 5.18
Zp1 zona pellucida glycoprotein 1 (sperm receptor) 9.93 10.00 0.01 0.01
Table E.3: Gene transcripts that were differentially expressed following treatment
with RU486 in the inner myometrium compared to the decidua on GD20. Transcript
expression levels are shown in transcripts per million (TPM) values (mean±SD).
Decidua Inner myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in inner myometrium
Chchd10 coiled-coil-helix-coiled-coil-helix domain containing 10 20.13 15.73 171.59 107.61
Fbln5 fibulin 5 10.56 4.41 102.02 66.08
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Figf c-fos induced growth factor 5.36 3.56 182.25 167.75
Igsf10 immunoglobulin superfamily, member 10 0.66 0.55 16.41 0.43
Stox2 storkhead box 2 1.92 0.84 28.39 20.14
Down-regulated in inner myometrium
Aif1l allograft inflammatory factor 1-like 343.61 170.50 14.89 4.75
Anxa3 annexin A3 122.77 109.38 8.75 8.55
Anxa8 annexin A8 125.08 87.82 3.90 0.40
Ccl27 chemokine (C-C motif) ligand 27 282.50 125.39 5.10 2.79
Cdh3 cadherin 3 192.41 170.29 15.35 15.77
Cyp26b1 cytochrome P450, family 26, subfamily b, 218.71 204.89 4.51 3.02
polypeptide 1
Doxl2 diamine oxidase-like protein 2 5.07 6.52 0.01 0.02
Efhd1 EF-hand domain family, member D1 55.55 33.46 0.29 0.16
Gata2 GATA binding protein 2 143.69 85.93 18.73 15.00
Gnat2 guanine nucleotide binding protein (G protein), 70.65 58.68 0.01 0.02
alpha transducing activity polypeptide 2
Hyal4 hyaluronoglucosaminidase 4 2.69 2.82 0.17 0.13
Irx4 iroquois homeobox 4 29.28 4.52 0.14 0.15
Lamc2 laminin, gamma 2 59.38 15.58 3.45 1.86
Mfap5 microfibrillar associated protein 5 119.62 95.81 3.43 2.21
Mrgprg MAS-related GPR, member G 37.67 21.48 0.12 0.07
Nsg2 neuron specific gene family member 2 85.79 71.77 1.77 0.85
Pgf placental growth factor 439.87 469.80 6.77 6.70
Prl3d4 prolactin family 3, subfamily d, member 4 1118.79 879.35 13.28 12.32
Prl7a3 prolactin family 7, subfamily a, member 3 566.61 496.56 4.53 4.00
Prl8a2 prolactin family 8, subfamily a, member 2 1046.66 498.79 13.20 6.32
Prl8a7 prolactin family 8, subfamily a, member 7 4599.90 3495.08 69.14 79.56
Procr protein C receptor, endothelial 104.44 64.93 4.17 3.19
Psg16 pregnancy specific glycoprotein 16 267.78 315.01 6.37 7.44
Rnf128 ring finger protein 128, E3 ubiquitin 84.23 35.20 8.31 5.60
protein ligase
Sbsn suprabasin 670.74 589.50 15.18 16.93
Slc38a4 solute carrier family 38, member 4 203.93 212.16 11.89 7.50
Slc6a12 solute carrier family 6, member 12 840.73 752.38 10.61 6.46
(neurotransmitter transporter)
Tfpi tissue factor pathway inhibitor 987.46 452.11 45.64 14.11
(lipoprotein-associated coagulation inhibitor)
Table E.4: Gene transcripts that were differentially expressed following treatment
with RU486 in the outer myometrium compared to the decidua on GD20. Transcript
expression levels are shown in transcripts per million (TPM) values (mean±SD).
Decidua Outer myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in outer myometrium
Irx1 iroquois homeobox 1 0.02 0.03 8.54 7.36
Down-regulated in outer myometrium
Irx1 iroquois homeobox 1 0.02 0.03 8.54 7.36
Pzp pregnancy-zone protein 79.83 137.85 0.55 0.63
Mmp10 matrix metallopeptidase 10 (stromelysin 2) 97.79 101.48 2.97 2.46
Rrm1 ribonucleotide reductase M1 159.00 117.95 11.08 9.76
Mt1a metallothionein 1a 979.42 285.58 142.14 60.40
Slc6a12 solute carrier family 6, member 12 840.73 752.38 10.60 15.12
(neurotransmitter transporter)
Pgf placental growth factor 439.87 469.80 12.00 17.81
Ehd3 EH-domain containing 3 496.17 437.17 32.14 24.67
Table E.5: Gene transcripts that were differentially expressed following treatment
with RU486 in the outer myometrium compared to the inner myometrium on GD20.
Transcript expression levels are shown in transcripts per million (TPM) values (mean±SD).
Inner myometrium Outer myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in outer myometrium
Prl8a2 prolactin family 8, subfamily a, member 2 221.96 355.86 814.23 1407.10
Psgb1 pregnancy-specific beta 1-glycoprotein 9.42 6.60 247.71 426.97
Ctsq cathepsin Q 2.51 2.18 238.80 412.27
Prl7a3 prolactin family 7, subfamily a, member 3 91.12 146.43 193.09 301.74
Taf7l TAF7-like RNA polymerase II, TATA box binding 9.59 6.48 99.41 154.73
protein (TBP)-associated factor
Ctsm cathepsin M 2.68 2.47 69.34 116.76
Ins2 insulin 2 0.41 0.71 62.95 87.82
Sftpc surfactant protein C 0.19 0.32 57.37 98.75
Serpinb9d serine (or cysteine) peptidase inhibitor, clade B, 0.16 0.17 46.61 69.33
member 9d
Lrp2 low density lipoprotein receptor-related 0.80 0.94 22.66 30.41
protein 2
Sftpb surfactant protein B 0.00 0.00 20.10 33.75
Cubn cubilin (intrinsic factor-cobalamin receptor) 0.20 0.11 14.61 16.24
Glp1r glucagon-like peptide 1 receptor 0.15 0.12 3.84 4.62
Tbx5 T-box 5 0.00 0.00 3.57 3.86
Aloxe3 arachidonate lipoxygenase 3 0.00 0.00 3.33 5.26
Down-regulated in outer myometrium
Apcs amyloid P component, serum 7.95 13.76 0.00 0.00
Clec4f C-type lectin domain family 4, member F 2.29 3.96 0.00 0.00
Crp C-reactive protein, pentraxin-related 24.65 42.70 0.00 0.00
Ctsg cathepsin G 7.02 12.15 0.00 0.00
Agr2 anterior gradient 2 11.75 20.35 0.01 0.02
Aspdh aspartate dehydrogenase domain containing 6.25 10.82 0.10 0.17
Dpys dihydropyrimidinase 4.24 7.26 0.10 0.08
Nefl neurofilament, light polypeptide 2.69 4.54 0.31 0.32
Pzp pregnancy-zone protein 209.84 362.79 0.55 0.63
Cldn1 claudin 1 30.78 53.05 1.06 0.53
Hpx hemopexin 161.40 277.84 1.59 1.63
Vtn vitronectin 255.66 439.88 2.00 0.74
Plg plasminogen 216.20 373.49 3.20 3.04
Hdc histidine decarboxylase 315.63 545.31 3.35 2.09
Igfbp1 insulin-like growth factor binding protein 1 152.42 263.60 3.41 4.54
Slc36a2 solute carrier family 36, member 2 4.68 7.93 4.36 7.31
(proton/amino acid symporter)
Fetub fetuin B 278.59 481.09 4.83 5.94
Aldob aldolase B, fructose-bisphosphate 338.37 584.28 4.84 5.44
Gc group specific component 142.65 246.56 5.34 4.60
Hist1h1b histone cluster 1, H1b 341.16 572.03 23.50 4.44
Serpinf2 serpin peptidase inhibitor, clade F 105.75 182.30 77.12 129.15
(alpha-2 antiplasmin, pigment epithelium derived factor), member 2
E.1 Temporal Expression Patterns
Table E.6: Gene transcripts that were differentially expressed in RU486-treated de-
cidua between GD19+6hrs and GD20. Transcript expression levels are shown in transcripts
per million (TPM) values (mean±SD).
GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD20
Apoa1 apolipoprotein A-I 2.04 1.26 767.55 1319.41
Continued on next page
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GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Actg2 actin, gamma 2, smooth muscle, enteric 25.57 15.60 758.45 368.90
Fgg fibrinogen gamma chain 2.23 1.56 608.78 1054.08
Fgb fibrinogen beta chain 1.86 0.80 515.52 891.80
Myl9 myosin, light chain 9, regulatory 29.60 44.99 382.53 246.39
Acta2 actin, alpha 2, smooth muscle, aorta 6.78 5.26 264.47 146.50
Aldob aldolase B, fructose-bisphosphate 1.24 0.72 239.98 414.93
Rbp4 retinol binding protein 4, plasma 2.35 1.03 238.32 409.14
Ambp alpha-1-microglobulin/bikunin precursor 1.09 0.87 223.74 387.53
Hdc histidine decarboxylase 1.01 0.27 163.80 283.27
Hp haptoglobin 3.03 3.64 143.68 240.74
Cnn1 calponin 1, basic, smooth muscle 5.21 3.93 116.59 26.05
Cps1 carbamoyl-phosphate synthetase 1 0.50 0.13 97.69 169.17
Hamp hepcidin antimicrobial peptide 0.01 0.01 91.15 157.88
Myh11 myosin, heavy chain 11, smooth muscle 4.39 3.36 84.29 29.92
Ins2 insulin 2 0.00 0.00 61.79 102.12
Phlda3 pleckstrin homology-like domain, family A, 0.60 0.55 45.70 28.78
member 3
Hpd 4-hydroxyphenylpyruvate dioxygenase 0.08 0.08 27.47 47.35
Vnn1 vanin 1 0.94 0.30 27.31 23.43
Kirrel kin of IRRE like (Drosophila) 0.43 0.21 24.60 9.39
Cpn1 carboxypeptidase N, polypeptide 1 0.00 0.00 12.50 21.66
Gnmt glycine N-methyltransferase 0.04 0.07 11.88 20.57
Slc13a3 solute carrier family 13, member 3 0.09 0.10 10.58 18.15
(sodium-dependent dicarboxylate transporter)
Rassf6 Ras association (RalGDS/AF-6) domain family 0.23 0.02 9.32 14.80
member 6
Lurap1l leucine rich adaptor protein 1-like 0.01 0.02 6.82 7.39
Pllp plasmolipin 0.02 0.04 6.05 8.26
Ggt5 gamma-glutamyltransferase 5 0.00 0.00 5.22 6.88
G6pc glucose-6-phosphatase, catalytic subunit 0.01 0.01 4.33 7.49
Down-regulated on GD20
Il2rg interleukin 2 receptor, gamma 143.59 102.85 20.06 8.57
Prl3d2 Prolactin family 3, subfamily d, member 2 159.94 10.16 21.62 29.80
Table E.7: Gene transcripts that were differentially expressed in RU486-treated inner
myometrium between GD19+6hrs and GD20. Transcript expression levels are shown in
transcripts per million (TPM) values (mean±SD).
GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD20
Aass aminoadipate-semialdehyde synthase 0.00 0.00 2.43 4.19
Aldob aldolase B, fructose-bisphosphate 1.29 0.57 338.12 584.50
Ambp alpha-1-microglobulin/bikunin precursor 2.12 1.84 296.30 512.15
Amdhd1 amidohydrolase domain containing 1 0.05 0.09 7.38 12.64
Apcs amyloid P component, serum 0.00 0.00 7.95 13.76
Bhmt2 betaine-homocysteine S-methyltransferase 2 0.00 0.00 11.39 19.67
C8b complement component 8, beta polypeptide 0.00 0.00 23.04 39.90
Camp cathelicidin antimicrobial peptide 0.00 0.00 9.35 16.13
Cpn2 carboxypeptidase N, polypeptide 2 0.03 0.06 8.75 15.16
Cps1 carbamoyl-phosphate synthetase 1 0.50 0.44 109.00 188.21
Crp C-reactive protein, pentraxin-related 0.05 0.09 24.69 42.67
Ctsg cathepsin G 0.02 0.04 7.02 12.15
Cyp2d2 cytochrome P450, family 2, subfamily d, 0.00 0.00 8.95 15.43
polypeptide 2
Dpys dihydropyrimidinase 0.07 0.12 4.23 7.27
F10 coagulation factor X 0.00 0.00 15.93 25.69
F11 coagulation factor XI 0.15 0.05 6.50 11.16
F13b coagulation factor XIII, B polypeptide 0.00 0.00 8.62 14.92
Fetub fetuin B 1.90 1.90 278.67 481.02
Fgb fibrinogen beta chain 2.21 2.01 415.60 716.50
Gc group specific component 1.14 0.95 142.71 246.51
Grem2 gremlin 2 0.00 0.00 2.81 4.48
Hdc histidine decarboxylase 1.99 0.37 315.80 545.16
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GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Hpd 4-hydroxyphenylpyruvate dioxygenase 0.00 0.00 32.67 56.41
Ly6c Ly6-C antigen 0.09 0.10 16.81 9.79
Mep1a meprin 1 alpha 0.00 0.00 4.11 6.80
Mmp11 matrix metallopeptidase 11 35.32 29.27 1023.38 759.76
Onecut1 one cut homeobox 1 0.22 0.19 7.84 12.86
Pah phenylalanine hydroxylase 0.00 0.00 5.38 9.27
Pbld1 phenazine biosynthesis-like protein domain 3.77 6.53 3.77 5.90
containing 1
Pon1 paraoxonase 1 1.49 2.58 5.03 8.72
Ppargc1a peroxisome proliferator-activated receptor 1.32 2.29 6.20 8.70
gamma, coactivator 1 alpha
Prodh2 proline dehydrogenase (oxidase) 2 0.00 0.00 12.38 21.44
Samd10 sterile alpha motif domain containing 10 0.06 0.05 6.83 3.95
Sbk1 SH3 domain binding kinase 1 0.68 1.18 5.25 0.68
Scg2 secretogranin II 1.26 2.18 2.24 1.10
Serpinb10 serpin peptidase inhibitor, clade B (ovalbumin), 0.00 0.00 8.50 13.94
member 10
Sgpp2 sphingosine-1-phosphate phosphatase 2 0.28 0.49 6.58 11.39
Slamf7 SLAM family member 7 0.00 0.00 4.70 1.56
Slc14a1 solute carrier family 14 (urea transporter), 0.01 0.02 10.74 14.41
member 1
Slc17a1 solute carrier family 17 (organic anion transporter), 0.00 0.00 8.96 15.52
member 1
St8sia3 ST8 alpha-N-acetyl-neuraminide 0.00 0.00 7.53 13.05
alpha-2,8-sialyltransferase 3
Tfr2 transferrin receptor 2 0.00 0.00 19.04 32.89
Tnni1 troponin I type 1 (skeletal, slow) 0.00 0.00 13.73 23.55
Trim10 tripartite motif-containing 10 0.81 0.22 14.08 22.17
Trim58 tripartite motif-containing 58 0.00 0.00 10.91 18.90
Tsx testis specific X-linked gene 0.00 0.00 8.25 13.90
Ttpa tocopherol (alpha) transfer protein 0.00 0.01 8.46 14.34
Vcam1 vascular cell adhesion molecule 1 1.39 0.81 18.21 11.76
Vtn vitronectin 2.18 0.58 256.49 439.16
Down-regulated on GD20
Cbln1 cerebellin 1 precursor 4.06 5.90 0.01 0.02
Ctsq cathepsin Q 254.32 395.88 2.75 1.78
Gjb2 gap junction protein, beta 2 400.71 88.75 37.84 43.46
Kank1 KN motif and ankyrin repeat domains 1 29.77 29.80 10.81 2.73
Lgals4 lectin, galactoside-binding, soluble, 4 83.96 145.32 18.88 32.70
Lrp2 low density lipoprotein receptor-related 12.97 13.22 0.80 0.93
protein 2
Mcam melanoma cell adhesion molecule 158.70 180.92 22.11 9.28
Ndufaf3 NADH dehydrogenase (ubiquinone) complex I, 57.34 23.72 11.93 8.86
assembly factor 3
Ppl periplakin 22.63 17.84 7.96 5.48
Sgcg sarcoglycan, gamma 8.93 15.28 0.00 0.00
(dystrophin-associated glycoprotein)
Table E.8: Gene transcripts that were differentially expressed in RU486-treated outer
myometrium between GD19+6hrs and GD20. Transcript expression levels are shown in
transcripts per million (TPM) values (mean±SD).
GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated on GD20
Apoa1 apolipoprotein A-I 17.43 19.35 699.44 937.94
Psg29 pregnancy-specific glycoprotein 29 1.34 1.13 466.71 801.10
Cldn4 claudin 4 2.68 2.35 268.77 456.88
Ins2 insulin 2 0.02 0.04 62.95 87.82
Cldn6 claudin 6 3.96 1.77 50.61 68.38
Ptges prostaglandin E synthase 0.00 0.00 25.58 42.75
Utf1 undifferentiated embryonic cell transcription 0.00 0.00 20.30 32.88
factor 1
Pax1 paired box 1 0.06 0.10 12.16 10.94
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GD19+6hrs GD20
Gene symbol Gene name TPM ±SD TPM ±SD
Slc22a3 solute carrier family 22, member 3 0.00 0.00 4.33 7.10
(organic cation transporter)
Grip2 glutamate receptor interacting protein 2 0.05 0.08 3.98 5.98
Down-regulated on GD20
Slc4a11 solute carrier family 4, sodium borate transporter, member 11 119.21 102.23 3.18 3.33
Lcn2 lipocalin 2 366.02 435.02 4.25 3.63
Mmp1a matrix metallopeptidase 1 (interstitial collagenase) 95.74 165.74 4.55 6.69
Pcsk6 proprotein convertase subtilisin/kexin type 6 57.97 36.35 6.98 7.57
E.2 Comparison with Control Tissues
Table E.9: Gene transcripts that were differentially expressed in response to treat-
ment with RU486 in the decidua. Comparisons were made between transcript expression
in control tissues obtained on GD19+6hrs and transcript expression in RU486-treated tissues ob-
tained on GD19+6hrs. Transcript expression levels are shown in transcripts per million (TPM)
values (mean±SD).
GD19+6hrs Control GD19+6hrs RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in RU486-treated tissue
Creg1 cellular repressor of E1A-stimulated genes 1 167.41 159.25 2259.82 1605.20
Fkbp11 FK506 binding protein 11 15.34 7.43 78.75 60.49
Slit1 slit homolog 1 (Drosophila) 3.67 3.13 37.60 36.10
Alb albumin 1.74 1.62 29.41 22.63
Defb36 defensin beta 36 0.00 0.00 17.48 30.28
Matn1 matrilin 1, cartilage matrix protein 0.11 0.20 10.55 18.27
Zp1 zona pellucida glycoprotein 1 (sperm receptor) 0.02 0.04 9.93 10.00
Lect1 leukocyte cell derived chemotaxin 1 1.26 2.03 6.31 10.94
Down-regulated in RU486-treated tissue
Clrn3 clarin 3 4.33 1.81 0.00 0.00
Ins2 insulin 2 27.87 35.55 0.00 0.00
Asic3 acid-sensing (proton-gated) ion channel 3 5.60 4.48 0.01 0.01
Bend7 BEN domain containing 7 1.83 1.17 0.01 0.02
Rgs1 regulator of G-protein signaling 1 2.50 3.48 0.01 0.02
Abcc8 ATP-binding cassette, subfamily C (CFTR/MRP), member 8 5.67 4.81 0.02 0.03
Pllp plasmolipin 2.60 2.50 0.02 0.04
Tnni1 troponin I type 1 (skeletal, slow) 7.08 4.18 0.03 0.03
Hgd homogentisate 1, 2-dioxygenase 0.85 0.76 0.03 0.04
Ace2 angiotensin I converting enzyme 2 8.28 3.87 0.06 0.10
Pdzk1ip1 PDZK1 interacting protein 1 25.36 22.95 0.06 0.06
Mybpc3 myosin binding protein C, cardiac 9.94 2.49 0.07 0.13
Slc22a3 solute carrier family 22 (organic cation transporter), member 3 2.36 3.10 0.09 0.08
Tm4sf20 transmembrane 4 L six family member 20 6.12 3.31 0.09 0.06
Slc13a3 solute carrier family 13 5.07 6.80 0.09 0.10
(sodium-dependent dicarboxylate transporter), member 3
RGD1305807 hypothetical LOC298077 2.14 2.08 0.09 0.16
Gcm1 glial cells missing homolog 1 (Drosophila) 8.82 6.00 0.09 0.09
Wnk3 WNK lysine deficient protein kinase 3 5.15 1.00 0.12 0.12
Ephx1 epoxide hydrolase 1, microsomal (xenobiotic) 5.28 1.37 0.13 0.06
Apoc2 apolipoprotein C-II 73.03 57.13 0.13 0.03
Hnf4a hepatocyte nuclear factor 4, alpha 5.87 1.83 0.15 0.14
Heph hephaestin 1.47 1.38 0.17 0.19
Psat1 phosphoserine aminotransferase 1 3.73 3.25 0.17 0.15
Slc2a2 solute carrier family 2 (facilitated glucose transporter), member 2 5.37 3.33 0.19 0.04
Kitlg KIT ligand 21.69 19.14 0.20 0.19
Apoa2 apolipoprotein A-II 255.70 230.37 0.21 0.36
Proc protein C 279.51 466.82 0.22 0.20
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GD19+6hrs Control GD19+6hrs RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Rbp1 retinol binding protein 1, cellular 13.18 11.46 0.22 0.17
Rassf6 Ras association (RalGDS/AF-6) domain family member 6 4.58 2.98 0.23 0.02
Fmo1 flavin containing monooxygenase 1 16.56 6.65 0.25 0.16
Aqp8 aquaporin 8 15.88 8.58 0.26 0.19
Adtrp androgen-dependent TFPI-regulating protein 12.39 4.12 0.29 0.27
F2 coagulation factor II 38.52 19.11 0.30 0.12
Rps6ka6 ribosomal protein S6 kinase polypeptide 6 9.10 3.19 0.30 0.25
Slc22a23 solute carrier family 22, member 23 7.98 7.51 0.32 0.33
Fxyd2 FXYD domain-containing ion transport regulator 2 23.85 15.48 0.33 0.58
B4galnt3 beta-1,4-N-acetyl-galactosaminyl transferase 3 9.43 5.75 0.37 0.21
Gcgr glucagon receptor 15.08 6.49 0.37 0.27
RGD1309313 similar to RIKEN cDNA 4930538D17 14.46 8.70 0.39 0.60
Gucy2c guanylate cyclase 2C 3.11 0.95 0.41 0.10
Slco4a1 solute carrier organic anion transporter family, member 4a1 18.89 16.96 0.41 0.30
RGD1563547 RGD1563547 1.98 1.38 0.41 0.24
Kirrel kin of IRRE like (Drosophila) 5.45 4.75 0.43 0.21
Epb41l3 erythrocyte membrane protein band 4.1-like 3 8.87 4.67 0.44 0.33
RGD1305347 similar to RIKEN cDNA 2610528J11 14.43 14.65 0.46 0.42
Apon apolipoprotein N 4.06 3.19 0.49 0.10
Cubn cubilin (intrinsic factor-cobalamin receptor) 34.90 17.01 0.50 0.53
Ervfrd.1 endogenous retrovirus group FRD, member 1 13.85 8.64 0.54 0.44
Tns4 tensin 4 29.34 16.37 0.56 0.53
Lrp2 low density lipoprotein receptor-related protein 2 31.12 15.16 0.57 0.14
Apom apolipoprotein M 87.18 33.70 0.58 0.45
Spp2 secreted phosphoprotein 2 100.64 96.49 0.59 0.11
Phlda3 pleckstrin homology-like domain, family A, member 3 23.65 11.12 0.60 0.55
Afap1l1 actin filament associated protein 1-like 1 10.31 3.97 0.60 0.40
Gc group specific component 10.20 5.38 0.61 0.24
Phlda2 pleckstrin homology-like domain, family A, member 2 15.88 18.86 0.62 0.54
Akr1e2 aldo-keto reductase family 1, member E2 9.77 2.96 0.65 0.74
Slc13a4 solute carrier family 13 (sodium/sulfate symporter), member 4 33.43 16.92 0.80 1.02
Tst thiosulfate sulfurtransferase 28.25 10.97 0.84 0.25
Aadat aminoadipate aminotransferase 20.54 12.08 0.89 1.03
Vnn1 vanin 1 17.52 3.75 0.94 0.30
Apob apolipoprotein B 535.64 256.06 0.97 0.24
Crip1 cysteine-rich protein 1 (intestinal) 38.08 22.05 1.14 1.58
Stbd1 starch binding domain 1 12.37 8.98 1.15 0.39
S100a16 S100 calcium binding protein A16 12.97 3.04 1.27 1.71
Ctsc cathepsin C 39.64 19.99 1.27 1.07
Cdh1 cadherin 1 60.65 26.14 1.45 0.80
Depdc7 DEP domain containing 7 13.42 3.79 1.52 0.99
S100g S100 calcium binding protein G 71.45 76.21 1.52 1.50
Pdpn podoplanin 31.84 19.37 1.68 1.68
Mlxipl MLX interacting protein-like 7.69 3.92 1.79 2.11
Cspg5 chondroitin sulfate proteoglycan 5 (neuroglycan C) 3.59 2.27 1.80 1.59
Fgb fibrinogen beta chain 33.96 11.46 1.86 0.80
Apoa1 apolipoprotein A-I 651.04 422.62 2.04 1.26
Ttr transthyretin 660.29 525.55 2.20 1.29
MGC114246 similar to cathepsin R 33.80 20.69 2.23 1.00
Fgg fibrinogen gamma chain 42.01 21.19 2.23 1.56
Rbp4 retinol binding protein 4, plasma 126.35 153.08 2.35 1.03
Car4 carbonic anhydrase 4 72.54 35.73 2.38 1.81
Padi3 peptidyl arginine deiminase, type III 285.62 494.62 2.75 2.25
Fga fibrinogen alpha chain 78.63 39.83 2.86 1.92
Klf5 Kruppel-like factor 5 35.75 25.56 3.15 2.01
Npl N-acetylneuraminate pyruvate lyase 30.75 19.15 3.27 1.87
Tns3 tensin 3 29.83 11.50 3.72 1.48
F2rl1 coagulation factor II (thrombin) receptor-like 1 15.96 3.91 5.06 6.17
Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 104.89 142.55 7.97 8.11
Sepp1 selenoprotein P, plasma, 1 119.39 108.66 8.85 9.59
Afp alpha-fetoprotein 2331.59 1656.67 15.58 10.49
Ctsql2 cathepsin Q-like 2 996.54 599.53 16.86 16.46
Ctsq cathepsin Q 206.52 82.99 19.77 14.49
Apoa4 apolipoprotein A-IV 213.84 113.78 23.92 2.78
Ctsr cathepsin R 955.05 500.72 28.19 18.16
Table E.10: Gene transcripts that were differentially expressed in response to treat-
ment with RU486 in the inner myometrium. Comparisons were made between transcript
expression in control tissues obtained on GD19+6hrs and transcript expression in RU486-treated
tissues obtained on GD19+6hrs. Transcript expression levels are shown in transcripts per million
(TPM) values (mean±SD).
GD19+6hrs Control GD19+6hrs RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in RU486-treated tissue
Lcn2 lipocalin 2 2.43 2.87 3.12 2.73
Down-regulated in RU486-treated tissue
Fam71f2 family with sequence similarity 71, member F2 2.05 2.88 0.00 0.00
Table E.11: Gene transcripts that were differentially expressed in response to treat-
ment with RU486 in the outer myometrium. Comparisons were made between transcript
expression in control tissues obtained on GD19+6hrs and transcript expression in RU486-treated
tissues obtained on GD19+6hrs. Transcript expression levels are shown in transcripts per million
(TPM) values (mean±SD).
GD19+6hrs Control GD19+6hrs RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in RU486-treated tissue
Spp1 secreted phosphoprotein 1 27.88 22.27 889.53 771.63
Kap kidney androgen regulated protein 9.83 12.09 713.32 665.47
Isyna1 inositol-3-phosphate synthase 1 25.10 12.58 684.90 600.84
Guca2b guanylate cyclase activator 2B 6.77 11.55 631.78 688.46
Lcn2 lipocalin 2 9.09 12.62 366.02 435.02
C3 complement component 3 6.39 1.02 328.78 314.39
Lrat lecithin-retinol acyltransferase 1.56 1.26 101.55 97.13
(phosphatidylcholine-retinol-O-acyltransferase)
Slc4a11 solute carrier family 4, member 11 1.86 2.84 33.47 42.01
(sodium borate transporter)
Defb1 defensin beta 1 0.00 0.00 31.84 38.48
Cldn10 claudin 10 1.01 1.41 27.51 23.67
Upk3bl uroplakin 3B-like 0.00 0.00 22.32 26.61
Kif12 kinesin family member 12 0.09 0.16 13.03 11.29
Slc17a3 solute carrier family 17, member 3 0.20 0.16 7.16 6.87
(organic anion transporter)
Down-regulated in RU486-treated tissue
Hs3st6 heparan sulfate (glucosamine) 3-O-sulfotransferase 6 18.57 31.97 0.00 0.00
Ptges prostaglandin E synthase 43.71 39.21 0.00 0.00
Slc22a3 solute carrier family 2, member 3 6.20 10.70 0.00 0.00
(organic cation transporter)
Ebf2 early B-cell factor 2 5.93 5.73 0.04 0.04
Pax1 paired box 1 14.59 19.58 0.06 0.10
Psg16 pregnancy specific glycoprotein 16 198.30 340.80 1.16 1.52
Psg29 pregnancy-specific glycoprotein 29 406.70 686.64 1.34 1.13
Dlk1 delta-like 1 homolog (Drosophila) 512.71 887.85 2.13 1.55
Atg9b autophagy related 9B 26.36 45.65 7.77 6.84
Table E.12: Gene transcripts that were differentially expressed in response to treat-
ment with RU486 in the decidua. Comparisons were made between transcript expression in
control tissues obtained on GD20 and transcript expression in RU486-treated tissues obtained on
GD20. Transcript expression levels are shown in transcripts per million (TPM) values (mean±SD).
GD20 Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Down-regulated in RU486-treated tissue
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GD20 Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 309.05 301.48 12.11 5.17
Ogdhl oxoglutarate dehydrogenase-like 17.81 16.91 2.13 1.77
Table E.13: Gene transcripts that were differentially expressed in response to treat-
ment with RU486 in the inner myometrium. Comparisons were made between transcript
expression in control tissues obtained on GD20 and transcript expression in RU486-treated tissues
obtained on GD20. Transcript expression levels are shown in transcripts per million (TPM) values
(mean±SD).
GD20 Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in RU486-treated tissue
Rnase1 ribonuclease, RNase A family, 1 (pancreatic) 4.73 4.61 402.21 586.18
Hdc histidine decarboxylase 0.97 0.32 315.80 545.16
Plg plasminogen 2.31 1.84 216.14 373.54
Pzp pregnancy-zone protein 0.66 0.29 209.88 362.76
Myh10 myosin, heavy chain 10, non-muscle 14.11 3.34 171.38 104.30
Serpinc1 serpin peptidase inhibitor, clade C 1.37 1.60 156.53 270.42
(antithrombin), member 1
Fgl2 fibrinogen-like 2 3.16 3.78 154.06 138.88
Cps1 carbamoyl-phosphate synthetase 1 0.81 0.63 109.00 188.21
Itih4 inter-alpha-trypsin inhibitor heavy chain 1.03 1.51 98.25 169.94
family, member 4
Bhmt betaine-homocysteine S-methyltransferase 2 1.38 1.69 93.58 161.30
Cpox coproporphyrinogen oxidase 2.54 0.41 88.22 140.65
Hamp hepcidin antimicrobial peptide 0.00 0.00 41.80 72.09
Ikzf1 IKAROS family zinc finger 1 0.93 1.44 39.49 38.11
Stox2 storkhead box 2 1.26 0.76 28.39 20.14
Lgals4 lectin, galactoside-binding, soluble, 4 0.01 0.01 18.88 32.70
Tmem178a transmembrane protein 178A 0.01 0.01 17.81 12.34
Nrgn neurogranin 3.56 2.74 17.33 8.89
Krt20 keratin 20 0.00 0.00 17.28 29.92
A1cf APOBEC1 complementation factor 0.00 0.00 14.00 24.25
Upb1 ureidopropionase, beta 0.00 0.00 13.87 24.02
Troap trophinin associated protein 0.00 0.00 13.55 22.76
Ptgfr prostaglandin F receptor 0.17 0.26 12.89 9.77
Prodh2 proline dehydrogenase (oxidase) 2 0.00 0.00 12.38 21.44
Gstm7 glutathione S-transferase, mu 7 0.18 0.23 12.18 20.42
Agr2 anterior gradient 2 0.00 0.00 11.77 20.33
Spc25 SPC25, NDC80 kinetochore complex component 0.01 0.02 10.21 15.94
Ccrl2 chemokine (C-C motif) receptor-like 2 0.01 0.03 10.15 10.49
RGD1559600 RGD1559600 0.02 0.04 10.11 17.52
C9 complement component 9 0.14 0.14 9.98 17.12
Camp cathelicidin antimicrobial peptide 0.00 0.00 9.35 16.13
Msi1 musashi RNA-binding protein 1 0.01 0.02 9.13 6.95
Nags N-acetylglutamate synthase 0.00 0.01 8.38 14.52
Apcs amyloid P component, serum 0.00 0.00 7.95 13.76
Fabp7 fatty acid binding protein 7, brain 0.00 0.00 7.59 13.14
St8sia3 ST8 alpha-N-acetyl-neuraminide 0.00 0.00 7.53 13.05
alpha-2,8-sialyltransferase 3
Zfp428 zinc finger protein 428 0.15 0.22 7.53 1.99
RGD1564614 similar to complement factor H-related protein 0.01 0.01 7.46 12.88
Amdhd1 amidohydrolase domain containing 1 0.00 0.00 7.38 12.64
Anxa13 annexin A13 0.00 0.00 7.26 12.57
Mamdc4 MAM domain containing 4 0.05 0.06 7.22 11.10
Ctsg cathepsin G 0.00 0.00 7.02 12.15
Sgpp2 sphingosine-1-phosphate phosphatase 2 0.00 0.00 6.58 11.39
Prkg2 protein kinase, cGMP-dependent, type II 0.00 0.01 6.03 10.38
Pah phenylalanine hydroxylase 0.00 0.00 5.38 9.27
Slamf7 SLAM family member 7 0.00 0.00 4.70 1.56
Nr1i2 nuclear receptor subfamily 1, group I, member 2 0.00 0.00 4.50 7.79
Cst7 cystatin F (leukocystatin) 0.02 0.03 4.49 2.62
Shisa3 shisa family member 3 0.00 0.00 4.31 7.47
Continued on next page
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GD20 Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Dpys dihydropyrimidinase 0.10 0.10 4.23 7.27
Igsf1 immunoglobulin superfamily, member 1 0.01 0.01 3.74 6.21
Gpr68 G protein-coupled receptor 68 0.00 0.00 2.50 1.44
Down-regulated in RU486-treated tissue
Agtr1b angiotensin II receptor, type 1b 1.90 3.27 0.00 0.00
Iapp islet amyloid polypeptide 37.67 55.80 0.00 0.00
Ica1l islet cell autoantigen 1-like 10.85 18.66 0.00 0.00
Nr0b2 nuclear receptor subfamily 0, group B, member 2 10.58 13.18 0.00 0.00
RGD1559493 similar to Hypothetical protein MGC58608 9.61 16.64 0.00 0.00
Sgcg sarcoglycan, gamma 3.48 3.55 0.00 0.00
(dystrophin-associated glycoprotein)
Syt6 synaptotagmin VI 9.02 15.04 0.00 0.00
Wfdc11 WAP four-disulfide core domain 11 8.88 9.60 0.00 0.00
Cbln1 cerebellin 1 precursor 3.21 5.55 0.01 0.02
Defb1 defensin beta 1 12.55 12.39 0.01 0.02
Col4a4 collagen, type IV, alpha 4 6.67 10.62 0.09 0.09
LOC688553 hypothetical protein LOC688553 20.63 15.17 0.26 0.24
Cubn cubilin (intrinsic factor-cobalamin receptor) 12.35 19.70 0.31 0.11
Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), 22.81 23.92 0.65 0.44
member 1A
Tshr thyroid stimulating hormone receptor 15.08 15.69 0.70 0.17
Scel sciellin 58.57 79.90 0.80 0.55
Lrp2 low density lipoprotein receptor-related protein 2 69.42 63.47 0.80 0.93
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), 448.31 578.32 1.00 0.72
member 1B
Ccdc64 coiled-coil domain containing 64 71.18 68.46 1.16 1.00
Tmprss4 transmembrane protease, serine 4 87.55 119.72 1.24 1.08
Pax8 paired box 8 161.20 170.81 1.29 0.16
Ehf ets homologous factor 45.68 35.58 1.56 1.15
Cyb561 cytochrome b-561 67.28 100.58 1.66 1.66
Jag1 jagged 1 4.04 7.00 2.10 1.91
Pkib protein kinase (cAMP-dependent, catalytic) 41.81 55.26 2.49 1.05
inhibitor beta
Mab21l3 mab-21-like 3 (C. elegans) 38.50 33.49 2.49 0.92
Folr1 folate receptor 1 (adult) 87.37 83.78 2.52 0.79
Slc34a2 solute carrier family 34, member 2 81.71 78.36 2.55 2.17
(type II sodium/phosphate contransporter)
Ctsm cathepsin M 167.78 254.19 2.68 2.46
Ctsq cathepsin Q 307.15 382.03 2.75 1.78
Sgms2 sphingomyelin synthase 2 35.69 35.97 3.19 3.02
Lamc2 laminin, gamma 2 41.50 43.65 3.45 1.86
Slc5a3 solute carrier family 5, member 3 57.11 54.54 3.46 3.21
(sodium/myo-inositol cotransporter)
Kazn kazrin, periplakin interacting protein 44.47 26.70 3.55 0.47
Chmp4c charged multivesicular body protein 4C 32.78 30.89 3.84 1.97
Taf7l TAF7-like RNA polymerase II, TATA box binding 132.46 211.15 3.97 3.45
protein (TBP)-associated factor
Fut2 fucosyltransferase 2 (secretor status included) 175.95 215.98 4.11 5.59
Arhgef6 Rac/Cdc42 guanine nucleotide exchange factor 6 76.26 85.24 4.16 1.84
Slco4a1 solute carrier organic anion transporter family, 277.95 180.45 4.17 1.51
member 4a1
Psgb1 pregnancy-specific beta 1-glycoprotein 368.01 616.85 4.18 4.30
Dysf dysferlin 25.19 11.95 4.77 2.88
Tppp3 tubulin polymerization-promoting protein family 77.74 70.19 5.36 1.05
member 3
Napsa napsin A aspartic peptidase 88.74 90.18 5.70 2.39
Lpo lactoperoxidase 98.90 75.56 5.70 9.33
Prss8 protease, serine, 8 90.32 62.40 6.19 5.28
Slc4a11 solute carrier family 4, sodium borate 392.42 478.35 6.45 2.86
transporter, member 11
Lrat lecithin-retinol acyltransferase 308.27 357.79 6.58 1.55
(phosphatidylcholine-retinol-O-acyltransferase)
St14 suppression of tumorigenicity 14 69.06 27.33 7.65 7.94
(colon carcinoma)
Ppl periplakin 63.45 32.27 7.96 5.48
RGD1562136 similar to D1Ertd622e protein 43.70 17.64 8.09 4.43
Pdzk1ip1 PDZK1 interacting protein 1 79.22 16.02 8.18 10.73
Continued on next page
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GD20 Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Csf1 colony stimulating factor 1 (macrophage) 346.31 424.63 8.22 1.42
Guca2b guanylate cyclase activator 2B 451.06 334.58 8.91 13.84
Oxt oxytocin/neurophysin 1 prepropeptide 435.40 359.58 8.93 12.40
Enpp1 ectonucleotide pyrophosphatase/ 57.85 13.55 11.39 7.16
phosphodiesterase 1
Wfs1 Wolfram syndrome 1 (wolframin) 142.57 163.66 12.07 5.56
Perp PERP, TP53 apoptosis effector 156.75 78.00 12.19 17.34
Thbs4 thrombospondin 4 289.73 348.89 12.22 17.80
Abhd2 abhydrolase domain containing 2 77.61 17.56 14.00 4.43
Ctsr cathepsin R 1663.16 2083.44 14.44 12.38
Prl3b1 Prolactin family 3, subfamily b, member 1 626.45 830.23 16.55 14.30
Ctsj cathepsin J 1622.67 2078.93 17.47 14.20
Crip2 cysteine-rich protein 2 127.22 107.48 22.67 12.13
Lcn2 lipocalin 2 329.97 238.57 28.72 26.02
Gjb2 gap junction protein, beta 2 493.48 360.92 37.84 43.46
Rexo2 RNA exonuclease 2 226.13 101.76 68.23 16.11
Table E.14: Gene transcripts that were differentially expressed in response to treat-
ment with RU486 in the outer myometrium. Comparisons were made between transcript
expression in control tissues obtained on GD20 and transcript expression in RU486-treated tissues
obtained on GD20. Transcript expression levels are shown in transcripts per million (TPM) values
(mean±SD).
GD20 Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in RU486-treated tissue
LOC171573 spleen protein 1 precursor 4.43 4.96 1303.85 2246.62
Prl8a2 prolactin family 8, subfamily a, member 2 3.19 2.34 814.23 1407.10
Serpine1 serpin peptidase inhibitor, clade E, member 1 36.01 19.61 430.89 633.87
(nexin, plasminogen activator inhibitor type 1)
Sbsn suprabasin 7.90 1.60 321.53 551.52
Slc38a4 solute carrier family 38, member 4 5.69 2.11 287.91 497.03
Dusp9 dual specificity phosphatase 9 8.21 6.96 161.84 214.60
Prl7a4 prolactin family 7, subfamily a, member 4 0.00 0.00 158.89 240.88
Fndc3c1 fibronectin type III domain containing 3C1 1.07 1.62 146.04 249.96
Prl3a1 Prolactin family 3, subfamily a, member 1 0.00 0.00 87.00 100.72
Slc13a4 solute carrier family 13, member 4 4.01 3.76 81.70 136.01
(sodium/sulfate symporter)
Pla2g10 phospholipase A2, group X 0.00 0.00 71.27 107.43
Sfmbt2 Scm-like with four mbt domains 2 4.54 2.69 62.35 101.24
RGD1564534 similar to CHCHD4 protein 3.30 1.98 47.16 78.82
Htr1d 5-hydroxytryptamine (serotonin) receptor 1D, 0.00 0.00 41.73 72.12
G protein-coupled
Kit v-kit Hardy-Zuckerman 4 feline sarcoma viral 2.72 1.07 23.64 33.60
oncogene homolog
Dmrtc1c DMRT-like family C1c1 0.00 0.00 22.44 38.74
Rimbp2 RIMS binding protein 2 0.58 0.14 15.27 19.89
Il17f interleukin 17F 0.00 0.00 6.81 11.75
LOC367830 similar to FAM48A protein 0.00 0.00 4.68 7.68
Grip2 glutamate receptor interacting protein 2 0.00 0.00 3.98 5.98
Tbx5 T-box 5 0.00 0.00 3.57 3.86
Tmem59l transmembrane protein 59-like 0.00 0.00 3.32 4.88
Atp4a ATPase, H+/K+ exchanging, alpha polypeptide 0.35 0.23 3.32 5.67
Cftr cystic fibrosis transmembrane conductance regulator 0.42 0.49 2.87 3.56
Gdap1l1 ganglioside-induced differentiation-associated 0.00 0.00 2.84 4.38
protein 1-like 1
Down-regulated in RU486-treated tissue
Crp C-reactive protein, pentraxin-related 10.39 15.09 0.00 0.00
Dpys dihydropyrimidinase 3.18 5.36 0.10 0.08
Pzp pregnancy-zone protein 45.48 78.08 0.55 0.63
Ect2 epithelial cell transforming 2 6.23 2.58 0.64 0.14
Cldn1 claudin 1 35.46 14.62 1.06 0.53
Tenm2 teneurin transmembrane protein 2 11.44 5.65 1.38 1.59
Continued on next page
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GD20 Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Atp6v0a4 ATPase, H+ transporting, lysosomal V0 subunit A4 47.10 52.05 1.61 1.18
Vtn vitronectin 71.06 87.40 2.00 0.74
F5 coagulation factor V (proaccelerin, labile factor) 32.97 18.54 2.91 1.81
Fst follistatin 33.92 23.08 2.93 0.69
Fam111a family with sequence similarity 111, member A 61.38 58.35 3.11 2.13
Slc4a11 solute carrier family 4, sodium borate transporter, 268.24 284.96 3.18 3.33
member 11
Plg plasminogen 69.47 109.37 3.20 3.04
Sult1a1 sulfotransferase family, cytosolic, 1A, 68.95 19.12 3.20 1.68
phenol-preferring, member 1
Igfbp1 insulin-like growth factor binding protein 1 94.70 69.66 3.41 4.54
Lcn2 lipocalin 2 162.92 103.93 4.25 3.63
Ahsg alpha-2-HS-glycoprotein 527.33 911.90 4.45 7.58
Col11a1 collagen, type XI, alpha 1 48.21 28.64 4.63 4.50
Fetub fetuin B 117.16 173.61 4.83 5.94
Aldob aldolase B, fructose-bisphosphate 105.04 166.77 4.84 5.44
Gc group specific component 121.95 116.89 5.34 4.60
Uchl1 ubiquitin carboxyl-terminal esterase L1 105.05 76.27 6.65 1.60
(ubiquitin thiolesterase)
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 61.29 34.41 8.00 7.37
(mitochondrial)
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), 271.55 265.10 9.05 12.49
member 1B
Gatm glycine amidinotransferase 183.23 227.90 12.50 0.81
(L-arginine:glycine amidinotransferase)
Tspan8 tetraspanin 8 334.97 393.33 12.61 2.91
Nnat neuronatin 177.76 149.85 13.33 7.06
Isyna1 inositol-3-phosphate synthase 1 1052.83 1069.36 23.59 16.69
Mt2A metallothionein 2A 1034.18 166.76 153.67 5.28
Table E.15: Gene transcripts that were differentially expressed in response to treat-
ment with RU486 in the decidua. Comparisons were made between transcript expression
in control tissues obtained on GD22 (NL) and transcript expression in RU486-treated tissues ob-
tained on GD20. Transcript expression levels are shown in transcripts per million (TPM) values
(mean±SD).
GD22 (NL) Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in RU486-treated tissue
Prl8a9 prolactin family 8, subfamily a, member 9 272.97 371.84 6801.82 5576.89
Prl3d4 prolactin family 3, subfamily d, member 4 16.49 23.55 1118.79 879.35
Psg19 pregnancy specific glycoprotein 19 27.38 18.58 1049.76 828.40
Creg1 cellular repressor of E1A-stimulated genes 1 36.21 43.63 811.68 708.11
Timp3 TIMP metallopeptidase inhibitor 3 40.32 26.12 466.68 333.89
Psg16 pregnancy specific glycoprotein 16 3.63 2.07 267.78 315.01
Slc38a4 solute carrier family 38, member 4 14.54 13.24 203.93 212.16
Psg29 pregnancy-specific glycoprotein 29 3.08 2.60 202.80 311.83
Hp haptoglobin 2.65 0.74 143.68 240.74
Slc4a1 solute carrier family 4, member 1 1.73 0.66 136.97 234.07
(anion exchanger)
Vtn vitronectin 1.75 1.28 84.33 136.99
Folr1 folate receptor 1 (adult) 2.35 1.50 70.90 118.51
Perp PERP, TP53 apoptosis effector 1.29 1.77 55.48 56.28
Apoa2 apolipoprotein A-II 0.00 0.00 50.15 86.86
Car1 carbonic anhydrase I 0.00 0.00 31.83 55.13
Hpd 4-hydroxyphenylpyruvate dioxygenase 0.02 0.03 27.47 47.35
Ocm hypothetical protein LOC498662 0.43 0.36 22.83 21.12
LOC498662 testis development related protein 0.98 0.37 22.51 16.46
Fabp1 fatty acid binding protein 1, liver 0.00 0.00 21.05 36.46
Slc2a2 solute carrier family 2, member 2 0.03 0.01 16.84 29.17
(facilitated glucose transporter)
Asgr1 asialoglycoprotein receptor 1 0.14 0.13 14.26 24.13
Cpn1 carboxypeptidase N, polypeptide 1 0.02 0.04 12.50 21.66
Cubn cubilin (intrinsic factor-cobalamin receptor) 0.14 0.03 12.15 19.31
Gnmt glycine N-methyltransferase 0.01 0.02 11.88 20.57
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GD22 (NL) Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
RGD1564894 similar to glycine-N-acyltransferase isoform a 0.00 0.00 10.56 18.29
Apof apolipoprotein F 0.12 0.22 9.17 15.88
Amdhd1 amidohydrolase domain containing 1 0.00 0.00 8.31 14.39
Down-regulated in RU486-treated tissue
Slc4a7 solute carrier family 4, sodium bicarbonate 26.01 19.54 5.25 1.57
cotransporter, member 7
Hsd11b2 hydroxysteroid 11-beta dehydrogenase 2 100.16 24.95 12.11 5.17
Table E.16: Gene transcripts that were differentially expressed in response to treat-
ment with RU486 in the inner myometrium. Comparisons were made between transcript
expression in control tissues obtained on GD22 (NL) and transcript expression in RU486-treated
tissues obtained on GD20. Transcript expression levels are shown in transcripts per million (TPM)
values (mean±SD).
GD22 (NL) Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in RU486-treated tissue
Fgg fibrinogen gamma chain 1.81 2.45 902.25 1559.17
Apoa1 apolipoprotein A-I 2.43 3.93 549.55 936.67
Hemgn hemogen 1.12 1.68 442.61 763.44
Fgb fibrinogen beta chain 1.40 2.16 415.60 716.50
Hist1h1b histone cluster 1, H1b 6.43 7.06 339.82 573.19
Hdc histidine decarboxylase 0.70 0.71 315.80 545.16
Rbp4 retinol binding protein 4, plasma 1.62 1.80 300.26 510.30
Vtn vitronectin 2.20 1.63 256.49 439.16
Plg plasminogen 1.14 1.10 216.14 373.54
Pzp pregnancy-zone protein 0.93 0.35 209.88 362.76
Itih4 inter-alpha-trypsin inhibitor heavy chain 1.13 0.81 98.25 169.94
family, member 4
Cfi complement factor I 2.19 1.94 94.25 162.29
Slc25a37 solute carrier family 25, member 37 2.14 1.18 86.27 133.28
(mitochondrial iron transporter)
Sptb spectrin, beta, erythrocytic 0.56 0.91 74.45 126.84
Pklr pyruvate kinase, liver and RBC 3.18 3.61 72.34 121.72
Ube2c ubiquitin-conjugating enzyme E2C 1.85 1.31 69.56 118.03
Defa defensin alpha-like 0.00 0.00 57.84 97.77
Psat1 phosphoserine aminotransferase 1 1.97 2.87 55.74 88.72
Spta1 spectrin, alpha, erythrocytic 1 0.33 0.24 54.07 93.02
(elliptocytosis 2)
Cldn1 claudin 1 1.31 1.20 32.06 51.98
F5 coagulation factor V 1.34 0.48 25.34 42.04
(proaccelerin, labile factor)
Crp C-reactive protein, pentraxin-related 0.00 0.00 24.69 42.67
Lgals4 lectin, galactoside-binding, soluble, 4 0.00 0.00 18.88 32.70
Krt20 keratin 20 0.00 0.00 17.28 29.92
Dmbt1 deleted in malignant brain tumors 1 0.64 0.51 15.28 9.87
Klkb1 kallikrein B, plasma 1 0.00 0.00 14.22 24.62
Prodh2 proline dehydrogenase (oxidase) 2 0.00 0.00 12.38 21.44
Haao 3-hydroxyanthranilate 3,4-dioxygenase 0.00 0.00 11.99 20.67
Agr2 anterior gradient 2 0.00 0.00 11.77 20.33
Alpi alkaline phosphatase, intestinal 0.01 0.02 10.55 18.28
RGD1559600 RGD1559600 0.00 0.00 10.11 17.52
C9 complement component 9 0.07 0.03 9.98 17.12
Camp cathelicidin antimicrobial peptide 0.00 0.00 9.35 16.13
Slc17a1 solute carrier family 17, member 1 0.00 0.00 8.96 15.52
(organic anion transporter)
Ttpa tocopherol (alpha) transfer protein 0.00 0.00 8.46 14.34
Slc30a10 solute carrier family 30, member 10 0.00 0.00 8.38 14.52
Apcs amyloid P component, serum 0.00 0.00 7.95 13.76
Hnf4g hepatocyte nuclear factor 4, gamma 0.00 0.00 7.82 13.55
RGD1564614 similar to complement factor H-related protein 0.06 0.07 7.46 12.88
Amdhd1 amidohydrolase domain containing 1 0.01 0.02 7.38 12.64
Anxa13 annexin A13 0.01 0.01 7.26 12.57
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Gene symbol Gene name TPM ±SD TPM ±SD
Mamdc4 MAM domain containing 4 0.00 0.00 7.22 11.10
Guca2a guanylate cyclase activator 2a (guanylin) 0.00 0.00 6.46 11.19
Aspdh aspartate dehydrogenase domain containing 0.00 0.00 6.25 10.82
Gcg glucagon 0.00 0.00 5.47 9.47
Pah phenylalanine hydroxylase 0.00 0.00 5.38 9.27
Gp5 glycoprotein V (platelet) 0.00 0.00 4.96 8.39
Slc17a3 solute carrier family 17, member 3 0.04 0.04 4.89 8.26
(organic anion transporter)
Slc26a3 solute carrier family 26, member 3 0.00 0.00 4.71 8.07
(anion exchanger)
Slc36a2 solute carrier family 36, member 2 0.05 0.06 4.68 7.93
(proton/amino acid symporter)
Nr1i2 nuclear receptor subfamily 1, group I, member 2 0.00 0.00 4.50 7.79
Aldh1a1 aldehyde dehydrogenase 1 family, member A1 0.00 0.00 4.01 6.93
Stmn2 stathmin-like 2 0.00 0.00 3.46 6.00
Tmem229a transmembrane protein 229A 0.25 0.06 3.40 4.85
Clec12b C-type lectin domain family 12, member B 0.00 0.00 3.38 5.46
Hepacam2 HEPACAM family member 2 0.00 0.00 2.93 5.08
Cpamd8 C3 and PZP-like, alpha-2-macroglobulin domain 0.00 0.00 2.44 4.10
containing 8
Aass aminoadipate-semialdehyde synthase 0.00 0.00 2.43 4.19
Slc5a1 solute carrier family 5, member 1 0.00 0.00 2.33 3.94
(sodium/glucose cotransporter)
Hhip Hedgehog-interacting protein 0.06 0.07 2.10 3.59
Cyp7a1 cytochrome P450, family 7, subfamily a, 0.13 0.00 2.09 3.09
polypeptide 1
Slitrk4 SLIT and NTRK-like family, member 4 0.00 0.00 1.21 2.09
Down-regulated in RU486-treated tissue
LOC685544 hypothetical protein LOC685544 106.53 184.51 0.00 0.00
Olr1218 olfactory receptor 1218 7.21 9.02 0.00 0.00
Gnat2 guanine nucleotide binding protein (G protein), 4.69 7.88 0.01 0.02
alpha transducing activity polypeptide 2
Krt17 keratin 17 7.67 13.28 0.02 0.03
Sftpc surfactant protein C 2.95 5.11 0.02 0.04
Drp2 dystrophin related protein 2 8.78 5.76 0.09 0.09
LOC690326 hypothetical protein LOC690326 28.36 25.68 0.63 0.66
Apod apolipoprotein D 17.56 17.10 0.74 0.56
Nppa natriuretic peptide A 58.89 63.00 1.47 1.19
Ebf3 early B-cell factor 3 18.63 21.52 1.48 1.03
Htr2a 5-hydroxytryptamine (serotonin) receptor 2A, 86.91 148.90 2.22 2.15
G protein-coupled
Prl7a4 prolactin family 7, subfamily a, member 4 267.85 446.91 2.32 2.86
Folr1 folate receptor 1 (adult) 41.98 70.89 2.52 0.79
PCOLCE2 procollagen C-endopeptidase enhancer 2 60.75 37.17 2.55 2.36
Rhox9 reproductive homeobox 9 59.41 43.55 2.58 3.50
Ctsm cathepsin M 224.42 353.44 2.68 2.46
Ctsq cathepsin Q 124.52 215.09 2.75 1.78
Hpgd hepatocyte nuclear factor 4, gamma 35.26 17.77 3.43 1.22
Dmkn dermokine 59.60 64.61 3.44 3.59
Fndc3c1 fibronectin type III domain containing 3C1 169.74 138.42 3.63 3.37
Taf7l TAF7-like RNA polymerase II, TATA box 321.55 209.52 3.97 3.45
binding protein (TBP)-associated factor
Psgb1 pregnancy-specific beta 1-glycoprotein 318.33 547.14 4.18 4.30
Prl7a3 prolactin family 7, subfamily a, member 3 153.98 51.71 4.53 4.00
Cilp cartilage intermediate layer protein, 46.49 28.93 5.54 5.38
nucleotide pyrophosphohydrolase
Prima1 proline rich membrane anchor 1 25.88 27.79 5.75 2.78
Adamts9 ADAM metallopeptidase with 36.93 4.63 6.99 2.15
thrombospondin type 1 motif, 9
Foxo4 forkhead box O4 132.66 49.22 10.48 8.63
Prl8a2 prolactin family 8, subfamily a, member 2 508.14 727.51 13.20 6.32
Ednrb endothelin receptor type B 346.91 137.08 13.54 3.49
Cited1 Cbp/p300-interacting transactivator with 483.54 198.23 33.07 41.19
Glu/Asp-rich carboxy-terminal domain 1
Prl2c1 Prolactin family 2, subfamily c, member 1 805.52 591.09 69.94 61.57
Prl5a1 prolactin family 5, subfamily a, member 1 1092.25 866.74 82.30 72.80
Prl2a1 Prolactin family 2, subfamily a, member 1 4322.65 1652.99 226.20 258.79
E.2. Comparison with Control Tissues
Table E.17: Gene transcripts that were differentially expressed in response to treat-
ment with RU486 in the outer myometrium. Comparisons were made between transcript
expression in control tissues obtained on GD22 (NL) and transcript expression in RU486-treated
tissues obtained on GD20. Transcript expression levels are shown in transcripts per million (TPM)
values (mean±SD).
GD22 (NL) Control GD20 RU486
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated in RU486-treated tissue
Car4 carbonic anhydrase 4 2.78 1.02 61.52 89.52
Tac1 tachykinin, precursor 1 0.00 0.00 11.13 15.99
Down-regulated in RU486-treated tissue
Apcs amyloid P component, serum 28.50 49.18 0.00 0.00
Crp C-reactive protein, pentraxin-related 23.28 40.33 0.00 0.00
Cyp2c12 cytochrome P450, family 2, subfamily c, 5.90 9.84 0.02 0.04
polypeptide 12
Dpys dihydropyrimidinase 6.69 11.25 0.10 0.08
Fabp7 fatty acid binding protein 7, brain 126.13 217.96 0.14 0.24
Aldh1a7 aldehyde dehydrogenase family 1, subfamily A7 9.44 9.53 0.18 0.13
Pzp pregnancy-zone protein 127.17 219.61 0.55 0.63
Cldn1 claudin 1 20.50 25.59 1.06 0.53
Vtn vitronectin 196.99 333.38 2.00 0.74
Lcn2 lipocalin 2 126.31 66.72 4.25 3.63
Hp haptoglobin 511.81 885.89 7.18 8.93
Glrx glutaredoxin (thioltransferase) 135.84 123.07 15.83 9.86
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F.1 Tissue dependent Gene Expression
Table F.1: Transcripts that were significantly differentially expressed between the
decidua and the inner myometrium in P4-treated samples. Transcript expression levels
are shown in transcripts per million (TPM) (mean±SD).
Decidua Inner Myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Prl2a1 Prolactin family 2 subfamily a member 1 1667.40 1446.93 9530.79 15251.66
Prl5a2 prolactin family 5 subfamily a member 2 13.26 6.55 3804.28 6382.97
Actg2 actin gamma 2 smooth muscle enteric 283.80 447.52 3496.57 3891.67
Prl7b1 prolactin family 7 subfamily b member 1 109.32 68.41 2862.78 2440.30
Postn periostin osteoblast specific factor 44.06 57.45 2349.30 2212.21
Lum lumican 31.89 49.35 2318.22 2911.58
Myl9 myosin light chain 9 regulatory 257.24 356.90 2047.32 1974.55
Serpine2 serpin peptidase inhibitor clade E 312.44 272.19 1710.00 1035.12
(nexin plasminogen activator inhibitor type 1) member 2
Mmp11 matrix metallopeptidase 11 10.30 14.50 1039.57 940.36
Gpnmb glycoprotein (transmembrane) nmb 204.66 93.34 1037.34 839.09
Sparcl1 SPARC-like 1 (hevin) 787.53 1327.26 838.87 1283.81
Plau plasminogen activator urokinase 11.44 13.25 792.04 736.94
Apoe apolipoprotein E 119.13 126.39 753.72 423.99
Igfbp2 insulin-like growth factor binding protein 2 56.88 50.68 628.57 701.20
Pltp phospholipid transfer protein 125.22 123.67 623.06 593.47
Cnn1 calponin 1 basic smooth muscle 25.90 27.46 620.15 723.62
Prl5a1 prolactin family 5 subfamily a member 1 168.44 238.01 609.38 165.58
Ifi27l2b interferon alpha-inducible protein 27 like 2B 124.71 147.14 457.83 155.50
Tmem176a transmembrane protein 176A 79.84 95.21 408.66 385.85
Continued on next page
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decidua Inner Myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
Gadd45a growth arrest and DNA-damage-inducible alpha 46.69 23.65 370.73 289.30
Mmp3 matrix metallopeptidase 3 1.35 1.18 353.47 344.19
Aebp1 AE binding protein 1 25.26 11.27 309.58 267.99
Sema6d semaphorin 6D 9.17 8.54 308.28 368.53
Serpinf1 serpin peptidase inhibitor clade F (alpha-2 antiplasmin 122.14 88.04 303.11 109.50
pigment epithelium derived factor) member 1
Igfbp6 insulin-like growth factor binding protein 6 8.92 13.16 292.33 377.57
Mylk myosin light chain kinase 15.42 13.21 291.49 367.94
Tmem176b transmembrane protein 176B 29.06 13.08 274.36 233.29
Prl2c1 Prolactin family 2 subfamily c member 1 10.78 15.34 272.41 344.78
Fhl1 four and a half LIM domains 1 39.31 32.94 261.58 285.63
Acta1 actin alpha 1 skeletal muscle 25.89 39.57 252.92 300.23
Ifitm2 interferon induced transmembrane protein 2 76.12 66.97 236.71 233.97
Ltbp1 latent transforming growth factor beta binding protein 1 10.94 7.06 202.69 174.93
Igfbp5 insulin-like growth factor binding protein 5 6.55 4.21 173.73 183.88
LOC100361444 rCG31799-like 3.48 2.69 161.64 138.36
Mmp12 matrix metallopeptidase 12 7.33 9.10 155.87 197.91
Antxr1 anthrax toxin receptor 1 40.00 37.90 148.87 115.38
Chchd10 coiled-coil-helix-coiled-coil-helix domain containing 10 8.41 6.09 141.60 196.53
Ly6e lymphocyte antigen 6 complex locus E 41.68 21.47 141.32 106.38
Figf c-fos induced growth factor 1.82 1.78 130.14 145.18
Fgl2 fibrinogen-like 2 14.71 16.48 126.26 140.89
Rnase4 ribonuclease RNase A family 4 21.61 18.95 124.89 111.54
Sod2 superoxide dismutase 2 mitochondrial 60.84 68.03 122.03 46.13
Plac8 placenta-specific 8 14.54 16.56 117.36 106.56
Csdc2 cold shock domain containing C2 RNA binding 24.85 18.27 107.86 67.91
Mgp matrix Gla protein 21.76 11.39 106.51 104.31
Tnn tenascin N 0.56 0.60 98.26 118.24
Gda guanine deaminase 21.57 9.39 94.86 67.63
Penk proenkephalin 7.58 7.81 85.69 73.73
F3 coagulation factor III (thromboplastin tissue factor) 25.71 10.10 81.13 52.80
C1s complement component 1 s subcomponent 6.71 6.21 80.16 74.87
Klf7 Kruppel-like factor 7 (ubiquitous) 30.90 19.82 78.39 31.41
C1r complement component 1 r subcomponent 14.92 8.84 71.68 57.92
Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1 27.02 15.90 71.29 64.49
Ednra endothelin receptor type A 11.59 2.87 68.53 55.36
Fbln5 fibulin 5 9.00 14.07 67.90 61.82
Mmp19 matrix metallopeptidase 19 13.49 6.32 67.88 66.65
Spon1 spondin 1 extracellular matrix protein 8.32 7.94 64.28 62.90
Neu2 sialidase 2 1.62 2.49 61.43 95.09
Rnf8 ring finger protein 8 E3 ubiquitin protein ligase 34.18 46.94 61.01 42.46
Pygb phosphorylase glycogen brain 9.58 2.77 58.98 45.71
Derl3 derlin 3 4.30 2.88 58.22 67.66
Mgst1 microsomal glutathione S-transferase 1 5.78 3.06 57.21 74.64
Cp ceruloplasmin (ferroxidase) 5.48 5.21 57.00 47.61
Plxdc2 plexin domain containing 2 8.93 6.16 56.68 64.79
Vwa1 von Willebrand factor A domain containing 1 5.45 5.58 55.67 73.12
Slc28a2 solute carrier family 28 (sodium-coupled nucleoside transporter) member 2 2.41 2.17 54.63 52.42
Ddr2 discoidin domain receptor tyrosine kinase 2 18.59 5.84 53.70 49.52
Pla1a phospholipase A1 member A 9.92 10.49 49.29 46.61
Rasd2 RASD family member 2 42.28 71.52 49.14 65.64
Krt75 keratin 75 0.76 1.03 47.78 41.48
Ifitm1 interferon induced transmembrane protein 1 13.25 10.73 47.19 38.89
Gpr88 G-protein coupled receptor 88 2.70 3.28 46.53 49.41
Gbp2 guanylate binding protein 2 interferon-inducible 4.77 4.54 44.60 35.47
Cxcl10 chemokine (C-X-C motif) ligand 10 1.22 1.88 44.15 39.93
Dclk1 doublecortin-like kinase 1 7.96 3.23 43.50 41.31
Kcnk2 potassium channel subfamily K member 2 1.72 2.32 42.86 36.78
Sh3kbp1 SH3-domain kinase binding protein 1 15.52 3.87 41.97 20.07
Adh1 alcohol dehydrogenase 1 (class I) 10.25 8.21 41.66 33.55
Plxdc1 plexin domain containing 1 3.99 5.35 40.43 35.28
Ctxn1 cortexin 1 1.57 2.42 40.01 35.29
Dram damage-regulated autophagy modulator 13.34 3.22 39.83 25.40
Npas2 neuronal PAS domain protein 2 4.72 3.10 39.57 29.91
Igf1 insulin-like growth factor 1 10.41 12.48 33.37 28.92
Ctsc cathepsin C 4.94 4.55 32.67 27.04
Lpcat2 lysophosphatidylcholine acyltransferase 2 5.81 2.71 31.85 24.62
Abcg4 ATP-binding cassette subfamily G (WHITE) member 4 1.57 1.64 30.86 31.07
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Pgm5 phosphoglucomutase 5 3.78 3.65 29.15 23.41
Nrp1 neuropilin 1 3.46 1.29 29.02 29.64
Aoc3 amine oxidase copper containing 3 5.19 4.26 26.75 23.56
Limd2 LIM domain containing 2 10.88 13.00 26.12 5.49
Slc26a2 solute carrier family 26 (sulfate transporter) member 2 4.85 4.77 25.11 22.66
Gem GTP binding protein overexpressed in skeletal muscle 1.36 0.79 24.54 21.55
Mafb v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 1.69 1.99 23.91 29.77
Kcnmb1 potassium large conductance calcium-activated channel subfamily M beta member 1 3.25 3.67 23.63 29.56
Cnr1 cannabinoid receptor 1 (brain) 11.39 14.20 21.92 16.24
Fam198b family with sequence similarity 198 member B 3.05 1.46 21.46 17.40
Ifi204 myeloid cell nuclear differentiation antigen 7.45 3.78 21.29 16.47
Fgf7 fibroblast growth factor 7 0.27 0.36 21.26 22.78
Enpp3 ectonucleotide pyrophosphatase/phosphodiesterase 3 3.90 4.16 21.17 17.93
Pla2g2a phospholipase A2 group IIA (platelets synovial fluid) 6.76 9.52 20.44 17.73
Acsbg1 acyl-CoA synthetase bubblegum family member 1 1.10 1.57 19.78 21.28
Osr2 odd-skipped related 2 (Drosophila) 1.90 2.47 18.94 17.99
Kcnj8 potassium inwardly-rectifying channel subfamily J member 8 1.72 1.23 18.68 23.40
C4b complement component 4B (Chido blood group) 0.64 0.79 18.53 18.80
Car12 carbonic anyhydrase 12 1.03 0.90 18.48 14.70
Stox2 storkhead box 2 1.29 0.91 17.65 18.26
Hpse heparanase 6.35 6.68 17.29 4.79
Asb5 ankyrin repeat and SOCS box-containing 5 3.58 3.28 16.86 12.54
Rprm reprimo TP53 dependent G2 arrest mediator candidate 2.95 5.10 16.65 6.80
C1qtnf7 C1q and tumor necrosis factor related protein 7 1.16 1.61 16.42 16.60
Cxcl16 chemokine (C-X-C motif) ligand 16 4.98 3.33 16.04 13.49
RGD1304595 similar to RIKEN cDNA 6330416G13 gene 2.90 1.27 14.62 12.90
Myo7b myosin VIIb 1.83 0.39 14.10 14.43
Frzb frizzled-related protein 1.71 1.22 13.93 12.96
Nkg7 natural killer cell group 7 sequence 2.56 4.35 13.85 12.03
Qprt quinolinate phosphoribosyltransferase 4.32 6.61 13.80 8.93
Ptprn protein tyrosine phosphatase receptor type N 5.98 9.60 13.05 3.61
Thbs2 thrombospondin 2 1.39 0.92 12.97 10.96
Rassf2 Ras association (RalGDS/AF-6) domain family member 2 4.10 6.30 11.91 2.26
Adcy2 adenylate cyclase 2 (brain) 2.31 0.48 11.54 11.96
Sall2 sal-like 2 (Drosophila) 5.89 9.11 11.39 6.79
Col11a1 collagen type XI alpha 1 0.77 0.97 11.32 9.88
Ube2ql1 ubiquitin-conjugating enzyme E2Q family-like 1 0.35 0.58 9.46 12.63
Cmtm5 CKLF-like MARVEL transmembrane domain containing 5 0.76 0.61 9.33 11.67
Fam163b family with sequence similarity 163 member B 0.00 0.00 8.75 15.15
Igsf10 immunoglobulin superfamily member 10 0.81 0.91 7.96 6.84
Rab27a RAB27A member RAS oncogene family 2.34 1.25 7.75 6.34
Atp1b2 ATPase Na /K transporting beta 2 polypeptide 1.00 0.56 7.69 7.02
Cacna1c calcium channel voltage-dependent L type alpha 1C subunit 0.43 0.27 7.36 6.72
Sash3 SAM and SH3 domain containing 3 4.08 6.61 7.24 3.99
Nptx2 neuronal pentraxin II 0.10 0.18 6.51 11.27
Prf1 perforin 1 (pore forming protein) 3.17 2.96 6.37 5.72
Ccl6 chemokine (C-C motif) ligand 6 0.28 0.41 6.06 8.33
Ptgfr prostaglandin F receptor 1.55 0.68 5.90 4.72
Rxfp2 relaxin/insulin-like family peptide receptor 2 1.05 1.27 5.12 5.25
Trpv4 transient receptor potential cation channel subfamily V member 4 0.12 0.16 5.06 7.55
Fez1 fasciculation and elongation protein zeta 1 (zygin I) 0.15 0.21 4.95 6.49
Rgs1 regulator of G-protein signaling 1 0.08 0.15 4.60 4.59
Arhgef28 Rho guanine nucleotide exchange factor (GEF) 28 0.50 0.34 4.41 4.72
Syk spleen tyrosine kinase 0.30 0.09 4.05 4.05
Aldh1a3 aldehyde dehydrogenase 1 family member A3 0.01 0.02 3.53 4.87
Egr2 early growth response 2 2.44 2.35 3.33 4.03
Cdca3 cell division cycle associated 3 0.10 0.10 2.96 3.11
Slamf8 SLAM family member 8 0.09 0.09 2.91 3.72
Ccl5 chemokine (C-C motif) ligand 5 0.11 0.16 2.68 3.01
Tdo2 tryptophan 23-dioxygenase 0.14 0.14 2.54 3.54
Ccl12 chemokine (C-C motif) ligand 12 0.03 0.02 2.42 3.35
Hey1 hairy/enhancer-of-split related with YRPW motif 1 0.18 0.28 1.97 1.55
Rnase1l1 ribonuclease RNase A family 1-like 1 (pancreatic) 0.00 0.00 0.83 0.87
Lrrn3 leucine rich repeat neuronal 3 0.00 0.00 0.06 0.11
down-regulated genes
Acsm5 acyl-CoA synthetase medium-chain family member 5 2.84 4.82 0.00 0.00
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Asic3 acid-sensing (proton-gated) ion channel 3 17.22 29.74 0.00 0.00
Hpd 4-hydroxyphenylpyruvate dioxygenase 5.10 8.57 0.00 0.00
Mir431 microRNA 431 128.54 222.64 0.00 0.00
Snx22 sorting nexin 22 38.94 66.27 0.00 0.00
Trim52 tripartite motif-containing 52 35.67 61.78 0.00 0.00
Triml2 tripartite motif family-like 2 26.51 45.83 0.00 0.01
Hcn2 hyperpolarization activated cyclic nucleotide-gated potassium channel 2 25.25 43.31 0.01 0.01
Got1l1 glutamic-oxaloacetic transaminase 1-like 1 4.97 8.60 0.01 0.01
Slc22a3 solute carrier family 22 (extraneuronal monoamine transporter) member 3 4.84 8.29 0.01 0.02
RGD1562871 similar to BMI1-like protein 6.62 11.43 0.02 0.02
Hmx3 H6 family homeobox 3 17.14 29.63 0.02 0.04
Camk1g calcium/calmodulin-dependent protein kinase IG 25.55 43.34 0.02 0.03
LOC680590 hypothetical protein LOC680590 21.86 37.48 0.03 0.06
Gbx2 gastrulation brain homeobox 2 13.32 22.92 0.04 0.05
Elf5 E74-like factor 5 4.21 6.71 0.04 0.03
Irx3 iroquois homeobox 3 12.48 20.35 0.04 0.04
MGC114246 similar to cathepsin R 16.97 28.97 0.08 0.10
Alox15 arachidonate 15-lipoxygenase 19.98 34.45 0.08 0.09
Ambp alpha-1-microglobulin/bikunin precursor 7.67 12.93 0.10 0.18
B4galnt3 beta-14-N-acetyl-galactosaminyl transferase 3 101.88 176.12 0.11 0.15
Cyp1a1 cytochrome P450 family 1 subfamily a polypeptide 1 5.11 8.65 0.11 0.04
Pnma5 paraneoplastic Ma antigen family member 5 7.03 11.87 0.12 0.21
Utf1 undifferentiated embryonic cell transcription factor 1 70.65 119.81 0.15 0.14
LOC498222 similar to specifically androgen-regulated protein 11.11 16.91 0.16 0.21
Syna syncytin a 166.53 287.80 0.17 0.11
Tns4 tensin 4 149.62 258.41 0.18 0.31
Grip2 glutamate receptor interacting protein 2 9.40 15.44 0.20 0.20
Tspyl4 TSPY-like 4 2.67 3.73 0.20 0.26
Sall3 sal-like 3 (Drosophila) 2.67 3.57 0.26 0.19
Insc inscuteable homolog (Drosophila) 7.84 13.01 0.31 0.37
Dlk1 delta-like 1 homolog (Drosophila) 237.27 408.86 0.43 0.23
Dlx3 distal-less homeobox 3 132.75 228.07 0.55 0.30
Foxc1 forkhead box C1 1.72 1.89 0.55 0.16
Plagl1 pleiomorphic adenoma gene-like 1 98.87 169.04 0.61 0.41
Hand1 heart and neural crest derivatives expressed 1 72.19 106.52 0.72 0.51
Aloxe3 arachidonate lipoxygenase 3 25.08 41.00 0.81 1.39
Kit v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 34.39 41.47 1.05 0.94
Hoxc4 homeo box C4 7.47 11.16 1.09 1.22
Epn3 epsin 3 52.58 84.46 1.15 1.07
Map7 microtubule-associated protein 7 10.27 14.82 1.25 0.47
Itm2a integral membrane protein 2A 193.05 333.78 1.53 2.60
Zim1 zinc finger imprinted 1 38.14 62.72 1.91 1.67
Cdh1 cadherin 1 108.55 173.41 1.91 1.27
Shroom4 shroom family member 4 57.82 94.12 2.14 1.31
Cyp11a1 cytochrome P450 family 11 subfamily a polypeptide 1 39.02 34.77 2.19 3.71
Eps8l2 EPS8-like 2 131.61 219.35 2.38 1.70
Epb4.1l5 erythrocyte protein band 4.1-like 5 37.25 54.83 3.10 2.42
Mrgpre MAS-related GPR member E 182.94 301.89 3.26 4.64
Pak6 p21 protein (Cdc42/Rac)-activated kinase 6 35.20 51.11 3.40 5.90
Slc38a4 solute carrier family 38 member 4 144.73 223.60 3.67 3.67
Lgalsl lectin galactoside-binding-like 28.16 39.50 3.76 2.01
Kif13b kinesin family member 13B 19.92 18.67 3.97 1.86
Arhgef6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 137.60 226.71 4.08 0.78
RGD1564534 similar to CHCHD4 protein 148.16 249.98 4.10 4.09
Ccnjl cyclin J-like 38.49 59.68 4.18 5.12
Wwc2 WW and C2 domain containing 2 12.03 9.46 4.24 3.71
Fbxl19 F-box and leucine-rich repeat protein 19 67.63 107.77 4.80 4.70
Oxsr1 oxidative-stress responsive 1 23.77 29.28 4.80 2.57
Ctsj cathepsin J 1071.79 1841.32 4.90 5.97
Sbsn suprabasin 137.67 119.05 5.20 6.91
Zfpm1 zinc finger protein multitype 1 76.07 118.92 5.32 3.32
Cmtm4 CKLF-like MARVEL transmembrane domain containing 4 70.30 111.40 5.32 3.91
Ctsr cathepsin R 900.80 1551.03 5.52 4.58
Prl3d4 prolactin family 3 subfamily d member 4 73.60 115.96 6.02 7.34
Nrm nurim (nuclear envelope membrane protein) 47.53 62.39 6.30 4.18
Lad1 ladinin 1 137.41 216.00 6.60 10.45
Ccdc92 coiled-coil domain containing 92 87.59 136.76 7.00 2.42
Ctsql2 cathepsin Q-like 2 1698.26 2928.99 7.35 6.25
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Ihh Indian hedgehog 15.32 13.19 7.47 12.90
Adora1 adenosine A1 receptor 8.89 15.01 8.74 15.14
Stra6 stimulated by retinoic acid 6 183.44 306.82 9.20 5.85
Stard8 StAR-related lipid transfer (START) domain containing 8 103.26 146.79 9.77 13.73
Rnf128 ring finger protein 128 E3 ubiquitin protein ligase 36.18 28.10 10.10 10.78
Slc16a3 solute carrier family 16 member 3 (monocarboxylic acid transporter 4) 120.68 194.36 10.12 10.57
Flt1 FMS-related tyrosine kinase 1 40.16 34.57 11.92 13.67
Fndc3c1 fibronectin type III domain containing 3C1 68.30 74.04 12.14 10.67
Prl2b1 Prolactin family 2 subfamily b member 1 72.72 94.83 12.50 21.66
Ppl periplakin 39.90 18.67 14.02 10.68
Flvcr2 feline leukemia virus subgroup C cellular receptor family member 2 38.13 39.67 14.21 15.37
Uaca uveal autoantigen with coiled-coil domains and ankyrin repeats 80.98 90.40 15.30 16.65
Tjp2 tight junction protein 2 36.59 8.27 15.90 17.90
Nrk Nik related kinase 71.61 61.75 18.80 14.63
Cldn4 claudin 4 47.15 17.50 21.50 34.07
Pdlim5 PDZ and LIM domain 5 125.27 84.33 24.94 7.54
Prl7a3 prolactin family 7 subfamily a member 3 179.30 274.49 25.51 5.23
Dysf dysferlin 42.05 29.62 26.40 28.75
Psgb1 pregnancy-specific beta 1-glycoprotein 29.38 46.37 27.64 47.81
Dscr6 ripply transcriptional repressor 3 50.59 46.44 31.03 42.55
Abhd2 abhydrolase domain containing 2 100.65 42.17 41.43 50.86
Creg1 cellular repressor of E1A-stimulated genes 1 87.02 36.84 42.64 56.25
Psg19 pregnancy specific glycoprotein 19 99.10 61.06 47.74 51.82
Cgm4 carcinoembryonic antigen gene family 4 110.49 150.82 98.11 160.21
Psg29 pregnancy-specific glycoprotein 29 103.43 172.57 102.36 173.48
Timp3 TIMP metallopeptidase inhibitor 3 310.24 110.24 124.74 92.11
Tfpi tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 497.90 400.24 146.49 174.07
Prl8a4 prolactin family 8 subfamily a member 4 462.84 534.50 149.60 132.52
LOC171573 spleen protein 1 precursor 772.77 695.57 292.37 481.57
Lamc2 laminin gamma 2 355.81 570.33 340.99 582.94
Prl8a9 prolactin family 8 subfamily a member 9 882.21 758.51 504.46 817.09
Prl8a5 prolactin family 8 subfamily a member 5 829.21 779.64 591.67 854.40
Table F.2: Transcripts that were significantly differentially expressed between the
decidua and the outer myometrium in P4-treated samples. Transcript expression levels
are shown in transcripts per million (TPM) (mean±SD).
Decidua Outer Myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Postn periostin osteoblast specific factor 44.06 57.45 2361.32 1367.00
Lum lumican 31.89 49.35 2344.62 2677.06
Acta1 actin alpha 1 skeletal muscle 25.89 39.57 1499.72 2277.22
Mmp11 matrix metallopeptidase 11 10.30 14.50 1098.70 905.78
Hapln1 hyaluronan and proteoglycan link protein 1 0.17 0.22 889.75 1540.59
Lect1 leukocyte cell derived chemotaxin 1 0.38 0.64 642.71 1112.33
Fhl1 four and a half LIM domains 1 39.31 32.94 537.32 117.61
Plau plasminogen activator urokinase 11.44 13.25 519.64 651.28
Cnn1 calponin 1 basic smooth muscle 25.90 27.46 456.50 365.57
Mgp matrix Gla protein 21.76 11.39 415.97 235.86
Tnnt3 troponin T type 3 (skeletal fast) 1.49 1.91 362.45 619.87
Matn3 matrilin 3 0.06 0.06 349.20 604.72
Actc1 actin alpha cardiac muscle 1 1.95 0.78 341.45 582.30
Aebp1 AE binding protein 1 25.26 11.27 327.55 160.36
Sema6d semaphorin 6D 9.17 8.54 307.30 359.10
RGD1311447 LOC363276 12.20 20.62 279.86 472.26
Igfbp5 insulin-like growth factor binding protein 5 6.55 4.21 275.08 167.71
Tmem176b transmembrane protein 176B 29.06 13.08 265.98 148.80
Leprel4 leprecan-like 4 30.59 20.35 255.44 374.95
Mfap2 microfibrillar-associated protein 2 5.39 8.85 248.02 375.19
Smoc2 SPARC related modular calcium binding 2 4.05 4.53 232.65 367.52
Capn6 calpain 6 0.30 0.26 225.78 382.74
Ltbp1 latent transforming growth factor beta binding protein 1 10.94 7.06 181.18 178.19
Ccl21 chemokine (C-C motif) ligand 21 0.08 0.13 179.26 306.59
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Fkbp10 FK506 binding protein 10 10.31 6.50 175.52 232.59
Figf c-fos induced growth factor 1.82 1.78 155.91 118.34
C1s complement component 1 s subcomponent 6.71 6.21 146.38 107.16
C1r complement component 1 r subcomponent 14.92 8.84 144.77 88.32
Frzb frizzled-related protein 1.71 1.22 135.53 155.67
Epyc epiphycan 0.01 0.01 112.12 194.21
Flrt2 fibronectin leucine rich transmembrane protein 2 9.03 13.68 111.39 36.96
Penk proenkephalin 7.58 7.81 106.51 44.86
Matn1 matrilin 1 cartilage matrix protein 0.04 0.07 105.89 183.32
Scrg1 stimulator of chondrogenesis 1 94.74 164.10 100.38 173.87
Mmp3 matrix metallopeptidase 3 1.35 1.18 94.88 97.50
Egr1 early growth response 1 4.91 2.71 93.67 75.82
Ednra endothelin receptor type A 11.59 2.87 89.84 59.17
Dpt dermatopontin 2.65 2.71 84.78 31.34
Olfml2b olfactomedin-like 2B 8.12 7.07 84.60 30.65
Nfia nuclear factor I/A 4.98 5.23 83.31 75.20
Mia melanoma inhibitory activity 0.04 0.07 78.53 135.58
Klf7 Kruppel-like factor 7 (ubiquitous) 30.90 19.82 76.46 22.22
Ctxn1 cortexin 1 1.57 2.42 75.14 44.09
Mafb v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 1.69 1.99 69.86 46.83
Spon1 spondin 1 extracellular matrix protein 8.32 7.94 62.34 18.52
Slc28a2 solute carrier family 28 (sodium-coupled nucleoside transporter) member 2 2.41 2.17 59.05 70.50
Aoc3 amine oxidase copper containing 3 5.19 4.26 58.42 28.70
Thbs2 thrombospondin 2 1.39 0.92 57.71 50.31
Ifi204 myeloid cell nuclear differentiation antigen 7.45 3.78 57.20 49.64
C4b complement component 4B (Chido blood group) 0.64 0.79 54.42 38.23
Clec11a C-type lectin domain family 11 member A 1.32 0.75 53.01 84.84
Zfp521 zinc finger protein 521 1.67 2.25 52.79 58.33
Cxcl12 chemokine (C-X-C motif) ligand 12 2.64 2.89 49.55 14.38
Prf1 perforin 1 (pore forming protein) 3.17 2.96 48.15 28.78
Pafah1b3 platelet-activating factor acetylhydrolase 1b catalytic subunit 3 21.48 31.57 47.91 30.20
Serpina3n serine (or cysteine) peptidase inhibitor clade A member 3N 1.50 1.93 47.46 56.32
Tnmd tenomodulin 0.01 0.02 43.15 74.74
Igsf10 immunoglobulin superfamily member 10 0.81 0.91 42.05 36.90
Crabp1 cellular retinoic acid binding protein 1 0.69 1.06 41.48 27.44
Fam101a family with sequence similarity 101 member A 0.00 0.00 40.90 67.63
Mmp16 matrix metallopeptidase 16 1.12 0.93 39.48 61.01
Fxyd2 FXYD domain-containing ion transport regulator 2 0.66 0.60 37.96 41.73
Nrp1 neuropilin 1 3.46 1.29 37.80 23.18
Cpz carboxypeptidase Z 1.68 2.33 36.61 11.30
Zfp354c zinc finger protein 354C 1.53 0.68 35.79 41.55
Ppp1r1b protein phosphatase 1 regulatory (inhibitor) subunit 1B 0.03 0.02 34.53 59.80
Tnn tenascin N 0.56 0.60 33.66 21.36
Adcy2 adenylate cyclase 2 (brain) 2.31 0.48 31.47 18.31
Pgm5 phosphoglucomutase 5 3.78 3.65 29.91 12.70
Gem GTP binding protein overexpressed in skeletal muscle 1.36 0.79 27.18 18.13
Trpv4 transient receptor potential cation channel subfamily V member 4 0.12 0.16 26.41 39.51
Atp1b4 ATPase (Na )/K transporting beta 4 polypeptide 0.49 0.28 25.70 43.63
Ptprs protein tyrosine phosphatase 4.13 2.04 24.89 17.00
Cd300le-ps1 Cd300 molecule-like family member E 0.44 0.45 22.56 18.15
Id4 inhibitor of DNA binding 4 7.03 9.07 20.93 9.79
Tac2 tachykinin 2 0.05 0.03 17.66 27.55
Cldn5 claudin 5 0.04 0.06 17.35 20.31
Tnxa-ps1 tenascin XA 0.15 0.19 16.19 5.70
Myoz1 myozenin 1 0.03 0.05 15.55 25.20
Rprm reprimo TP53 dependent G2 arrest mediator candidate 2.95 5.10 15.09 4.74
B4galt2 UDP-Gal:betaGlcNAc beta 14- galactosyltransferase polypeptide 2 0.19 0.03 14.39 16.15
Myh2 myosin heavy chain 2 skeletal muscle adult 0.01 0.02 14.23 24.56
Rassf2 Ras association (RalGDS/AF-6) domain family member 2 4.10 6.30 13.66 6.34
Tpsb2 tryptase beta 2 0.11 0.04 13.13 5.20
Cacna1c calcium channel voltage-dependent L type alpha 1C subunit 0.43 0.27 12.42 6.97
Fap fibroblast activation protein alpha 0.04 0.04 12.35 9.40
Ngfr nerve growth factor receptor 1.03 1.23 12.32 4.38
Msi1 musashi RNA-binding protein 1 0.12 0.18 11.91 14.36
Gpr77 complement component 5a receptor 2 0.08 0.11 11.88 10.05
Krt75 keratin 75 0.76 1.03 11.75 10.69
G0s2 G0/G1switch 2 4.35 3.72 11.74 5.26
Cacng1 calcium channel voltage-dependent gamma subunit 1 0.00 0.00 11.55 19.45
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Gene symbol Gene name TPM ±SD TPM ±SD
Rtn2 reticulon 2 0.12 0.02 10.82 7.78
Bves blood vessel epicardial substance 0.33 0.57 10.41 2.93
Tceal7 transcription elongation factor A (SII)-like 7 0.06 0.10 10.17 13.19
Cpxm2 carboxypeptidase X (M14 family) member 2 1.59 1.14 10.10 14.38
Sgca sarcoglycan alpha (dystrophin-associated glycoprotein) 0.04 0.06 10.01 11.46
Lhfpl2 lipoma HMGIC fusion partner-like 2 0.16 0.14 9.95 8.02
Klf14 Kruppel-like factor 14 4.08 6.86 9.46 6.61
Rnase1l1 ribonuclease RNase A family 1-like 1 (pancreatic) 0.00 0.00 8.25 13.48
Ccl19 chemokine (C-C motif) ligand 19 0.00 0.00 8.08 12.25
Arhgef28 Rho guanine nucleotide exchange factor (GEF) 28 0.50 0.34 7.64 4.61
Kazald1 Kazal-type serine peptidase inhibitor domain 1 2.70 4.64 7.13 10.29
Egr2 early growth response 2 2.44 2.35 7.09 2.03
Hey1 hairy/enhancer-of-split related with YRPW motif 1 0.18 0.28 6.83 4.63
Rasgrp4 RAS guanyl releasing protein 4 1.39 2.20 6.54 7.76
Slamf8 SLAM family member 8 0.09 0.09 5.69 4.28
Cib2 calcium and integrin binding family member 2 1.19 0.75 5.56 6.49
Tpsab1 tryptase alpha/beta 1 0.01 0.02 5.05 4.12
Lsamp limbic system-associated membrane protein 1.42 1.07 5.03 3.91
Tcf21 transcription factor 21 0.13 0.16 4.65 6.52
Nsg1 neuron specific gene family member 1 0.09 0.11 4.23 2.34
Fam19a5 family with sequence similarity 19 (chemokine (C-C motif)-like) member A5 0.01 0.02 4.09 3.35
Kcnn4 potassium intermediate/small conductance calcium-activated 0.08 0.15 3.63 1.72
channel subfamily N member 4
Bcl11a B-cell CLL/lymphoma 11A (zinc finger protein) 1.92 0.76 3.44 1.22
Vstm2b V-set and transmembrane domain containing 2B 0.07 0.02 3.36 4.30
Lrrn3 leucine rich repeat neuronal 3 0.00 0.00 3.36 5.52
Aldh1a3 aldehyde dehydrogenase 1 family member A3 0.01 0.02 2.84 1.64
Ccbp2 chemokine binding protein 2 0.09 0.06 2.54 1.22
Klhl4 kelch-like family member 4 0.05 0.07 2.04 3.30
Myh1 myosin heavy chain 1 skeletal muscle adult 0.01 0.01 1.23 1.95
Down-regulated genes
Ces4a carboxylesterase 4A 1.73 1.43 0.00 0.00
Hmx3 H6 family homeobox 3 17.14 29.63 0.00 0.00
LOC680590 hypothetical protein LOC680590 21.86 37.48 0.00 0.00
Lpo lactoperoxidase 32.58 56.31 0.00 0.00
Phactr3 phosphatase and actin regulator 3 2.75 2.42 0.00 0.00
Acsm5 acyl-CoA synthetase medium-chain family member 5 2.84 4.82 0.02 0.04
Hyal4 hyaluronoglucosaminidase 4 3.51 2.10 0.16 0.05
Psg16 pregnancy specific glycoprotein 16 30.32 37.21 1.57 1.50
Ppp1r3a protein phosphatase 1 regulatory subunit 3A 5.18 8.18 2.04 2.97
Cgm4 carcinoembryonic antigen gene family 4 110.49 150.82 2.84 2.60
LOC171573 spleen protein 1 precursor 772.77 695.57 3.33 3.87
Lamc2 laminin gamma 2 355.81 570.33 3.40 2.37
Gnai1 guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 22.19 18.58 3.45 2.08
Prdm1 PR domain containing 1 with ZNF domain 37.93 30.17 3.49 1.41
Slc22a5 solute carrier family 22 (organic cation/carnitine transporter) member 5 15.35 13.22 4.24 1.98
Itpripl1 inositol 145-trisphosphate receptor interacting protein-like 1 22.01 38.00 5.66 2.75
Slc6a12 solute carrier family 6 (neurotransmitter transporter betaine/GABA) member 12 209.04 359.00 6.00 5.15
Usp53 ubiquitin specific peptidase 53 70.43 61.14 6.65 1.90
Cdh3 cadherin 3 189.71 153.30 10.16 6.84
Kif3c kinesin family member 3C 26.96 21.34 12.37 3.16
Creg1 cellular repressor of E1A-stimulated genes 1 87.02 36.84 14.25 6.36
Tmem204 transmembrane protein 204 134.18 71.70 17.61 7.66
Psg19 pregnancy specific glycoprotein 19 99.10 61.06 17.90 11.02
Pgf placental growth factor 446.64 771.11 20.81 15.20
Prl8a9 prolactin family 8 subfamily a member 9 882.21 758.51 25.59 33.78
Tgfb2 transforming growth factor beta 2 239.98 170.11 31.57 17.84
Hopx HOP homeobox 211.07 272.70 38.26 11.78
F.1. Tissue dependent Gene Expression
Table F.3: Transcripts that were significantly differentially expressed between the in-
ner myometrium and the outer myometrium in P4-treated samples. Transcript expression
levels are shown in transcripts per million (TPM) (mean±SD).
inner Myometrium Outer Myometrium
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Igf2 insulin-like growth factor 2 1198.03 2013.74 3180.07 3014.82
Dlk1 delta-like 1 homolog (Drosophila) 237.27 408.86 2564.29 3955.38
LOC689064 beta-globin 429.62 676.80 2150.31 3410.46
Ctsr cathepsin R 900.80 1551.03 2055.89 3437.70
Ucma upper zone of growth plate and cartilage matrix associated 0.98 1.61 1172.11 2027.06
Itm2a integral membrane protein 2A 193.05 333.78 1111.71 1574.43
Alb albumin 115.79 174.01 559.77 919.82
C1qtnf3 C1q and tumor necrosis factor related protein 3 0.60 0.63 453.63 771.85
Plagl1 pleiomorphic adenoma gene-like 1 98.87 169.04 408.40 455.53
Mest mesoderm specific transcript 80.99 137.85 323.67 380.50
Myh8 myosin heavy chain 8 skeletal muscle perinatal 0.14 0.19 269.58 458.13
Hist2h3c2 histone cluster 2 H3c2 79.55 102.95 264.37 254.04
Mfap2 microfibrillar-associated protein 2 5.39 8.85 248.02 375.19
Capn6 calpain 6 0.30 0.26 225.78 382.74
Synpo synaptopodin 20.13 9.12 144.76 201.46
Col14a1 collagen type XIV alpha 1 2.25 2.86 135.26 166.79
Eln elastin 60.82 102.71 130.55 97.67
Zim1 zinc finger imprinted 1 38.14 62.72 130.36 183.00
Scrg1 stimulator of chondrogenesis 1 94.74 164.10 100.38 173.87
MGC114246 similar to cathepsin R 16.97 28.97 89.72 150.53
Serpina1 serpin peptidase inhibitor clade A 37.50 51.32 87.73 136.99
(alpha-1 antiproteinase antitrypsin) member 1
Dpt dermatopontin 2.65 2.71 84.78 31.34
Gpc3 glypican 3 26.58 44.16 84.62 64.79
Col27a1 collagen type XXVII alpha 1 2.65 2.27 61.86 102.86
Alas2 aminolevulinate delta-synthase 2 26.68 44.86 56.22 83.53
Cytl1 cytokine like 1 1.84 3.11 49.51 78.52
Ccnd2 cyclin D2 8.19 11.03 44.36 43.46
Ltbp4 latent transforming growth factor beta binding protein 4 9.08 14.26 43.56 34.79
Flvcr2 feline leukemia virus subgroup C cellular receptor family member 2 38.13 39.67 38.24 43.00
Ppp1r1b protein phosphatase 1 regulatory (inhibitor) subunit 1B 0.03 0.02 34.53 59.80
Myl3 myosin light chain 3 alkali ventricular skeletal slow 0.28 0.35 33.63 55.40
Sim2 single-minded homolog 2 (Drosophila) 0.31 0.19 33.32 57.63
Stxbp6 syntaxin binding protein 6 (amisyn) 10.58 12.20 31.92 25.96
Lrp5 low density lipoprotein receptor-related protein 5 19.19 23.20 29.43 20.55
Leprel1 leprecan-like 1 21.51 32.58 28.72 23.42
Podxl podocalyxin-like 25.31 34.96 28.19 28.21
Ambp alpha-1-microglobulin/bikunin precursor 7.67 12.93 26.20 43.91
Atp1b4 ATPase (Na )/K transporting beta 4 polypeptide 0.49 0.28 25.70 43.63
Sh2d3c SH2 domain containing 3C 12.33 18.86 24.73 8.31
Etv5 ets variant 5 13.00 14.68 24.69 19.35
Ninj2 ninjurin 2 1.99 3.31 23.37 35.05
Kitlg KIT ligand 20.01 15.33 23.29 32.46
Egfl6 EGF-like-domain multiple 6 1.02 1.12 19.96 29.69
Slc1a3 solute carrier family 1 (glial high affinity glutamate transporter) member 3 0.33 0.41 19.18 29.02
Zfp385b zinc finger protein 385B 1.20 1.89 18.82 31.56
Cdo1 cysteine dioxygenase type 1 2.95 1.80 18.75 14.11
Kif23 kinesin family member 23 11.16 10.38 18.00 17.70
Lpar4 lysophosphatidic acid receptor 4 3.74 1.34 17.37 14.51
Cma1 chymase 1 mast cell 0.24 0.39 16.08 16.78
Foxc1 forkhead box C1 1.72 1.89 14.99 23.82
Fgf18 fibroblast growth factor 18 0.13 0.19 14.76 23.66
Nlgn3 neuroligin 3 2.40 1.98 14.74 23.56
Myom1 myomesin 1 1.88 2.29 14.01 21.90
Fry furry homolog (Drosophila) 2.09 0.66 13.13 13.27
Fzd9 frizzled family receptor 9 0.77 1.23 11.57 20.03
Cacng1 calcium channel voltage-dependent gamma subunit 1 0.00 0.00 11.55 19.45
Gucy1a3 guanylate cyclase 1 soluble alpha 3 0.98 1.11 11.45 9.03
Csn2 casein beta 0.51 0.81 10.87 18.80
Pth1r parathyroid hormone 1 receptor 1.83 3.01 10.86 12.88
Hoxc4 homeo box C4 7.47 11.16 10.54 14.12
Six2 SIX homeobox 2 0.22 0.18 10.48 10.61
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Gene symbol Gene name TPM ±SD TPM ±SD
Galnt16 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 1.53 2.28 10.46 2.68
N-acetylgalactosaminyltransferase 16
Kif18b kinesin family member 18B 3.36 3.94 10.30 7.98
Tceal7 transcription elongation factor A (SII)-like 7 0.06 0.10 10.17 13.19
Cpxm2 carboxypeptidase X (M14 family) member 2 1.59 1.14 10.10 14.38
Ggnbp1 gametogenetin-binding protein 1 2.29 2.45 8.82 7.92
Kera keratocan 0.02 0.02 7.63 13.06
Cav3 caveolin 3 0.00 0.00 7.43 12.79
Mcf2l MCF.2 cell line derived transforming sequence-like 3.72 3.72 7.27 3.64
Sox8 SRY (sex determining region Y)-box 8 2.21 0.89 6.94 4.28
RGD1561795 similar to RIKEN cDNA 1700012B09 3.20 5.47 6.31 8.87
Slc25a23 solute carrier family 25 (mitochondrial carrier; phosphate carrier) 2.58 3.03 6.19 5.02
Hoxa2 homeo box A2 0.88 1.49 6.17 9.35
Zic3 Zic family member 3 4.04 3.52 6.02 8.23
LOC688276 transmembrane channel-like 8 3.06 3.32 5.99 2.00
Zfpm2 zinc finger protein multitype 2 0.90 1.46 5.91 6.20
Cacna1s calcium channel voltage-dependent L type alpha 1S subunit 0.05 0.06 5.65 9.25
Gcgr glucagon receptor 3.47 5.43 5.46 8.35
Hpd 4-hydroxyphenylpyruvate dioxygenase 5.10 8.57 5.46 6.41
Asb4 ankyrin repeat and SOCS box-containing 4 1.17 1.49 5.39 6.41
Tpsab1 tryptase alpha/beta 1 0.01 0.02 5.05 4.12
LOC361016 similar to RIKEN cDNA 4933406L09 4.08 5.49 4.66 6.25
Trdn triadin 0.13 0.09 4.19 7.15
Pgc progastricsin (pepsinogen C) 0.75 0.65 4.18 4.78
Bmper BMP-binding endothelial regulator 1.89 2.97 3.99 3.70
Epha3 Eph receptor A3 0.29 0.28 3.56 5.09
Tspyl4 TSPY-like 4 2.67 3.73 3.33 3.35
Megf6 multiple EGF-like-domains 6 0.35 0.56 3.30 4.59
Cntn2 contactin 2 (axonal) 0.35 0.57 3.20 5.22
Lrrn1 leucine rich repeat neuronal 1 0.15 0.15 2.37 2.59
Slco4c1 solute carrier organic anion transporter family member 4C1 0.81 0.68 2.33 3.10
Kcna6 potassium voltage gated channel shaker related subfamily member 6 0.33 0.30 1.76 2.59
Down-regulated genes
Lpo lactoperoxidase 32.58 56.31 0.00 0.00
Olr773 olfactory receptor 773 5.08 8.78 0.00 0.00
Fancd2os FANCD2 opposite strand 0.44 0.49 0.15 0.02
Chrm2 cholinergic receptor muscarinic 2 1.94 1.78 1.14 0.97
Rorb RAR-related orphan receptor B 9.31 10.73 1.20 0.66
Ppp1r3a protein phosphatase 1 regulatory subunit 3A 5.18 8.18 2.04 2.97
Prdm1 PR domain containing 1 with ZNF domain 37.93 30.17 3.49 1.41
Pnma5 paraneoplastic Ma antigen family member 5 7.03 11.87 3.61 6.25
Insc inscuteable homolog (Drosophila) 7.84 13.01 3.80 3.56
Elf5 E74-like factor 5 4.21 6.71 4.17 6.88
Slc22a3 solute carrier family 22 (extraneuronal monoamine transporter) member 3 4.84 8.29 4.53 7.18
Grip2 glutamate receptor interacting protein 2 9.40 15.44 5.55 9.13
Slc6a12 solute carrier family 6 (neurotransmitter transporter betaine/GABA) member 12 209.04 359.00 6.00 5.15
Alox15 arachidonate 15-lipoxygenase 19.98 34.45 6.10 9.73
LOC498222 similar to specifically androgen-regulated protein 11.11 16.91 6.24 8.82
Smtnl1 smoothelin-like 1 9.02 15.53 6.93 11.83
Pak6 p21 protein (Cdc42/Rac)-activated kinase 6 35.20 51.11 8.46 9.57
Irx3 iroquois homeobox 3 12.48 20.35 8.92 13.05
Cdkn3 cyclin-dependent kinase inhibitor 3 0.22 0.25 9.45 6.30
Prl2b1 Prolactin family 2 subfamily b member 1 72.72 94.83 11.82 20.47
RGD1309139 similar to CG5435-PA 55.45 71.41 13.20 5.76
Baiap2l1 BAI1-associated protein 2-like 1 15.34 20.61 13.98 9.80
Zfp423 zinc finger protein 423 1.80 0.29 16.19 7.60
Sgcd sarcoglycan, delta (dystrophin-associated glycoprotein) 0.64 0.55 17.89 15.44
Caskin2 cask-interacting protein 2 23.62 34.63 18.20 17.94
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) 32.95 49.45 19.55 7.89
Pgf placental growth factor 446.64 771.11 20.81 15.20
Utf1 undifferentiated embryonic cell transcription factor 1 70.65 119.81 22.91 34.34
B4galnt3 beta-14-N-acetyl-galactosaminyl transferase 3 101.88 176.12 22.92 25.32
Dock8 dedicator of cytokinesis 8 3.07 0.72 25.88 15.89
Vwf von Willebrand factor 1.61 1.66 25.89 24.95
Stard10 StAR-related lipid transfer (START) domain containing 10 38.84 66.06 30.28 12.21
Ptp4a3 protein tyrosine phosphatase type IVA member 3 44.38 56.70 33.19 11.85
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Sort1 sortilin 1 2.65 0.65 36.02 19.03
Dlc1 deleted in liver cancer 1 4.21 1.22 36.19 14.22
Glis2 GLIS family zinc finger 2 3.22 2.40 38.66 36.18
Lgalsl lectin, galactoside-binding-like 3.43 1.91 38.89 29.93
St14 suppression of tumorigenicity 14 (colon carcinoma) 48.79 38.29 41.47 64.00
Sema4d semaphorin 4D 2.20 1.06 43.94 46.50
Shroom4 shroom family member 4 57.82 94.12 45.02 58.27
Dlx3 distal-less homeobox 3 132.75 228.07 47.80 76.50
Stard8 StAR-related lipid transfer (START) domain containing 8 103.26 146.79 58.84 75.41
Hand1 heart and neural crest derivatives expressed 1 72.19 106.52 65.12 109.39
Tns3 tensin 3 10.29 0.74 67.51 48.28
Cdh1 cadherin 1 108.55 173.41 72.03 107.33
Slc38a4 solute carrier family 38 member 4 144.73 223.60 75.16 107.29
Csgalnact1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 7.81 5.46 79.87 79.72
Eps8l2 EPS8-like 2 131.61 219.35 83.50 98.29
Tns4 tensin 4 149.62 258.41 86.50 130.57
Slc16a3 solute carrier family 16 member 3 (monocarboxylic acid transporter 4) 120.68 194.36 87.70 48.37
Fbn1 fibrillin 1 7.71 2.29 87.95 30.19
Nrk Nik related kinase 12.39 8.16 124.60 86.77
Nrep neuronal regeneration related protein 3.49 2.50 159.63 176.43
Slc7a5 solute carrier family 7 (amino acid transporter light chain L system) member 5 499.07 857.67 237.93 338.10
F.2 Early Response to Progesterone Withdrawal
Table F.4: Genes that change significantly in the decidua. Transcript expression levels
are shown in transcripts per million values (mean±SD) for control samples (GD19+6hrs) and P4-
treated samples.
Control P4
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Proc protein C 279.51 466.82 1140.36 1974.03
Tagln transgelin 47.17 10.26 397.46 105.16
Alb albumin 1.74 1.62 115.79 174.01
Eln elastin 2.07 0.67 60.82 102.71
Rarres1 retinoic acid receptor responder (tazarotene induced) 1 8.86 6.43 56.18 56.98
Plekhd1 pleckstrin homology domain containing, family D (with coiled-coil domains) member 1 11.83 13.23 31.43 52.11
Hmx3 H6 family homeobox 3 0.09 0.13 17.14 29.63
Rgs4 regulator of G-protein signaling 4 2.46 2.79 13.01 15.41
Downregulated genes
Aqp8 aquaporin 8 15.88 8.58 0.01 0.01
Clrn3 clarin 3 4.33 1.81 0.02 0.04
Il20ra interleukin 20 receptor, alpha 1.16 1.66 0.03 0.05
Slc34a3 solute carrier family 34 (type II sodium/phosphate contransporter), member 3 5.19 4.41 0.03 0.05
Abcc8 ATP-binding cassette, subfamily C (CFTR/MRP), member 8 5.67 4.81 0.05 0.09
RGD1305807 hypothetical LOC298077 2.14 2.08 0.06 0.07
Mybpc3 myosin binding protein C, cardiac 9.94 2.49 0.07 0.09
Akr7a3 aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) 5.64 3.15 0.08 0.13
Tm4sf20 transmembrane 4 L six family member 20 6.12 3.31 0.14 0.17
Apoa2 apolipoprotein A-II 255.70 230.37 0.22 0.20
Kcnj16 potassium inwardly-rectifying channel, subfamily J, member 16 1.42 0.78 0.22 0.07
Hnf4a hepatocyte nuclear factor 4, alpha 5.87 1.83 0.22 0.26
Colec10 collectin sub-family member 10 (C-type lectin) 1.00 0.57 0.26 0.21
Slc2a2 solute carrier family 2 (facilitated glucose transporter), member 2 5.37 3.33 0.27 0.38
Cubn cubilin (intrinsic factor-cobalamin receptor) 34.90 17.01 0.28 0.26
Apom apolipoprotein M 87.18 33.70 0.32 0.16
Agt angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 15.52 7.91 0.46 0.28
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Gene symbol Gene name TPM ±SD TPM ±SD
Fmo1 flavin containing monooxygenase 1 16.56 6.65 0.47 0.55
Aadat aminoadipate aminotransferase 20.54 12.08 0.54 0.18
Amn amnion associated transmembrane protein 17.79 3.29 0.56 0.20
Apon apolipoprotein N 4.06 3.19 0.63 0.38
Fxyd2 FXYD domain-containing ion transport regulator 2 23.85 15.48 0.66 0.60
Sdsl serine dehydratase-like 4.46 4.03 0.72 1.25
Doxl1 diamine oxidase-like protein 1 62.80 87.77 1.07 1.48
Tst thiosulfate sulfurtransferase 28.25 10.97 1.17 0.34
Hbe1 hemoglobin, epsilon 1 148.03 215.78 1.65 1.95
Apoc2 apolipoprotein C-II 73.03 57.13 1.83 3.14
F2 coagulation factor II 38.52 19.11 2.49 3.36
Apob apolipoprotein B 535.64 256.06 2.69 1.59
Spp2 secreted phosphoprotein 2 100.64 96.49 2.85 4.10
Apoa4 apolipoprotein A-IV 213.84 113.78 3.16 3.33
Prf1 perforin 1 (pore forming protein) 6.90 5.57 3.17 2.96
Fgg fibrinogen gamma chain 42.01 21.19 3.35 2.48
Ctsz cathepsin Z 63.74 27.75 5.95 3.31
RGD1310507 similar to RIKEN cDNA 1300017J02 25.76 23.50 6.60 5.13
Entpd2 ectonucleoside triphosphate diphosphohydrolase 2 71.15 33.86 7.90 2.34
Fga fibrinogen alpha chain 78.63 39.83 10.23 13.56
Afp alpha-fetoprotein 2331.59 1656.67 14.59 14.92
Apoa1 apolipoprotein A-I 651.04 422.62 15.92 25.90
Rbp4 retinol binding protein 4, plasma 126.35 153.08 16.81 26.73
Ttr transthyretin 660.29 525.55 20.28 32.71
Table F.5: Genes that change significantly in the inner myometrium. Transcript expres-
sion levels are shown in transcripts per million (TPM) values (mean±SD) for control (GD19+6hrs)
samples and P4-treated samples.
Control P4
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Slc6a12 solute carrier family 6 (neurotransmitter transporter), member 12 11.46 4.59 164.12 248.29
Plce1 phospholipase C, epsilon 1 7.35 2.84 34.70 12.62
Itga8 integrin, alpha 8 4.07 3.06 23.08 13.44
Ibsp integrin-binding sialoprotein 0.71 0.43 7.68 12.31
Duoxa1 dual oxidase maturation factor 1 0.11 0.01 5.48 3.52
Downregulated genes
Atg9b autophagy related 9B 16.12 18.50 0.00 0.00
Cbs cystathionine beta synthase 3.70 6.07 0.00 0.00
Wfdc16 WAP four-disulfide core domain 16 10.14 11.47 0.00 0.00
Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 15.32 19.78 0.00 0.01
Tspyl4 TSPY-like 4 4.47 2.67 0.03 0.06
Mchr1 melanin-concentrating hormone receptor 1 17.12 19.70 0.06 0.03
Il17rb interleukin 17 receptor B 9.03 7.81 0.11 0.15
Atp6v0a4 ATPase, H+ transporting, lysosomal V0 subunit A4 25.42 21.81 0.35 0.10
Fam160a1 family with sequence similarity 160, member A1 12.03 7.82 0.37 0.23
Dio3 deiodinase, iodothyronine, type III 32.23 19.05 0.47 0.43
Doxl1 diamine oxidase-like protein 1 49.84 48.50 1.10 1.02
Lrp2 low density lipoprotein receptor-related protein 2 31.21 28.24 1.13 1.02
Col14a1 collagen, type XIV, alpha 1 13.78 5.92 1.37 0.53
Slc4a11 solute carrier family 4, sodium borate transporter, member 11 125.33 110.33 1.41 1.32
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) 78.42 71.42 1.43 1.28
Ctsj cathepsin J 53.08 59.67 1.47 1.15
Ltbp4 latent transforming growth factor beta binding protein 4 29.47 30.97 1.49 0.37
Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B 129.18 118.61 1.81 2.10
Lrat lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-acyltransferase) 120.84 118.41 2.91 1.51
Ctsr cathepsin R 83.06 86.91 3.02 4.60
Ca2 carbonic anhydrase 2 52.53 35.79 3.39 1.73
Mill1 MHC I like leukocyte 1 36.28 8.50 3.99 1.03
Ctsql2 cathepsin Q-like 2 67.21 73.38 4.32 5.98
Bcam basal cell adhesion molecule (Lutheran blood group) 89.57 73.51 5.34 2.49
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Gene symbol Gene name TPM ±SD TPM ±SD
Csf1 colony stimulating factor 1 (macrophage) 159.80 202.04 7.74 6.55
Pcsk6 proprotein convertase subtilisin/kexin type 6 49.75 20.09 9.20 3.25
Tns3 tensin 3 43.07 10.26 10.29 0.74
Isyna1 inositol-3-phosphate synthase 1 718.80 625.89 30.47 6.85
Spp1 secreted phosphoprotein 1 607.02 435.91 47.12 22.63
Ezr ezrin 288.55 57.09 62.12 24.20
Table F.6: Genes that change significantly in the outer myometrium. Transcript expres-
sion levels are shown in transcripts per million (TPM) values (mean±SD) for control (GD19+6hrs)
samples and P4-treated samples.
Control P4
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Penk proenkephalin 7.65 3.75 106.51 44.86
Olfml2b olfactomedin-like 2B 8.62 7.09 84.60 30.65
Csf2rb colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 8.78 10.10 44.01 24.43
Tnn tenascin N 0.41 0.33 33.66 21.36
Tpsb2 tryptase beta 2 0.01 0.02 13.13 5.20
Zcchc12 zinc finger, CCHC domain containing 12 0.01 0.01 4.24 3.82
Downregulated genes
Gucy2c guanylate cyclase 2C 1.44 1.62 0.31 0.16
LOC171573 spleen protein 1 precursor 1612.19 2779.47 3.33 3.87
Psg29 pregnancy-specific glycoprotein 29 406.70 686.64 4.19 1.97
Itga10 integrin, alpha 10 16.88 29.22 5.99 10.17
Table F.7: Biological functions of genes that were upregulated in the decidua of P4-
treated samples. The genes were analysed for GO term enrichment using BiNGO. The overrep-
resented GO terms are shown with their corresponding adjusted p-values and the number of genes
within the test set that are annotated to that function.
Description Corrected p-value No. Genes
cholesterol transport 7.64E-08 6
sterol transport 7.64E-08 6
positive regulation of cholesterol esterification 9.61E-08 4
regulation of cholesterol esterification 9.61E-08 4
regulation of lipid metabolic process 9.61E-08 8
cholesterol eﬄux 9.61E-08 5
positive regulation of lipid metabolic process 2.36E-07 6
lipid homeostasis 4.29E-07 6
reverse cholesterol transport 7.05E-07 4
regulation of biological quality 7.05E-07 17
phospholipid eﬄux 9.40E-07 4
transport 9.79E-07 20
establishment of localization 1.03E-06 20
lipid transport 1.03E-06 7
positive regulation of fatty acid biosynthetic process 1.03E-06 4
chemical homeostasis 1.49E-06 11
lipid localization 1.49E-06 7
positive regulation of steroid metabolic process 1.49E-06 4
protein-lipid complex remodeling 1.49E-06 4
plasma lipoprotein particle remodeling 1.49E-06 4
macromolecular complex remodeling 1.49E-06 4
regulation of steroid metabolic process 2.49E-06 5
regulation of fatty acid biosynthetic process 6.50E-06 4
localization 7.03E-06 20
regulation of lipid biosynthetic process 1.15E-05 5
positive regulation of fatty acid metabolic process 1.21E-05 4
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positive regulation of lipid biosynthetic process 1.21E-05 4
cholesterol metabolic process 2.25E-05 5
homeostatic process 2.25E-05 11
phospholipid transport 2.25E-05 4
coagulation 2.25E-05 5
blood coagulation 2.25E-05 5
hemostasis 2.25E-05 5
protein-lipid complex assembly 2.31E-05 3
sterol metabolic process 2.81E-05 5
regulation of lipase activity 3.12E-05 5
lipoprotein metabolic process 3.68E-05 5
sterol homeostasis 4.53E-05 4
cholesterol homeostasis 4.53E-05 4
lipoprotein transport 5.77E-05 3
macromolecular complex subunit organization 7.08E-05 10
regulation of transport 7.20E-05 9
steroid metabolic process 8.86E-05 6
positive regulation of lipid catabolic process 1.15E-04 3
regulation of localization 1.16E-04 10
regulation of body fluid levels 1.16E-04 5
negative regulation of lipoprotein oxidation 1.28E-04 2
regulation of lipoprotein oxidation 1.28E-04 2
lipoprotein particle clearance 1.29E-04 3
regulation of cholesterol transport 1.85E-04 3
regulation of sterol transport 1.85E-04 3
response to wounding 1.86E-04 8
regulation of fatty acid metabolic process 2.31E-04 4
platelet activation 2.43E-04 3
phosphatidylcholine metabolic process 2.43E-04 3
negative regulation of very-low-density lipoprotein particle remodeling 3.28E-04 2
regeneration 3.71E-04 5
amine metabolic process 3.75E-04 7
regulation of very-low-density lipoprotein particle remodeling 5.92E-04 2
negative regulation of cytokine secretion involved in immune response 5.92E-04 2
high-density lipoprotein particle assembly 5.92E-04 2
high-density lipoprotein particle clearance 5.92E-04 2
regulation of cellular ketone metabolic process 6.98E-04 4
cellular amino acid derivative metabolic process 7.14E-04 5
negative regulation of transport 7.45E-04 5
regulation of lipid catabolic process 7.51E-04 3
regulation of secretion 7.51E-04 6
anatomical structure morphogenesis 7.53E-04 10
response to chemical stimulus 8.32E-04 18
negative regulation of lipid metabolic process 8.37E-04 3
regulation of cytokine secretion involved in immune response 8.37E-04 2
negative regulation of lipoprotein metabolic process 8.37E-04 2
low-density lipoprotein particle remodeling 8.37E-04 2
ethanolamine and derivative metabolic process 9.04E-04 3
cellular biogenic amine metabolic process 9.31E-04 4
wound healing 9.41E-04 5
regulation of lipid transport 9.55E-04 3
response to organic substance 1.01E-03 11
positive regulation of triglyceride catabolic process 1.13E-03 2
negative regulation of sterol transport 1.13E-03 2
negative regulation of cholesterol transport 1.13E-03 2
regulation of cellular localization 1.28E-03 6
macromolecular complex assembly 1.32E-03 8
cellular amino acid and derivative metabolic process 1.39E-03 6
regulation of triglyceride catabolic process 1.45E-03 2
regulation of lipoprotein metabolic process 1.45E-03 2
triglyceride-rich lipoprotein particle remodeling 1.45E-03 2
plasma lipoprotein particle assembly 1.45E-03 2
negative regulation of protein transport 1.48E-03 3
response to stimulus 1.49E-03 21
response to inorganic substance 1.55E-03 6
hormone metabolic process 1.66E-03 4
regulation of production of molecular mediator of immune response 1.75E-03 3
positive regulation of lipoprotein lipase activity 1.75E-03 2
negative regulation of lipase activity 1.75E-03 2
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toxin metabolic process 1.75E-03 2
high-density lipoprotein particle remodeling 1.75E-03 2
response to metal ion 2.02E-03 5
response to carbohydrate stimulus 2.02E-03 4
regulation of protein transport 2.12E-03 4
neutral lipid catabolic process 2.12E-03 2
glycerol ether catabolic process 2.12E-03 2
acylglycerol catabolic process 2.12E-03 2
regulation of establishment of protein localization 2.40E-03 4
lipid metabolic process 2.47E-03 8
negative regulation of cytokine secretion 3.08E-03 2
axon regeneration in the peripheral nervous system 3.08E-03 2
glycerolipid catabolic process 3.08E-03 2
positive regulation of lipase activity 3.47E-03 3
alcohol metabolic process 3.47E-03 6
secondary metabolic process 3.50E-03 3
phosphatidylcholine biosynthetic process 3.50E-03 2
positive regulation of triglyceride metabolic process 3.50E-03 2
ovulation from ovarian follicle 3.50E-03 2
sex differentiation 3.62E-03 4
regulation of protein localization 3.73E-03 4
regulation of protein secretion 3.73E-03 3
positive regulation of catabolic process 3.73E-03 3
cellular amine metabolic process 3.78E-03 5
cellular component organization 4.42E-03 13
glycerolipid metabolic process 4.42E-03 4
cellular component assembly 4.42E-03 8
SMAD protein signal transduction 4.42E-03 2
regulation of triglyceride metabolic process 4.42E-03 2
regulation of hormone levels 4.74E-03 4
regulation of insulin secretion 4.84E-03 3
negative regulation of lipid transport 4.97E-03 2
development of primary female sexual characteristics 4.97E-03 3
positive regulation of hydrolase activity 5.05E-03 4
female sex differentiation 5.98E-03 3
regulation of peptide hormone secretion 5.98E-03 3
ovulation 6.18E-03 2
negative regulation of multicellular organismal process 6.41E-03 4
regulation of peptide transport 6.53E-03 3
regulation of peptide secretion 6.53E-03 3
vitamin transport 6.68E-03 2
negative regulation of protein secretion 6.68E-03 2
small molecule metabolic process 6.74E-03 10
organ morphogenesis 6.77E-03 6
regulation of hydrolase activity 6.95E-03 5
organ regeneration 7.26E-03 3
cellular component biogenesis 7.53E-03 8
macromolecule localization 7.59E-03 8
negative regulation of cellular protein metabolic process 7.76E-03 4
axon regeneration 7.82E-03 2
regulation of lipoprotein lipase activity 8.57E-03 2
negative regulation of secretion 8.87E-03 3
regulation of cytokine production involved in immune response 9.27E-03 2
cell activation 9.27E-03 4
negative regulation of protein metabolic process 9.74E-03 4
aromatic compound catabolic process 9.95E-03 2
neuron projection regeneration 1.08E-02 2
response to glucose stimulus 1.10E-02 3
response to nutrient levels 1.12E-02 5
cellular amino acid derivative catabolic process 1.15E-02 2
response to hexose stimulus 1.21E-02 3
response to monosaccharide stimulus 1.24E-02 3
regulation of hormone secretion 1.34E-02 3
regulation of organ growth 1.35E-02 2
response to extracellular stimulus 1.35E-02 5
cardiac chamber development 1.35E-02 2
cardiac chamber morphogenesis 1.35E-02 2
regulation of immune effector process 1.35E-02 3
gonad development 1.35E-02 3
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innate immune response in mucosa 1.35E-02 1
response to muscle activity involved in regulation of muscle adaptation 1.35E-02 1
mucosal immune response 1.35E-02 1
negative regulation of cholesterol transporter activity 1.35E-02 1
regulation of cholesterol transporter activity 1.35E-02 1
positive regulation of phospholipid catabolic process 1.35E-02 1
mycotoxin catabolic process 1.35E-02 1
mycotoxin metabolic process 1.35E-02 1
negative regulation of lipoprotein lipid oxidation 1.35E-02 1
regulation of lipoprotein lipid oxidation 1.35E-02 1
negative regulation of interleukin-1 beta secretion 1.35E-02 1
female genitalia morphogenesis 1.35E-02 1
sugar utilization 1.35E-02 1
renal control of peripheral vascular resistance
involved in regulation of systemic arterial blood pressure 1.35E-02 1
isoprenoid transport 1.35E-02 1
terpenoid transport 1.35E-02 1
spermatogonial cell division 1.35E-02 1
retinol transport 1.35E-02 1
establishment of blood-nerve barrier 1.35E-02 1
aflatoxin metabolic process 1.35E-02 1
aflatoxin catabolic process 1.35E-02 1
toxin catabolic process 1.35E-02 1
diacylglycerol catabolic process 1.35E-02 1
regulation of blood vessel size by renin-angiotensin 1.35E-02 1
angiotensin mediated vasoconstriction
involved in regulation of systemic arterial blood pressure 1.35E-02 1
negative regulation of plasma lipoprotein oxidation 1.35E-02 1
regulation of plasma lipoprotein oxidation 1.35E-02 1
response to stress 1.37E-02 10
negative regulation of cellular process 1.39E-02 10
glycerophospholipid metabolic process 1.46E-02 3
regulation of multicellular organismal process 1.56E-02 8
regulation of cytokine secretion 1.58E-02 2
reproductive developmental process 1.58E-02 4
response to drug 1.61E-02 5
development of primary sexual characteristics 1.61E-02 3
cellular protein complex assembly 2.05E-02 3
protein complex assembly 2.15E-02 5
protein complex biogenesis 2.15E-02 5
reproductive structure development 2.15E-02 3
acylglycerol metabolic process 2.18E-02 2
neutral lipid metabolic process 2.18E-02 2
protein polymerization 2.18E-02 2
female gamete generation 2.18E-02 2
response to osmotic stress 2.18E-02 2
carbohydrate homeostasis 2.18E-02 2
regulation of protein stability 2.18E-02 2
glucose homeostasis 2.18E-02 2
positive regulation of cellular metabolic process 2.18E-02 7
organ or tissue specific immune response 2.18E-02 1
cholesterol import 2.18E-02 1
negative regulation of protein import into nucleus, translocation 2.18E-02 1
female genitalia development 2.18E-02 1
maintenance of gastrointestinal epithelium 2.18E-02 1
regulation of phospholipid catabolic process 2.18E-02 1
hemoglobin import 2.18E-02 1
response to lipid hydroperoxide 2.18E-02 1
epithelial structure maintenance 2.18E-02 1
sterol transmembrane transport 2.18E-02 1
sterol import 2.18E-02 1
negative regulation of cholesterol import 2.18E-02 1
regulation of cholesterol import 2.18E-02 1
negative regulation of interleukin-1 secretion 2.18E-02 1
smooth muscle cell proliferation 2.18E-02 1
cellular response to prostaglandin stimulus 2.18E-02 1
embryonic retina morphogenesis in camera-type eye 2.18E-02 1
fructose transport 2.18E-02 1
NADPH oxidation 2.18E-02 1
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negative regulation of transmembrane transport 2.18E-02 1
germ-line cyst formation 2.18E-02 1
male germ-line cyst formation 2.18E-02 1
multicellular organismal lipid catabolic process 2.18E-02 1
renin-angiotensin regulation of aldosterone production 2.18E-02 1
glycerol ether metabolic process 2.19E-02 2
positive regulation of biosynthetic process 2.20E-02 6
positive regulation of cellular catabolic process 2.37E-02 2
organic ether metabolic process 2.37E-02 2
negative regulation of biological process 2.37E-02 10
regulation of cellular protein metabolic process 2.38E-02 5
response to axon injury 2.44E-02 2
gamete generation 2.49E-02 4
digestion 2.63E-02 2
regulation of growth 2.65E-02 4
lipid catabolic process 2.70E-02 3
positive regulation of metabolic process 2.70E-02 7
positive regulation of phospholipase activity 2.80E-02 2
cellular lipid metabolic process 2.85E-02 5
negative regulation of cellular component organization 2.93E-02 3
negative regulation of metabolic process 2.93E-02 6
regulation of microvillus organization 2.93E-02 1
regulation of microvillus assembly 2.93E-02 1
establishment of tissue polarity 2.93E-02 1
positive regulation of muscle hypertrophy 2.93E-02 1
positive regulation of cardiac muscle hypertrophy 2.93E-02 1
negative regulation of tyrosine phosphorylation of Stat5 protein 2.93E-02 1
urinary bladder development 2.93E-02 1
uterus development 2.93E-02 1
ovarian follicle rupture 2.93E-02 1
phenylpropanoid catabolic process 2.93E-02 1
coumarin catabolic process 2.93E-02 1
response to lipopolysaccharide 3.06E-02 3
rhythmic process 3.10E-02 3
positive regulation of ion transport 3.15E-02 2
regulation of phospholipase activity 3.15E-02 2
cardiac muscle tissue development 3.36E-02 2
anatomical structure development 3.49E-02 11
response to molecule of bacterial origin 3.51E-02 3
sexual reproduction 3.51E-02 4
heart morphogenesis 3.51E-02 2
negative regulation of hydrolase activity 3.51E-02 2
phospholipid metabolic process 3.51E-02 3
negative regulation of very-low-density lipoprotein particle clearance 3.51E-02 1
regulation of very-low-density lipoprotein particle clearance 3.51E-02 1
triglyceride mobilization 3.51E-02 1
genitalia morphogenesis 3.51E-02 1
kynurenine metabolic process 3.51E-02 1
response to stimulus involved in regulation of muscle adaptation 3.51E-02 1
regulation of intestinal cholesterol absorption 3.51E-02 1
Cdc42 protein signal transduction 3.51E-02 1
negative regulation of tyrosine phosphorylation of STAT protein 3.51E-02 1
negative regulation of nerve growth factor receptor signaling pathway 3.51E-02 1
negative regulation of receptor-mediated endocytosis 3.51E-02 1
myosin filament assembly 3.51E-02 1
myosin filament assembly or disassembly 3.51E-02 1
astrocyte activation 3.51E-02 1
brain renin-angiotensin system 3.51E-02 1
regulation of renal output by angiotensin 3.51E-02 1
lipoprotein catabolic process 3.51E-02 1
renal response to blood flow involved in circulatory
renin-angiotensin regulation of systemic arterial blood pressure 3.51E-02 1
dehydroascorbic acid transport 3.51E-02 1
cell development 3.52E-02 5
regulation of protein metabolic process 3.56E-02 5
regulation of cell growth 3.61E-02 3
metal ion transport 3.64E-02 4
female gonad development 3.66E-02 2
response to external stimulus 3.95E-02 5
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organophosphate metabolic process 3.99E-02 3
regulation of protein amino acid phosphorylation 3.99E-02 3
muscle structure development 4.02E-02 3
cellular hormone metabolic process 4.02E-02 2
glycerophospholipid biosynthetic process 4.02E-02 2
developmental process 4.02E-02 12
ornithine metabolic process 4.02E-02 1
negative regulation of interleukin-1 beta production 4.02E-02 1
positive regulation of gluconeogenesis 4.02E-02 1
smooth muscle cell differentiation 4.02E-02 1
regulation of gastrulation 4.02E-02 1
positive regulation of immunoglobulin secretion 4.02E-02 1
regulation of nerve growth factor receptor signaling pathway 4.02E-02 1
vagina development 4.02E-02 1
negative regulation of cardiac muscle cell proliferation 4.02E-02 1
canalicular bile acid transport 4.02E-02 1
very-low-density lipoprotein particle remodeling 4.02E-02 1
chylomicron remnant clearance 4.02E-02 1
diacylglycerol metabolic process 4.02E-02 1
lipid digestion 4.02E-02 1
inorganic anion transport 4.17E-02 2
cellular ion homeostasis 4.45E-02 4
system development 4.45E-02 10
cellular chemical homeostasis 4.45E-02 4
ovulation cycle process 4.45E-02 2
response to calcium ion 4.45E-02 2
tryptophan catabolic process 4.45E-02 1
negative regulation of lipoprotein particle clearance 4.45E-02 1
cellular phosphate ion homeostasis 4.45E-02 1
positive regulation of cholesterol storage 4.45E-02 1
negative regulation of interleukin-1 production 4.45E-02 1
cellular di-, tri-valent inorganic anion homeostasis 4.45E-02 1
positive regulation of potassium ion transport 4.45E-02 1
positive regulation of interleukin-8 biosynthetic process 4.45E-02 1
cellular sodium ion homeostasis 4.45E-02 1
cellular response to superoxide 4.45E-02 1
cellular response to oxygen radical 4.45E-02 1
coumarin metabolic process 4.45E-02 1
negative regulation of astrocyte differentiation 4.45E-02 1
fibrinolysis 4.45E-02 1
indolalkylamine catabolic process 4.45E-02 1
progesterone metabolic process 4.45E-02 1
indole derivative catabolic process 4.45E-02 1
negative regulation of JAK-STAT cascade 4.45E-02 1
removal of superoxide radicals 4.45E-02 1
tryptophan catabolic process to kynurenine 4.45E-02 1
phenylpropanoid metabolic process 4.45E-02 1
regulation of peptidyl-tyrosine phosphorylation 4.49E-02 2
cofactor metabolic process 4.49E-02 3
multicellular organismal development 4.49E-02 11
glycerolipid biosynthetic process 4.67E-02 2
response to cAMP 4.67E-02 2
inflammatory response 4.67E-02 3
regulation of immune response 4.72E-02 3
vitamin metabolic process 4.73E-02 2
regulation of muscle system process 4.73E-02 2
cellular lipid catabolic process 4.83E-02 2
regulation of lipoprotein particle clearance 4.86E-02 1
response to hydroperoxide 4.86E-02 1
peristalsis 4.86E-02 1
response to muscle activity 4.86E-02 1
natriuresis 4.86E-02 1
detection of light stimulus involved in sensory perception 4.86E-02 1
detection of light stimulus involved in visual perception 4.86E-02 1
phosphate ion homeostasis 4.86E-02 1
di-, tri-valent inorganic anion homeostasis 4.86E-02 1
heart trabecula formation 4.86E-02 1
cellular response to tumor necrosis factor 4.86E-02 1
endothelial cell development 4.86E-02 1
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low-density lipoprotein particle clearance 4.86E-02 1
transmembrane receptor protein serine/threonine kinase signaling pathway 4.87E-02 2
ovulation cycle 4.97E-02 2
Table F.8: Biological functions of genes that were downregulated in the decidua of
P4-treated samples. The genes were analysed for GO term enrichment using BiNGO. The
overrepresented GO terms are shown with their corresponding adjusted p-values and the number
of genes within the test set that are annotated to that function.
Description Corrected p-value No. Genes
sequestering of actin monomers 2.98E-02 1
regulation of formin-nucleated actin cable assembly 2.98E-02 1
positive regulation of formin-nucleated actin cable assembly 2.98E-02 1
positive regulation of cytoskeleton organization 2.98E-02 1
regulation of actin filament bundle assembly 2.98E-02 1
positive regulation of actin filament bundle assembly 2.98E-02 1
negative regulation of actin filament polymerization 3.13E-02 1
negative regulation of protein polymerization 3.13E-02 1
negative regulation of protein complex assembly 3.18E-02 1
regulation of actin filament length 3.30E-02 1
regulation of actin filament polymerization 3.30E-02 1
regulation of protein polymerization 3.30E-02 1
regulation of actin polymerization or depolymerization 3.30E-02 1
negative regulation of cytoskeleton organization 3.57E-02 1
regulation of actin cytoskeleton organization 4.23E-02 1
regulation of actin filament-based process 4.23E-02 1
Table F.9: Biological functions of genes that were upregulated in the inner my-
ometrium of P4-treated samples. The genes were analysed for GO term enrichment using
BiNGO. The overrepresented GO terms are shown with their corresponding adjusted p-values and
the number of genes within the test set that are annotated to that function.
Description Corrected p-value No. Genes
extracellular matrix organization 1.80E-02 2
cellular water homeostasis 1.80E-02 1
kidney development 1.80E-02 2
renal system development 1.80E-02 2
extracellular structure organization 1.80E-02 2
urogenital system development 1.91E-02 2
cellular hyperosmotic response 3.12E-02 1
cellular response to osmotic stress 4.77E-02 1
Table F.10: Biological functions of genes that were down-regulated in the inner my-
ometrium of P4-treated samples. The genes were analysed for GO term enrichment using
BiNGO. The overrepresented GO terms are shown with their corresponding adjusted p-values and
the number of genes within the test set that are annotated to that function.
Description Corrected p-value No. Genes
positive regulation of bone resorption 8.04E-03 2
positive regulation of bone remodeling 8.04E-03 2
ossification 8.04E-03 4
bone development 9.41E-03 4
positive regulation of tissue remodeling 1.05E-02 2
regulation of biological quality 1.10E-02 10
osteoclast differentiation 1.21E-02 2
regulation of hormone levels 1.29E-02 4
regulation of bone resorption 1.89E-02 2
regulation of bone remodeling 1.96E-02 2
response to nutrient levels 2.16E-02 5
response to extracellular stimulus 2.52E-02 5
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regulation of tissue remodeling 2.52E-02 2
positive regulation of myeloid leukocyte differentiation 2.52E-02 2
skeletal system development 2.93E-02 4
response to nutrient 2.93E-02 4
hormone metabolic process 2.93E-02 3
secretion 2.93E-02 4
response to vitamin D 2.93E-02 2
myeloid leukocyte differentiation 2.93E-02 2
cation homeostasis 2.93E-02 4
positive regulation of myeloid cell differentiation 2.93E-02 2
small molecule metabolic process 2.93E-02 8
cysteine biosynthetic process from serine 2.93E-02 1
boron transport 2.93E-02 1
response to linoleic acid 2.93E-02 1
negative regulation of collateral sprouting of intact axon in response to injury 2.93E-02 1
regulation of collateral sprouting of intact axon in response to injury 2.93E-02 1
fat cell proliferation 2.93E-02 1
brown fat cell proliferation 2.93E-02 1
naphthalene metabolic process 2.93E-02 1
trichloroethylene metabolic process 2.93E-02 1
homocysteine catabolic process 2.93E-02 1
phosphoenolpyruvate-dependent sugar phosphotransferase system 2.93E-02 1
sphinganine-1-phosphate metabolic process 2.93E-02 1
cysteine biosynthetic process via cystathionine 2.93E-02 1
regulation of pH 2.93E-02 2
response to vitamin 3.24E-02 3
regulation of myeloid leukocyte differentiation 3.41E-02 2
tissue development 3.41E-02 5
response to external stimulus 3.41E-02 5
positive regulation of homeostatic process 3.41E-02 2
monovalent inorganic cation homeostasis 3.41E-02 2
organ development 3.41E-02 8
regulation of collateral sprouting 3.41E-02 1
negative regulation of collateral sprouting 3.41E-02 1
neurotrophin production 3.41E-02 1
nerve growth factor production 3.41E-02 1
response to triglyceride 3.41E-02 1
establishment of endothelial blood-brain barrier 3.41E-02 1
cysteine catabolic process 3.41E-02 1
homoserine metabolic process 3.41E-02 1
hemoglobin import 3.41E-02 1
establishment of blood-brain barrier 3.41E-02 1
response to prostaglandin F stimulus 3.41E-02 1
L-cysteine metabolic process 3.41E-02 1
transsulfuration 3.41E-02 1
cysteine biosynthetic process 3.41E-02 1
L-cysteine catabolic process 3.41E-02 1
chlorinated hydrocarbon metabolic process 3.41E-02 1
halogenated hydrocarbon metabolic process 3.41E-02 1
hydrogen sulfide metabolic process 3.41E-02 1
hydrogen sulfide biosynthetic process 3.41E-02 1
amine metabolic process 3.41E-02 4
multicellular organismal development 3.78E-02 10
odontogenesis 4.16E-02 2
system development 4.27E-02 9
response to steroid hormone stimulus 4.27E-02 4
L-serine catabolic process 4.27E-02 1
homocysteine metabolic process 4.27E-02 1
sulfur amino acid catabolic process 4.27E-02 1
negative regulation of axon regeneration 4.27E-02 1
establishment of endothelial barrier 4.27E-02 1
ketone body biosynthetic process 4.27E-02 1
sphinganine metabolic process 4.27E-02 1
response to acid 4.27E-02 2
response to starvation 4.63E-02 2
ion homeostasis 4.73E-02 4
regulation of myeloid cell differentiation 4.79E-02 2
proton transport 4.91E-02 2
isoprenoid metabolic process 4.91E-02 2
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hydrogen transport 4.91E-02 2
epithelium development 4.91E-02 3
negative regulation of neuron projection regeneration 4.91E-02 1
positive regulation of cellular pH reduction 4.91E-02 1
nerve growth factor processing 4.91E-02 1
bicarbonate transport 4.91E-02 1
sulfur compound catabolic process 4.91E-02 1
response to abiotic stimulus 4.93E-02 4
F.3 Response to Treatment with Progesterone
Table F.11: Genes that change significantly in the decidua. Transcript expression levels
are shown in transcripts per million values (mean±SD) for control samples and P4-treated samples.
Control P4
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Htra4 HtrA serine peptidase 4 211.30 132.10 1074.14 1806.54
Plvap plasmalemma vesicle associated protein 8.69 4.43 311.06 435.70
Itm2a integral membrane protein 2A 1.77 0.47 193.05 333.78
Csf1r colony stimulating factor 1 receptor 14.57 5.08 167.00 242.44
RGD1564534 similar to CHCHD4 protein 4.61 3.56 148.16 249.98
Eps8l2 EPS8-like 2 5.21 2.40 131.61 219.35
Alb albumin 0.98 0.19 115.79 174.01
Rab11fip1 RAB11 family interacting protein 1 (class I) 6.06 4.10 113.13 97.06
Slco4a1 solute carrier organic anion transporter family, member 4a1 2.74 2.31 109.62 151.91
Cdh1 cadherin 1 2.09 1.21 108.55 173.41
Stard8 StAR-related lipid transfer (START) domain containing 8 4.99 2.29 103.26 146.79
Plagl1 pleiomorphic adenoma gene-like 1 2.10 2.32 98.87 169.04
Tf transferrin 1.63 0.72 81.91 136.90
Shroom4 shroom family member 4 4.62 0.68 57.82 94.12
Rarres1 retinoic acid receptor responder (tazarotene induced) 1 5.94 2.27 56.18 56.98
Plekhg5 pleckstrin homology domain containing,
family G (with RhoGef domain) member 5 5.40 1.24 55.53 89.63
Epn3 epsin 3 2.79 1.98 52.58 84.46
Scel sciellin 0.98 0.89 46.36 65.98
Kazn kazrin, periplakin interacting protein 4.02 1.89 35.35 55.38
Shisa6 shisa family member 6 0.00 0.00 34.57 40.62
Rhox12 reproductive homeobox 12 0.06 0.03 33.15 56.85
LOC498662 similar to RIKEN cDNA 2610019F03 0.98 0.37 32.81 51.88
Slc4a1 solute carrier family 4 (anion exchanger), member 1 1.73 0.66 29.76 26.43
Arid3b AT rich interactive domain 3B (Bright like) 1.95 0.88 23.73 39.85
LOC680590 hypothetical protein LOC680590 0.04 0.08 21.86 37.48
P2ry4 pyrimidinergic receptor P2Y, G-protein coupled, 4 0.00 0.00 19.86 28.34
Hmx3 H6 family homeobox 3 0.01 0.01 17.14 29.63
Fhdc1 FH2 domain containing 1 1.32 0.72 16.92 25.82
Ihh Indian hedgehog 0.00 0.00 15.32 13.19
Epb41l3 erythrocyte membrane protein band 4.1-like 3 0.66 0.13 12.03 19.83
Capn8 calpain 8 0.02 0.02 11.59 19.95
Dsc2 desmocollin 2 1.96 0.75 10.90 5.23
Fbn2 fibrillin 2 1.02 0.34 8.31 11.22
Mchr1 melanin-concentrating hormone receptor 1 0.00 0.01 7.93 13.74
Hoxc4 homeo box C4 1.38 0.91 7.47 11.16
Sall3 spalt-like transcription factor 3 0.56 0.41 2.67 3.57
Downregulated genes
Rnase1l1 ribonuclease, RNase A family, 1-like 1 (pancreatic) 11.86 11.55 0.00 0.00
Tac1 tachykinin, precursor 1 9.63 8.51 0.00 0.00
Hey1 hes-related family bHLH transcription factor with YRPW motif 1 3.72 2.78 0.18 0.28
Tnn tenascin N 38.22 39.91 0.56 0.60
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Gene symbol Gene name TPM ±SD TPM ±SD
Thbs2 thrombospondin 2 24.72 25.11 1.39 0.92
Figf c-fos induced growth factor 36.53 38.14 1.82 1.78
Derl3 derlin 3 80.72 56.52 4.30 2.88
G0s2 G0/G1switch 2 8.24 9.15 4.35 3.72
Igfbp5 insulin-like growth factor binding protein 5 125.97 82.39 6.55 4.21
Mmp11 matrix metallopeptidase 11 886.79 608.51 10.30 14.50
Ceacam9 carcinoembryonic antigen-related cell adhesion molecule 9 514.25 886.25 17.75 23.14
Mgp matrix Gla protein 508.86 346.75 21.76 11.39
Table F.12: Genes that change significantly in the inner myometrium in response to
P4-treatment. Transcript expression levels are shown in transcripts per million (TPM) values
(mean±SD) for control samples and P4-treated samples.
Control P4
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Gatm glycine amidinotransferase (L-arginine:glycine amidinotransferase) 23.16 18.54 500.98 382.05
Olr773 olfactory receptor 773 0.00 0.00 192.67 333.72
Vom2r34 vomeronasal 2 receptor, 34 8.51 1.50 165.20 228.69
Pla2g2a phospholipase A2, group IIA (platelets, synovial fluid) 2.00 1.81 141.15 191.37
Pdlim3 PDZ and LIM domain 3 22.08 11.12 104.52 20.75
Kcnk2 potassium channel, subfamily K, member 2 11.70 3.79 71.42 14.02
Ism1 isthmin 1, angiogenesis inhibitor 2.37 1.23 68.39 50.24
Hspb7 heat shock protein B7 4.71 5.10 62.19 39.29
Cspg4 chondroitin sulfate proteoglycan 4 7.53 3.13 40.30 22.60
Car5b carbonic anhydrase 5b, mitochondrial 8.54 1.27 39.97 6.35
Fam163b family with sequence similarity 163, member B 0.05 0.09 8.75 15.15
Col2a1 collagen, type II, alpha 1 0.05 0.05 7.53 12.63
Clec12b C-type lectin domain family 12, member B 0.00 0.00 3.73 2.36
Ntf3 neurotrophin 3 0.06 0.11 3.40 3.85
Colq collagen-like tail subunit (single strand of homotrimer) 0.00 0.00 3.27 4.78
of asymmetric acetylcholinesterase
Fancd2os FANCD2 opposite strand 0.07 0.03 2.95 2.70
Cdh16 cadherin 16 0.00 0.00 2.35 4.03
Syt4 synaptotagmin IV 0.05 0.02 1.51 1.18
Nr1i2 nuclear receptor subfamily 1, group I, member 2 0.00 0.00 1.42 1.81
Downregulated genes
Fam150b family with sequence similarity 150, member B 21.86 36.95 0.00 0.00
Hs3st6 heparan sulfate (glucosamine) 3-O-sulfotransferase 6 10.02 17.36 0.00 0.00
Il17f interleukin 17F 6.94 11.96 0.00 0.00
Lypd3 Ly6/Plaur domain containing 3 5.26 5.58 0.00 0.00
Tff3 trefoil factor 3, intestinal 5.48 9.02 0.00 0.00
Tns4 tensin 4 19.81 27.72 0.00 0.00
Tssk6 testis-specific serine kinase 6 42.14 72.99 0.00 0.00
Cd70 Cd70 molecule 16.60 27.92 0.00 0.01
MGC114246 similar to cathepsin R 29.97 51.43 0.01 0.02
Kcnn2 potassium intermediate/small conductance
calcium-activated channel, subfamily N, member 2 2.85 4.86 0.02 0.03
Psgb1 pregnancy-specific beta 1-glycoprotein 318.33 547.14 0.02 0.04
Mpp2 membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2) 11.23 16.61 0.04 0.07
Irx3 iroquois homeobox 3 4.20 5.74 0.05 0.05
Utf1 undifferentiated embryonic cell transcription factor 1 14.24 24.67 0.06 0.10
LOC685544 hypothetical protein LOC685544 106.53 184.51 0.08 0.09
Il22ra1 interleukin 22 receptor, alpha 1 9.54 5.21 0.13 0.18
Hand1 heart and neural crest derivatives expressed 1 54.15 92.96 0.50 0.41
Dlx3 distal-less homeobox 3 26.97 46.14 0.83 0.65
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) 27.14 36.72 1.43 1.28
Ctsj cathepsin J 827.48 1426.78 1.47 1.15
Htr2a 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled 86.91 148.90 1.86 1.35
Ebf3 early B-cell factor 3 18.63 21.52 1.91 1.63
Cmbl carboxymethylenebutenolidase homolog (Pseudomonas) 45.50 38.94 2.04 0.53
Sema4d sema domain, immunoglobulin domain (Ig),
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Gene symbol Gene name TPM ±SD TPM ±SD
transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D 17.81 15.11 2.20 1.06
Psg29 pregnancy-specific glycoprotein 29 662.38 1056.85 2.22 0.91
Htr1d 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled 38.84 54.17 2.58 1.59
Sh2d3c SH2 domain containing 3C 25.17 15.34 2.71 0.58
Cldn4 claudin 4 248.75 405.09 2.72 2.26
Cldn7 claudin 7 56.65 97.63 2.86 2.88
Ctsr cathepsin R 602.94 1037.01 3.02 4.60
Acvr1 activin A receptor, type I 36.67 52.66 3.13 1.91
Eps8l2 EPS8-like 2 37.79 61.61 3.14 2.98
Slc38a4 solute carrier family 38, member 4 369.43 607.05 3.32 4.05
Cilp cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 46.49 28.93 3.56 1.77
Podxl podocalyxin-like 27.00 26.85 3.88 1.16
Mill1 MHC I like leukocyte 1 37.52 48.49 3.99 1.03
Cgm4 carcinoembryonic antigen gene family 4 785.39 1204.63 4.04 5.66
Rnf128 ring finger protein 128, E3 ubiquitin protein ligase 72.10 105.07 4.13 3.67
Folr1 folate receptor 1 (adult) 41.98 70.89 4.14 0.61
Rhox9 reproductive homeobox 9 59.41 43.55 5.51 4.94
Ctsm cathepsin M 224.42 353.44 5.54 4.33
Prl3d4 prolactin family 3, subfamily d, member 4 1052.22 1680.08 5.54 7.69
Rsad2 radical S-adenosyl methionine domain containing 2 50.42 21.61 6.03 1.98
Dmkn dermokine 59.60 64.61 7.19 3.98
Fndc3c1 fibronectin type III domain containing 3C1 169.74 138.42 8.10 4.53
Oasl 2’-5’-oligoadenylate synthetase-like 131.13 159.32 8.26 4.19
Sbsn suprabasin 238.85 372.54 9.03 5.96
LOC171573 spleen protein 1 precursor 919.26 1472.08 10.12 14.78
Sfmbt2 Scm-like with four mbt domains 2 73.02 34.22 10.94 4.37
Creg1 cellular repressor of E1A-stimulated genes 1 296.56 352.72 13.00 6.01
Gab1 GRB2-associated binding protein 1 74.93 35.56 16.00 4.00
Prl7a3 prolactin family 7, subfamily a, member 3 153.98 51.71 16.85 9.83
Foxo4 forkhead box O4 132.66 49.22 18.85 8.46
Fbln1 fibulin 1 62.05 107.47 31.66 20.91
Ednrb endothelin receptor type B 346.91 137.08 32.70 22.04
Hmox1 heme oxygenase (decycling) 1 155.63 67.00 34.47 8.49
Cited1 Cbp/p300-interacting transactivator
with Glu/Asp-rich carboxy-terminal domain 1 483.54 198.23 80.33 45.66
Cited2 Cbp/p300-interacting transactivator,
with Glu/Asp-rich carboxy-terminal domain, 2 675.80 617.52 86.67 40.77
Prl4a1 prolactin family 4, subfamily a, member 1 4709.14 2435.51 949.93 414.88
Table F.13: Genes that change significantly in response to P4-treatment in the outer
myometrium. Transcript expression levels are shown in transcripts per million (TPM) values
(mean±SD) for control samples and P4-treated samples.
Control P4
Gene symbol Gene name TPM ±SD TPM ±SD
Upregulated genes
Itm2a integral membrane protein 2A 9.51 6.30 1111.71 1574.43
C1qtnf3 C1q and tumor necrosis factor related protein 3 0.82 0.67 453.63 771.85
Tnnt3 troponin T type 3 (skeletal, fast) 5.50 5.69 362.45 619.87
Myh8 myosin, heavy chain 8, skeletal muscle, perinatal 0.74 0.24 269.58 458.13
Leprel4 leprecan-like 4 30.21 13.07 255.44 374.95
Mfap2 microfibrillar-associated protein 2 3.94 5.63 248.02 375.19
Cthrc1 collagen triple helix repeat containing 1 5.00 4.47 239.17 293.61
Leprel2 leprecan-like 2 18.33 13.70 233.25 276.65
Smoc2 SPARC related modular calcium binding 2 4.85 2.62 232.65 367.52
Mylpf myosin light chain, phosphorylatable, fast skeletal muscle 2.99 1.83 226.56 379.60
Capn6 calpain 6 0.42 0.40 225.78 382.74
Fkbp10 FK506 binding protein 10 9.75 7.62 175.52 232.59
Zim1 zinc finger, imprinted 1 3.70 0.75 130.36 183.00
RGD1305645 similar to RIKEN cDNA 1500015O10 5.20 5.17 126.34 191.09
Epyc epiphycan 0.00 0.00 112.12 194.21
Scrg1 stimulator of chondrogenesis 1 0.01 0.01 100.38 173.87
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Gene symbol Gene name TPM ±SD TPM ±SD
Car4 carbonic anhydrase 4 2.78 1.02 68.02 86.28
Col27a1 collagen, type XXVII, alpha 1 1.98 0.95 61.86 102.86
Prf1 perforin 1 (pore forming protein) 7.04 1.63 48.15 28.78
Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 3.26 2.18 40.99 34.09
Mmp16 matrix metallopeptidase 16 1.69 1.01 39.48 61.01
Ndn necdin, melanoma antigen (MAGE) family member 2.66 2.13 37.57 11.48
Sln sarcolipin 0.35 0.25 37.19 63.13
Myl3 myosin, light chain 3, alkali; ventricular, skeletal, slow 0.01 0.01 33.63 55.40
Efs embryonal Fyn-associated substrate 2.49 1.06 27.53 16.62
Atp1b4 ATPase, (Na+)/K+ transporting, beta 4 polypeptide 0.50 0.41 25.70 43.63
Aff3 AF4/FMR2 family, member 3 1.19 0.90 20.30 21.21
Sgcd sarcoglycan, delta (dystrophin-associated glycoprotein) 2.11 2.52 17.89 15.44
Tpsb2 tryptase beta 2 0.10 0.14 13.13 5.20
Fzd9 frizzled class receptor 9 0.02 0.03 11.57 20.03
Sgca sarcoglycan, alpha (dystrophin-associated glycoprotein) 0.00 0.00 10.01 11.46
Kera keratocan 0.01 0.01 7.63 13.06
Smtnl1 smoothelin-like 1 0.01 0.02 6.93 11.83
RGD1561795 similar to RIKEN cDNA 1700012B09 0.01 0.02 6.31 8.87
Itga10 integrin, alpha 10 0.02 0.04 5.99 10.17
Tpsab1 tryptase alpha/beta 1 0.00 0.00 5.05 4.12
Trdn triadin 0.06 0.02 4.19 7.15
Pak3 p21 protein (Cdc42/Rac)-activated kinase 3 0.20 0.26 3.58 5.27
Clstn3 calsyntenin 3 0.05 0.04 3.36 5.25
Asb12 ankyrin repeat and SOCS box-containing 12 0.00 0.00 3.13 2.92
Kcnj12 potassium inwardly-rectifying channel, subfamily J, member 12 0.36 0.16 3.06 0.23
Downregulated genes
Lpo lactoperoxidase 99.94 125.95 0.00 0.00
Pax2 paired box 2 36.73 47.52 0.00 0.00
Npbwr1 neuropeptides B/W receptor 1 21.42 27.19 0.00 0.00
Psca prostate stem cell antigen 18.54 17.82 0.00 0.00
B3gnt3 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 18.10 18.09 0.00 0.00
Capsl calcyphosine-like 17.18 12.89 0.00 0.00
Prl3a1 Prolactin family 3, subfamily a, member 1 16.33 5.06 0.00 0.00
Smlr1 small leucine-rich protein 1 9.12 12.15 0.00 0.00
Aadac arylacetamide deacetylase 8.90 15.32 0.00 0.00
Sult1b1 sulfotransferase family, cytosolic, 1B, member 1 6.82 9.63 0.00 0.00
Alox15b arachidonate 15-lipoxygenase, type B 6.34 8.35 0.00 0.00
Slc30a10 solute carrier family 30, member 10 6.05 10.27 0.00 0.00
Pla2g4c phospholipase A2, group IVC 4.57 4.58 0.00 0.00
Noxo1 NADPH oxidase organizer 1 4.47 3.81 0.00 0.00
Igfals insulin-like growth factor binding protein, acid labile subunit 4.22 5.21 0.00 0.00
Slc17a1 solute carrier family 17, member 1 3.70 6.08 0.00 0.00
Marco macrophage receptor with collagenous structure 3.64 6.16 0.00 0.00
Iqcg IQ motif containing G 3.60 4.26 0.00 0.00
Tmprss11g transmembrane protease, serine 11G 3.30 3.28 0.00 0.00
Ccdc64b coiled-coil domain containing 64B 3.01 3.04 0.00 0.00
Entpd8 ectonucleoside triphosphate diphosphohydrolase 8 2.76 2.25 0.00 0.00
Adam28 ADAM metallopeptidase domain 28 2.68 2.07 0.00 0.00
Il24 interleukin 24 2.37 2.59 0.00 0.00
Slc5a1 solute carrier family 5, member 1 2.26 3.41 0.00 0.00
Ttll10 tubulin tyrosine ligase-like family, member 10 1.54 0.44 0.00 0.00
Serpinb11 serpin peptidase inhibitor, clade B (ovalbumin), member 11 1.51 1.20 0.00 0.00
Macc1 metastasis associated in colon cancer 1 4.52 3.27 0.01 0.02
Kap kidney androgen regulated protein 1514.85 999.61 2.48 3.96
Apoa1 apolipoprotein A-I 1327.79 1142.31 20.91 29.46
Psg16 Psg16 716.10 1237.31 1.57 1.50
Psg29 pregnancy-specific glycoprotein 29 648.04 1117.62 4.19 1.97
Cgm4 carcinoembryonic antigen gene family 4 558.99 961.92 2.84 2.60
Cuzd1 CUB and zona pellucida-like domains 1 492.78 409.84 0.59 1.03
Krt19 keratin 19 396.19 327.46 90.59 59.13
Cldn4 claudin 4 367.31 529.47 9.97 8.21
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Ceacam3 carcinoembryonic antigen-related cell adhesion molecule 3 353.04 608.70 4.70 5.23
Apoh apolipoprotein H (beta-2-glycoprotein I) 324.36 443.23 7.02 11.13
LOC171573 spleen protein 1 precursor 312.83 523.46 3.33 3.87
Slc9a3r1 solute carrier family 9, subfamily A , member 3 regulator 1 311.36 201.25 76.73 16.63
RGD1309676 family with sequence similarity 213, member A 178.41 127.27 35.13 18.42
F2 coagulation factor II 172.70 238.48 6.63 10.91
Gpx2 glutathione peroxidase 2 160.81 81.14 6.87 8.63
Cfb complement factor B 157.75 97.41 27.78 16.27
Glrx glutaredoxin (thioltransferase) 135.84 123.07 22.67 11.60
Hmox1 heme oxygenase (decycling) 1 135.48 62.26 27.66 24.25
Cldn2 claudin 2 135.04 114.17 0.83 0.46
RGD1310507 similar to RIKEN cDNA 1300017J02 133.95 103.79 6.49 1.27
Mmp7 matrix metallopeptidase 7 131.36 56.43 0.18 0.15
Lcn2 lipocalin 2 126.31 66.72 25.73 24.45
Gnmt glycine N-methyltransferase 107.74 186.61 0.23 0.39
RGD1309139 similar to CG5435-PA 106.99 138.26 13.20 5.76
Prom1 prominin 1 105.22 100.68 1.91 0.60
Gstt3 glutathione S-transferase, theta 3 104.84 71.91 5.78 4.25
Tnfaip6 tumor necrosis factor alpha induced protein 6 101.61 108.15 13.50 13.20
Alcam activated leukocyte cell adhesion molecule 86.39 83.80 9.89 7.56
Cyp4a8 cytochrome P450, family 4, subfamily a, polypeptide 8 85.73 103.28 12.04 4.27
Pllp plasmolipin 77.98 94.38 4.74 1.35
Elf3 E74-like factor 3 70.44 73.54 3.02 3.86
Slc26a4 solute carrier family 26 (anion exchanger), member 4 69.38 68.87 0.16 0.23
Lpcat4 lysophosphatidylcholine acyltransferase 4 67.64 67.55 8.49 1.53
Tspan1 tetraspanin 1 67.06 39.29 3.44 3.06
Serpinb1a serine (or cysteine) proteinase inhibitor, clade B, member 1a 63.64 34.31 11.93 9.60
Slc10a1 solute carrier family 10, member 1 61.59 87.32 3.66 3.26
Slc13a3 solute carrier family 13, member 3 55.69 51.79 1.92 1.95
Pigr polymeric immunoglobulin receptor 55.40 69.41 0.31 0.36
Sh2d4a SH2 domain containing 4A 53.59 31.99 11.89 2.43
RGD1309313/Tmem180 transmembrane protein 180 53.18 40.76 9.63 4.99
Ptprh protein tyrosine phosphatase, receptor type, H 49.37 42.47 0.28 0.24
Lamc2 laminin, gamma 2 44.77 46.30 3.40 2.37
Napsa napsin A aspartic peptidase 42.31 33.89 5.00 2.50
Aadat aminoadipate aminotransferase 41.93 42.22 2.10 2.65
F5 coagulation factor V (proaccelerin, labile factor) 39.50 32.53 3.67 2.53
Eya2 eyes absent homolog 2 (Drosophila) 37.63 37.38 1.30 1.08
Hnf4a hepatocyte nuclear factor 4, alpha 36.88 22.69 0.47 0.30
Cndp1 carnosine dipeptidase 1 (metallopeptidase M20 family) 35.15 22.93 3.81 3.11
Mal2 mal, T-cell differentiation protein 2 32.51 32.69 1.41 1.60
Lgals2 lectin, galactoside-binding, soluble, 2 30.51 23.52 0.41 0.39
Ehf ets homologous factor 29.02 34.55 0.12 0.14
RGD1563547/Smim22 small integral membrane protein 22 28.31 20.33 0.48 0.17
Slc16a14 solute carrier family 16, member 14 28.20 33.75 1.22 0.55
Fermt1 fermitin family member 1 28.01 32.36 1.11 0.60
Pklr pyruvate kinase, liver and RBC 27.71 27.58 3.11 1.89
Cubn cubilin (intrinsic factor-cobalamin receptor) 25.73 21.78 0.54 0.09
LOC500797 mitotic spindle positioning 24.58 20.86 0.78 0.69
Chdh choline dehydrogenase 24.26 22.69 1.30 0.86
Gpa33 glycoprotein A33 (transmembrane) 24.22 28.58 0.64 1.05
Hgfac HGF activator 23.55 23.19 0.55 0.90
Cftr cystic fibrosis transmembrane conductance regulator 22.54 29.22 0.07 0.07
Ehhadh enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase 21.25 16.87 1.93 1.39
Cldn1 claudin 1 20.50 25.59 2.83 2.01
Fcgbp Fc fragment of IgG binding protein 20.48 25.88 0.90 0.98
Irf6 interferon regulatory factor 6 20.26 14.60 2.10 0.55
LOC689065 hypothetical protein LOC689065 18.99 14.78 0.84 1.23
Dcdc2 doublecortin domain containing 2 18.15 13.93 1.94 0.55
Rab17 RAB17, member RAS oncogene family 17.60 13.99 0.05 0.08
Unc5cl unc-5 homolog C (C. elegans)-like 17.36 9.72 0.19 0.33
Trib3 tribbles pseudokinase 3 16.37 18.18 0.05 0.09
Prss22 protease, serine, 22 16.08 13.44 0.30 0.18
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Vil1 villin 1 15.99 13.20 0.40 0.53
Abcg2 ATP-binding cassette, subfamily G (WHITE), member 2 15.93 11.24 0.65 0.31
Wfdc10 WAP four-disulfide core domain 10 13.74 14.94 0.05 0.09
RGD1565844 similar to RIKEN cDNA 1700045I19 12.92 14.81 0.08 0.07
Pemt phosphatidylethanolamine N-methyltransferase 12.90 11.75 0.37 0.11
Cdh16 cadherin 16 12.25 12.69 0.10 0.11
Grpr gastrin releasing peptide receptor 11.69 6.82 0.23 0.23
Wnt7a wingless-type MMTV integration site family, member 7A 11.54 9.93 0.09 0.02
Gucy2c guanylate cyclase 2C 11.04 8.82 0.31 0.16
Usp43 predicted ubiquitin specific peptidase 43 9.24 9.55 0.05 0.08
Tcerg1l transcription elongation regulator 1-like 7.00 11.83 0.02 0.03
Kcnj16 potassium inwardly-rectifying channel, subfamily J, member 16 6.87 6.70 0.14 0.04
LOC691352 similar to Robo-1 6.84 5.45 0.59 0.07
Epor erythropoietin receptor 6.53 11.11 0.04 0.06
Grik2 glutamate receptor, ionotropic, kainate 2 6.42 2.72 0.08 0.07
Glp1r glucagon-like peptide 1 receptor 6.40 5.13 0.22 0.21
Fut9 fucosyltransferase 9 (alpha (1,3) fucosyltransferase) 5.57 4.91 0.32 0.07
Lgals12 lectin, galactoside-binding, soluble, 12 4.37 4.30 0.12 0.14
Cldn8 claudin 8 4.29 5.87 0.03 0.05
Fam84a family with sequence similarity 84, member A 3.90 2.47 0.10 0.12
Tmprss4 transmembrane protease, serine 4 3.84 2.88 0.02 0.04
Slco1a1 solute carrier organic anion transporter family, member 1a1 2.91 4.91 0.02 0.04
Acsm5 acyl-CoA synthetase medium-chain family member 5 2.70 4.68 0.02 0.04
Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 2.68 4.16 0.02 0.04
Gad1 glutamate decarboxylase 1 1.15 0.56 0.02 0.02
Table F.14: Biological functions of genes that were upregulated in the decidua of
P4-treated samples. The genes were analysed for GO term enrichment using BiNGO. The
overrepresented GO terms are shown with their corresponding adjusted p-values and the number
of genes within the test set that are annotated to that function.
Description Corrected p-value No. Genes
maternal process involved in female pregnancy 3.54E-02 2
disruption by symbiont of host cells 3.54E-02 1
camera-type eye photoreceptor cell fate commitment 3.54E-02 1
response to platinum ion 3.54E-02 1
regulation of eye pigmentation 3.54E-02 1
negative regulation of eye pigmentation 3.54E-02 1
negative regulation of developmental pigmentation 3.54E-02 1
hemolysis by symbiont of host erythrocytes 3.54E-02 1
hemolysis of cells in other organism involved in symbiotic interaction 3.54E-02 1
modification by organism of cell membrane in other organism involved in symbiotic interaction 3.54E-02 1
retinal pigment epithelium development 3.54E-02 1
modification by symbiont of host cell membrane 3.54E-02 1
modification by symbiont of host cellular component 3.54E-02 1
modification by symbiont of host structure 3.54E-02 1
modification of cellular component in other organism involved in symbiotic interaction 3.54E-02 1
modification of structure of other organism involved in symbiotic interaction 3.54E-02 1
hemolysis of cells in other organism 3.54E-02 1
killing by symbiont of host cells 3.54E-02 1
cytolysis by symbiont of host cells 3.54E-02 1
cytolysis of cells of another organism 3.54E-02 1
cytolysis of cells in other organism involved in symbiotic interaction 3.54E-02 1
tube morphogenesis 3.76E-02 3
chloride transport 3.76E-02 2
intein-mediated protein splicing 4.02E-02 1
camera-type eye photoreceptor cell differentiation 4.02E-02 1
vitelline membrane formation 4.02E-02 1
maintenance of mitochondrion location 4.02E-02 1
maintenance of organelle location 4.02E-02 1
eye photoreceptor cell fate commitment 4.02E-02 1
embryo sac morphogenesis 4.02E-02 1
gametophyte development 4.02E-02 1
megagametogenesis 4.02E-02 1
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embryo sac development 4.02E-02 1
tube lumen cavitation 4.02E-02 1
protein splicing 4.02E-02 1
photoreceptor cell fate commitment 4.02E-02 1
salivary gland cavitation 4.02E-02 1
Table F.15: Biological functions of genes that were down-regulated in the decidua
of P4-treated samples. The genes were analysed for GO term enrichment using BiNGO. The
overrepresented GO terms are shown with their corresponding adjusted p-values and the number
of genes within the test set that are annotated to that function.
Description Corrected p-value No. Genes
regulation of cell migration 3.57E-02 3
regulation of cellular component movement 3.57E-02 3
regulation of locomotion 3.57E-02 3
regulation of developmental process 4.14E-02 4
regulation of ossification 4.14E-02 2
positive regulation of developmental process 4.14E-02 3
positive regulation of response to external stimulus 4.14E-02 2
regulation of angiogenesis 4.14E-02 2
regulation of mast cell chemotaxis 4.14E-02 1
positive regulation of mast cell chemotaxis 4.14E-02 1
signaling 4.82E-02 7
ossification 4.82E-02 2
bone development 4.82E-02 2
positive regulation of action potential 4.82E-02 1
positive regulation of natriuresis 4.82E-02 1
skeletal muscle tissue growth 4.82E-02 1
regulation of multicellular organismal process 4.82E-02 4
positive regulation of cell migration 4.82E-02 2
negative regulation of heart rate 4.82E-02 1
positive regulation of synaptic transmission, cholinergic 4.82E-02 1
regulation of synaptic transmission, cholinergic 4.82E-02 1
positive regulation of cellular component movement 4.82E-02 2
positive regulation of locomotion 4.82E-02 2
tachykinin receptor signaling pathway 4.97E-02 1
negative regulation of insulin-like growth factor receptor signaling pathway 4.97E-02 1
Table F.16: Biological functions of genes that were upregulated in the outer my-
ometrium of P4-treated samples. The genes were analysed for GO term enrichment using
BiNGO. The overrepresented GO terms are shown with their corresponding adjusted p-values and
the number of genes within the test set that are annotated to that function.
Description Corrected p-value No. Genes
ventricular cardiac muscle tissue morphogenesis 7.83E-04 3
ventricular cardiac muscle tissue development 7.83E-04 3
cardiac ventricle morphogenesis 7.83E-04 3
cardiac ventricle development 7.83E-04 3
cardiac muscle tissue morphogenesis 7.83E-04 3
muscle tissue morphogenesis 7.83E-04 3
cardiac chamber development 1.20E-03 3
cardiac chamber morphogenesis 1.20E-03 3
cardiac muscle tissue development 8.20E-03 3
heart morphogenesis 8.20E-03 3
regulation of striated muscle contraction 1.31E-02 2
cardiac muscle contraction 1.37E-02 2
muscle structure development 1.55E-02 4
heart process 1.55E-02 2
heart contraction 1.55E-02 2
muscle contraction 1.89E-02 3
muscle system process 2.68E-02 3
striated muscle contraction 3.18E-02 2
striated muscle tissue development 3.18E-02 3
Continued on next page
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regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum 3.32E-02 1
muscle tissue development 3.32E-02 3
Table F.17: Biological functions of genes that were downregulated in the outer my-
ometrium of P4-treated samples. The genes were analysed for GO term enrichment using
BiNGO. The overrepresented GO terms are shown with their corresponding adjusted p-values and
the number of genes within the test set that are annotated to that function.
Description Corrected p-value No. Genes
chemical homeostasis 2.03E-02 12
response to wounding 2.03E-02 11
lipid metabolic process 2.03E-02 14
homeostatic process 2.03E-02 14
wound healing 2.03E-02 7
organic anion transport 2.03E-02 4
ion homeostasis 2.87E-02 10
regulation of biological quality 3.06E-02 20
F.4 Regulation of Differentially Expressed Genes in
Control Tissues
Table F.18: Biological functions of genes that were common to P4 and control, GD20-
GD22(NL), differentially expressed gene sets in the decidua. The genes were analysed
for GO term enrichment using BiNGO. The overrepresented GO terms are shown with their corre-
sponding adjusted p-values and the number of genes within the test set that are annotated to that
function.
Description Corrected p-value No. Genes
disruption by symbiont of host cells 3.13E-03 1
modification by symbiont of host cell membrane 3.13E-03 1
modification by symbiont of host cellular component 3.13E-03 1
response to platinum ion 3.13E-03 1
modification by symbiont of host structure 3.13E-03 1
modification of cellular component in other organism involved in symbiotic interaction 3.13E-03 1
modification of structure of other organism involved in symbiotic interaction 3.13E-03 1
hemolysis of cells in other organism 3.13E-03 1
killing by symbiont of host cells 3.13E-03 1
cytolysis by symbiont of host cells 3.13E-03 1
hemolysis by symbiont of host erythrocytes 3.13E-03 1
hemolysis of cells in other organism involved in symbiotic interaction 3.13E-03 1
cytolysis of cells of another organism 3.13E-03 1
modification by organism of cell membrane in other organism involved in symbiotic interaction 3.13E-03 1
cytolysis of cells in other organism involved in symbiotic interaction 3.13E-03 1
tube morphogenesis 4.70E-03 2
maintenance of mitochondrion location 4.70E-03 1
maintenance of organelle location 4.70E-03 1
tube lumen cavitation 4.70E-03 1
salivary gland cavitation 4.70E-03 1
response to metal ion 7.54E-03 2
tube development 8.70E-03 2
disruption of cells of other organism involved in symbiotic interaction 8.70E-03 1
killing of cells in other organism involved in symbiotic interaction 8.70E-03 1
response to indole-3-methanol 8.70E-03 1
cellular response to indole-3-methanol 8.70E-03 1
positive regulation of circadian sleep/wake cycle, non-REM sleep 8.70E-03 1
cellular response to lithium ion 1.01E-02 1
response to inorganic substance 1.21E-02 2
regulation of branching involved in salivary gland morphogenesis 1.21E-02 1
killing of cells of another organism 1.21E-02 1
regulation of circadian sleep/wake cycle, non-REM sleep 1.28E-02 1
positive regulation of circadian sleep/wake cycle, sleep 1.28E-02 1
positive regulation of circadian rhythm 1.38E-02 1
response to mercury ion 1.52E-02 1
mitochondrion localization 1.52E-02 1
trophectodermal cell differentiation 1.52E-02 1
positive regulation of biological process 1.53E-02 3
positive regulation of transcription factor import into nucleus 1.53E-02 1
blastocyst formation 1.53E-02 1
modification by symbiont of host morphology or physiology 1.60E-02 1
positive regulation of protein import into nucleus 1.79E-02 1
salivary gland morphogenesis 1.97E-02 1
regulation of circadian sleep/wake cycle, sleep 1.97E-02 1
cell killing 1.97E-02 1
synapse assembly 1.97E-02 1
regulation of circadian sleep/wake cycle 1.97E-02 1
circadian sleep/wake cycle process 1.97E-02 1
salivary gland development 1.97E-02 1
cellular response to metal ion 1.97E-02 1
positive regulation of nucleocytoplasmic transport 2.02E-02 1
circadian sleep/wake cycle 2.02E-02 1
cellular response to inorganic substance 2.02E-02 1
circadian behavior 2.02E-02 1
response to lithium ion 2.02E-02 1
vasodilation 2.02E-02 1
regulation of transcription factor import into nucleus 2.02E-02 1
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modification of morphology or physiology of other organism involved in symbiotic interaction 2.02E-02 1
rhythmic behavior 2.07E-02 1
regulation of morphogenesis of a branching structure 2.15E-02 1
exocrine system development 2.15E-02 1
pituitary gland development 2.27E-02 1
positive regulation of intracellular protein transport 2.31E-02 1
positive regulation of intracellular transport 2.38E-02 1
regulation of circadian rhythm 2.38E-02 1
tube formation 2.38E-02 1
blastocyst development 2.38E-02 1
regulation of apoptosis 2.43E-02 2
interaction with host 2.43E-02 1
regulation of programmed cell death 2.43E-02 2
regulation of cell death 2.51E-02 2
cellular response to starvation 2.51E-02 1
diencephalon development 2.51E-02 1
maintenance of location in cell 2.53E-02 1
synapse organization 2.56E-02 1
regulation of protein import into nucleus 2.70E-02 1
regulation of tube size 2.70E-02 1
regulation of blood vessel size 2.70E-02 1
positive regulation of behavior 2.73E-02 1
symbiosis, encompassing mutualism through parasitism 2.99E-02 1
vascular process in circulatory system 3.00E-02 1
cellular response to stimulus 3.00E-02 2
interspecies interaction between organisms 3.10E-02 1
regulation of intracellular protein transport 3.10E-02 1
anatomical structure morphogenesis 3.10E-02 2
gland morphogenesis 3.10E-02 1
regulation of nucleocytoplasmic transport 3.12E-02 1
maintenance of location 3.30E-02 1
response to starvation 3.37E-02 1
positive regulation of protein transport 3.48E-02 1
endocrine system development 3.51E-02 1
regulation of behavior 3.51E-02 1
regulation of intracellular transport 3.52E-02 1
regulation of multicellular organismal process 3.53E-02 2
cellular response to nutrient levels 3.57E-02 1
circadian rhythm 3.57E-02 1
organelle localization 3.57E-02 1
regulation of caspase activity 3.82E-02 1
regulation of endopeptidase activity 4.15E-02 1
response to organic substance 4.31E-02 2
regulation of peptidase activity 4.35E-02 1
cellular response to extracellular stimulus 4.44E-02 1
response to toxin 4.44E-02 1
cellular response to external stimulus 4.44E-02 1
extracellular structure organization 4.89E-02 1
Table F.19: Biological functions of genes that were common to P4 and control,
GD22(NL)-GD22(L), differentially expressed gene sets in the decidua. The genes were
analysed for GO term enrichment using BiNGO. The overrepresented GO terms are shown with
their corresponding adjusted p-values and the number of genes within the test set that are annotated
to that function.
Description Corrected p-value No. Genes
disruption by symbiont of host cells 0.002 1
hemolysis of cells in other organism 0.002 1
killing by symbiont of host cells 0.002 1
modification by symbiont of host cell membrane 0.002 1
cytolysis by symbiont of host cells 0.002 1
hemolysis by symbiont of host erythrocytes 0.002 1
hemolysis of cells in other organism involved in symbiotic interaction 0.002 1
cytolysis of cells of another organism 0.002 1
modification by organism of cell membrane in other organism involved in symbiotic interaction 0.002 1
cytolysis of cells in other organism involved in symbiotic interaction 0.002 1
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modification by symbiont of host cellular component 0.002 1
response to platinum ion 0.002 1
modification by symbiont of host structure 0.002 1
modification of cellular component in other organism involved in symbiotic interaction 0.002 1
modification of structure of other organism involved in symbiotic interaction 0.002 1
maintenance of mitochondrion location 0.004 1
maintenance of organelle location 0.004 1
positive regulation of myelination 0.005 1
ferric iron transport 0.005 1
disruption of cells of other organism involved in symbiotic interaction 0.007 1
killing of cells in other organism involved in symbiotic interaction 0.007 1
positive regulation of circadian sleep/wake cycle, non-REM sleep 0.007 1
positive regulation of multicellular organismal process 0.007 2
transepithelial chloride transport 0.008 1
regulation of myelination 0.009 1
killing of cells of another organism 0.009 1
positive regulation of circadian sleep/wake cycle, sleep 0.010 1
regulation of circadian sleep/wake cycle, non-REM sleep 0.010 1
positive regulation of circadian rhythm 0.011 1
transepithelial transport 0.011 1
response to mercury ion 0.012 1
mitochondrion localization 0.012 1
modification by symbiont of host morphology or physiology 0.013 1
transport 0.015 3
establishment of localization 0.015 3
cell killing 0.016 1
regulation of circadian sleep/wake cycle 0.016 1
regulation of circadian sleep/wake cycle, sleep 0.016 1
circadian sleep/wake cycle process 0.017 1
circadian sleep/wake cycle 0.018 1
circadian behavior 0.018 1
vasodilation 0.018 1
modification of morphology or physiology of other organism involved in symbiotic interaction 0.018 1
localization 0.018 3
rhythmic behavior 0.018 1
ion transport 0.021 2
acute-phase response 0.022 1
regulation of circadian rhythm 0.022 1
interaction with host 0.023 1
iron ion transport 0.023 1
cellular response to starvation 0.024 1
maintenance of location in cell 0.024 1
chloride transport 0.024 1
cellular iron ion homeostasis 0.024 1
positive regulation of neurological system process 0.024 1
regulation of blood vessel size 0.024 1
regulation of tube size 0.024 1
positive regulation of behavior 0.024 1
iron ion homeostasis 0.025 1
symbiosis, encompassing mutualism through parasitism 0.026 1
vascular process in circulatory system 0.026 1
interspecies interaction between organisms 0.028 1
maintenance of location 0.030 1
response to starvation 0.031 1
transition metal ion transport 0.032 1
regulation of behavior 0.032 1
inorganic anion transport 0.032 1
regulation of multicellular organismal process 0.032 2
cellular response to nutrient levels 0.032 1
circadian rhythm 0.032 1
organelle localization 0.032 1
acute inflammatory response 0.036 1
response to organic substance 0.039 2
cellular response to extracellular stimulus 0.040 1
cellular response to external stimulus 0.040 1
anion transport 0.045 1
regulation of homeostatic process 0.050 1
Table F.20: Biological functions of genes that were common to P4 and control,
GD22(NL)-GD22(L), differentially expressed gene sets in the inner myometrium. The
genes were analysed for GO term enrichment using BiNGO. The overrepresented GO terms are
shown with their corresponding adjusted p-values and the number of genes within the test set that
are annotated to that function.
Description Corrected p-value No. Genes
embryonic skeletal joint morphogenesis 0.007 1
collagen fibril organization 0.019 1
embryonic skeletal system morphogenesis 0.019 1
embryonic skeletal system development 0.019 1
sensory perception of sound 0.019 1
cartilage development 0.019 1
extracellular matrix organization 0.019 1
sensory perception of mechanical stimulus 0.019 1
visual perception 0.019 1
sensory perception of light stimulus 0.019 1
skeletal system morphogenesis 0.019 1
embryonic organ morphogenesis 0.021 1
extracellular structure organization 0.021 1
embryonic organ development 0.028 1
skeletal system development 0.036 1
embryonic morphogenesis 0.036 1
chordate embryonic development 0.038 1
embryonic development ending in birth or egg hatching 0.038 1
F.5 Regulation of Differentially Expressed Genes in
RU486-treated Tissues
Table F.21: Biological functions of genes that were regulated differently in P4 and
RU486 decidua samples. The genes were analysed for GO term enrichment using BiNGO. The
overrepresented GO terms are shown with their corresponding adjusted p-values and the genes
within the test set that are annotated to that function.
Description Corrected Genes
p-value in test set
tube lumen cavitation 0.0275 CDH1
salivary gland cavitation 0.0275 CDH1
response to indole-3-methanol 0.0298 CDH1
cellular response to indole-3-methanol 0.0298 CDH1
cellular response to lithium ion 0.0298 CDH1
regulation of branching involved in salivary gland morphogenesis 0.0298 CDH1
trophectodermal cell differentiation 0.0298 CDH1
thyroid hormone metabolic process 0.0298 SLCO4A1
cortical actin cytoskeleton organization 0.0298 EPB41L3
cortical cytoskeleton organization 0.0298 EPB41L3
blastocyst formation 0.0298 CDH1
positive regulation of transcription factor import into nucleus 0.0298 CDH1
positive regulation of protein import into nucleus 0.0327 CDH1
salivary gland morphogenesis 0.0327 CDH1
synapse assembly 0.0327 CDH1
cellular response to metal ion 0.0327 CDH1
salivary gland development 0.0327 CDH1
positive regulation of nucleocytoplasmic transport 0.0327 CDH1
cellular response to inorganic substance 0.0327 CDH1
response to lithium ion 0.0327 CDH1
regulation of transcription factor import into nucleus 0.0327 CDH1
regulation of morphogenesis of a branching structure 0.0333 CDH1
exocrine system development 0.0333 CDH1
pituitary gland development 0.0333 CDH1
positive regulation of intracellular protein transport 0.0333 CDH1
positive regulation of intracellular transport 0.0333 CDH1
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p-value in test set
blastocyst development 0.0333 CDH1
tube formation 0.0333 CDH1
diencephalon development 0.0369 CDH1
synapse organization 0.0375 CDH1
regulation of protein import into nucleus 0.0389 CDH1
regulation of intracellular protein transport 0.0467 CDH1
gland morphogenesis 0.0467 CDH1
regulation of nucleocytoplasmic transport 0.0467 CDH1
Table F.22: Biological functions of genes that were regulated differently in P4 and
RU486 outer myometrium samples. The genes were analysed for GO term enrichment using
BiNGO. The overrepresented GO terms are shown with their corresponding adjusted p-values and
the genes within the test set that are annotated to that function.
Description Corrected Genes
p-value in test set
cholesterol transport 0.0073 APOA1, CFTR
sterol transport 0.0073 APOA1, CFTR
response to steroid hormone stimulus 0.0106 APOA1, CLDN4, CFTR
response to organic substance 0.0106 LCN2, APOA1, CLDN4, CFTR
cholesterol metabolic process 0.0106 APOA1, CFTR
response to drug 0.0106 LCN2, APOA1, CFTR
sterol metabolic process 0.0106 APOA1, CFTR
negative regulation of interleukin-1 beta secretion 0.0124 APOA1
multi-organism process 0.0124 LCN2, PSG29, CLDN4
female pregnancy 0.0124 PSG29, CLDN4
lipid transport 0.0124 APOA1, CFTR
cholesterol import 0.0124 APOA1
iodide transport 0.0124 CFTR
sterol transmembrane transport 0.0124 APOA1
sterol import 0.0124 APOA1
negative regulation of interleukin-1 secretion 0.0124 APOA1
lipid localization 0.0137 APOA1, CFTR
response to hormone stimulus 0.0142 APOA1, CLDN4, CFTR
negative regulation of very-low-density lipoprotein particle remodeling 0.0146 APOA1
response to herbicide 0.0146 LCN2
response to cytokine stimulus 0.0146 LCN2, CFTR
response to endogenous stimulus 0.0146 APOA1, CLDN4, CFTR
negative regulation of cytokine secretion involved in immune response 0.0146 APOA1
regulation of very-low-density lipoprotein particle remodeling 0.0146 APOA1
bicarbonate transport 0.0146 CFTR
high-density lipoprotein particle assembly 0.0146 APOA1
Cdc42 protein signal transduction 0.0146 APOA1
steroid metabolic process 0.0146 APOA1, CFTR
response to estrogen stimulus 0.0160 APOA1, CFTR
regulation of cytokine secretion involved in immune response 0.0160 APOA1
negative regulation of interleukin-1 beta production 0.0160 APOA1
positive regulation of cholesterol esterification 0.0165 APOA1
regulation of cholesterol esterification 0.0165 APOA1
negative regulation of interleukin-1 production 0.0165 APOA1
protein homotrimerization 0.0165 LCN2
transepithelial chloride transport 0.0165 CFTR
cellular response to stimulus 0.0165 LCN2, APOA1, CFTR
plasma lipoprotein particle assembly 0.0178 APOA1
cellular response to tumor necrosis factor 0.0178 LCN2
negative regulation of lipase activity 0.0189 APOA1
protein trimerization 0.0189 LCN2
protein-lipid complex assembly 0.0189 APOA1
cellular response to interleukin-1 0.0203 LCN2
regulation of interleukin-1 beta secretion 0.0203 APOA1
reverse cholesterol transport 0.0216 APOA1
regulation of interleukin-1 secretion 0.0216 APOA1
phospholipid eﬄux 0.0218 APOA1
transepithelial transport 0.0218 CFTR
axon regeneration in the peripheral nervous system 0.0218 APOA1
negative regulation of cytokine secretion 0.0218 APOA1
Continued on next page
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phosphatidylcholine biosynthetic process 0.0231 APOA1
lipid biosynthetic process 0.0231 APOA1, CFTR
water transport 0.0243 CFTR
cellular response to organic substance 0.0248 LCN2, CFTR
positive regulation of steroid metabolic process 0.0252 APOA1
fluid transport 0.0266 CFTR
response to nutrient levels 0.0288 LCN2, APOA1
regulation of interleukin-1 beta production 0.0288 APOA1
positive regulation of vasodilation 0.0288 CFTR
cholesterol eﬄux 0.0288 APOA1
cellular response to cytokine stimulus 0.0288 LCN2
negative regulation of protein secretion 0.0288 APOA1
response to extracellular stimulus 0.0294 LCN2, APOA1
phosphatidylcholine metabolic process 0.0294 APOA1
axon regeneration 0.0296 APOA1
body fluid secretion 0.0296 CFTR
regulation of interleukin-1 production 0.0296 APOA1
alcohol metabolic process 0.0304 APOA1, CFTR
response to chemical stimulus 0.0307 LCN2, APOA1, CLDN4, CFTR
regulation of cytokine production involved in immune response 0.0307 APOA1
protein stabilization 0.0307 APOA1
neuron projection regeneration 0.0326 APOA1
regulation of vasodilation 0.0326 CFTR
vasodilation 0.0330 CFTR
cholesterol biosynthetic process 0.0330 CFTR
cellular response to lipopolysaccharide 0.0334 LCN2
Rho protein signal transduction 0.0334 APOA1
cellular response to molecule of bacterial origin 0.0354 LCN2
cellular response to chemical stimulus 0.0354 LCN2, CFTR
response to tumor necrosis factor 0.0354 LCN2
phospholipid transport 0.0354 APOA1
sterol biosynthetic process 0.0358 CFTR
cellular response to hydrogen peroxide 0.0358 LCN2
cellular response to stress 0.0368 LCN2, APOA1
regulation of cellular component organization 0.0368 LCN2, APOA1
ethanolamine and derivative metabolic process 0.0368 APOA1
regulation of cytokine secretion 0.0375 APOA1
cholesterol homeostasis 0.0400 APOA1
sterol homeostasis 0.0400 APOA1
transmembrane transport 0.0413 APOA1, CFTR
cellular response to reactive oxygen species 0.0413 LCN2
negative regulation of protein transport 0.0413 APOA1
response to external stimulus 0.0413 LCN2, APOA1
response to progesterone stimulus 0.0413 CLDN4
cellular response to protein stimulus 0.0413 LCN2
response to interleukin-1 0.0413 LCN2
organic anion transport 0.0413 CFTR
chloride transport 0.0413 CFTR
regulation of protein stability 0.0415 APOA1
regulation of steroid metabolic process 0.0415 APOA1
regulation of production of molecular mediator of immune response 0.0416 APOA1
negative regulation of cytokine production 0.0416 APOA1
regulation of tube size 0.0427 CFTR
regulation of blood vessel size 0.0427 CFTR
response to axon injury 0.0433 APOA1
positive regulation of lipid metabolic process 0.0447 APOA1
macromolecular complex assembly 0.0463 LCN2, APOA1
vascular process in circulatory system 0.0475 CFTR
reproductive process 0.0484 PSG29, CLDN4
lipid homeostasis 0.0484 APOA1
cellular response to biotic stimulus 0.0488 LCN2
reproduction 0.0488 PSG29, CLDN4
macromolecular complex subunit organization 0.0492 LCN2, APOA1
cellular response to oxidative stress 0.0493 LCN2
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F.6. Identification of Common Regulatory Features
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  =	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  x	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Hunchback	  (hb)	  
(Distance	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  =	  9.3)	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55.4%	  
54.8%	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  1	  (SP1)	  
(Distance	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  =	  8.1)	  
E-­‐value	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  7.7	  x	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43.3%	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(Distance	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  =	  2.9)	  
E-­‐value	  =	  7	  x	  10-­‐18	  
Figure F.1: Motifs identified in 1000 bp-long promoter regions of genes that were
responsive to progesterone in the decidua. MEME-LaB was used to identify motifs that were
enriched within promoter regions of P4-responsive genes.
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Enriched	  mo,f	   Similar	  known	  mo,f	  
Associated	  
	  genes	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  myo	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97.9%	  
E-­‐value	  =	  2.1	  x	  10-­‐14	  
Krüppel-­‐like	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  =	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Speciﬁcity	  protein	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(Distance	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  6.5)	  
Krüppel-­‐like	  factor	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  score	  =	  8.3)	  
97.9%	  
E-­‐value	  =	  1.7	  x	  10-­‐8	  
Figure F.2: Motifs identified in 1000 bp-long promoter regions of genes that were
responsive to progesterone in the inner myometrium. MEME-LaB was used to identify
motifs that were enriched within promoter regions of P4-responsive genes.
Enriched	  mo,f	   Similar	  known	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Associated	  
	  genes	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E-­‐value	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  (Distance	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64.9%	  
Krüppel-­‐like	  factor	  4	  (Klf4)	  
(Distance	  score	  =	  9.0)	  
Figure F.3: Motifs identified in 1000 bp-long promoter regions of genes that were
responsive to progesterone in the outer myometrium. MEME-LaB was used to identify
motifs that were enriched within promoter regions of P4-responsive genes.
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(Distance	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Figure F.4: Motifs identified in 2000 bp-long promoter regions of genes that were
responsive to progesterone in the decidua. MEME-LaB was used to identify motifs that were
enriched within promoter regions of P4-responsive genes.
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  protein	  1	  (SP1)	  (Distance	  score	  =	  4.0)	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  (SP1)	  
(Distance	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Figure F.5: Motifs identified in 2000 bp-long promoter regions of genes that were
responsive to progesterone in the inner myometrium. MEME-LaB was used to identify
motifs that were enriched within promoter regions of P4-responsive genes.
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Figure F.6: Motifs identified in 2000 bp-long promoter regions of genes that were
responsive to progesterone in the outer myometrium. MEME-LaB was used to identify
motifs that were enriched within promoter regions of P4-responsive genes.
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Figure F.7: Occurrence of motifs in random sets of genes. The genes were selected from
the expressed uterine transcriptome.
